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Background: Giant cell arteritis (GCA) is the most common form of medium and large 
vessel vasculitis. This condition is associated with serious complications, such as blindness 
if left untreated, and is therefore considered a medical emergency. However, GCA 
remains difficult to diagnose, in part, due to the wide variation of presenting symptoms, 
resulting in some patients facing significant diagnostic delay.  
Aim: To evaluate clinical features experienced by patients prior to a diagnosis of GCA. 
Methods: Four studies were undertaken. Firstly, a systematic review and meta-analysis of 
clinical features previously associated with a diagnosis of GCA. Subsequently using the 
Clinical Practice Research Datalink (CPRD), the remaining three studies investigated; the 
trends in incidence of GCA; the association of individual clinical features on the 
subsequent diagnosis of GCA; and finally, combinations of presenting clinical features 
prior to a GCA diagnosis. 
Results: The systematic review found 30 distinct clinical features, with the strongest 
pooled association for jaw claudication and elevated ESR. A total of 9205 GCA cases were 
identified from 1990-2017 in CPRD. Consultation incidence of GCA was 1.46 per 10,000 
person-years in 2017. In the CPRD analysis, individual features most strongly associated 
with GCA prior to diagnosis were headache, hypertension, and visual impairment. 
Application of latent class analysis (LCA) suggested five distinct patterns of presenting 
features; polymyalgia rheumatica (PMR), hypertension and multiple other features, single 
or no feature, hypertension, and elevated ESR.  
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Conclusion: GCA remains a difficult condition to recognise in primary care. Clinical 
features, such as headache, PMR, elevated ESR, and hypertension were consistently 
identified as important clinical features experienced prior to GCA diagnosis. This thesis 
has highlighted the need to research patterns of clinical features rather than individual 
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“Picking the best solution really depended on your definition of best.”  
― V.E Schwab, Vicious
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Chapter 1: Introduction  
1.1 Chapter overview 
This chapter will introduce the subject of the thesis, outlining the main aim, specific 
objectives, and rationale of the work conducted. An overview of the epidemiology of GCA 
and use of electronic health records in research will also be presented in this chapter. 
 
1.2 Giant cell arteritis 
Giant cell arteritis (GCA), also known as temporal arteritis, is the most common form of 
medium and large vessel vasculitis (Smeeth, Cook, & Hall, 2006). It occurs when arteries, 
particularly cranial arteries, become inflamed (Carlo Salvarani, Cantini, Boiardi, & Hunder, 
2002). It is associated with serious complications, such as blindness, if left untreated and 
therefore is considered a medical emergency requiring immediate attention if suspected. 
However, GCA is a relatively rare condition, with the most recent United Kingdom (UK) 
incidence estimate in the over 50s from 2015 reported as 1 per 10,000 person-years, with 
higher rates being found in women aged between 70 and 80 years old (Petri, Nevitt, Sarsour, 
Napalkov, & Collinson, 2015). 
 
1.2.1 Clinical features of GCA 
Clinical features of GCA include the symptoms, signs, comorbidities and laboratory tests 
which occur in patients prior to their diagnosis. In previous literature the term “classic” 
symptoms of GCA has been used widely to denote those symptoms which more commonly 
reflect a presentation of GCA. These “classic” symptoms usually include; headache, scalp 
tenderness, jaw claudication, and visual complications (Mackie et al., 2011; Marí et al., 2009; 
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Toren et al., 2016). However, the symptoms which can be accepted as “classical” vary 
throughout the literature. It has also been raised that medical practitioners, such as GPs, 
may over-rely on these symptoms to diagnose GCA when they are not universally observed 
in every patient with GCA (Chean et al., 2019; Ezeonyeji, Borg, & Dasgupta, 2011b). This 
potential for over reliance on clinical features that may not be present in every GCA patient 
can potentially lead to increased diagnostic delay for patients. 
GCA symptoms which have previously been reported to have a high association with the 
condition include; new onset headache, jaw claudication (pain in jaw whilst chewing), 
temporal artery abnormality (a temporal artery that is tender, swollen, or protruding), visual 
disturbances including diplopia (double vision), and blurred vision (NICE CKS, 2020; Smetana 
& Shmerling, 2002). However, the prevalence and strengths of association of these 
symptoms in patients with GCA varies between studies. Additionally, inflammatory markers 
(classically erythrocyte sedimentation rate (ESR) but also C-reactive protein) are almost 
universally raised (Smetana & Shmerling, 2002). 
The prevalence of clinical features vary greatly by study. For example, amongst confirmed 
cases of GCA in secondary care, the proportion of patients reporting headache can range 
from 52.4% (Toren et al., 2016) to 92.9% (Duhaut, Pinede, et al., 1999), and visual 
disturbances in biopsy proven GCA cases can vary between 30% (Gabriel, O’Fallon, Achkar, 
Lie, & Hunder, 1995) and 60% (Chmelewski, McKnight, Kevin, Agudelo, & Wise, 1992). Other 
commonly reported symptoms of GCA include fever, weight loss, and other constitutional 
symptoms. Furthermore, many of these symptoms are commonly seen in UK primary care 
and are frequently linked to other, more prevalent conditions than GCA in the UK 
population. For example, cancer is more prevalent than GCA and is associated with 
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unexplained weight loss (Moller, Flatt, & Moran, 2011), and headache may represent a 
malignant primary cancer or more likely metastatic disease in such populations.  
Reported prevalence of abnormal temporal artery also varies, with current estimates from 
secondary care of between 10% (Gabriel et al., 1995) and 75% (Marí et al., 2009), and 
inflammatory markers, such as elevated ESR, have high variation between previous studies, 
with estimates ranging from 40% (Chmelewski et al., 1992) to 98% (Rivero Puente et al., 
2001). 
A comorbidity commonly linked with GCA is polymyalgia rheumatica (PMR). PMR is the most 
common inflammatory rheumatic disease affecting patients over the age of 50 years, with a 
UK incidence of 95.9 per 100,000 person years in the over 40s (Partington, Muller, Helliwell, 
Mallen, & Abdul Sultan, 2018). Common symptoms include shoulder and/or pelvic girdle 
ache, morning stiffness, and raised inflammatory markers (Helliwell, Hider, Barraclough, 
Dasgupta, & Mallen, 2012). Although no common biological pathway has been defined to 
explain the association between GCA and PMR, PMR type symptoms have been frequently 
shown to occur, with one study indicating between 40% and 60% of GCA patients developing 
symptoms of PMR during the course of their illness (Hassan, Dasgupta, & Barraclough, 2011). 
In a study looking into the comorbidities considered to be associated with GCA, PMR was 
found to be the most prevalent in the GCA population (Petri et al., 2015) and it has been 
reported that patients who have a history of PMR have been more rapidly diagnosed with 
GCA (Mackie et al., 2011). Prevalence estimates of PMR prior to a diagnosis of GCA have 
predominately been conducted in secondary care, usually at the time of GCA diagnosis, and 
therefore there is no information available on how long a patient has had PMR type 
symptoms prior to their GCA diagnosis. A study conducted using primary care records could 
explore the relationship between PMR and a GCA diagnosis further. 
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Other comorbidities reported in GCA patients before their diagnosis include cardiovascular 
diseases and diabetes, but wide ranging estimates from these studies have also been 
reported. Prevalence of cardiovascular diseases (conditions affecting the heart or blood 
vessels, such as a stroke) amongst GCA patients prior to their diagnosis has been reported to 
be 4% (Sun, Ma, Zheng, Tian, & Zeng, 2016) and 22% (Unizony et al., 2017), and between 5% 
and 37% for diabetes (Espitia et al., 2012; Pugnet, Sailler, Bourrel, Montastruc, & 
LapeyreMestre, 2015), a common condition that causes a patient’s blood sugar level to 
become too high (NHS, 2019). 
 
1.2.2 Diagnosis 
Identifying GCA in primary care remains challenging due to the spectrum of clinical features 
reported to be associated with GCA (Petri et al., 2015; Smetana & Shmerling, 2002). 
Symptoms generally thought to be indicative of GCA are a headache (often in the temporal 
area), visual symptoms, and jaw claudication (Smetana & Shmerling, 2002). However, 
research has found that there are many other symptoms that could be associated.  
In 2002, Smetana & Shmerling examined the role of different clinical features in determining 
a diagnosis of GCA. The clinical features with the highest prevalence in patients prior to GCA 
in this review were any headache (76%), weight loss (43%), and fever (42%). Although jaw 
claudication is thought to be indicative of a GCA diagnosis, Smetana & Shmerling found that 
the prevalence was relatively low, but found that it was highly predictive of a positive 
temporal artery biopsy. The prevalence of any visual symptoms in this review was equally 
low, and it was diplopia that was found to have a higher predictive value of a positive 
temporal artery biopsy than any other visual symptoms (Smetana & Shmerling, 2002). In line 
with these findings, guidelines used by healthcare practitioners to identify and diagnose 
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patients with GCA include a range of clinical features that are thought to be associated with 
a GCA diagnosis.  
In the UK, the National Institute for Health and Care Excellence (NICE) provide evidence-
based best practice guidelines for diagnosis, management, and treatment for most clinical 
conditions seen in the UK, for both primary and specialist care settings. For GCA, NICE 
recommends to use the patient’s headache symptoms (of new onset and considered a red 
flag symptom in need of urgent attention in someone over 50), temporal artery abnormality, 
and age (GCA is rare in people under the age of 50 (Petri et al., 2015)), which are identified 
in primary care, as guidance for diagnosis/referral (Mackie et al., 2020; NICE, 2014; NICE CKS, 
2020). In order to aid in the prompt diagnosis of the patient, blood tests such as C-reactive 
protein (CRP) and Erythrocyte sedimentation rate (ESR) are also recommended (NICE CKS, 
2020). 
One of the tools used to identify GCA is the American College of Rheumatology (ACR) 
classification criteria. This was developed to create a standardised phenotype for research 
into different forms of vasculitis, and has been the usual standard for many studies 
previously. However, it has also been used (potentially inappropriately) for diagnostic 
purposes (Gene G. Hunder et al., 1990). The criteria include age of the patient (over 50 
years), presence of headache, and laboratory measurements such as elevated ESR, and 
temporal artery abnormality (Gene G. Hunder et al., 1990).  
Referral to secondary care is only the first part of the diagnostic pathway of GCA. In 
secondary care the current gold standard diagnostic method to determine the presence of 
GCA is a temporal artery biopsy, though increasingly ultrasound is seen as a viable method. 
On some occasions diagnosis may also be confirmed by a rheumatologist or other specialist 




1.2.3 Diagnostic delay 
As a result of the difficulties described in achieving prompt diagnosis of GCA, diagnostic 
delay (the time from symptom onset to final diagnosis) continues to be a major concern in 
the diagnosis and treatment of GCA. 
A systematic review and meta-analysis conducted by Prior et al (2017) investigated the 
extent of diagnostic delay in GCA. The review identified 22 articles that sufficiently reported 
information about diagnostic delay in patients diagnosed with GCA. Overall, the study found 
a mean of 9.2 weeks of diagnostic delay from symptom onset in all GCA patients. However, 
there was variation in diagnostic delay depending upon the clinical feature a patient 
presented with. Patients with cranial symptoms, such as headache and scalp tenderness, had 
a shorter time from onset to diagnosis (7.7 weeks), compared to those without cranial 
symptoms, where the diagnostic delay was more than double (17.6 weeks). This review also 
found that patients presenting with a headache had a much shorter time between onset and 
diagnosis than those who did not present with a headache. 
It remains unclear where on the clinical pathway diagnostic delay for patients with GCA 
occurs. Whether it is that patients self-manage the initial symptoms and only visit a GP when 
they do not improve, or exacerbate, or whether it is the time from referral from primary 
care to secondary care, can only be hypothesised (Raza et al., 2011).  
As will be described in further detail in Chapter 2, diagnostic delay in GCA remains a concern 
given that it is a medical emergency and that the many presenting clinical features, sparse 
levels of evidence of their prevalence and strength of association can cause difficulties in 
achieving a prompt diagnosis in primary care or referral for further investigation. In order to 
investigate which clinical features are associated with a GCA diagnosis, information about a 
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patients’ diagnostic pathway from initial symptom onset to final diagnosis should be 
examined. This is something which can be achieved through the use of primary care medical 
records. 
  
1.3 Electronic health records 
Primary care electronic health records (EHR) are a useful longitudinal resource to examine 
conditions which are rare in the population, such as GCA, where recruitment of enough 
cases may be difficult using a prospective study design. Information on patients prior to their 
diagnosis of GCA is available in EHR, due to patients typically remaining registered at their 
practice for long periods of time, and is free from the problems experienced by some 
research study designs, where certain participants may not provide the requested data (non-
response bias) or struggle to accurately recall information from their past health (recall bias). 
In the UK, 95% of the population is registered with a general practice (NHS, 2012). EHR 
contain records of diagnosis, disease management, referral information, and prescription 
details from patient consultations (Cowie et al., 2017), from a relatively stable population 
that are followed over a long period of time (R. S. Evans, 2016; Herrett et al., 2015).  
There are several EHR databases that contain primary care consultation data available for 
the purposes of research in the UK, with some of the most widely used being; the Health 
Improvement Network (THIN), the Clinical Practice Research Datalink (CPRD), QResearch, 
and ResearchOne. EHR databases can, and have been used to investigate consultation 
history prior to the onset of a disease, as well as its progression (Durand & Thomas, 2012; 
Muller et al., 2019). Since the main concern of GCA lies in the process of events from 
symptom onset to the initiation of treatment, via the point of diagnosis, medical records 
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from primary care can potentially be used to identify clinical features that may contribute to 
a more prompt diagnosis of GCA (Barnes et al., 2020; Mallitt et al., 2018; Rees et al., 2017). 
 
1.4 Aims and objectives of the thesis 
The aim of this thesis is to examine and quantify the association between relevant clinical 
features experienced by patients prior to a subsequent diagnosis of GCA. This will be 
achieved through four main objectives: 
1. To systematically review current evidence on the prevalence and association of 
clinical features reported in patients with GCA prior to diagnosis. 
2. To quantify the UK incidence and prevalence estimates of GCA using longitudinal 
primary care consultation data. 
3. To measure the frequency and association of individual clinical features prior to a 
GCA diagnosis using longitudinal primary care consultation data. 
4. To investigate common patterns of presenting clinical features prior to a GCA 
diagnosis using longitudinal primary care consultation data. 
Two secondary methodological objectives will also be undertaken: 
1. To assess the potential of using routine primary care EHR data to investigate clinical 
features prior to a GCA diagnosis, and other similar difficult to diagnose conditions. 
2. To assess the use of Latent Class Analysis (LCA) applied to primary care EHR as a 




1.5 Thesis rationale 
One of the main barriers facing current GCA research is diagnostic delay. Due to the risk of 
permanent visual impairment or complete sight loss, GCA is classed as a medical emergency, 
and therefore treatment should be prompt (Mackie et al., 2020). 
In order to consolidate the evidence around the varying clinical features reported prior to a 
diagnosis, an extensive review of the literature is required. The clinical features found by this 
review will inform the subsequent studies conducted in this thesis, by highlighting which 
clinical features have previously been examined, and guiding the selection of features for 
further investigation. 
The UK has an ageing population and hence more people may be at risk of a GCA diagnosis 
than there was at the time of the previous study (Petri et al., 2015), which included data up 
to 2011. GCA is more likely in patients aged between 70 and 80 years. Given the lack of 
current incidence estimates in the UK population, and to assess whether the trends found in 
the previous study by Petri et al (2015) have remained the same over time, the analysis will 
start by deriving the current incidence/prevalence estimates.  
Due to the problem of diagnostic delay for patients with GCA, this thesis will endeavour to 
provide new information to support GPs in identifying patients with potential GCA by 
assessing associations of individual clinical features, and patterns of presenting features in 
the time-period prior to a GCA diagnosis. Previous studies that have investigated the 
association/prevalence of clinical features and a GCA diagnosis are largely based on small 
sample sizes from secondary care (Mohamed & Bates, 2002; Zenone & Puget, 2013), hence a 
study including a much larger sample size, available from EHR, is needed, with the ability to 
accurately assess the time between symptom onset and GCA diagnosis. Investigating the 
effect of clinical features that have not been previously thoroughly investigated, or few 
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previous studies have included, on a diagnosis with GCA in tandem with other more 
accepted clinical features could allow for a more robust and prompter diagnosis of GCA. 
Finally, in order to be able to examine patterns of clinical features, the role of individual 
clinical features on a GCA diagnosis must first be examined. 
 
1.6 Thesis overview 
This thesis will investigate the clinical features presented to primary care prior to diagnosis 
of GCA. The first two chapters of this thesis will provide a detailed background into GCA and 
how its epidemiology can be investigated via primary care records, current methods of 
diagnosis, and treatment pathways available to patients. A systematic review of previously 
published literature will then be conducted in Chapter 3 to identify previously reported 
presenting clinical features of GCA. Chapter 4 will introduce the concept of the electronic 
health record database to be used throughout the thesis. Three studies will then be 
undertaken using primary care data from electronic health records to investigate GCA in the 
UK. Chapter 5 will include the methods, results, and discussion of a consultation incidence 
and prevalence study using electronic health records. In Chapter 6, a case-control study will 
be conducted to investigate the association between individual presenting clinical features 
and a subsequent diagnosis of GCA. The final study will be presented in Chapter 7 and will 
involve applying clustering methodology to identify common patterns of presenting clinical 
features. Finally, an overview of all findings, and implications for clinical practice and future 




Chapter 2: Background  
2.1 Chapter overview 
This chapter will focus on describing the epidemiology and diagnosis of giant cell arteritis 
(GCA), common clinical features experienced alongside this condition, and the primary 
management and treatment provided to patients with GCA in the UK. 
 
2.2 Giant Cell Arteritis 
Giant cell arteritis (GCA) is the most common medium and large vessel vasculitis, mostly 
affecting the aorta, branches of the ophthalmic artery, and extracranial branches of the 
carotid arteries (Baig, Pascoe, Kini, & Lee, 2019; Dasgupta et al., 2010; Lyons, Quick, Sinclair, 
Nagaraju, & Mollan, 2020). GCA occurs when there is inflammation in the vascular wall, 
prompting a physiological reaction in the artery that can lead to structural changes, intimal 
hyperplasia, and luminal occlusion (Weyand & Goronzy, 2000). Such changes in the 
vasculature can lead to visual loss due to vascular occlusion of ocular arteries, intermittent 
claudication or angina, and in some cases heart attack and stroke (Weyand & Goronzy, 
2000).  
 
2.2.1 Incidence and prevalence of GCA 
Overall incidence rates in the UK have been most recently estimated as between 1 and 2 per 
10,000 person-years in patients over the age of 40 years (Petri et al., 2015; Smeeth et al., 
2006). Both of these studies were conducted using an EHR database, the Clinical Practice 
Research Datalink (CPRD), and covered the years 1990 to 2001 (Smeeth et al., 2006), and 
2000 to 2011 (Petri et al., 2015). GCA onset is typically after the age of 50, but most 
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commonly affects patients aged between 70 and 79 years, and is more common in females 
than males (Mackie et al., 2020; Petri et al., 2015; Smeeth et al., 2006).  
A study predicting the world disease burden of GCA by 2050 estimated that the incidence of 
GCA would increase in both Oceania and Europe by 2050, but acknowledged that there were 
few studies conducted in Asia regarding GCA in the population (De Smit, Palmer, & Hewitt, 
2015). Despite this global perspective, incidence and prevalence estimates of GCA varies 
widely between countries, with this typically being greater in countries where the 
population is of mainly northern European descent. In Norway the overall average annual 
incidence of GCA was found to be 1.7 per 10,000 person-years in the period from 1972-2012 
for patients aged over 50 years (Brekke et al., 2017). In Sweden the most recent estimates 
from 1976-1995 show an incidence of 2.2 per 10,000 person-years (Nordborg, Nordborg, & 
Petursdottir, 2000). A study conducted in Olmsted County, Minnesota, USA, a population of 
mainly northern European descent, found an age and sex adjusted incidence rate of 1.9 per 
10,000 person-years in patients aged 50 years and over (Carlo Salvarani, Crowson, O’Fallon, 
Hunder, & Gabriel, 2004). Incidence estimates in northern European countries differ from 
countries in southern Europe, like Italy and Spain. The incidence in Italy has been reported as 
0.7 per 10,000 person-years from 1980-1988 (Salvarani et al., 1991), and incidence in Spain 
is reported as 1.3 per 10,000 person-years from 2001-2005 (Gonzalez-Gay et al., 2007). In 
Oceania and Asia incidence estimates are lower than Europe and the USA (De Smit et al., 
2015). In Australia the incidence estimate is 0.3 per 10,000 person-years in patients 50 years 
and over (Dunstan et al., 2014). A study comparing the incidence of GCA between 
Caucasians and Asians found that GCA was 20 times less likely in the Asian population 
(Pereira et al., 2011). However, this study had a small sample size, and the incidence rate 




2.2.2 Clinical features of GCA 
For the purposes of this thesis, clinical features of GCA will be defined as symptoms 
(subjective manifestations of an illness such as headache), signs (objective physical 
manifestations of an illness such as abnormal temporal artery), comorbidities (conditions 
happening concurrently with a primary condition), and laboratory test findings. The current 
NICE guidelines indicate that if a patient is over 50 years of age, and presents with either a 
new onset headache in the temporal area, or temporal artery abnormality, such as redness 
or inflammation, then GCA should be suspected (NICE CKS, 2020). Other symptoms that may 
be suggestive of GCA include; constitutional features such as fever, weight loss, and fatigue; 
features of polymyalgia rheumatica (PMR); abnormal temporal artery; intermittent jaw 
claudication; and visual disturbances (NICE CKS, 2020). 
 
2.2.2.1 Headache 
Headache is widely considered to be the symptom most indicative of the presence of GCA 
(Mackie et al., 2020). However, previously published studies have found that the prevalence 
of headache in patients with GCA can range from 52% to 93% (Duhaut, Pinede, et al., 1999; 
Toren et al., 2016), whilst a further study reported at least 24% of patients diagnosed with 
GCA can report no headache at all prior to their GCA diagnosis (Smetana & Shmerling, 2002). 
Low presentation of headache may present issues related to prompt diagnosis, as a previous 
study investigating the diagnosis and management of GCA in UK primary care showed that 




2.2.2.2 Visual disturbance  
In the same study by Helliwell et al (2018), the second most common symptom used by GPs 
to identify possible GCA was visual disturbances, which are also included in the NICE 
guidelines as clinical indicators of GCA. GCA is classed as a medical emergency due to the 
possibility of irreversible visual impairment in patients with GCA (Mackie et al., 2020; NICE 
CKS, 2020). Patients with GCA can present with a range of visual disturbances from diplopia, 
through to complete  blindness in one or both eyes (NICE CKS, 2020). NICE estimates that 
blindness in one or both eyes occurs in 20% of GCA patients prior to their diagnosis 
(Barraclough, Mallen, Helliwell, Hider, & Dasgupta, 2012; NICE CKS, 2020; Salvarani et al., 
2005). Previous studies estimate that visual complications occur in between 16 and 30% of 
patients (Salvarani et al., 2005; Vodopivec & Rizzo, 2018). In a study of patients with GCA, 
those who had visual complications were less likely to have headaches than those with no 
visual complications, and the overall incidence of visual complications in the GCA population 
was found to be 20.9 patients per 10,000 person years (Saleh, Turesson, Englund, Merkel, & 
Mohammad, 2016). Serious visual complications, such as blindness, are irreversible 
(Dasgupta, 2010). The key to managing GCA promptly, therefore, is avoiding diagnostic delay 
and initiating treatment prior to visual disturbances developing.  
 
2.2.2.3 Temporal artery abnormality  
Temporal artery abnormality is an indicator of GCA on NICE’s list, and the third most 
commonly used feature to diagnose GCA by GPs (Helliwell et al., 2018). Abnormal temporal 
artery is a temporal artery that is tender, swollen, or has nodular lesions (Banz & Stone, 
2018). Similar to headache, there are a range of prevalence estimates for the presence of an 
abnormal temporal artery in patients prior to their GCA diagnosis. Previous studies have 
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reported prevalence estimates of abnormal temporal artery from 19% to 85% of patients 
prior to a GCA diagnosis (Hayreh, Podhajsky, Raman, & Zimmerman, 1997; Narvaez et al., 
2003). 
 
2.2.2.4 Jaw claudication  
Another symptom of GCA hypothesised to be related to a subsequent diagnosis is jaw 
claudication. In the study conducted by Helliwell et al (2018) jaw symptoms were the fourth 
most common symptom used by GPs to diagnose GCA and Ezeonyeji et al (2011) found that 
jaw claudication occurred in 48% of patients with GCA (Ezeonyeji et al., 2011b), although this 
estimate varies between studies (Desmet, Knockaert, & Bobbaers, 1990; A.G Singh et al., 
2015). However, jaw claudication has also been shown to have limited usefulness in the aid 
of a diagnosis for GPs when it is the only feature without any other symptom more 
commonly associated with GCA and can cause a GCA diagnosis to be missed. (Hassan et al., 
2011). For example, Younge et al (2004) found that the combination of jaw claudication and 
double vision predicted a positive temporal artery biopsy result with 100% specificity and 2% 
sensitivity (Younge, Cook, Bartley, Hodge, & Hunder, 2004). This implies that jaw 
claudication may not be as useful as other clinical features to diagnose GCA, particularly as 
Aiello et al (1993) found that patients presenting with jaw claudication are also at a higher 
risk of future blindness (Aiello, Trautmann, McPhee, Kunselman, & Hunder, 1993), which 
may be related to missed or delayed diagnosis. 
 
2.2.2.5 Constitutional symptoms 
Other symptoms that are reported in studies and recommended by NICE as potential  
indicators of GCA include; fever, malaise, anorexia or weight loss, sometimes grouped as 
16 
 
“constitutional symptoms” (Carlo Salvarani, Cantini, & Hunder, 2008). One study found that 
in a population of GCA patients only 32% presented with constitutional symptoms (Ezeonyeji 
et al., 2011b). However, Helliwell et al (2018) found few GPs used constitutional symptoms 
as an indicator for GCA, preferring headache and scalp tenderness (Helliwell et al., 2018). It 
should be noted that there is no generally accepted definition of which symptoms are 
included under the term “constitutional symptoms”. 
 
2.2.2.6 Comorbidities 
A common comorbidity hypothesised to be associated with GCA is PMR. PMR classically 
presents with stiffness or pain in the neck, shoulders or hips (which is typically bilateral) 
raised inflammatory markers, and responds dramatically to glucocorticoid treatment 
(Mackie et al., 2020). It is currently estimated that between 40% and 60% of patients have 
PMR type symptoms at the time of their GCA diagnosis, and between 16% and 21% of 
patients with PMR will go onto develop GCA (Christian Dejaco, Duftner, Dasgupta, Matteson, 
& Schirmer, 2011).  
There are few studies which focus on investigating the occurrence and association of other 
comorbidities prior to a diagnosis of GCA. Petri et al (2015) listed the 25 most frequent 
comorbidities recorded in a patient’s record prior to their diagnosis of GCA. The most 
common was PMR, followed by chest infection, hypertension, and joint pain. Hypertension, 
diabetes, and osteoarthritis were also included in the list of 25 most frequently recorded. 
There have been studies which focus on the occurrence and association of one comorbidity 
prior to a GCA diagnosis, such as Venous Thromboembolism (VTE), or other vascular 
conditions (Li, Neogi, & Jick, 2017; Unizony et al., 2017). However, studies that investigate 
comorbidities prior to a GCA diagnosis are few. It is important to determine which 
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comorbidities are present prior to a GCA diagnosis, as some GCA treatments can exacerbate 
pre-existing comorbidities, such as hypertension, and diabetes (Lyons et al., 2020). 
 
2.2.2.7 Laboratory tests 
If GCA is suspected based on presenting clinical features, NICE recommends that patients 
should have an immediate blood test to check for inflammatory markers (NICE CKS, 2020). 
GCA causes an increase in platelet count, hence higher levels of Erythrocyte sedimentation 
rate (ESR) are thought to be an indicator of GCA (Mackie et al., 2020). The accepted level of 
ESR that indicates GCA as a possible diagnosis is ≥50 mm/h (Mackie et al., 2020; NICE CKS, 
2020). C-reactive protein (CRP) and plasma viscosity (PV) are also shown to be indicators of a 
GCA diagnosis (Lyons et al., 2020). A combination of CRP and ESR are thought to have the 
best sensitivity and specificity for a diagnosis of GCA (Lyons et al., 2020). One study has 
shown that levels of CRP and ESR were significantly lower in patients presenting with 
permanent visual loss (Salvarani et al., 2005). Patients with GCA may also show elevated 
liver function test results, and normochromic normocytic anaemia in their blood test (NICE 
CKS, 2020). 
 
2.3 Diagnosis of GCA 
Diagnosis of GCA can prove difficult due to the inconsistency and wide variation of 
presenting symptoms. For example, as indicated in section 2.2.2.1 above, not every patient 
who is diagnosed with GCA will have presented with a headache (Gideon Nesher, 2014), a 




2.3.1 NICE guidelines 
NICE guidelines, the main authority for guidance when diagnosing and managing conditions 
in UK primary care, instructs GPs to immediately refer patients with suspected GCA to a 
specialist (usually a rheumatologist) on a fast-track pathway if available (Mackie et al., 2020; 
NICE CKS, 2020). The guidance advises that patients with visual symptoms should be 
immediately referred to an ophthalmologist. Additionally Patients with suspected GCA 
should be treated with glucocorticoids without waiting for confirmation of diagnosis from 
the referral (NICE CKS, 2020). Higher doses of glucocorticoids or intravenous glucocorticoids 
should be considered for patients with visual symptoms to prevent further sight loss, and 
preservation of remaining sight. It is generally accepted that a temporal artery biopsy should 
be conducted on patients with suspected GCA to confirm diagnosis (Hassan et al., 2011). 
However, NICE do not state a gold standard method of confirming GCA diagnosis and 
recommend that any patient suspected of having GCA should be immediately referred to a 
specialist (NICE CKS, 2020). 
 
2.3.2 Classification criteria 
A common form of criteria used to distinguish GCA from other vasculitides are the American 
College of Rheumatology (ACR) classification criteria. This classification is based on the age 
of the patient, if they are newly presenting with a headache, if they have an elevated ESR, if 
they have temporal artery abnormality, and an abnormal biopsy result  (Gene G. Hunder et 
al., 1990). Whilst temporal artery biopsies reportedly have a very high specificity (proportion 
of true negatives correctly identified), of 100% (Davies & May, 2011), it has poor sensitivity 
(proportion of true positives), which has been reported as low as 39% (Chase, Patel, & 
Ramsey, 2020).  
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In the original study to develop the criterion, the authors looked at over two hundred 
patients with GCA in order to create a classification criteria for GCA compared to control 
patients with other forms of vasculitides (Gene G. Hunder et al., 1990). Patient information 
was collected, via questionnaire, from 48 hospital departments in the USA, Canada, and 
Mexico, to confirm GCA diagnosis through biopsy results, laboratory results, findings from 
physical examinations, and collate patient demographics (Bloch et al., 1990). 
Using two methods, “traditional format” (a rule that usually takes the format “if, for a given 
subject, at least X out of Y characteristics are present, then classify subject as having Z”) and 
classification trees (built through a process of binary recursive partitioning, which splits data 
into binary partitions, and iteratively repeats this step until a decision tree has been made) 
(Bloch et al., 1990), they produced a classification tool made up of 5 criteria. If a patient 
fulfilled 3 out of the 5 then they were classed as having GCA. The resulting criteria from both 
methods had sensitivity and specificity above 90%, with slightly better results from the 
classification tree (Gene G. Hunder et al., 1990).  
However, this study had a number of limitations. Only 214 patients with confirmed GCA 
were used to build and validate the tool, which is a small sample size on which to create 
classification criteria and could lead to any analysis being underpowered. The criteria have 
not been extensively validated within a vasculitides population, which it was originally 
intended for, or within a general population cohort, where it has been subsequently used 
since its development (Murchison et al., 2012). The criteria have also been used as a 
diagnostic tool which they were not developed for (Murchison et al., 2012). The tool was 
only built using samples taken from North America, thereby making its generalisability to 
European (including UK) populations unclear. It has also been more than 20 years since the 
tool was developed, making it potentially outdated. 
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Despite its limitations, it has become the most frequently used classification tool for referral 
for patients presenting with possible GCA, and has been used to inform the current UK 
guidelines on GCA diagnosis and management (Dunstan et al., 2014; NICE CKS, 2020; Abha 
G. Singh et al., 2015; Sun et al., 2016). However, with only 5 criteria on the tool, it may miss 
other common symptoms reported in GCA patients, such as weight loss, and fever (Mackie 
et al., 2020). 
 
2.3.3 Temporal artery biopsy 
Temporal artery biopsy is the currently accepted gold standard diagnostic test for GCA 
diagnosis (Chase et al., 2020; NICE, 2014). A temporal artery biopsy involves taking a sample 
of a patient’s temporal artery (Chase et al., 2020). The recommended sample length of a 
temporal artery biopsy is at least 1cm (Mackie et al., 2020). A positive biopsy sample will 
show signs of infiltration of the vessel wall by mononuclear inflammatory cells and giant cells 
(Lie, 1990; Mackie et al., 2020). 
Whilst temporal artery biopsies generally have high specificity it can have poor sensitivity, 
which has been reported to be as low as 39% (Ball, Walsh, Tang, Gohil, & Clarke, 2010; 
Davies & May, 2011; Karassa, Matsagas, Schmidt, & Ioannidis, 2005; Luqmani et al., 2016). 
Limitations of a temporal artery biopsy are that it is an invasive procedure (Davies & May, 
2011), and complications following the biopsy can arise (Chase et al., 2020). These are 
mostly common surgical complications such as bleeding, and infection of the biopsy site, but 
in rare instances can be more serious, such as permanent nerve damage to the facial nerve 





Due to the limitations and complications of temporal artery biopsy, ultrasound has recently 
been investigated as an alternative diagnostic method, with several studies advocating the 
use of an ultrasound (US) scan to diagnose GCA rather than a temporal artery biopsy. 
An initial meta-analysis found the pooled sensitivity of US to be 69% compared to biopsy, 
which was 55%, and specificity of US to be 82% compared to 94% for a biopsy (Karassa et al., 
2005). Another meta-analysis, which only included clinical trials, comparing temporal artery 
biopsy to US found the sensitivity of US versus a biopsy was 75% and the specificity was 83% 
(Ball et al., 2010). One pilot study, which included 10 patients with suspected GCA, 
conducted an US first followed by a biopsy, then measured the sensitivity and specificity of 
each method (Suelves et al., 2010). The results of this study found no false positives, and 
both sensitivity and specificity were 100% for the US. 
Following on from these initial studies the National Institute for Health Research (NIHR) 
funded a study evaluating the diagnostic performance and cost effectiveness of US in 
diagnosing patients with suspected GCA (Luqmani et al., 2016). A total of 35 secondary care 
centres across the UK were recruited for the study, and a total of 381 patients with 
suspected GCA were included in the primary analysis. The median age of the population was 
71 years, whilst 72% were female. In 70% of patients the results from the US and biopsy 
were consistent. The sensitivity of a biopsy was 39%, compared to 54% for US. However, the 
specificity of temporal artery biopsy was 100%, compared with 81% for US. The study 
concluded that US was more sensitive and cost-effective than temporal artery biopsy, but 
did highlight that a third of included patients had negative temporal artery biopsy and US 
results, but were still diagnosed with GCA based on clinical criteria such as ACR. The 
conclusions of this study support previously published literature that US is more sensitive 
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than temporal artery biopsy, correctly identifying patients with GCA more frequently than a 
biopsy; however, the specificity has consistently shown to be lower than that of a temporal 
artery biopsy (Schmidt, 2018). 
In general US has been found to have higher sensitivity, be more cost-effective, and less 
evasive than a temporal artery biopsy (Mackie et al., 2020) but the sensitivity of US 
decreases more rapidly after the initiation of glucocorticoid treatment than a temporal 
artery biopsy (Luqmani et al., 2016). However, the use of a biopsy or US is dependent on an 
initial suspicion of GCA by a healthcare professional at the primary care level. 
 
2.3.5 Diagnostic delay 
As discussed in Chapter 1 section 1.2.3, diagnostic delay has significant implications for 
patients with GCA as outcomes can be poorer and more serious including permanent visual 
loss (Ezeonyeji et al., 2011b). Due to the rarity of GCA, and the spectrum of reported early 
symptoms, patients sometimes face delays in diagnosis. Such delays in other 
rheumatological conditions, such as rheumatoid arthritis (RA), have been shown to increase 
the risk of complications (Raza et al., 2011).  
A meta-analysis aimed to pool the estimates of diagnostic delay reported in studies which 
included patients with GCA (Prior et al., 2017). They found that articles stratified GCA 
patients by cranial symptoms, defined by the presence of scalp tenderness or headache, and 
non-cranial as presenting with constitutional symptoms such as fever or anorexia. Patients 
with cranial symptoms had a diagnostic delay of 7.7 weeks from symptom onset, whilst 
those with non-cranial symptoms waited 17.6 weeks for a diagnosis. 
A delay in diagnosis is of concern considering the complications of untreated GCA. Once 
patients present to their GP with visual problems, or sight loss as a result of GCA, then it may 
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be too late as these symptoms are often irreversible. Patients with suspected GCA are also 
susceptible to stroke and aortic aneurysms (J. M. Evans, O’Fallon, & Hunder, 1995) 
Diagnostic delay can arise from multiple sources. Raza et al (2011) classified delay into four 
main areas of delay for referral to a rheumatologists for rheumatoid arthritis (Raza et al., 
2011), which translates appropriately to diagnostic delay of GCA and many other illnesses. 
Sources of delay included; time between onset of symptoms and request by a patient for 
assessment by a health care professional (HCP), time between request to see an HCP and 
attending a consultation, time between the initial HCP assessment and referral to a 
rheumatologist, and the time between referral and being assessed by a rheumatologist. 
Although there are significant variations in referral pathways for GCA across the UK 
(Helliwell et al., 2018)(Helliwell et al., 2018)(Helliwell et al., 2018)(Helliwell et al., 
2018)(Helliwell et al., 2018) given that GCA is considered a medical emergency the time 
between deciding to refer and seeing a specialist for diagnostic confirmation needs to be 
minimised, but treatment should be started immediately. An improved understanding of the 
clinical features associated with a diagnosis of GCA could therefore have a positive impact 
on reducing the delay in referral after presenting to a GP.  
Not all patients with GCA will present with the same symptoms. Reasons for delays from the 
onset of symptoms to seeking medical advice and actually seeing a GP are multifactorial. 
Symptoms such as headache and minor visual impairment, such as blurred vision are 
possibly ones that a patient would not immediately go to see their GP about. Instead they 
may self-manage the condition or make an appointment at the optician, assuming it is a 






Once a diagnosis of GCA is considered, treatment typically takes the form of Glucocorticoids. 
These are a pharmaceutical form of steroid hormone (steroids that act like hormones) and 
are used for a myriad of illnesses and are highly effective at reducing inflammation in 
immune responses (BNF, 2020). Glucocorticoids have been used to treat a number of 
diseases, such as asthma, since the 1940s. Possible adverse events encountered from short-
term use include myopathy, pancreatitis, and hypertension (Buchman, 2001). Side effects 
from long-term use can include osteoporosis, gastrointestinal disease, and ophthalmologic 
events such as glaucoma (Rice, White, Scarpati, Wan, & Nelson, 2017). Although there are 
several types of glucocorticoid, prednisolone is most commonly used to treat GCA in the UK 
(Petri et al., 2015). NICE currently recommends patients presenting without visual symptoms 
should be given 40-60mg of oral prednisolone daily, and patients with visual symptoms 
should be given a one-off dose of 60-100mg and should be seen by an ophthalmologist on 
the same day (NICE CKS, 2020). Oral prednisolone is then  tapered, ideally within 2 years of 
first GCA diagnosis (NICE, 2014). 
In recent years there has been growing concern around the long-term effects of 
glucocorticoid use in GCA patients, with a call to investigate how harmful it is (Dejaco et al., 
2017). NICE recommends to prescribe this drug to patients with suspected GCA before it has 
been confirmed by biopsy or further tests (NICE CKS, 2020). In one general population based 
study that included 4671 GCA diagnosed patients, 99.67% had been prescribed prednisolone 
(Petri et al., 2015). Glucocorticoids are thought to improve the visual symptoms commonly 
seen in patients with GCA, and when started on treatment the risk of vision loss becomes 
low (Salvarani et al., 2005). However, one study has found that it is not the dose, but the 
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time between the onset of symptoms to first treatment that is more indicative of 
improvement to visual complications (González-Gay & Pina, 2015). It should be noted that if 
total visual loss occurs in a patient then glucocorticoids will not reverse this and the aim of 
high dose glucocorticoids is to limit visual loss progression and preserve any remaining sight 
(Carlo Salvarani et al., 2008).  
Simultaneously with glucocorticoids patients are prescribed a proton pump inhibitor (PPI), 
for example omeparzole (NICE, 2014). This is because studies have found that high-dose 
steroids are associated with gastrointestinal ulcerations, and so to protect the stomach PPIs 
are prescribed (Hassan, Dasgupta and Barraclough, 2011). There have been a number of 
studies investigating the side-effects of glucocorticoid use (Buchman, 2001; McDonald et al., 
2018; Rice et al., 2017), with possible adverse effects of long-term glucocorticoid use 
including peptic ulcers, myocardial infarction, diabetes, higher risk of infections, and 
hypertension (Rice et al., 2017). For these reasons it is important to accurately and promptly 




Tocilizumab (TCZ) has been advocated by a number of trials and several studies as an 
effective treatment for GCA (J. Evans, Steel, Borg, & Dasgupta, 2016; Stone et al., 2017; 
Villiger et al., 2016; Vitiello et al., 2018). TCZ is a mono-clonal IL-6 receptor blocker that has 
shown promise in recent studies and trials in the treatment of GCA, and as an alternative to 
glucocorticoids (Ponte, Rodrigues, O’Neill, & Luqmani, 2015). 
Following on from case reports and case series, looking at a small number of patients’ 
response to TCZ (J. Evans et al., 2016; Loricera et al., 2015; S. Unizony et al., 2012), a large 
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multicentre blinded randomised trial was conducted to investigate the effect of TCZ on 
disease remission in GCA patients over 1 year (Stone et al., 2017; S. H. Unizony et al., 2013). 
Patients were allocated on a ratio of 2:1:1:1 to four groups; those receiving weekly 
tocilizumab plus a 26-week taper of prednisone (group 1), a group receiving tocilizumab 
every other week plus the 26-week prednisone taper (group 2), a third receiving a weekly 
placebo plus the 26-week prednisone taper (group 3), and a placebo group receiving a 52-
week prednisone taper (group 4) (Stone et al., 2017). The authors of the trial concluded that 
a regimen of TCZ, whether weekly or every other week, along with a prednisone taper, was 
superior to prednisone on its own (Stone et al., 2017). The proposed 2 year open-label 
follow-up of this trial, which aimed to look at long-term safety and efficiency of tocilizumab 
is completed as of 2020. In the UK, as of March 2020, NICE do not currently have TCZ on 
their guidelines for the treatment of GCA. 
 
2.5 Evidence gap 
There are two main guidelines in UK primary care for the referral and management of GCA, 
from NICE and the British Society of Rheumatology (BSR) (Mackie et al., 2020; NICE CKS, 
2020). However, identifying patients in primary care when they present with GCA remains 
challenging for GPs, and as such there remains a long diagnostic delay for this medical 
emergency. Symptoms recommended as indicators of GCA in clinical guidelines, such as 
headache and jaw claudication, are used by GPs to determine GCA diagnosis, but these are 
only found within a proportion of cases, and therefore, relying on these individual indicators 
to identify every GCA case remains problematic.  
Further research is required to determine the true extent of “classic” GCA symptoms, 
identify other symptoms, signs, comorbidities, and tests (clinical features) that could aid the 
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diagnosis of GCA in primary care, and explore how such clinical features may be co-occurring 




Chapter 3: Clinical features prior to GCA diagnosis: a systematic review and 
meta-analysis 
3.1 Chapter overview 
As reported in Chapter 2, section 2.2.2, whilst several clinical features have been suggested 
to be associated with GCA in individual studies there has been no recent systematic 
synthesis of evidence across all studies on their prevalence and association with a diagnosis 
of GCA. This chapter describes the methods and findings of a systematic review and meta-
analysis examining the prevalence and association of clinical features (i.e. symptoms, signs, 
comorbidities, and laboratory test findings) reported by patients prior to diagnosis of GCA. 
 
3.2 Introduction 
Chapter 2 highlighted that GCA can be difficult to clinically identify in primary care. This in-
part can be because there is a wide range of reported clinical features for GCA. Many of 
these, such as fever or weight loss, may be commonly seen in primary care and can be 
attributed to other more prevalent conditions. GPs may also over rely on headache as an 
indicator of GCA, with its absence excluding the illness (Helliwell et al., 2018). Such issues 
may be a reason for diagnostic delay commonly occurring in GCA populations (Prior et al., 
2017). Pooling available articles which have reported the clinical features experienced prior 
to a GCA diagnosis may aid in understanding what the most common presenting features of 
GCA are, and the extent of the role they have in any subsequent GCA diagnosis. Such 
information may contribute to greater diagnostic precision which can steer future guidelines 
for clinicians to reduce diagnostic delays, and inform future research studies. 
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Previous pooling of data on the clinical features with which GCA patients present prior to 
diagnosis, or associated with GCA diagnosis, is limited, with only one study having pooled 
available information on GCA symptoms (Smetana & Shmerling, 2002). The aim of this 
previous review was to investigate which clinical features would be predictive of a positive 
temporal artery biopsy (TAB), and therefore only articles where a TAB had been conducted 
were included. They used likelihood ratios to present their results, and found that tender 
temporal artery, weight loss, diplopia, any headache, and jaw claudication all had high 
predictive value of a positive TAB (Smetana & Shmerling, 2002). However, their review was 
conducted in 2000 was limited in the scope of its search by only using MEDLiNE and English 
language-only articles, and has not included the research into GCA conducted over the 
interceding decades. 
The aim of the review reported in this chapter was to expand on the scope of the previous 
research by also including studies performed in the 17 years since that review was 
conducted, searching more bibliographic databases, performing a search with no English-
language filter and not limiting to studies which only used temporal artery biopsy (TAB) as 
diagnostic confirmation. Whilst TAB is considered the gold standard diagnostic test for GCA 
and therefore maximising diagnostic precision of the review, it is considered to have poor 
sensitivity (Davies & May, 2011). Therefore, limiting a search to only TAB positive cases may 
limit the scope of the review, as TAB negative GCA patients would not have been included, 
potentially missing important, yet relevant findings. Although TAB is considered the gold 
standard method to confirm a diagnosis of GCA, there are studies which use recognised 
classification criteria, temporal artery ultrasound, electronic health record medical codes, 




3.3 Aims and Objectives 
The aim of this systematic review was to identify from the literature clinical features that 
were reported in patient samples prior to their diagnosis of GCA. The specific objectives 
were: 
1. To determine the prevalence of clinical features prior to GCA diagnosis. 
2. To determine the strength of association between clinical features and subsequent 




A systematic review of the current literature was conducted, with each stage including 
multiple reviewers. Articles were chosen based on pre-defined inclusion/exclusion criteria. 
Final inclusion of articles in the review were agreed by consensus and then required data 
extracted. Where possible, data was pooled using meta-analysis, followed by a meta-
regression to investigate potential reasons for heterogeneity between studies. 
 
3.4.2 Medical Databases 
The bibliographical databases searched to identify articles for inclusion were Medline, 
Embase, CinAHL, and Web of Science. These databases were searched from inception to the 
date of search, on the 4th December 2017.  
• MEDLINE: accessed via Ovid interface. This is a bibliographic database that includes 
literature published around the world from 1966 onwards. It covers a broad range of 
subject areas and has the ability to search for Medical Subject Headings (MeSH) 
terms. MeSH terms are a pre-defined list of medical labels that are used to describe 
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topics the article is linked to, used by the National Library of Medicine (Baumann, 
2016). Within the MEDLINE database articles are linked to relevant MeSH terms, 
which allows for more efficient searching, and the avoidance of spelling differences 
(Baumann, 2016). 
• Embase: accessed via Ovid interface. This biomedical, pharmacological, and 
pharmacovigilance database includes literature from 1947 onwards, and has over 32 
million records available. MeSH terms are also available to be searched, giving a 
broader range to search strategies. 
• CiNAHL: CINAHL is a nursing literature database aimed at all medical practitioners, 
but with a nursing specialities focus. With some full-text articles available as far back 
as 1937, this covers a wide range of relevant journals. 
• Web of Science: is a collation of databases that includes MEDLINE. Since MEDLINE 
was already searched separately only core databases, such as Science Citation Index 
Expanded and Social Sciences Citation Index, in Web of Science were included. There 
are more than 12,000 journals available to search through this database ranging from 
social sciences to humanities. 
These databases were searched because they were the largest and most relevant 
bibliographic databases available at the time of the review, have been used in previous 
reviews on GCA (Hill et al., 2017; Smetana & Shmerling, 2002), and effectively cover all 
aspects of GCA care and research. 
A protocol for the systematic review was created to ensure all key aspects were planned 
prior to commencement. This protocol was then internally reviewed by the host 
department’s (School of Medicine) systematic review team and once finalised was registered 
with PROSPERO (registration number: CRD42018083411) in January 2018 (Appendix 3.1). 
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PROSPERO is a database, hosted by the National Institute of Health Research (NIHR) in 
collaboration with the University of York that collates systematic reviews which have a 
health-related outcome. Systematic reviews are registered with PROSPERO at inception, or 
at the start of database searching, so as to avoid duplication between different research 
teams, and prevent reporting bias by allowing the protocol and finished review to be 
compared (University of York, 2020). 
 
3.4.3 Inclusion criteria 
To be included in the review, articles had to have: 
1. GCA diagnosis confirmed by at least one of the following methods: 
a. The American College of Rheumatology classification criteria  (Gene G. 
Hunder et al., 1990) 
b. A positive temporal artery biopsy 
c. A qualified medical expert 
d. A medical code for GCA in the patient’s record such as a Read code (a 
hierarchical structure of codes that record diagnoses, tests and other 
information regarding the patient’s record in UK primary care), or ICD-10 
code (a coding system used in UK secondary care). 
e. A patient self-reported diagnosis of GCA. 
2. Reported any clinical feature(s) with which the samples had presented pre-diagnosis 
of GCA. 
3. A report of either the prevalence of the clinical feature(s), a measure of association 
for the clinical feature with a diagnosis of GCA, or both. 
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There was no restriction on type of healthcare or study design from which samples were 
extracted. Articles could: 
1. Be conducted in primary, secondary, or tertiary care 
2. Use any of the following study designs: 
a. Cohort (when patients are selected based on exposure) 
b. Case-control (where patients are selected based on outcome) 
c. Randomised control trial (where patients with a condition are randomised to 
two or more treatment groups and followed up for a set amount of time to 
see if they improve) 
d. Cross-sectional (when patients are investigated at a specific point in time).  
Articles were not excluded based on language, with the view to translate them at full-text 
review if they were retained to that stage of the process. The translation would be 
conducted using the in-house translation services.  
 
3.4.4 Exclusion criteria 
Articles were excluded from the review based on the following specific criteria: 
1. If the study was focused on clinical features reported post-diagnosis of GCA. 
2. If the study contained no original data, i.e. literature reviews, editorials, systematic 
reviews, and meta-analysis. 
3. If the study was conducted on human tissue, such as gene research, or laboratory-
based research, or on non-human subjects. 
4. Case report, case studies, or case series. 
5. If the study was focused on evaluating or comparing a method of diagnosis, such as 
temporal artery biopsy, colour ultrasonography, etc. 
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6. If the study focused on PMR as a condition with GCA as a comorbidity. 
 
3.4.5 Search Strategy 
3.4.5.1 Initial identification of clinical features 
Prior to searching the four selected bibliographic databases, a scoping review was conducted 
on general databases, such as PubMed and Google Scholar, to identify suitable clinical 
features to build the formal search strategy for the review. This involved searching for 
general terms, such as GCA, and appraising articles that were relevant, along with their 






Table 3.1: Clinical features identified through scoping exercise. 
Clinical feature included in 
systematic review search strategy 
Reference where clinical feature identified 
PMR Smetana et al. (2002); Hassan et al. (2011); Salvarani et al. 
(2008) 
Visual disturbances - all Smetana et al. (2002); Barraclough et al (2012); Hassan et 
al. (2011); Salvarani et al (2005) 
Infections - all Russo et al (1995); Falardeau et al. (2010) 
Headache - all Smetana et al. (2002); Barraclough et al (2012); Hassan et 
al. (2011); Prior et al. (2017) 
Abnormal temporal artery/scalp 
tenderness 
Barraclough et al (2012); Yates et al. (2016); Prior et al 
(2017) 
Jaw/tongue claudication Smetana et al. (2002); Hassan et al. (2011); Barraclough et 
al. (2012); Prior et al. (2017) 
Weight loss Smetana et al. (2002); Falardeau et al. (2010); Hassan et al. 
(2011); Barraclough et al. (2012); Yates (2016) 
Fever Smetana et al. (2002); Barraclough et al. (2012) 
ESR Hassan et al. (2011); Barraclough et al. (2012) 
Cardiovascular/cerebrovascular 
conditions 
Mackie et al. (2011); Tomasson et al. (2014); Saleh et al. 
(2016) 
Diabetes Mackie et al. (2011); Falardeau et al. (2010); Saleh et al. 
(2016) 
Osteoporosis Petri et al. (2015); Sozen et al. (2017) 
VTE Saleh et al. (2016); Lin et al. (2017) 
Falls Petri et al. (2015); Al-Aama (2011) 
Asthenia Salvarani et al. (2005); Gonzalez-Gay et al. (2015) 
Musculoskeletal 
conditions/symptoms 
Falardeau et al. (2010); Petri (2015) 
Atherosclerosis Mackie et al. (2011); Saleh et al. (2016) 
Aortic aneurysm Evans et al. (1995); Dejaco et al. (2017); Falardeu et al. 
(2010) 
ESR - erythrocyte sedimentation rate; VTE - Venous thromboembolism; PMR - Polymyalgia Rheumatica; 





3.4.5.2 Development of search strategy 
MEDLINE, Embase, CiNAHL, and Web of Science were all searched. The search strategy for 
each database is outlined in Appendix 3.2. Strategies differed little between MEDLINE and 
Embase, and included MeSH terms where possible. The “explode” option for MeSH terms 
was added to the search strategy for CINAHL, where available, since this has the capability to 
search for all associated terms, such as synonyms for stroke, aortic aneurysm, and diabetes. 
The “classical” features of GCA, such as headache, PMR symptoms, and visual disturbances, 
which have been established in the literature (Dasgupta et al., 2010), were included in the 
search strategy. These were expanded to include the type of headache (temporal, frontal, 
etc.), and type of visual disturbance (complete, transient or permanent loss, blurred vision, 
etc.). 
Other features, for example, jaw claudication, scalp tenderness, fever, and weight loss were 
added based on the scoping literature search. Infections, such as urinary tract infections 
were included after being found to have been investigated in a number of studies 
(Falardeau, 2010; Russo, Waxman, Abdoh, & Serebro, 1995). There was no minimum 
number of studies in which a clinical feature was reported to warrant its inclusion in the 
search criteria. Features common in an elderly population such as falls, the wide term of 
“musculoskeletal conditions", and osteoporosis were also included. The laboratory based 
measurement ESR was also included since this has been assessed in a number of studies 
(Barraclough et al., 2012; Hassan et al., 2011). 
Titles and abstracts of articles were searched using the final search strategy. The resulting 
citations from all databases were exported and entered into Refworks (ProQuest, Version 
2018), a reference managing software system available online (ProQuest, 2020). Before title 
screening began, exact duplicates were removed using the function within Refworks, this 
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software was only used for title screening due to its superior ability to remove duplicate 
articles. Remaining articles were then moved to Mendeley (V1.17.11), a citation software 
(Elsevier, 2020), similar to Refworks, to continue the filtering process. 
 
3.4.6 Article screening process  
One reviewer (Lauren A. Barnett (LAB)) screened all titles. If an article title failed to meet any 
of the exclusion criteria it was kept for abstract review. Two reviewers (LAB and Chris 
Morton (CM)) then independently screened the remaining articles by abstract. Any article 
kept by either reviewer (LB or CM) was moved through to full-text review. These articles 
were reviewed by a single reviewer (LAB), with a third of articles completed by two 
independent reviewers (Alyshah Abdul-Sultan (AAS), and James Prior (JAP)). At full-text 
review stage, reference lists of included papers were searched by LAB for further relevant 
studies to include in the final review and analysis.  
 
3.4.7 Quality assessment 
It is important to assess the quality of articles included in any systematic review (Moher et 
al., 1999). Systematic reviews should always aim to reduce bias of the eventual conclusions 
by reviewing literature in a systematic and logical way (Moja et al., 2005). Conducting a 
quality assessment on individual studies included in a systematic review indicates how 
strong the conclusions of that study are (Seehra, Pandis, Koletsi, & Fleming, 2016). 
To assess the quality of the studies included in this review, the Newcastle-Ottowa (N-O) 
scale for cohort, and case-control studies was used. Any cross-sectional studies were 




 Each question on the Newcastle-Ottowa scale is given a star rating dependent upon the 
answers, for both the cohort and case-control studies. For instance the “Representativeness 
of cohort” question in the cohort scale has four possible answers; “truly”, “somewhat”, “of 
selected group of users”, or “no description”. Stars are only allocated to the “truly” and 
“somewhat” answer categories. Articles of cohort studies which received between zero and 
one star (out of a maximum of seven stars) were rated as poor quality. Articles which had 
two or three stars were fair quality, and articles which had three stars or more were good 
quality. For the case-control studies zero or one star defined poor quality, two stars indicate 
fair quality, and three or four stars indicate good quality (Wells et al., 2019).  
For trials that reached the full text review stage, the Cochrane Collaboration tool for 
assessing bias would be used. This is a tool developed in 2008 and updated in 2011 that 
assesses the risk of bias in randomised controlled-trials based on seven criteria (Jørgensen et 
al., 2016). Quality assessment of all included studies was conducted by LAB. 
 
3.4.8 Data extraction 
Data extraction from included studies was conducted by LAB based on a created data 
extraction form (Appendix 3.3, Table 1). This was used to collect information on study 
setting, country and continent of study origin, gender distribution of study population, 
method of GCA diagnosis, length of retrospective/prospective follow-up, reported clinical 
feature, duration of clinical feature prior to diagnosis, the percentage of confirmed GCA 
patients reporting features (i.e. prevalence) and any estimate of association reported 
(derived from raw data, or a reported unadjusted or adjusted estimate). If any required data 
was not reported in the articles, then the corresponding author was contacted and asked to 
share the appropriate data. Where the prevalence was already reported in an article, this 
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was used as the estimate. Where it was not stated in the article, the proportion of patients 
in the study population who reported the clinical feature prior to their GCA diagnosis (n) and 
the total study population (N) was extracted from each article. The prevalence estimates 
were calculated by n/N. The number of patients with GCA and who did (a) and did not (c) 
experience the clinical feature, and non-GCA patients who did (b) and did not (d), was 
extracted and the risk estimate (unadjusted odds ratio) was calculated by ad/bc for all 
relevant articles. 
 
3.4.9 Narrative synthesis 
A narrative synthesis was conducted on the articles included in the final review. A narrative 
synthesis is a method of summarising and synthesising data from a review using text. It is 
predominately used prior to a meta-analysis, or in lieu of one when there is not sufficient 
studies or data to complete a formal quantitative analysis. Study characteristics were 
compared and critically appraised. These clinical features were synthesised, with the sample 
size, study quality, setting, and estimates associated with the clinical feature compared 
between included articles. The design of the study was reported, along with the type of 
diagnosis of GCA used in the article. Any possible differences in estimate size or direction of 
association between articles was also discussed. 
Clinical features which affected the same biological system were grouped together where 
numbers of articles were low, for ease of comparison. Visual symptoms included all 
variations of sight loss (transient, permanent, etc.), double vision, blurred vision, and field 
loss. Cardiovascular/cerebrovascular diseases included: arterial hypertension and coronary 
artery disease, myocardial infarction, stroke, atrial fibrillation, transient ischaemic attacks, 
and congestive heart failure. Systemic/constitutional symptoms were defined as one or 
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more of fatigue, fever, weight loss, night sweats, dizziness, anorexia, malaise, and asthenia. 
Mental health manifestations included psychiatric disorders (undefined), dementia, and 
mental deterioration. Anorexia was interpreted as loss of appetite, so as to separate it from 
weight loss. 
Originally reported values which pertained to the presence or absence of a clinical feature 
were retained, where stated in an article (e.g. the presence of a fever determined by a 
temperature above 38 degrees Celsius). 
 
3.4.10 Meta-analysis 
There are two possible methods of meta-analysis available; fixed effect and random effect. 
In recent years, random effect meta-analyses have been recommended as generally the 
most appropriate (Riley, Higgins, & Deeks, 2011). A random effects meta-analysis assumes 
that effect size (for example, odds ratio relating to association of a clinical feature with GCA) 
varies between studies due to reasons other than chance, as opposed to fixed effects meta-
analysis which assumes any differences in effect size between studies is entirely due to 
chance (Riley et al., 2011). Heterogeneity in effect size may occur because of differences in 
demographics, sample size, study design, or follow-up time, between studies. In the case of 
fixed-effects meta-analysis, since it assumes the effect size is the same, from the largest to 
the smallest study, it tends to assign a smaller weight to the small studies since the same 
study information about the effect size can be found in the larger studies (Borenstein, 
Hedges, Higgins, & Rothstein, 2010). In the random-effects models the weight of each study 
is determined by the within-study variance (Borenstein et al., 2010). Often, fixed-effects 
meta-analysis is not plausible as all studies will not have the same underlying effect size, due 
to factors such as study design rather than chance (Borenstein et al., 2010). The 
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interpretation of differences between fixed and random effects meta-analysis is that in fixed 
effects the meta-analysis provides the best estimate of an effect that is assumed to be 
constant across all studies. However, in random effects meta-analysis the results show the 
average effect from the distribution of effects across all studies (Riley et al., 2011). 
Random-effects meta-analyses were conducted on the prevalence and association data for 
each reported clinical feature. The Freeman-Tukey double arcsine method is recommended 
to transform the prevalence estimates reported in studies with small sample sizes prior to 
conducting a meta-analysis. This method normalises the variance and sampling distribution 
of the prevalence estimates (Freeman & Tukey, 1950), the estimate is then back transformed 
(Miller, 1978). 
For the meta-analyses pooling estimates of association, only the articles that had a control 
population could be included. Controls were defined to be either the general population 
without disease, or temporal artery biopsy-negative patients. Odds ratios were calculated 
from the raw data (for example, biopsy positive, biopsy negative, clinical feature present, 
and clinical feature not present) irrespective of if the article reported one. Only unadjusted 
odds ratios were extracted since covariates were not consistent across all articles or not 
stated in the methods. Articles that only examined GCA positive cases could not be included 
in this meta-analysis since there was no comparison, or “control” group, where the risk 
estimate could be calculated. 
Meta-analysis has heterogeneity, relating to the uniformity between data, typically between 
the effect sizes of each article (Sedgwick, 2015). There are commonly two sources of 
variability that would explain heterogeneity (Huedo-Medina, Sanchez-Meca, Marin-
Martinez, & Botella, 2006). The first is “within-study” variability, defined as variability due to 
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sampling error, and the other is “between-study” variability, defined as differences in effect-
sizes between studies (Huedo-Medina et al., 2006). 
Heterogeneity of the prevalence estimates and estimates of association was reported using 
the I2 statistic and the τ2 statistic. The I2 is the proportion of variation between the estimates 
that is due to variability among studies, rather than sampling error (Huedo-Medina et al., 




     (1) 
 
Where: 






Assuming there are k studies, wi is the weight of study i (i = 1...k), and yi is the effect size in 
that study. I2 takes values between 0% and 100%, with general categorical cut-offs at 25% 
for low, 50% for moderate, and 75% for high heterogeneity (Sedgwick, 2015). An advantage 
of I2 is that it is not reliant on the number of studies included in the meta-analysis, unlike 
other available measures of heterogeneity (Sedgwick, 2015). However, I2 increases as the 
precision, proportional to the sample size, of the studies included in the meta-analysis 
increase. This can be illustrated in the interpretation of I2. Since it is the amount of 
heterogeneity due to between-study variability, its inverse 1-I2 is the variability due to 
sampling error. As the sampling error becomes smaller, I2 becomes larger (Rücker, 
Schwarzer, Carpenter, & Schumacher, 2008). Therefore, I2 increases as the sample size of 
included studies increases, and hence has its limitations as a measure of true heterogeneity. 

















Q is Cochrane’s Q-statistic defined as above, k is the number of studies in a meta-analysis, 
and wi is the weight of study i (i = 1,…k). This measure does not increase with the number of 
studies in the meta-analysis, or the precision of the studies (Rücker et al., 2008), therefore it 
is a more stable estimate of heterogeneity than I2. It can take values from 0 to ∞, and the 
larger the value it takes the more heterogeneity is present in the meta-analysis. There is 
currently no recommended cut-off value for high heterogeneity for τ2. Both I2 and τ2will be 
reported in this review. 
There will be variability around the pooled estimates from the meta-analysis. This will be 
illustrated using 95% confidence intervals, and 95% prediction intervals. The confidence 
interval gives a range of values where the true estimate (prevalence or risk) can lie (Riley et 
al., 2011). The wider the confidence interval, the greater the uncertainty surrounding the 
estimate. 
However, prediction intervals have been advocated for reporting in systematic reviews in 
addition to confidence intervals (Riley et al., 2011). These can give a range where the 
predicted estimate of a new study is likely to lie rather than a range where the current 
estimate can lie. This future study would have to be of a similar design to the ones used in 
the meta-analysis for the predicted range to be valid (Higgins, Thompson, & Spiegelhalter, 
2009). Despite the usefulness of prediction intervals they are rarely reported in published 
meta-analyses, which instead choose confidence intervals which are more frequently 
reported in published articles (Riley et al., 2011). For this reason both the confidence 




Pooled estimates, measures of heterogeneity, confidence intervals, and prediction intervals 
were all calculated and added to a forest plot. A forest plot is a method of visualising the 
individual study and pooled estimates from a meta-analysis.  
As data on both the prevalence and association of a clinical feature was extracted through 
the systematic review, one meta-analysis pooled together the prevalence estimates in the 
study population, and another pooled the estimates of association for each clinical feature.  
Meta-analysis was not conducted on clinical features reported in less than three articles. 
Currently, there is no set guidance about the minimal number of articles that should be 
included in a meta-analysis, but three is the recommended minimum required to calculate a 
prediction interval (Riley et al., 2011), and a previously published systematic review and 
meta-analysis on diagnostic delay in GCA also used three as the minimum number of articles 
for a meta-analysis (Prior et al., 2017). 
Random-effects meta-analyses were conducted on the data for each reported clinical 
feature, and where possible, further stratified by the point at which the feature was 
recorded prior to GCA diagnosis (for example recording when GCA was diagnosed, when 
temporal artery biopsy was taken, when patient was referred for GCA). This review aimed to 
find clinical features that were indicative of a GCA diagnosis. The association between a 
clinical feature and a GCA diagnosis may differ depending on when the clinical feature was 
recorded, i.e. at diagnosis, or 3 months prior. Hence why the subgroup analysis, stratified by 
point at which clinical feature was recorded, was conducted. All analyses were conducted 





Meta-regression can be used to investigate the cause of any amount of heterogeneity in a 
pooled analysis, but it is more efficiently used in the cases where there are large amounts of 
heterogeneity that may be caused by multiple variables (Thompson & Higgins, 2002). When 
there were ten or more articles reporting prevalence of the clinical feature or the association 
of the clinical feature and a diagnosis of GCA, and there was heterogeneity over 80% 
(Thompson & Higgins, 2002) in the estimates, a meta-regression was conducted on available 
data to further investigate the cause of any heterogeneity.  
A meta-regression is a form of modelling that attempts to explain the heterogeneity 
observed between studies included in a meta-analysis (Thompson & Higgins, 2002). It is 
conducted on article-level data, as opposed to regression analyses which are conducted on 
patient-level data (Thompson & Higgins, 2002). The independent variables of the models 
performed in this review were the study characteristics, and the outcome variable is the 
effect size measured for the meta-analysis, in this case prevalence or estimate of association 
of the clinical feature (Israel & Richter, 2011). To compare the fit of models including 
different covariates, the coefficient of determination (R2) was reported. The R2 value is a 
model fit statistic that explains how much variation in the data that the fitted model 
explains, and is mainly used to identify models with good fit (Asuero, Sayago, & González, 
2006), taking values from 0% to 100%. The higher the percentage the better the model fit. 
Data extracted from the articles included in the review were used as the independent 
variables in the meta-regression analysis. There were no a priori hypotheses about the 
source of heterogeneity prior to the analysis, hence all extracted variables from the review 
were used as covariates. Only articles where the clinical features had been recorded at 
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diagnosis/TAB were included in the meta-regression, since the scoping search suggested this 
would be the largest group. The variables that were included in the meta-regression were: 
1. Continent of study origin - a categorical variable; divided into Americas (reference 
category), Europe, and Other (Africa, Oceania, and Asia).  
2. Study quality – based on the Newcastle-Ottowa scale categorised into the 3 levels 
defined by the authors who developed the tool (Wells et al., 2019), good (reference 
category), fair, and poor. 
3. Study design – categorised into 2 levels (originally 4 to include trials and crossover 
studies); case-control (reference category) and cohort. 
4. Proportion of females in the study population – a continuous variable indicating the 
percentage of patients in the study population that were female. 
5. Year of publication – a categorical variable with 3 levels; 1970-2000 (reference 
category), 2001-2010, and 2011-present. 
6. Mean age – a continuous variable. 
7. Method of GCA diagnosis – categorised into 4 levels, TAB (reference category), ACR, 
ACR/TAB, and “other”. “Other” included criteria that was not ACR/TAB, or medical 
codes such as ICD-10. 
A univariable model was fitted initially for each independent variable. The covariates from 
the univariable models with the largest R2 value were then added together to a multivariable 





3.5.1 Database searches 
A total of 10,192 articles were identified in the initial search; 2611 duplicates were identified 
and removed, resulting in 7581 unique titles for review. 6992 articles were excluded through 
title screening as they did not meet the inclusion criteria, leaving 589 abstracts for review. Of 
these, 66 could not be sourced (due to the journals in which they were published having no 
archive access), 262 were excluded due to study design, and 171 did not meet the inclusion 
criteria detailed in section 3.4.3. A total of 90 articles were identified for full-text review. Of 
the 90 full-text articles that were reviewed independently, 4 were found to be duplicates, 7 
were unavailable as full-text articles (because no UK library could access a copy), and 41 did 
not meet the inclusion criteria, leaving 38 articles. A further 5 studies were added after a 
manual reference list search of the 38 articles, giving a total of 43 studies (35 reporting 
prevalence estimates, and 18 reporting association estimates) included in the systematic 

























3.5.2 General characteristics of included articles 
Articles included in the review were published between 1979 and 2017 ( 
Table 3.2). The most common study design was cohort (n = 38), whilst the remaining studies 
were case-control design (n = 5). No cross-sectional studies or trials were identified. Cohorts 
were either retrospective (89.5%) or prospective (10.5%). In the case of retrospective articles 
these were usually conducted by a medical record review in one or more secondary/tertiary 
care departments. In these instances, authors determine patients who had been diagnosed 
with GCA within a certain time-period and extract healthcare data from their records and 
report what clinical features they had presented with prior to diagnosis. In the case of 
prospective cohorts, the authors would determine patients who had been diagnosed with 
GCA within a certain time period and summarise the clinical features they had reported at 
their diagnosis before following the patient’s forwards. 
Three articles were based in the UK. The most common country of sample origin was the 
USA (n = 14), followed by Spain (n = 6). Only one article included in the review required 
translation as this was written in Spanish (Rivero Puente et al., 2001). Only one article in this 
review used a national electronic health records (EHR) database (Unizony et al., 2017), the 
rest were record reviews conducted in secondary/tertiary care departments.  
The minimum overall sample size (all subjects recruited to the study, regardless of GCA 
status) was 22 (Espitia et al., 2012), whilst the maximum was 6414 (Unizony et al., 2017). The 
median sample size was 116. The period in which cases were identified varied between 
studies, with the shortest being during a 6 month period (Fainaru, Friedman, & Friedman, 
1979), and the longest was a population cohort where cases were identified from 1950 to 
2004 (Abha G. Singh et al., 2015). 
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The highest proportion of female patients in the study samples was 82% (Alba, Mena-
Madrazo, Reyes, & FloresSuarez, 2011), whilst the lowest was 50% (Sun et al., 2016). There 
were six articles that reported no information on the proportion of females in the study 
sample. Age of the samples was similar between studies, with most articles reporting on 
patients aged over 50 years. The highest mean age reported was 76.1 years (Garrity et al., 
2017), whilst the lowest was 66.4 years (Sun et al., 2016). Eleven articles did not report the 
age of the study sample. 
 
3.5.3 Quality assessment 
The majority of the articles included were of fair quality (n = 27). Only 2 articles were of poor 
quality (Rivero Puente et al., 2001; Sun et al., 2016). The remaining articles were of good 
quality. The elements of the N-O scale where these articles rated poorly were 
representativeness of cohort, and selection of comparison group. Neither article had a 
comparison group since all patients included had been diagnosed with GCA. Both articles 







Table 3.2: Extracted information for all articles in the review. 




Length of  
sampling 
period (years) 











Alba 2011 Retrospective 
cohort 
Mexico Fair Secondary ACR/TAB 21 At diagnosis/TAB 22 82.0 73.0 57-84 
Chmelewski 1992 Retrospective 
cohort 
USA Fair Secondary TAB 5 At diagnosis/TAB 98 68.4 73.1 56-93 
de Boysson 2016 Retrospective 
cohort 
France Good Secondary ACR criteria 10 At diagnosis/TAB 143 66.0 NA 50-86 
Desmet 1990 Retrospective 
cohort 
Belgium Fair Secondary clinical or 
histological 
6 At referral to 
secondary care 
82 73.5 70.0 60-99 
Duhaut 1999 Prospective 
cohort 
France Good Secondary ACR & TAB 6 At diagnosis/TAB 292 72.9 74.9 NA 




Fair Pathology lab TAB 19 At diagnosis/TAB 314 72.0 NA NA 
El-Dairi 2015 Retrospective 
cohort 
USA Fair Secondary TAB 9 At diagnosis/TAB 204 71.0 75.0 54-90 
England 2017 Retrospective 
cohort 





8 At diagnosis/TAB 5942 NA NA NA 
Espitia 2012 Retrospective 
cohort 
France Fair Secondary TAB & ACR 13 At diagnosis/TAB 22 NA NA NA 
Ezeonyeji 2010 Retrospective 
cohort 
UK Fair Medical records Rheumatologist 5 average 35 days 65 NA NA NA 
Fainaru 1979 Retrospective 
cohort 
Israel Fair Secondary TAB 0.5 At diagnosis/TAB 47 55.3 69.4 60-84 
Gabriel 1995 Prospective 
cohort 
USA Fair Secondary TAB 3 At diagnosis/TAB 525 64.0 72.5 NA 
Garrity 2017 Retrospective 
cohort 
USA Fair Any TAB 10 At diagnosis/TAB 32 69.0 72.6 46-91 
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Garrity 2017 Retrospective 
cohort 
USA Good Any TAB 10 At diagnosis/TAB 84 71.0 76.1 57-93 
Gonzalez 1989 Retrospective 
cohort 
USA Fair Secondary TAB & defined 
criteria 
10 At diagnosis/TAB 27 77.8 NA NA 
Gonzalez-Gay 2001 Retrospective 
cohort 
Spain Fair Secondary TAB 17 At diagnosis/TAB 190 50.9 74.8 NA 




Fair Secondary TAB 15 At diagnosis/TAB 320 61.9 74.2 NA 
Gonzalez-Gay 2005 Retrospective 
cohort 
Spain Good Secondary TAB 23 At diagnosis/TAB 240 54.2 75.0 NA 
Gonzalez-
Lopez 
2013 Case-control Spain Good Secondary TAB 9 At diagnosis/TAB 335 65.7 74.2 NA 
Grossman 2016 Retrospective 
cohort 
Israel Fair Medical centre TAB 14 At diagnosis/TAB 224 66.0 73.0 NA 
Haugeberg 2000 Retrospective 
cohort 
Norway Fair Secondary ICD codes & TAB 4 At diagnosis/TAB 53 71.7 72.7 NA 
Hayreh 1997 Prospective 
cohort 
USA Good Any TAB 21 At referral to 
secondary care 
363 66.1 72.0 20-95 
Kermani 2012 Retrospective 
cohort 
USA Fair Secondary TAB 8 At diagnosis/TAB 764 73.4 74.5 NA 
Khalifa 2009 Retrospective 
cohort 
Tunisia Fair Secondary ACR/TAB 17 At diagnosis/TAB 96 53.0 70.8 50-91 
Kobayashi 2003 Questionnaire Japan Good Secondary ACR 1 At onset of illness 66 63.6 72.5 49-92 
Lugo 2011 Retrospective 
cohort 
USA Good Secondary TAB 7 At diagnosis/TAB 138 76.0 74.0 NA 
Machado 1988 Prospective 
cohort 
USA Good Medical records TAB, and other 
criteria 
35 At diagnosis/TAB 94 NA NA NA 
Mari 2009 Retrospective 
cohort 
Spain Fair Secondary TAB 18 At diagnosis/TAB 278 65.1 74.8 59-89 
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Mohamed 2002 Retrospective 
cohort 
UK Fair Secondary TAB 9 At diagnosis/TAB 51 71.0 69.5 19-85 
Myklebust 1996 Prospective 
cohort 
Norway Fair Secondary ACR 7 At diagnosis/TAB 335 74.4 70.4 NA 
Narveaz 2003 Retrospective 
cohort 
Spain Fair Secondary ACR/TAB 14 At diagnosis/TAB 73 67.0 72.0 51-89 
Nesher 1996 Retrospective 
cohort 
Israel Good Secondary ACR 12 At diagnosis/TAB 91 66.0 NA 60-80 
Pugnet 2015 Case-control France Poor Medical records ICD-10 code 6 >1 month before 
diagnosis 
103 77.7 74.8 51-91 
Rivero-Puente 2001 Retrospective 
cohort 
Spain Good Secondary TAB 9 At diagnosis/TAB 57 52.6 72.7 56-85 
Roth 1984 Retrospective 
cohort 
USA Fair Secondary TAB 16 At diagnosis/TAB 51 71.0 76.1 61-97 
Russo 1995 Case-control USA Fair Medical records TAB NA average 60 days 200 81.0 70.5 48-88 
Salvarani 1999 Secondary 
analysis 
USA Fair Any ACR criteria/TAB 41 >2 months before 
diagnosis 
128 NA NA NA 
Silva de Souza 2013 Retrospective 
cohort 
Brazil Fair Tertiary ACR 1 At onset of illness 45 64.4 NA NA 
Singh 2015 Retrospective 
cohort 
USA Good Medical records ACR 54 At diagnosis/TAB 204 80.0 76.0 NA 




Poor Secondary TAB 4 At diagnosis/TAB 75 79.0 NA 50-88 
Sun 2016 Retrospective 
cohort 
China Fair Secondary ACR criteria/TAB 22 At diagnosis/TAB 70 50.0 66.4 NA 
Toren 2016 Prospective 
cohort 
Canada Good Secondary TAB 3 At diagnosis/TAB 250 70.0 73.7 58-95 
Unizony 2017 Retrospective 
cohort 
UK Fair Medical records GCA code & 
 steroid  
prescription code 
23 ≤12 months 
before diagnosis 
6414 70.0 73.0 NA 
Zenone 2013 Prospective 
cohort 
France Fair Secondary ACR 11 At referral to 
secondary care 
88 67.0 74.9 59-92 
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3.5.3.1 Definition of a GCA diagnosis 
Almost half of the articles used temporal artery biopsy (TAB) as the method of GCA diagnosis 
(n = 21), followed by the ACR classification (n = 6). Articles that were published prior to 1990, 
when the ACR classification criteria were published, often created their own criteria for 
study inclusion, which were generally similar to the ACR criteria (n=7).  
3.5.3.2 Duration of clinical features prior to diagnosis 
The majority of articles did not state the duration of clinical features reported by patients 
prior to a GCA diagnosis. Only 5 articles reported length of exposure period, and all differed. 
Two articles reported average durations of 35 days and 2 months prior. The remaining three 
included features that had been experienced by patients for more than 1 month prior, more 
than 2 months prior, and less than or equal to 12 months prior.  
Thirty-three articles recorded features present at diagnosis or at temporal artery biopsy, and 
gave no further information on duration. Information on clinical features was taken from 
internal medical records. Three articles recorded patient features at time of referral to 
secondary care, but no further information was available as to how long a patient waited to 
be seen in secondary care. The remaining two articles contained features that were present 
at disease onset, with no information on how long this time was before diagnosis. 
3.5.3.3 Clinical features examined in included studies  
A total of 50 different clinical features, which GCA patients presented with before GCA 
diagnosis, were examined in these studies. The clinical features most frequently examined in 
studies were headache (n = 35), jaw claudication (n = 32) and PMR (n = 32). All articles 
reporting headache gave the proportion of patients presenting with overall or general 
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headache of recent onset, whilst one also gave numbers for more specified types, such as 
temporal and occipital (Souza et al., 2013). Visual impairment (excluding diplopia, which was 
reported in eight articles hence enough for a separate meta-analysis) was reported in 31 
articles. However, the majority of these articles simply defined this as visual impairment, 
disorders, symptoms, disturbances, or manifestations, with little detail about what these 
included.  
Some studies did include detail about cut-offs used to define clinical features. Elevated ESR 
(n = 8) was defined as >50 mm/h in four articles (El-Dairi et al., 2015; Marí et al., 2009; 
Mohamed & Bates, 2002; Rivero Puente et al., 2001), >40 mm/h in one article (E. B. V 
Machado et al., 1987),  >100 mm/h in one article (Chmelewski et al., 1992), and was 
undefined in two articles (T.A. Kermani et al., 2012; Toren et al., 2016). Where weight loss 
pre-GCA diagnosis was examined (n = 17), only four articles actually defined a value for 
weight loss. Three defined it as >10% loss within six months (Alba et al., 2011; Duhaut, 
Pinède, et al., 1999; A.G Singh et al., 2015) and one article (Desmet et al., 1990) defined it as 
>2kg loss in two weeks, or >5kg loss over no specified time period. Fever (n = 26) was 
defined in two articles as >38 degrees Celsius (Gabriel et al., 1995; M.A. Gonzalez-Gay et al., 
2005). One article defined it as >100 degrees Fahrenheit (Abha G. Singh et al., 2015). The 
remaining articles did not define a cut-off value for fever. 
 
3.5.4 Infrequently reported clinical features  
Cancer was only reported in two articles (Table 3.3). The two articles (Pugnet et al., 2015; 
Unizony et al., 2017) reporting cancer found that 9.7% and 12.6% of GCA patients 
respectively had (unspecified) cancer prior to their diagnosis. The article by Pugnet et al. 
(2015), conducted in France, included 103 GCA cases compared to 606 controls taken from 
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the general population. This case-control study used data from the French National Health 
Insurance (FNHIS) database (Pugnet et al., 2015). This covers more than 95% of the French 
population, hence the population in this study is likely to be generalizable. Unizony et al. 
(2017) used the Health Improvement Network (THIN) for their study which includes medical 
records for 10.2 million patients in the UK (Unizony et al., 2017). They used a matched 
cohort with cases having new-onset GCA each matched to 10 controls taken from the rest of 
the population, and with no diagnosis of GCA. This study included 6414 cases of GCA and 
was rated “Good” on the quality scale. 
An article by Russo et al. (1995) reported different infections in patients up to four months 
prior to their diagnosis of GCA (Russo et al., 1995). Three other articles also reported 
infections, but due to none reporting the same infection this was not included in the meta-
analyses reported below. Russo’s findings for any infection in GCA patients prior to their 
diagnosis, which included any of the 13 infections investigated, was 63.0% of patients. The 
most commonly reported infection in this sample was urinary tract. Gabriel et al. (1995) 
reported 5.8% of GCA patients had been diagnosed with synovitis prior to their diagnosis, 
recorded at the time of diagnosis (Gabriel et al., 1995). England et al. (2017) found that the 
uncomplicated strain of herpes zoster was more prevalent than the complicated strain, but 
was only found in 3.0% of patients prior to a diagnosis of GCA, recorded at the time of 
diagnosis (England et al., 2017). 
Night sweats were reported in two articles (Haugeberg, Paulsen, & Bie, 2000; Myklebust, 
Gran, & G., 1996), both conducted in Norway. Myklebust et al. (1996) conducted a 
prospective cohort study in south Norway, following patients until cessation of treatment for 
GCA. Only histologically proven cases of GCA were included in the study. A total of 39 
patients were found to have GCA, of which 74.4% were female. Of the 39 patients included 
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in the study, 10 reported night sweats prior to a diagnosis of GCA (Myklebust et al., 1996). 
Haugeberg et al. (2000) used secondary care medical records (hospital records and a biopsy 
database) to identify GCA patients over a period of 4 years in southern Norway. The final 
sample size of GCA patients was 53, of which only four of these had reported night sweats 




Table 3.3: Clinical features of GCA prior to a diagnosis, reported in 2 articles or less. 












Asthenia Duhaut 1999 207 171 82.61 
Asthenia Sun 2016 70 33 47.14 
Aortitis Zenone 2013 88 5 5.68 
Appetite loss Dunstan 2014 88 37 42.05 
Associated malignancy Gonzalez 1989 10 2 20.00 
Arthritis Stuart 1989 14 1 7.14 
Arthritis (Rheumatoid) Salvarani 1999 30 6 20.00 
Cranial manifestations (headaches, 
scalp tenderness, jaw claudication, 
ophthalmologic symptoms) 
de Boysson 2016 143 112 78.32 
Central retinal artery occlusion Garrity 2017 116 16 13.79 
Cancer Unizony 2017 6414 810 12.63 
Cancer Pugnet 2015 103 10 9.71 
Chronic kidney disease Unizony 2017 6414 583 9.09 
Chronic obstructive pulmonary 
disease 
Unizony 2017 6414 498 7.76 
Claudication on mastication, 
deglutition 
Kobayashi 2003 65 2 3.08 
Claudication (masseter) Fainaru 1979 47 10 21.28 




2001 57 14 24.56 
Dental abscess Russo 1995 100 3 3.00 
Deafness Khalifa 2009 96 1 1.04 
Dizziness Haugeberg 2000 53 2 3.77 
Dysphagia Gonzalez-Gay 2005 240 12 5.00 
Dysphagia Kobayashi 2003 66 1 1.52 
Dyspnoea Desmet 1990 34 6 17.65 
Dyslipidaemia de Boysson 2016 143 37 25.87 
Ear/nose/throat symptoms Desmet 1990 34 11 32.35 
Eye pain Garrity 2017 116 16 13.79 
Extracranial vessel involvement Silva de 
Souza 
2013 45 8 17.78 
Extracranial manifestations de Boysson 2016 143 68 47.55 
Facial pain Machado 1988 94 13 13.83 
Facial pain Alba 2011 11 5 45.45 
Fracture or trauma Unizony 2017 6414 126 1.96 
Herpes Zoster (uncomplicated) England 2017 5942 177 2.98 
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Herpes Zoster (complicated) England 2017 5942 59 0.99 
Hypercholesterolemia Espitia 2012 22 5 22.73 
Hypertension - systolic (>160 
mm/Hg) 
Kobayashi 2003 60 8 13.33 
Inflammatory bowel disease Unizony 2017 6414 81 1.26 
Ischemic complications (Severe 
permanent cranial) 
Alba 2011 11 3 27.27 
Ischemic manifestations -severe  Sun 2016 70 29 41.43 
Ischemic optic neuropathy - 
posterior  
Garrity 2017 116 8 6.90 
Ischemic stroke Zenone 2013 88 5 5.68 
Ischaemic attacks - transient Sun 2016 70 1 1.43 
Ischaemic stroke Gonzalez-
Lopez 
2013 81 1 1.23 
Infection - synovitis Gabriel 1995 172 10 5.81 
Infection - endocarditis Kobayashi 2003 55 1 1.82 
Infection - any  Russo 1995 100 63 63.00 
Infection - amebiasis Russo 1995 100 1 1.00 
Infection - bacterial endocarditis Russo 1995 100 1 1.00 
Infection - bronchitis Russo 1995 100 1 1.00 
Infection - cellulitis Russo 1995 100 1 1.00 
Infection - diverticulitis Russo 1995 100 1 1.00 
Infection - otitis media Russo 1995 100 1 1.00 
Infection - upper respiratory tract Russo 1995 100 4 4.00 
Infection - pneumonia Russo 1995 100 4 4.00 
Infection - viral illness Russo 1995 100 4 4.00 
Infection - pharyngitis Russo 1995 100 7 7.00 
Infection - sinusitis Russo 1995 100 8 8.00 
Infection - urinary tract Russo 1995 100 23 23.00 
Loss of hearing Fainaru 1979 47 8 17.02 
Loss of appetite Myklebust 1996 39 5 12.82 
Lower limb arterial thrombosis Khalifa 2009 96 1 1.04 
Lung diseases Pugnet 2015 103 1 0.97 
Muscle atrophy Kobayashi 2003 57 1 1.75 
Night sweats Myklebust 1996 39 10 25.64 
Night sweats Haugeberg 2000 53 4 7.55 
Neck pain Garrity 2017 101 20 19.80 
Neck pain Heyreh 1997 106 17 16.04 
Oedema (facial/swelling) Duhaut 1999 207 9 4.35 
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Oedema Kobayashi 2003 57 1 1.75 
Optic nerve atrophy Kobayashi 2003 66 5 7.58 
Pain in temporal artery region Kobayashi 2003 65 38 58.46 




2013 81 42 51.85 
Peripheral artery disease Unizony 2017 6414 317 4.94 
Pulmonary symptoms Desmet 1990 34 12 35.29 
Respiratory symptoms Machado 1988 94 22 23.40 
Skeletal and muscle manifestation Kobayashi 2003 66 13 19.70 
Submandibular glands Russo 1995 100 2 2.00 
Systematic arteritis Gonzalez 1989 10 2 20.00 
Taste changes Myklebust 1996 39 4 10.26 
Temporal tenderness (on exam) Singh 2015 204 52 25.49 
Temporal tenderness Mohamed 2002 17 11 64.71 
Temporal artery tenderness Roth 1984 18 1 5.56 
Temporal artery prominence Gonzalez 1989 10 5 50.00 
Temporal cutaneous hyperalgesia Gonzalez-
Lopez 
2013 81 40 49.38 
Varicose vein Unizony 2017 6414 715 11.15 







3.5.5 Meta-analysis  
There were 30 clinical features across 43 articles that were eligible for meta-analysis, 35 for 
prevalence, and 18 for association. The overall pooled prevalence estimates were 
determined from 30 individual meta-analyses, each examining the prevalence of a clinical 
feature experienced prior to GCA diagnosis. Prevalence of symptoms, signs, and laboratory 
tests reported prior to a diagnosis of GCA are reported here separately from comorbidities 
and are summarised in forest plots found in Appendix 3.4, Figures 1 – 29. Findings from the 
meta-analyses are presented in detail below, and summarised in Table 3.4 for the 
prevalence of all clinical features, and Table 3.5 for the associations. 
The clinical features with the largest prevalence were headache, elevated ESR, and 
constitutional/systemic symptoms. Clinical features with the lowest prevalence were 
cerebrovascular accidents, psychological conditions, and limb claudication. Clinical features 
with the strongest association with GCA confirmed through a positive temporal artery biopsy 
were jaw claudication, elevated ESR, and anorexia. Clinical features with the weakest 
associations were fever, PMR, and any visual symptoms. 
Subgroup analysis for prevalence, stratified by point at which clinical features were 
reported, was conducted for 13 clinical features (Appendix 3.5, Table 1). The largest 
subgroup was at diagnosis/TAB, where the clinical features were recorded at or prior to the 
patient’s diagnosis of GCA. Meta-regression were conducted only on clinical features with 
sufficient articles for prevalence (Appendix 3.6, Table 1). No estimate of association for any 
clinical feature was reported in enough articles to conduct a meta-regression. The 
association (odds ratio) between clinical features and a subsequent diagnosis of GCA are 




Table 3.4: Pooled prevalence estimates of reported clinical features. 
Clinical feature N Pooled 
prevalence (%) 
95% CI 95% PI I2 
(%) 
τ2 
Headache 35 77 (72%, 82%) (47%, 97%) 89.2 0.02 
Elevated ESR (>50 
mm/h) 
8 76 (59%, 90%) (25%, 100%) 94.5 0.06 
Constitutional/systemic 
symptoms 
15 62 (48%, 74%) (14%, 98%) 96.4 0.06 
Abnormal temporal 
artery 
30 54 (42%, 65%) (9%, 95%) 95.8 0.06 
Fatigue 7 45 (32%, 57%) (15%, 77%) 89.2 0.02 
Any visual impairment 31 44 (34%, 53% (3%, 90%) 95.8 0.07 
Anorexia 9 37 (25%, 50%) (6%, 76%) 91.6 0.03 
Jaw Claudication 32 36 (31%, 41%) (14%, 61%) 84.9 0.02 
Neurological conditions 5 35 (9%, 67%) (0%, 98%) 95.9 0.12 
PMR 32 34 (29%, 39%) (12%, 61%) 86.7 0.02 
Malaise 6 34 (20%, 50%) (5%, 72%) 90.7 0.03 
Scalp tenderness 17 34 (26%, 42%) (9%, 65%) 90.6 0.02 
Weight loss 17 34 (28%, 41%) (13%, 60%) 83.5 0.02 
Ischaemic optic 
neuropathy 
6 32 (11%, 58%) (0%, 92%) 96.3 0.10 
Arthralgia 3 31 (21%, 43%) (21%, 43%) 0.0 0.00 
Hypertension 3 31 (10%, 58%) (0%, 82%) 97.8 0.06 
Fever 26 30 (23%, 37%) (4%, 65%) 91.3 0.03 
Smoking 4 28 (11%, 48%) (1%, 71%) 94.7 0.04 
Cardiovascular diseases 3 28 (4%, 61%) (0%, 88%) 96.5 0.08 
Myalgia 5 26 (11%, 43%) (0%, 66%) 88.2 0.03 
Peripheral arthritis 3 19 (0%, 56%) (0%, 88%) 96.3 0.11 
Ophthalmic symptoms 3 19 (10%, 30%) (5%, 39%) 68.9 0.08 
Ocular symptoms 4 18 (7%, 33%) (0%, 51%) 83.2 0.02 
Anaemia 3 18 (10%, 27%) (7%, 32%) 49.9 0.04 
Amaurosis Fugax 5 16 (6%, 30%) (0%, 50%) 84.6 0.03 
Cough 4 13 (3%, 28%) (0%, 49%) 91.1 0.03 
Diabetes 4 13 (4%, 24%) (0%, 40%) 93.2 0.02 
Diplopia 8 6 (5%, 8%) (5%, 8%) 0.0 0.00 
Cerebrovascular 
accidents 
6 7 (2%, 13%) (0%, 26%) 92.7 0.02 
Psychological 
conditions 
4 5 (1%, 12%) (0%, 19%) 72.4 0.01 




Table 3.5: Pooled associations of symptoms with GCA diagnosis. 
Clinical feature N Pooled Odds Ratios 95% CI 95% PI I2 (%) τ2 
Jaw claudication 13 4.84 (3.55, 6.58) (2.50, 9.37) 32.0 0.09 
Elevated ESR 7 2.22 (1.71, 2.87) (1.47, 3.34) 21.7 0.03 
Anorexia 4 2.00 (1.41, 2.83) (1.41, 2.83) 0.0 0.00 
Constitutional 
symptoms 
6 1.94 (0.96, 3.92) (0.41, 9.26) 75.8 0.51 
Headache 14 1.75 (1.16, 2.62) (0.50, 6.06) 72.4 0.04 
Scalp tenderness 4 1.63 (0.99, 2.66) (0.99, 2.66) 0.0 0.00 
Abnormal Temporal 
artery 
8 1.43 (0.58, 3.55) (0.12, 17.44) 90.2 1.41 
Malaise 3 1.34 (0.87, 2.05) (0.87, 2.05) 0.0 0.00 
Myalgia 4 1.27 (0.83, 1.96) (0.83, 1.96) 0.0 0.00 
Fever 7 1.25 (0.92, 1.72) (0.79. 1.99) 16.6 0.03 
PMR 11 1.07 (0.84, 1.36) (0.84, 1.36) 0.0 0.00 
Any visual symptoms 14 0.97 (0.63, 1.48) (0.26, 3.58) 71.6 0.40 
Ocular symptoms 3 0.74 (0.45, 1.20) (0.45, 1.20) 0.0 0.00 





Headache was assessed in 35 articles included in this study (Table 3.4), and was the most 
reported clinical feature in this systematic review. It had the highest overall pooled 
prevalence of 77% (95% CI: 77%, 82%; 95% PI: 47%, 97%). Heterogeneity was high with an I2 
of 89.2% (τ2 = 0.02). 
The meta-analysis on the prevalence of headache (Figure 3.2) contained four subgroups, 
based on the point at which headache was recorded prior to a diagnosis of GCA, these 
included; at diagnosis/TAB (n = 29), at referral to secondary care (n = 3), at disease onset (n = 
2), and average 35 days prior (n = 1). The pooled prevalence for at diagnosis/TAB was 78% 
(95% CI: 72%, 83%), which is similar to the overall estimate for all subgroups (77%). All 
remaining subgroups (at referral, at disease onset and 35 days prior groups) were too small 
to conduct a subgroup analysis, containing two, two, and one article, respectively. 
The heterogeneity for headache prevalence was high so a meta-regression was conducted. 
The covariate that explained most of the heterogeneity between studies was year of 
publication. In papers published between 2001 and 2010 the prevalence for headache was 
15.8% higher than for papers published between 1970 and 2000. This was a statistically 
significant result. Whereas papers published between 2011 and present had a non-
statistically significant decrease in prevalence of 5.6% compared to papers published in 
1970-2000. Categorised year of publication explained 37.6% of the heterogeneity.  
The other statistically significant result for this analysis was continent of origin. Articles from 
Europe had a 12.6% increase in prevalence of headache than those conducted in the 
Americas. The multivariable model, fitted with year of publication and continent of origin, 




Fourteen articles reported an odds ratio estimate of the association between headache and 
subsequent GCA (Table 3.5 & Figure 3.3). The pooled OR was 1.75 (95% CI: 1.16, 2.62; 95% 
PI: 0.50, 6.06) indicating that patients reporting a headache had 1.75 times higher odds of a 
subsequent GCA diagnosis. Heterogeneity was high with an I2 of 72.4% (τ2 = 0.04). Thirteen 
articles that reported an odds ratio recorded a headache at the time of diagnosis/temporal 






Figure 3.2: Forest plot for prevalence of Headache meta-analysis showing number of GCA cases in study (n), total sample size (N), mean 




Figure 3.3: Forest plot of meta-analysis of association of headache and a diagnosis of GCA. Showing; diagnosis status (GCA+, GCA-), clinical feature present 




3.5.5.2 Elevated ESR 
Elevated ESR was assessed in eight of the articles included in this review, with an overall 
pooled prevalence of 76% (95% CI: 59%, 90%; 25%, 100%). Heterogeneity was high with an I2 
of 94.5% (τ2 = 0.06). A forest plot can be seen in Appendix 3.5, Figure 1. 
Elevated ESR was recorded at diagnosis/TAB in all included articles. There were three articles 
where the prevalence estimate differed considerably from the overall pooled result found in 
the meta-analysis. An older study, Machado et al (1988), found the prevalence of elevated 
ESR amongst GCA patients was 97%. Chmelewski (1992) and Toren (2016) reported the 
prevalence of elevated ESR in their study populations as 40% and 49%, respectively. Due to 
there being fewer than 10 articles reporting elevated ESR, a meta-regression could not be 
conducted.  
An odds ratio was reported in seven articles, with a pooled odds ratio of 2.22 (95% CI: 1.71, 
2.87); 95% PI: 1.47, 3.34) suggesting a strong association between elevated ESR and GCA. 
Patients with elevated ESR have more than 2 times higher odds of a subsequent GCA 
diagnosis. Heterogeneity for this meta-analysis was low, with an I2 of 21.7 (τ2 = 0.03). All 
seven articles recorded elevated ESR at the time of diagnosis/temporal artery biopsy. A 
forest plot can be seen in Appendix 3.7, Figure 1. 
3.5.5.3 Constitutional/Systemic symptoms 
Constitutional/systemic symptoms were reported in 15 articles, with an overall pooled 
prevalence of 62% (95% CI: 48%, 74%; 95% PI: 14%, 98%). Heterogeneity was high, with an I2 
of 96.4% (τ2 = 0.06) (Appendix 3.5, Figure 2). The majority of articles (80%) recorded 
constitutional/systemic symptoms at diagnosis/TAB. The pooled prevalence estimate for this 
subgroup was 62% (95% CI: 48%, 75%). One article recorded these symptoms at referral 
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(Desmet et al., 1990), one at disease onset (Silva de Souza et al., 2013), and the final study 
on average 35 days prior to a diagnosis of GCA (Ezeonyeji et al., 2011b). 
There were enough articles to conduct a meta-regression. The three variables that explained 
most of the heterogeneity in prevalence were continent, proportion of females, and year of 
publication. Prevalence of constitutional/systemic symptoms was 48.1% higher in Europe 
than America, and 46.5% higher in other parts of the world than America, these were 
statistically significant results. The prevalence of constitutional/systemic symptoms was 
44.9% lower in articles published from 2011-present than those published between 1970 
and 2000, again this was statistically significant. As the proportion of females in the study 
sample increased by 1%, the prevalence of constitutional/systemic symptoms increased 
significantly by 1.2%. 
The multivariable model with continent, year of publication, and proportion of females 
explained 96.5% of the total heterogeneity. Articles published between 2001 and 2011 had 
an adjusted 31.7% lower prevalence of constitutional/systemic symptoms, and articles 
published between 2011 and present had 46.0% lower prevalence than articles published 
between 1970 and 2000, which were statistically significant. Proportions of females in the 
study sample was the only non-significant variable. The prevalence of 
constitutional/systemic symptoms was an adjusted 60.1% higher in Europe, and 69.1% 
higher in other countries than in America. These were statistically significant. 
An odds ratio of constitutional/systemic symptoms was reported in six articles. The overall 
pooled odds ratio was 1.94 (95% CI: 0.96, 3.92; 95% PI: 0.41, 9.26), indicating an association, 
which is not statistically significant, between constitutional/systemic symptoms and GCA. 
Heterogeneity was high, with an I2 of 75.8% (τ2 = 0.51). Five articles recorded 
constitutional/systemic symptoms at the time of diagnosis/temporal artery biopsy. The 
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remaining article (Hayreh et al., 1997) recorded constitutional/systemic symptoms at the 
time of referral. A forest plot can be seen in Appendix 3.7, Figure 2. 
3.5.5.4 Abnormal Temporal Artery 
Abnormal temporal artery (defined as tenderness, swelling, prominence, or pulsating) was 
recorded in twenty articles. The overall pooled prevalence was 54% (95% CI: 42%, 65%; 95% 
PI: 9%, 95%). Heterogeneity was high, with an I2 of 95.8% (τ2 = 0.06). A forest plot can be 
seen in Appendix 3.5, Figure 3. 
There were two subgroups of time of feature recording. Three articles recorded features at 
referral (Desmet et al., 1990; Hayreh et al., 1997; Zenone & Puget, 2013), whilst the 
remaining articles recorded features at diagnosis/TAB. The pooled prevalence of the “at 
referral” subgroup was 27% (95% CI: 17%, 39%), and 58% (95% CI: 46%, 70%) for the at 
diagnosis/TAB subgroup. 
There were sufficient articles in the “at diagnosis/TAB” subgroup to conduct a meta-
regression to investigate the high heterogeneity. The covariate that explained the most 
heterogeneity in the univariable model was year of publication. Articles published between 
2001 and 2010 had 29.2% higher prevalence of abnormal temporal artery than those 
published between 1970 and 2000. This was statistically significant. Overall year of 
publication explained 46.2% of the total heterogeneity. When added to a multivariable 
model, along with continent, studies published between 2001 and 2010 had an adjusted 
21.9% higher prevalence of abnormal temporal artery than those published between 1970 
and 2000. However, year of publication was no longer statistically significant. The 




An odds ratio was reported in eight of the articles relating to the presence of an abnormal 
temporal artery prior to GCA diagnosis. The overall pooled OR was 1.43 (95% CI: 0.58, 3.55; 
95% PI: 0.12, 17.44) suggesting an association between abnormal temporal artery and a GCA 
diagnosis. Patients with an abnormal temporal artery have 1.43 times higher odds of a GCA 
diagnosis. Heterogeneity was high with an I2 of 90.2% (τ2 = 1.41). Seven of the articles 
recorded abnormal temporal artery at diagnosis/temporal artery biopsy. The remaining 
article (Hayreh et al., 1997) recorded abnormal temporal artery at the time of referral. A 
forest plot can be seen in Appendix 3.7, Figure 3. 
3.5.5.5 Fatigue 
Fatigue was reported in seven articles included in the review. The overall pooled prevalence 
was 45% (95% CI: 32%, 57%; 95% PI: 15%, 77%). Heterogeneity was high with an I2 of 89.2% 
(τ2 = 0.02). A forest plot can be seen in Appendix 3.5, Figure 4. 
All but one article reported fatigue at diagnosis/TAB (Desmet et al., 1990). The article by 
Desmet et al (1990) reported fatigue at referral to secondary care. It did not state the length 
of time between being referred and being diagnosed with GCA. This article was conducted in 
Belgium and rated as being of good quality on the Newcastle-Ottowa scale. They confirmed 
GCA diagnosis by temporal artery biopsy and found a total of 34 GCA cases. The prevalence 
of fatigue in this sample of patients was reported to be 79%, higher than the overall pooled 





3.5.5.6 Visual impairment 
Visual impairment was reported in thirty-one articles. Visual impairment included any type 
of visual condition, such as blindness and blurred vision. The overall pooled prevalence was 
44% (95% CI: 34%, 53%; 95% PI: 3%, 90%). Heterogeneity was high with an I2 of 95.8% (τ2 = 
0.07). A forest plot can be seen in Appendix 3.5, Figure 5. 
In the univariable model of the meta-regression, year of publication explained most of the 
heterogeneity (37.6%). Articles published between 2001 and 2010 had 15.8% higher 
prevalence of visual impairment than articles published between 1970 and 2000, this was a 
statistically significant result. However, when added to a multivariable model with continent 
and study quality, this model only explained 27.1% of the heterogeneity. 
An odds ratio for visual impairment was reported in fourteen articles. The overall pooled 
odds ratio was 0.97 (95% CI: 0.63, 1.48; 95% PI: 0.26, 3.58) indicating no association with 
GCA diagnosis. Heterogeneity was high with an I2 of 71.6% (τ2 = 0.07). All fourteen articles 
recorded visual impairment at the time of diagnosis/temporal artery biopsy. A forest plot 
can be seen in Appendix 3.7, Figure 4. 
3.5.5.7 Anorexia 
Anorexia (interpreted as loss of appetite in this systematic review) was reported in nine 
articles. The overall pooled prevalence was 37% (95% CI: 25%, 50%; 95% PI: 6%, 76%). 
Heterogeneity was high with an I2 of 91.6% (τ2 = 0.03). A forest plot can be seen in Appendix 
3.5, Figure 5. 
There were two articles that differed considerably from the pooled estimate. Desmet et al 
(1990) reported the prevalence of anorexia in their study as 74%. This was a single-centre 
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cohort study conducted in Belgium that was rated good on the Newcastle-Ottowa scale and 
recruited 34 patients with a positive temporal artery biopsy. 
The second outlier was a cohort study conducted in the USA (T.A. Kermani et al., 2012). The 
article reviewed the records of patients who had undergone a temporal artery biopsy using 
the Mayo clinic database. Of the 177 patients who had a positive temporal artery biopsy the 
prevalence of anorexia in this population was reported to be 11%. 
An odds ratio for anorexia was reported in four articles. The overall pooled odds ratio was 
2.00 (95% CI: 1.41, 2.83; 95% PI: 1.41, 2.83) indicating that patients with anorexia have two 
times higher odds of a GCA diagnosis. Heterogeneity was low, with an I2 of 0.0% (τ2 = 0.00). A 
forest plot can be seen in Appendix 3.7, Figure 5. Three articles recorded anorexia at 
diagnosis/temporal artery biopsy, whilst the remaining article (Hayreh et al., 1997) recorded 
it at the time of referral. 
3.5.5.8 Jaw claudication 
Thirty-two articles reported jaw claudication. The overall pooled prevalence was 36% (95% 
CI: 31%, 41%; 95% PI: 14%, 61%). Heterogeneity was high with an I2 of 84.9% (τ2 = 0.02). A 
forest plot can be seen in (Figure 3.4). 
The majority of articles recorded jaw claudication at diagnosis/TAB (26 studies), enough to 
conduct a meta-regression. The univariable model that explained most of the heterogeneity 
(37.5%) was type of diagnosis. Patients diagnosed using the ACR criteria had 6.4% higher 
prevalence of jaw claudication than those diagnosed using TAB; however, this was not 
statistically significant. The only statistically significant relationship was the 29.5% lower 
prevalence of jaw claudication in those diagnosed by other means compared to a TAB. Type 
of diagnosis was added to a multivariable model with mean age, which explained 14.2% of 
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the heterogeneity in the univariable model. The multivariable model explained 72.7% of the 
heterogeneity. Only the association between other methods of diagnosis and the prevalence 
of jaw claudication was statistically significant. Those diagnosed with other means had an 
adjusted 27.9% lower prevalence of jaw claudication than those diagnosed using TAB. 
Thirteen articles recorded an odds ratio of jaw claudication. The overall pooled OR was 4.84 
(95% CI: 3.55, 6.58; 95% PI: 2.50, 9.37), the largest pooled odds ratio found in the association 
meta-analysis. Heterogeneity was low/moderate with an I2 of 32.0% (τ2 = 0.09). A forest plot 
can be seen in Appendix 3.7, Figure 6. Twelve articles recorded jaw claudication at the time 
of diagnosis/temporal artery biopsy. The remaining article (Hayreh et al., 1997) recorded it 







Figure 3.4: Forest plot for prevalence of jaw claudication meta-analysis showing number of GCA cases in study (n), total sample size (N), 




3.5.5.9 Neurological conditions 
Four articles included in the review reported neurological conditions. The overall pooled 
prevalence was 35% (95% CI: 9%, 67%; 95% PI: 0%, 98%). Heterogeneity was high, with an I2 
of 95.9% (τ2 = 0.12). A forest plot can be seen in Appendix 3.5, Figure 8. 
Three of the five articles (Chmelewski et al., 1992; Khalifa et al., 2009; Mohamed & Bates, 
2002) recorded neurological conditions at the time of diagnosis/TAB, whilst the remaining 2 
(Kobayashi et al., 2003; Souza et al., 2013) recorded them at disease onset. 
Kobayashi et al (2003), a cohort study conducted in Japan, reported the prevalence of 
neurological conditions in their population of 66 confirmed GCA cases as 78%. This article 
did not define what neurological conditions were included. No articles assessed the 
association between neurological conditions and a diagnosis of GCA. 
3.5.5.10 PMR 
Thirty-two studies reported on PMR prior to GCA diagnosis. The pooled prevalence of PMR 
was 34% (95% CI: 29%, 39%; 95% PI: 12%, 61%). Heterogeneity was high, with an I2 of 86.7% 
(τ2 = 0.02). A forest plot can be seen in Appendix 3.5, Figure 9. 
Twenty-seven articles reported PMR at diagnosis/TAB. One (C. Salvarani & Hunder, 1999) 
recorded clinical features a median of 30 months prior to a diagnosis of GCA. One (Desmet 
et al., 1990) recorded PMR at the time of referral to secondary care, without stating how 
long before diagnosis this period was. Two (Kobayashi et al., 2003; Silva de Souza et al., 
2013) recorded PMR at the time of disease onset, but did not define how long this was prior 
to a diagnosis of GCA. One (Ezeonyeji, Borg, & Dasgupta, 2011a) recorded clinical features 
with a reported average of 35 days prior to a diagnosis of GCA. 
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There was high heterogeneity in the prevalence meta-analysis and enough articles to 
conduct a meta-regression. In the univariable models, the covariate that explained the 
largest amount of heterogeneity was year of publication (19.4%); however, only one level of 
this variable was statistically significant. Articles published between 2011 and 2017 had 
14.9% lower prevalence of PMR than those published prior to 2000. There were two other 
covariates in the model that explained a proportion of the heterogeneity; continent (12.3%), 
and proportion of females (1.6% per 1% increase in proportion of females). This model 
explained 54.0% of the heterogeneity. Statistically significant results showed that articles 
published in other continents had an adjusted 22.8% higher prevalence of PMR than those 
published in the Americas, the prevalence of PMR increased by 0.5% with every increase in 
1% of population who were female, and articles published from 2011-2017 had 16.9% lower 
adjusted prevalence of PMR than those published prior to 2000. 
Eleven articles reported an odds ratio for PMR. The overall pooled OR was 1.07 (95% CI: 
0.84, 1.36; 95% PI: 0.84, 1.36) suggesting no association of PMR with GCA. Heterogeneity 
was low, with an I2 of 0.0% (τ2 = 0.00). A forest plot can be seen in Appendix 3.7, Figure 7. All 
articles recorded PMR at the time of diagnosis/temporal artery biopsy. 
3.5.5.11 Malaise 
Six articles included in this review reported their findings on malaise (general discomfort, 
weakness, or not feeling well). The overall pooled prevalence was 34% (95% CI: 20%, 50%; 
95% PI: 5%, 72%). Heterogeneity was high, with an I2 of 90.7% (τ2 = 0.03). A forest plot can 
be seen in Appendix 3.5, Figure 10. 
Five articles recorded malaise at the time of diagnosis/TAB, whilst the remaining one 
(Hayreh et al., 1997) recorded it at the time of referral to secondary care, without defining 
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how long this period was. All but two articles (Duhaut, Pinède, et al., 1999; Dunstan et al., 
2014) showed a prevalence of malaise between 30% and 40%. Dunstan et al (2014) 
conducted a cohort study in South Australia that was rated as fair on the Newcastle-Ottowa 
scale. The method of GCA diagnosis used in the study was a temporal artery biopsy, and 
malaise was recorded at the time of diagnosis/TAB. The article found 314 biopsy-proven 
cases of GCA, 59% of which recorded malaise as a symptom prior to their diagnosis of GCA. 
Duhaut et al (1999) conducted a cohort study in France, which was rated as fair on the 
Newcastle-Ottowa scale. They identified GCA patients using a combination of a variation of 
the ACR criteria and a positive temporal artery biopsy and recorded clinical features at the 
time of diagnosis/TAB. This article included information on 207 biopsy-proven GCA cases, 
72.9% were female and the mean age was 74.9 years. The reported prevalence of malaise in 
this study population was 11%, lower than the overall pooled prevalence of 34%. 
Three articles reported an odds ratio for malaise. The overall pooled OR was 1.34 (95% CI: 
0.87, 2.05; 95% PI: 0.87, 2.05) indicating a (non-statistically significant) association between 
malaise and a GCA diagnosis. Heterogeneity was low, with an I2 of 0.0% (τ2 = 0.00). A forest 
plot can be seen in Appendix 3.7, Figure 8. Two articles recorded malaise at the time of 
diagnosis/temporal artery biopsy, whilst the remaining article recorded it at the time of 
referral (Hayreh et al., 1997). 
3.5.5.12 Scalp tenderness 
Seventeen articles included scalp tenderness as a clinical feature for assessment. The overall 
pooled prevalence of scalp tenderness was 34% (95% CI: 26%, 42%; 95% PI: 9%, 65%) and 
heterogeneity was high, with an I2 of 90.6% (τ2 = 0.02). A forest plot can be seen in Appendix 
3.5, Figure 11. 
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All but three articles recorded this symptom at diagnosis/TAB. One (Hayreh et al., 1997) 
recorded it at referral to secondary care. One (Kobayashi et al., 2003) recorded it at disease 
onset. The remaining article (Ezeonyeji et al., 2011a) recorded clinical features with a mean 
of 35 days prior to the date of GCA diagnosis. 
A meta-regression model was fitted to the data. The univariable model that explained the 
largest amount of heterogeneity was type of diagnosis (51.0%). The only statistically 
significant result showed that studies which used other methods of diagnosing GCA had 42% 
lower prevalence of scalp tenderness than articles that used a temporal artery biopsy. The 
other univariable model that explained the most heterogeneity was study quality, and these 
variables were all added into the multivariable model. This model explained 70.6% of the 
heterogeneity. The statistically significant results showed that articles of fair quality had 
17.8% lower adjusted prevalence of scalp tenderness than those of good quality, and articles 
that used other means of GCA diagnosis had 37% lower adjusted prevalence of scalp 
tenderness than those that used a temporal artery biopsy. 
An odds ratio of scalp tenderness was reported in four articles. The overall pooled OR was 
1.63 (95% CI: 0.99, 2.66; 95% PI: 0.99, 2.66). Heterogeneity was low, with an I2 of 0.0% (τ2 = 
0.00). A forest plot can be seen in Appendix 3.7, Figure 9. Only one article did not record 
scalp tenderness at the time of diagnosis/temporal artery biopsy. Instead it recorded scalp 




3.5.5.13 Weight loss 
Seventeen articles reported weight loss as a clinical feature. The overall pooled prevalence 
was 34% (95% CI: 28%, 41%; 95% PI: 13%, 60%). Heterogeneity was high, with an I2 of 83.5% 
(τ2 = 0.02). A forest plot can be seen in Appendix 3.5, Figure 12. 
All but three of the articles recorded weight loss at the time of diagnosis/TAB. One article 
(Desmet et al., 1990) recorded this symptom at the time of referral to secondary care. Two 
articles (Kobayashi et al., 2003; Silva de Souza et al., 2013) recorded weight loss at disease 
onset. 
There were enough articles that recorded weight loss at diagnosis/TAB to conduct a meta-
regression. In the univariable model the covariate that explained the largest amount of 
heterogeneity was mean age (100.0%). With every year increase in mean age there was a 
2.5% decrease in the prevalence of weight loss, this was a statistically significant result. 
Other variables that explained some of the heterogeneity in univariable models were 
proportion of females in the study sample (44.2%) and continent (33.9%). However, when 
these were added into the multivariable model they did not explain as much of the 
heterogeneity as the univariable model containing mean age. No articles reported the 
association between weight loss and GCA. 
3.5.5.14 Ischaemic optic neuropathy  
Ischaemic optic neuropathy (ION) was reported in six articles. The overall pooled prevalence 
was 32% (95% CI: 11%, 58%; 95% PI: 0%, 92%). Heterogeneity was high with an I2 of 96.3% 
(τ2 = 0.10). A forest plot can be seen in Appendix 3.5, Figure 13. 
Half of the articles (Garrity et al., 2017; Gonzalez-Lopez et al., 2013; Roth, Milsow, & Keltner, 
1984) recorded ischaemic optic neuropathy at the time of diagnosis/TAB. Two articles 
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(Kobayashi et al., 2003; Silva de Souza et al., 2013) recorded the symptom at disease onset. 
The final article (Zenone & Puget, 2013) recorded it at referral to secondary care. 
Two articles (Garrity et al., 2017; Silva de Souza et al., 2013) had a higher reported 
prevalence than the overall pooled result at 69% and 76% respectively. Silva de Souza et al 
(2013) used the ACR criteria to identify patients with GCA, along with two other articles 
(Kobayashi et al., 2003; Zenone & Puget, 2013), which reported the prevalence as 16% and 
15% respectively. None of the six articles were conducted in the same country. Garrity et al 
(2017) recorded ION at the time of diagnosis; however, two other articles (Gonzalez-Lopez et 
al., 2013; Roth et al., 1984) also recorded it at the same time and reported the prevalence as 
12% and 15% respectively. There is no apparent explanation as to why Silva de Souza et al’s 
(2013) article and Garrity et al’s (2017) reported high prevalence of ION. 
The study by Gonzalez-Lopez et al (2013) was the only case-control study to report ION. They 
found that patients with ION had 1.67 times higher odds of being diagnosed with GCA than 
controls who had no history of GCA. However, this relationship was not statistically 
significant (95% CI: 0.79, 3.50).  
3.5.5.15 Arthralgia 
Arthralgia (joint pain) was one of the least reported clinical features in this review, reported 
in three articles. The overall pooled prevalence in these three articles was 31% (95% CI: 21%, 
43%; 95% PI: 21%, 43%). Heterogeneity was low, with an I2 of 0.0% (τ2 = 0.00). A forest plot 
can be seen in Appendix 3.5, Figure 14. 
All articles recorded arthralgia at the time of diagnosis/TAB. Two articles (Gonzalez, Varner, 
Lisse, Collins, & Daniels, 1986; Roth et al., 1984) were cohort studies conducted in the USA, 
and used a positive temporal artery biopsy to identify patients with GCA. The final article 
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(Fainaru et al., 1979) was a cohort study conducted in Israel and also used a positive 
temporal artery biopsy to identify GCA patients. This article was the only one to be rated as 
poor on the Newcastle-Ottowa scale, whilst the remaining two (Gonzalez et al., 1986; Roth 
et al., 1984) were rated as good. Article sample sizes varied from 10 to 47, whilst the 
prevalence estimates ranged from 22% to 50%. Gonzalez et al (1986) had the smallest 
sample size and reported the largest prevalence of 50%.  
3.5.5.16 Hypertension 
Three articles included in this review reported hypertension as a clinical feature. The overall 
pooled prevalence was 31% (95% CI: 10%, 58%; 95% PI: 0%, 82%). Heterogeneity was high, 
with an I2 of 97.8% (τ2 = 0.06). A forest plot can be seen in Appendix 3.5, Figure 15. 
Prevalence varied across the three studies. Two were conducted in Europe,  France and the 
UK (de Boysson et al., 2016; Unizony et al., 2017). Unizony et al (2017) used electronic health 
records (EHR) from the UK based health research network, THIN, whilst de Boysson et al 
(2016) used the medical records from three university hospitals in France. Unizony et al 
(2017) used medical Read codes and a record of a prescription for glucocorticoids to define 
GCA cases, whereas de Boysson et al (2016) used the ACR criteria. The reported prevalence 
of hypertension in their study samples was similar, with Unizony et al (2017) finding it 
recorded in 42% of their sample, whilst de Boysson et al (2016) recorded it in 46%. 
Kobayashi et al (2003) was an outlier to these and reported the prevalence of hypertension 
as 9%. This article had the smallest sample size, reporting their findings on 60 GCA cases 
identified using the ACR criteria. This difference in prevalence could be due to the overall 
prevalence of hypertension in the Asian population, reported to be less than the prevalence 




Fever was reported in twenty-six articles included in this review. The overall pooled 
prevalence was 30% (95% CI: 23%, 37%; 95% PI: 4%, 65%). Heterogeneity was high, with an 
I2 of 91.3% (τ2 = 0.03). A forest plot can be seen in Appendix 3.5, Figure 16. 
Two articles (Desmet et al., 1990; Hayreh et al., 1997) recorded fever at the time of referral 
to secondary care, whilst two articles (Kobayashi et al., 2003; Silva de Souza et al., 2013) 
recorded fever at disease onset. The remaining 22 articles reported fever at the time of 
diagnosis/TAB.  
There was enough articles to conduct a meta-regression and in the univariable models, the 
covariate that explained the most heterogeneity was the mean age of the study sample 
(24.9%). With every year increase in the mean age there was a 3.6% statistically significant 
decrease in the prevalence of fever. Continent of origin explained 10.9% of the 
heterogeneity. If an article was conducted in “other” continents there was a 20.5% increase 
in the prevalence of fever compared with articles conducted in the Americas. As the 
proportion of females in the study sample increased by 1%, there was a 0.5% statistically 
significant decrease in the prevalence of fever. The final model included mean age and 
continent of origin, which explained 67.4% of the heterogeneity. The only statistically 
significant covariate was if an article was conducted in other continents they had 59.4% 
lower adjusted prevalence of fever than articles conducted in the Americas. 
Seven articles reported the odds ratio of fever, six of which recorded fever at the time of 
diagnosis/TAB. The remaining article recorded fever at the time of referral (Hayreh et al., 
1997). The overall pooled odds ratio was 1.25 (95% CI: 0.92, 1.72; 95% PI: 0.79. 1.99), 
indicating that patients who present with fever as a symptom have 25% higher odds of a 
positive temporal artery biopsy than those who do not. However, this was not a statistically 
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significant finding. Heterogeneity was low, with an I2 of 16.6% (τ2 = 0.03). A forest plot can 
be seen in Appendix 3.7, Figure 10. 
3.5.5.18 Cardiovascular diseases  
Three articles reported findings on cardiovascular diseases. The overall pooled prevalence 
was 28% (95% CI: 4%, 61%; 95% PI: 0%, 88%). There was a high level of heterogeneity 
between articles, with an I2 of 88.2% (τ2 = 0.08). A forest plot can be seen in Appendix 3.5, 
Figure 17. 
Two articles (Espitia et al., 2012; A.G Singh et al., 2015) recorded cardiovascular diseases at 
the time of diagnosis/TAB, with the remaining article (Pugnet et al., 2015) recording clinical 
features that had occurred between 1 and 12 months prior to a diagnosis of GCA.  
Espitia et al (2012) conducted secondary analysis of a cohort study in France that 
consecutively recruited 22 GCA patients over 18 months. To be diagnosed with GCA, patients 
had to have a positive temporal artery biopsy and satisfy 3 of the 5 ACR criteria. The article 
did not report the mean age of the sample or the gender distribution, and reported 
cardiovascular diseases in 63% of patients. Singh et al (2015) conducted a record review of 
all patients diagnosed with GCA between 1950 and 2004 in a single county, Minnesota, USA, 
by using the medical record linkage system available in the county. To be classed as having 
GCA, patients had to satisfy the ACR criteria. The mean age of the sample was 76 years, and 
80% were female. Coronary artery disease was recorded at diagnosis in 20% of the GCA 
patients.  
Pugnet et al (2015) conducted a case-control study in France using the French National 
Health Insurance system (FNHIS). GCA patients had to be 50 years of age or over, have an 
ICD-10 code for GCA in their record, and have at least one prescription of a glucocorticoid. 
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To be eligible as controls, patients could not have a history of GCA, PMR or vasculitis. Cases 
were matched with controls on a ratio of 1:6 on age, sex, and calendar year of diagnosis. 
Clinical features were reported if they had been in a patient’s record between 1 and 12 
months prior to their date of GCA diagnosis. This article did not define cardiovascular 
disease, and reported how many patients had “cardiovascular diseases” in their record. This 
article reported findings on 103 patients with GCA, with mean age of 75 years and 78% 
female. The prevalence of cardiovascular diseases in this sample was 11%. 
Two of the articles (Espitia et al., 2012; Pugnet et al., 2015) were conducted in France, but 
reported vastly different prevalence estimates of cardiovascular diseases in patients with 
GCA. This could be due to a number of factors since country of origin was the only similarity 
between the two articles. They used different methods of classifying GCA patients (the ACR 
criteria and ICD-10 codes), and had differing, but small sample sizes (22 GCA patients and 
103 GCA patients,). It is not possible to compare the study samples further as Espitia et al 
(2012) did not report sample characteristics in their article. Singh et al (2015) reported a 
similar estimate of cardiovascular disease to Pugnet et al (2015) (20% and 11%, respectively), 
and was the only article that reported cardiovascular diseases outside of Europe. 
3.5.5.19 Myalgia 
Myalgia was reported in five articles included in this review. The overall pooled prevalence 
was 26% (95% CI: 11%, 43%; 95% PI: 0%, 66%). Heterogeneity was high with an I2 of 88.2% 
(τ2 = 0.03). A forest plot can be seen in Appendix 3.5, Figure 18. 
All but one of the articles recorded clinical features at the time of diagnosis/temporal artery 
biopsy, with Hayreh et al (1997) recording myalgia at the time of referral to secondary care. 
Rivero-Puente et al (2001) conducted a cohort study in Spain. To be classified as having GCA, 
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patients had to have a positive temporal artery biopsy. A total of 57 patients were diagnosed 
with GCA, the mean age of the sample was 73 years, and 53% were female. The reported 
prevalence of myalgia in the study sample was 10%. Garrity et al (2017) conducted a cohort 
study in the USA and included data from 30 healthcare institutions. To be classified as having 
GCA, patients had to have a positive temporal artery biopsy. This article examined the 
differences in GCA between Caucasian patients and African-American patients, but for the 
purposes of this review these will be combined. The prevalence of myalgia in the combined 
study sample was 14%. Roth et al (1984) conducted a cohort study in the USA in a single 
secondary care centre. To be classified as having GCA, patients had to have a positive 
temporal artery biopsy. This article reported findings on 18 patients with GCA, recording 
clinical features at the time of diagnosis/temporal artery biopsy. The mean age of the 
sample was 76 years, with 71% female, and the prevalence of myalgia was 28%.  
Hayreh et al (1997) conducted a cohort study in a single secondary care centre in the USA 
and patients with GCA were identified if they had a positive temporal artery biopsy. The 
mean age of the study sample was 72 years, with 66% being female and they reported the 
prevalence of myalgia in the 106 GCA patients as 29%. The largest prevalence estimate of 
myalgia was reported in Stuart et al’s (1989) cohort study conducted in New Zealand. GCA 
patients were identified by a positive temporal artery biopsy. The mean age of the sample 
was not reported; however, 79% were female. This article reported the prevalence of 
myalgia as 64% in the 14 patients they identified as GCA positive. 
The article conducted in Spain (Rivero Puente et al., 2001) reported the lowest prevalence of 
myalgia, whilst the articles conducted in the USA gave varying estimates from 14-29%. The 
largest prevalence was in New Zealand, at 64%. Despite only including 5 articles, 
heterogeneity between the articles was high, with an I2 88.2%. 
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Four articles reported an odds ratio of myalgia. The overall pooled OR was 1.27 (95% CI: 
0.83, 1.96; 95% PI: 0.83, 1.96). Heterogeneity was low, with an I2 of 0.0% (τ2 = 0.00). A forest 
plot can be seen in Appendix 3.7, Figure 11.  
3.5.5.20 Peripheral arthritis 
Three articles included in this review reported findings on peripheral arthritis. The overall 
pooled prevalence was 19% (95% CI: 0%, 56%; 95% PI: 0%, 88%) and the heterogeneity of 
the meta-analysis was high, with an I2 of 96.3% (τ2 = 0.11). A forest plot can be seen in 
Appendix 3.5, Figure 19. 
The three articles recorded clinical features at different times prior to a diagnosis of GCA. 
Zenone et al (2013) conducted a cohort study in France, using the ACR criteria to identify 
patients with GCA at a single secondary care centre over a period of 11 years. The article 
reported clinical features of 88 patients with GCA at the time of their referral to secondary 
care. They reported the prevalence of peripheral arthritis in their study sample as 3%. 
Narvaez et al (2003) conducted a cohort study in Spain and used a combination of the ACR 
criteria and positive temporal artery biopsy to identify patients with GCA. Findings on clinical 
features were recorded at the time of diagnosis/temporal artery biopsy. They identified 73 
patients with GCA, and the prevalence of peripheral arthritis in this sample was 11%. 
Salvarani et al (1999) conducted a cohort study in the USA, using a combination of the ACR 
criteria and positive temporal artery biopsies to identify patients with GCA. This article did 
not report the mean age or the gender distribution of the sample of 30 GCA patients. The 




3.5.5.21 Ophthalmologic symptoms 
Three articles included in this review reported findings of ophthalmologic symptoms. The 
overall pooled prevalence is 19% (95% CI: 10%, 30%; 95% PI: 5%, 39%). Heterogeneity was 
moderate/high, with an I2 of 69% (τ2 = 0.08). A forest plot can be seen in Appendix 3.5, 
Figure 20. 
All three articles recorded ophthalmologic symptoms at different times prior to a diagnosis 
of GCA. Kobayashi et al (2003) conducted a cohort study in Japan, using the ACR criteria to 
identify patients with GCA, ophthalmologic symptoms were recorded at disease onset. The 
mean age of the sample was 73 years, and 64% were female. The reported prevalence of 
ophthalmologic symptoms was 11%. De Boysson et al (2016) conducted a cohort study in 
France, using the ACR criteria to identify GCA patients. Clinical features were recorded at the 
time of diagnosis/temporal artery biopsy. The reported prevalence of ophthalmologic 
symptoms was 21%. The final article, by Desmet et al (1990), was conducted in Belgium, and 
used the opinion of two medical professionals and a positive temporal artery biopsy to 
identify GCA patients. Clinical features were recorded at the time of referral to secondary 
care. The prevalence of ophthalmologic symptoms was 30%. 
The two articles that used the ACR criteria (de Boysson et al., 2016; Kobayashi et al., 2003) 
had similar samples (mean age 73 years and 71 years, 64% and 66% of females, respectively) 
and reported low prevalence of ophthalmologic symptoms (11% and 21%, respectively). The 
country of origin was the main difference between these two articles. The two articles 
conducted in Europe (de Boysson et al., 2016; Desmet et al., 1990) had similar prevalence 
estimates of ophthalmologic symptoms (30% and 21%, respectively), but differing from 




3.5.5.22 Ocular symptoms 
Ocular symptoms were reported in four articles included in this review. The overall pooled 
prevalence of ocular symptoms was 18% (95% CI: 7%, 33%; 95% PI: 0%, 51%). Heterogeneity 
was high, with an I2 of 83.2% (τ2 = 0.02). A forest plot can be seen in Appendix 3.5, Figure 21. 
Three articles recorded ocular symptoms at the time of diagnosis/temporal artery biopsy 
(Chmelewski et al., 1992; Gabriel et al., 1995; Mohamed & Bates, 2002). Chmelewski et al 
(1992) conducted a cohort study in the USA and used a positive temporal artery biopsy to 
identify GCA patients. The reported prevalence of ocular symptoms in this study sample was 
23%. Gabriel et al (1995) conducted a cohort study in the USA and used positive temporal 
artery biopsy to identify patients with GCA. The prevalence of ocular symptoms was 10%. 
Mohamed and Bates (2002) conducted a cohort study in the UK using positive temporal 
artery biopsy to identify patients with GCA in secondary care. The mean age of the sample 
was 71 years, with 71% female and a prevalence of ocular symptoms in this study population 
was 7%. The sample characteristics from these three articles is very similar, and two were 
conducted in the USA but have differing prevalence estimates of ocular symptoms. The 
remaining article by Kobayashi et al (2003) recorded ocular symptoms at the time of disease 
onset, and found the prevalence to be 36%, the highest of the 4 articles that reported it as a 
symptom. 
Three articles reported the odds ratio of ocular symptoms. The overall pooled OR was 0.74 
(95% CI: 0.45, 1.20; 95% PI: 0.45, 1.20). Heterogeneity was low with an I2 of 0.0% (τ2 = 0.00). 
A forest plot can be seen in Appendix 3.7, Figure 12. All articles recorded cough at the time 





Three of the articles included in this review reported findings on anaemia prior to a diagnosis 
of GCA. The overall pooled prevalence was 18% (95% CI: 10%, 27%; 95% PI: 7%, 32%) and 
heterogeneity was moderate, with an I2 of 49.9% (τ2 = 0.04). A forest plot can be seen in 
Appendix 3.5, Figure 22. 
Two articles recorded anaemia at the time of diagnosis/temporal artery biopsy (Garrity et 
al., 2017; R. A. Stuart, 1989). Stuart et al (1989) recorded the prevalence of anaemia in their 
study sample as 36%. Garrity et al (2017) (a cohort study in the USA that has been described 
previously) reported the prevalence of anaemia as 19%. The remaining article (Hayreh et al., 
1997) recorded clinical features at the time of referral to secondary care. This was a cohort 
study, also conducted in the USA, that used a positive temporal artery biopsy to identify 
patients with GCA. The reported prevalence of anaemia was 12%. The two articles 
conducted in the USA had similar prevalence estimates (12% and 19%), whereas the article 
conducted in New Zealand reported the largest prevalence of anaemia (35%). 
3.5.5.24 Amaurosis Fugax 
Five of the articles reported the prevalence of amaurosis fugax prior to a diagnosis of GCA. 
The overall pooled prevalence was 16% (95% CI: 6%, 30%: 95% PI: 0%, 50%), though 
heterogeneity was high, with an I2 of 84.6% (τ2 = 0.03). A forest plot can be seen in Appendix 
3.5, Figure 23. 
Three articles recorded amaurosis fugax at the time of diagnosis/temporal artery biopsy 
(Alba et al., 2011; Garrity et al., 2017; Abha G Singh et al., 2012). All three articles were 
cohort studies conducted in the Americas (Mexico and USA). They reported the prevalence 
of amaurosis fugax as; 27% (Alba et al, 2011); 15% (Singh et al 2012); and 27% (Garrity et al, 
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2017) respectively. Garrity et al (2017) used a positive temporal artery biopsy to identify GCA 
patients, whereas Alba et al (2011) and Singh et al (2012) used the ACR criteria. 
The remaining two articles recorded amaurosis fugax at the time of disease onset (Kobayashi 
et al., 2003; Silva de Souza et al., 2013). Both articles were cohort studies, conducted in 
Brazil and Japan, with an overall pooled prevalence of 24% and 2%, respectively. This large 
difference in reported prevalence is most likely due to country of origin. Articles conducted 
in the Americas (Alba et al., 2011; Garrity et al., 2017; Silva de Souza et al., 2013; Abha G 
Singh et al., 2012) reported similar prevalence estimates of amaurosis fugax, ranging from 
15% (Singh et al, 2012) to 27% (Alba et al 2011, Garrity et al 2017). 
3.5.5.25 Cough 
Four articles reported the prevalence of cough prior to a diagnosis of GCA. The overall 
pooled prevalence was 13% (95% CI: 3%, 28%; 95% PI: 0%, 49%). Heterogeneity between the 
articles was high, with an I2 of 91.1% (τ2 = 0.03). A forest plot can be seen in Appendix 3.5, 
Figure 24. 
Two of the articles recorded cough at the time of referral to secondary care (Desmet et al., 
1990; Zenone & Puget, 2013). Both were cohort studies conducted in Europe and the 
prevalence estimates for cough were 35% and 14% respectively. Mean age was similar; 
however, the proportion of females in the sample differed at 74% and 67%, respectively. 
Zenone and Puget used the ACR criteria to identify patients with GCA, and Desmet et al 
(1990) identified patients with GCA through the clinical and histological information kept 
within a patient’s file. 
The prevalence estimate for cough produced by Zenone and Puget (2013) was closer to the 
prevalence estimate of 10%, found by Khalifa et al (2009) in their cohort study conducted in 
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Tunisia. Khalifa et al (2009) used a combination of the ACR criteria and positive temporal 
artery biopsy to identify patients with GCA. The final article recorded cough as a presenting 
feature of GCA on average 60 days prior to a diagnosis of GCA (Russo et al., 1995). This case-
control study conducted in the USA reported the smallest prevalence of 2%. 
3.5.5.26 Diabetes  
Four articles reported the prevalence of diabetes prior to a diagnosis of GCA. The overall 
pooled prevalence was 13% (95% CI: 4%, 24%; 955 PI: 0%, 40%). Heterogeneity was high, 
with an I2 of 93.2% (τ2 = 0.02). A forest plot can be seen in Appendix 3.5, Figure 25. 
Three articles (de Boysson et al., 2016; Espitia et al., 2012; Unizony et al., 2017) were cohort 
studies, with the remaining article being case-control (Pugnet et al., 2015). All articles were 
conducted in Europe, and conducted/published from 2010-present. Only 2 articles (de 
Boysson et al., 2016; Espitia et al., 2012) recorded diabetes at the time of diagnosis. Espitia 
et al (2012) reported the highest prevalence of diabetes, at 36%, using a combination of the 
ACR criteria and temporal artery biopsy to identify the 22 patients with GCA included in the 
study. De Boysson et al (2016) reported diabetes prevalence at 13% and used the ACR 
criteria to identify the 143 patients with GCA included in the study. Both studies were 
conducted in France. 
The remaining articles (Pugnet et al., 2015; Unizony et al., 2017) reported the smallest 
prevalence estimates of diabetes (10% and 5%, respectively). Pugnet et al (2015) conducted 
a case-control study in France, using ICD-10 codes to identify patients with GCA. Diabetes 
was defined based on a record in the patient’s file less than a month prior to the date of GCA 
diagnosis. Unizony et al (2017) conducted a cohort study in the UK, also using medical codes 
or prescription information to identify patients with GCA. Diabetes was defined based on a 
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record in the patient’s file less than a year prior to the date of their GCA diagnosis. Mean age 
of the article populations and proportion of females included were similar between both 
articles. 
3.5.5.27 Cerebrovascular accidents 
Seven articles reported the prevalence of cerebrovascular accidents (CA) prior to a diagnosis 
of GCA. The overall pooled prevalence was 7% (95% CI: 2%, 13%l 95% PI: 0%, 26%). 
Heterogeneity was high with an I2 of 92.7% (τ2 = 0.02). A forest plot can be seen in Appendix 
3.5, Figure 26. 
One article (Ezeonyeji et al., 2011b) recorded CA on average 35 days prior to a diagnosis of 
GCA. Another article recorded CA between 1 and 12 months prior to a GCA diagnosis 
(Unizony et al., 2017). The remaining 5 articles recorded CA at the time of 
diagnosis/temporal artery biopsy. 
Half of the articles were conducted in Europe, two in the UK (Ezeonyeji et al., 2011b; 
Unizony et al., 2017) and one in Spain (M.A. Gonzalez-Gay et al., 2005). All three used 
differing methods of diagnosis for GCA. Ezeonyeji et al (2011) used a positive temporal 
artery biopsy, Unizony et al (2017) used diagnostic codes and prescription information, and 
Gonzalez-Gay et al (2005) used the diagnosis given by Rheumatologists. All recorded CA at 
the time of diagnosis. Unizony et al (2017) reported the highest prevalence estimate for CA 
(22%), whilst the other article conducted in the UK reported a prevalence of 8%. However, 
the difference sample sizes between these two articles was large (6414 and 65, 




The remaining studies were conducted in Israel, China, and Tunisia (Grossman, Barshack, 
KorenMorag, BenZvi, & Bornstein, 2016; Khalifa et al., 2009; Sun et al., 2016), and reported 
prevalence estimates of CA as 4%, 6%, and 3%, respectively. Despite being conducted in 
different countries these estimates were more similar to one another than the estimates 
from the articles conducted in Europe. 
3.5.5.28 Diplopia 
Eight articles reported the prevalence of diplopia. The overall pooled prevalence of diplopia 
was 6% (95% CI: 5%, 8%; 95% PI: 5%, 8%). Heterogeneity was low, with an I2 of 0.0% (τ2 = 
0.00). A forest plot can be seen in Appendix 3.5 Figure 27. 
Only one of the articles recorded diplopia at the time of disease onset (Kobayashi et al., 
2003), whilst the remaining seven recorded diplopia at the time of diagnosis/temporal artery 
biopsy. Four of these seven articles were conducted in continental Europe (Duhaut, Pinede, 
et al., 1999; M A Gonzalez-Gay, Garcia-Porrua, Rivas, Rodriguez-Ledo, & Llorca, 2001; 
Gonzalez-Lopez et al., 2013; Haugeberg et al., 2000). The prevalence of diplopia in these 
articles were consistent at 5-6%. Three (Duhaut, Pinede, et al., 1999; M A Gonzalez-Gay et 
al., 2001; Gonzalez-Lopez et al., 2013) used either a positive temporal artery biopsy or the 
ACR criteria to identify patients with GCA, whilst Haugeberg et al (2000) used ICD-9 codes 
and a positive temporal artery biopsy. Overall these 4 articles produced similar results to 
each other. 
The outlying article that produced a prevalence estimate that was largely different from the 
other articles was the cohort study conducted by Machado et al (1988) in the USA. The 
reported prevalence of diplopia in the 94 patients with GCA they identified was 12%. This 
study was conducted prior to the release of the 1990 ACR criteria, and so this article used a 
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combination of internally developed criteria and a positive temporal artery biopsy to confirm 
a GCA diagnosis. The other study conducted in the USA (Garrity et al., 2017) estimated the 
prevalence of diplopia on GCA patients with a positive temporal artery biopsy to be 8%. This 
would imply that diplopia may be more prevalent as a symptom in the American continent, 
however the remaining article which reported diplopia (Toren et al., 2016), conducted in 
Canada, produced a prevalence estimate more similar to those found in Europe (5%). The 
final article (Kobayashi et al., 2003) also produced a similar prevalence estimate of 6%. 
3.5.5.29 Mental health conditions 
Four articles reported the prevalence of psychological conditions. The overall pooled 
prevalence was 5% (95% CI: 1%, 12%; 95% PI: 0%, 19%). Heterogeneity was moderately high, 
with an I2 of 72.4% (τ2 = 0.01). A forest plot can be seen in Appendix 3.5, Figure 28. 
Half of the articles were conducted in Europe (Desmet et al., 1990; Pugnet et al., 2015), in 
Belgium and France, respectively. Desmet et al (1990) conducted a cohort study, and 
recorded clinical features at the time of referral to secondary care. They identified patients 
with GCA using medical records. This article investigated mental deterioration, but gave no 
details as to what would constitute this diagnosis. They reported the prevalence of mental 
deterioration in the 34 patients prior to their diagnosis of GCA as 12%. Pugnet et al (2015) 
conducted a case control study, recording clinical features which had occurred less than a 
month prior to a GCA diagnosis. They used ICD-10 codes to identify patients with GCA. They 
recorded the proportion of patients who had a recorded diagnosis of dementia or psychiatric 
disorders, and these proportions were combined for the sake of this meta-analysis under the 
heading of psychological conditions. The reported prevalence was 2%. Continent of origin is 
the only variable these two articles have in common. 
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The remaining 2 articles (Khalifa et al., 2009; Kobayashi et al., 2003) were conducted in 
Japan and Tunisia, respectively. Kobayashi et al (2003) conducted a cohort study in which 
they recorded clinical features at the time of disease onset. Patients with GCA were 
identified using a positive temporal artery biopsy. They reported findings on psychiatric 
symptoms, and found a prevalence of 2%. Khalifa et al (2009) conducted a cohort study and 
recorded clinical features at the time of diagnosis. GCA patients were identified using a 
combination of the ACR criteria and a positive temporal artery biopsy. The reported 
prevalence of psychiatric manifestations was 10%. 
3.5.5.30 Limb claudication 
Four articles reported limb claudication as a clinical feature. The overall pooled prevalence 
was 3% (95% CI: 1%, 4%; 95% PI: 1%, 4%). Heterogeneity was low, with an I2 of 0% (τ2 = 
0.00). A forest plot can be seen in Appendix 3.5, Figure 29. 
All articles produced similar prevalence estimates of between 2.5% and 3%. Three articles 
were conducted in Europe (de Boysson et al., 2016; M.A. Gonzalez-Gay et al., 2005; Narvaez 
et al., 2003) whilst the remaining article was in China (Sun et al., 2016). All articles used 
either the ACR criteria, a positive temporal artery biopsy, or a combination of both to 






The results of this systematic review and meta-analysis show that the clinical features which 
patients experience prior to their GCA diagnosis are extremely varied, and that the clinical 
features with the highest prevalence and strongest associations with GCA were headache, 
jaw claudication, constitutional/systemic symptoms, and elevated ESR. Features with strong 
evidence of a lack of association with GCA from the meta-analysis included PMR, and visual 
symptoms. However, there were many features including anorexia and fever where 
evidence is limited and more research is needed to fully understand the role (if any) of such 
clinical features prior to GCA diagnosis. 
Headache was the most commonly experienced clinical feature prior to GCA diagnosis in this 
review, and whilst over three quarters of patients did experience this before GCA diagnosis, 
it is not a definitive precursor to eventually developing GCA. Prior to this review, estimates 
reported that a third of GCA patients did not experience a headache prior to their diagnosis, 
but that it is relied upon by GPs for diagnosis in primary care (Helliwell, Muller, Hider, 
Richardson, & Mallen, 2014). Though headache is clearly and commonly experienced prior to 
GCA, this is also a very common symptom in older patients. Whilst closely associated with 
GCA, and recommended as an indicating symptom in NICE guidelines, on its own in patients 
over 50 this could be indicative of a number of other conditions that are more prevalent in 
primary care populations, such as migraine or cancer (Prencipe et al., 2001; Rasmussen & 
Olesen, 1992), or a headache that is not associated with a disease (Boardman, Thomas, 
Millson, & Croft, 2005). This problem is highlighted by the fact that, despite the known 
association between headache and GCA, diagnostic delay persists.  
When visual impairments, such as blindness and diplopia, are present with a headache, this 
is when GPs will typically become alert to a potential GCA diagnosis (Helliwell et al., 2014). 
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From this review, the overall pooled prevalence of visual impairment was less than half, 
suggesting that fewer GCA patients present with visual impairments than do not. Though 
this is a relatively small proportion of patients with GCA presenting with this symptom, it is a 
potentially serious and irreversible one. However, no significant increase in risk of GCA 
patients having a positive biopsy and presenting with visual symptoms was found in this 
review. This result could be due to “visual impairments” being a very broad definition and 
defined very differently between articles, or that patients may be consulting an optician 
rather than a GP, hence the visual impairment will not be in their medical record. 
Constitutional/systemic symptoms were defined with moderate consistency across articles. 
Some articles defined it as one symptom, such as pain or stiffness (Alba et al., 2011; Hayreh 
et al., 1997), whilst others included two or more symptoms such as asthenia, weight loss, 
and anorexia (M.A. Gonzalez-Gay, Garcia-Porrua, Llorca, Gonzalez-Louzao, & Rodriguez-
Ledo, 2001; Gonzalez-Lopez et al., 2013). There were a number of papers which did not 
define it at all (El-Dairi et al., 2015; Grossman et al., 2016; Marí et al., 2009). 
Constitutional/systemic symptoms appear to be common in GCA patients, but are also a 
possible contributor to making the diagnosis of GCA more challenging. The definitions of 
constitutional/systemic symptoms was broad, and arguably they are not necessarily 
associated with a diagnosis of GCA. A patient may present with a fever prior to their 
diagnosis of GCA, but on its own this is not necessarily indicative of GCA, but possibly 
something else, like an impending cold. These symptoms highlight the disadvantage of 
considering clinical features independently of each other. Constitutional/systemic symptoms 
are a broad range of symptoms that even if grouped together would not necessarily be 
associated with GCA. Fever, weight loss, malaise, are all highly prevalent symptoms 
associated with a multitude of other, more prevalent, conditions from influenza to 
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malignancy (Wajngarten & Sampaio Silva, 2019). Grouping these symptoms under an 
umbrella term makes inference of a relationship between their presentation and a GCA 
diagnosis more difficult. Defining succinct combinations of these symptoms and investigating 
their association with GCA is an area for future research. 
Elevated ESR had the second highest pooled prevalence, and was found to be strongly 
associated with a positive temporal artery biopsy. However, elevated ESR was only reported 
in 8 of the articles included in the review. What level of ESR was considered elevated 
differed between articles. One article defined it as >40 mm/h (E. Machado et al., 1988), 
whilst half of the articles defined it as ≥50 mm/h (El-Dairi et al., 2015; Marí et al., 2009; 
Mohamed & Bates, 2002; Rivero Puente et al., 2001). Only two articles did not give a cut-off 
value (T.A. Kermani et al., 2012; Toren et al., 2016). Elevated ESR is an inflammatory marker 
that can be an indicator of GCA (NICE CKS, 2020), but was not reported in many articles 
included in this review. This could be because blood tests may be conducted mainly in 
primary care, rather than secondary/tertiary care where all of the articles were conducted. 
There has been little to no previous research that has investigated the association between 
anorexia and GCA. Anorexia was only reported in nine of the articles included in this review, 
but had one of the highest pooled prevalence estimates, with just over a third of patients 
reporting this feature prior to their GCA diagnosis. Only four articles reported a risk 
estimate, and the pooled odds ratio indicated there was a strong association between 
anorexia and a positive temporal artery biopsy. The articles that included anorexia did not 
provide a definition of anorexia, whether it was severe weight loss, or a loss of appetite. As a 
result of the findings in this review, future research should focus on further investigating the 




3.6.1 Heterogeneity  
High levels of heterogeneity were consistently seen across the meta-analyses of clinical 
features, with articles included whose results consistently diverged from the other articles 
reporting the same clinical feature. The article by Desmet et al (1990) conducted in Belgium 
was consistently an outlier, and reported higher prevalence rates than other articles 
reporting the same clinical feature. It recorded higher prevalence rates of; 
constitutional/systemic symptoms, fatigue, anorexia, weight loss, fever, and cough; and a 
lower prevalence rate or jaw claudication. This article rated as fair on the N-O scale and 
included results from a small sample of thirty-four GCA patients. The method of diagnosis 
was patients who had either a clinical or histological diagnosis of GCA in their medical 
records in one single secondary care centre. This was one of the few papers in the review 
that recorded clinical features at the time of referral. It is not clear from the extracted 
information on this article why it would consistently report higher prevalence rates for six 
clinical features, but could be due to the small and possibly select sample used for this study. 
However, the prevalence estimates reported for other clinical features, such as abnormal 
temporal artery, visual impairment, PMR, and headache were all consistent with other 
articles, and close to the overall pooled prevalence rate. It is not possible to identify why the 
article by Desmet et al (1990) is inconsistent with other articles regarding some clinical 
features, whilst being an outlier in others. 
The second article that reported higher prevalence estimates on some clinical features was 
an old study conducted by Fainaru et al (1979) in Israel on 47 GCA patients. This article was 
rated as fair on the N-O scale and identified GCA patients via a positive temporal artery 
biopsy from nine major hospitals. This study reported higher prevalence rates for; fever, 
visual impairment, and abnormal temporal artery. However, for the remaining clinical 
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features it reported (arthralgia, weight loss, fatigue, and headache), the prevalence 
estimates were similar to the overall pooled prevalence rate, and the prevalence reported in 
other studies. One other possible reason for these higher prevalence estimates could simply 
be because presenting features of GCA are different in the population studied in this paper. 
There were two measures of heterogeneity reported in this thesis, I2 and τ2. For the majority 
of meta-analysis both measures appeared to agree in terms of extent of heterogeneity. 
However, with τ2 on a continuous scale, and no validated cut-off values, it was difficult to 
assess what value of τ2 indicated high heterogeneity. Without the I2 value as a comparator, it 
would have been difficult to identify where meta-regression was to be applied. In the cases 
where there was very high heterogeneity, indicated by an I2 of over 95%, the value of τ2 was 
variable and counter-intuitive. For example, the I2 value for the meta-analysis conducted on 
articles reporting constitutional/systemic symptoms was the highest reported at 96.4%. 
Fifteen articles reported this clinical feature, and the resulting τ2 value was 0.06. The meta-
analysis with the second highest I2 (ischaemic optic neuropathy at 96.3%) reported a τ2 of 
0.10 on the six articles that reporting ION. The difference in the values of τ2, despite almost 
identical I2 values, could be due to the precision of the studies included in each meta-
analysis. Precision is proportional to the sample size of each study, and many of the studies 
included in the meta-analyses had small samples. I2 is affected by precision, whereas τ2 is 
not, making it a more stable and precise value. Regardless of this advantage over I2, it still 
remains that τ2 is difficult to interpret and will probably not be implemented as a 
replacement for I2 in practice in the future. 
What can be drawn from both I2 & τ2, is that the majority of meta-analyses conducted in this 
thesis had high levels of heterogeneity in prevalence estimates. In order to find the source of 
this heterogeneity meta-regression was conducted. However, the sources of heterogeneity 
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in the estimates of association could not be examined. No variable consistently explained 
heterogeneity in prevalence across the nine clinical features for which a meta-regression 
could be undertaken. However, continent of origin was included in the final model for 
constitutional/systemic symptoms, abnormal temporal artery, PMR, and fever. Year of 
publication was included in the final model for headache, constitutional/systemic symptoms, 
and abnormal temporal artery. This shows that for constitutional/systemic symptoms and 
abnormal temporal artery, a combination of geographical region and year of publication 
contributes to the differences in prevalence estimates between studies included in the 
meta-analysis. Heterogeneity associated with continent of origin could reflect differing 
models of healthcare in different countries. Affluent, or more developed countries, have 
increased access to healthcare technology and professional expertise than countries with a 
lower economic status. Year of publication may explain the differences between articles due 
to the slow progression on understanding and recognising GCA as a condition over time (G. 
G. Hunder, 2005). Articles conducted after the publication of the 1990 ACR criteria had the 
advantage of using it to classify GCA as a condition, in contrast to studies conducted prior 
which did not. 
Overall the high levels of heterogeneity do not invalidate the results found in this review, but 
instead indicate wide variability in prevalence estimates and measures of association 
between studies. The results should be viewed with caution, and with the knowledge that 
there was a high amount of heterogeneity. There was little added benefit in using two 
measures of heterogeneity, and until τ2 has been further developed regarding accepted cut-
off values indicating high heterogeneity and used more widely in further systematic reviews, 




3.6.2 Comparison to previous GCA review  
To date, only one other review has investigated the clinical features with which patients 
present prior to a GCA diagnosis. More specifically, they identified which features had 
predictive value of a positive temporal artery biopsy. The results reported by Smetana & 
Shmerling (2002) agreed with several of the findings found in this review, also finding 
headache, jaw claudication, and elevated ESR to be predictive of a GCA diagnosis. Smetana 
& Shmerling (2002) found a positive association between visual symptoms and GCA. 
However, this was not statistically significant, agreeing with the results produced in this 
thesis. Fever, weight loss, and fatigue (symptoms that were included in the definition of 
constitutional/systemic symptoms in this thesis) all had predictive value in the previous 
review, but only weight loss was statistically significant in this work. The prevalence 
estimates for anorexia, arthralgia, headache, jaw claudication, and PMR were similar in 
Smetana’s review and the one conducted here. However, this review included more clinical 
features than Smetana’s, and therefore provides a richer examination of experiences prior to 
a GCA diagnosis. 
However, Smetana & Shmerling (2002) conducted their review on articles published from 
1966 to 2000 in MEDLINE only (Smetana & Shmerling, 2002). The final number of articles 
included in their review and meta-analysis was 21, as opposed to the 43 included in this 
review. Smetana & Shmerling (2002) only included English-language articles, which may 
have introduced bias into their results. The use of MEDLINE only could have increased the 
possibility of missing relevant articles. Smetana & Shmerling (2002) also conducted their 
review almost 20 years ago, and the results from this review show that there is a difference 
in results depending on year of publication for certain clinical features, such as headache, 
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The main strength of this review is that it is the first to conduct a meta-analysis on the 
relationship (prevalence and risk) between potential clinical features of GCA and a diagnosis, 
using 30 individual clinical features. This was a systematic search and identification of 
articles with no language filter, and articles were from a wide variety of countries. 
Another strength is the number of articles included in the final review. Suitable data to be 
used for a meta-analysis was extracted from a total of 43 articles, with the most frequently 
reported symptoms, such as headache, being extracted from 30 individual articles. 
Quality scores were validated independently by three reviewers and compared for 
agreement, reducing the amount of bias present in the results. A further strength was the 
relative consistency between articles regarding the method of GCA diagnosis. The majority 
of articles included in the review diagnosed GCA using a temporal artery biopsy, and all of 
the articles included in the measure of association meta-analysis used a temporal artery 
biopsy to define GCA. 
 
3.6.4 Limitations 
Despite the comprehensive review there is a possibility that some relevant articles were 
missed. Grey literature, such as theses, books, and unpublished material were not searched 
due to the likely benefits not outweighing the cost of time and resources required to 
conduct a search into multiple grey literature databases (Mahood, Van Eerd, & Irvin, 2014; 
Paez, 2017), and some articles were unable to be sourced. 
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The articles included in the risk estimate meta-analysis used biopsy results to define GCA 
and non-GCA patients, with the latter group defined as having a negative biopsy. However, 
all patients in these articles were suspected of having GCA when they were referred for a 
biopsy. Therefore it is reasonable to assume that measures of association based on 
comparing biopsy positive GCA cases, or GCA diagnosed patients, and the general population 
would be different to those found in this review comparing biopsy positive and negative 
patients. 
It is a point of discussion whether the articles should be pooled together for a meta-analysis, 
considering very few were consistent in recording the duration of clinical features prior to a 
diagnosis. The largest subgroup was at diagnosis/TAB. Due to its large size, the pooled 
prevalence estimate for this subgroup was very close to the overall pooled estimate for all 
subgroups together. There was a high amount of heterogeneity found in the results for the 
meta-analysis conducted on the prevalence estimates. Some meta-analyses yielded large I2 
as high as 98%. A meta-regression was conducted to try to find the source of the 
heterogeneity. This is a useful model and should be applied to future meta-analyses that find 
high levels of heterogeneity between articles. Meta-regression, as well as explaining how 
much heterogeneity can be explained by the variables in the model, also has the ability to 
make comparisons of levels within the variables. In the case of this review, the meta-
regression showed how the prevalence of a clinical feature differed between continent of 
origin or year of publication. A limitation was that meta-regression could not be conducted 
on the measures of association meta-analysis as there was not enough articles to include in 
the analysis.  
The high heterogeneity between the results could not be fully explained by any of the 
covariates used in the models fit to the data. The results from the meta-regression showed 
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that no variable available from the data extraction was enough on its own to completely 
account for the high levels of heterogeneity, but did manage to explain a good proportion 
when combined with other covariates for some clinical features such as jaw claudication and 
fever. These results could mean that the high levels of heterogeneity observed in the 
proportion meta-analysis were due to a variable that was not recorded or not available to be 
extracted from the articles. Without further information it is difficult to come to a conclusion 
on the source of the heterogeneity across articles. 
Sample size of articles included in the review were also a limitation. The majority of articles 
were conducted in single secondary care centres, and rarely reported outcomes on more 
than 100 patients, but this is to be expected with a condition as rare as GCA. 
The timeline for when and how long patients had experienced clinical features prior to a 
diagnosis also varied across articles. The largest subgroup were the articles which had 
reported information on clinical features when the patient was being diagnosed with GCA, 
the “at diagnosis/TAB” group. These articles contained no information on the duration of 
clinical features prior to a diagnosis. This problem was shared with the “at referral” group 
whose clinical features had been recorded when they were referred onto secondary care or 
for a biopsy. There was no way to extract information from these articles about how long 
patients had experienced these clinical features, or how long it had taken them to be 
diagnosed from when they were referred. Together both the “at referral” and “at 
diagnosis/TAB” groups made up 36 out of the 43 articles included in this review. Arguably, 
the third largest group of “at disease onset” was also ambiguous regarding duration of 
clinical features prior to a diagnosis, as an amount of time from symptom onset to diagnosis 
was never specified in the articles (Kobayashi et al., 2003; Souza et al., 2013). Only 5 articles 
specified the duration of clinical features prior to a diagnosis of GCA (Ezeonyeji et al., 2011a; 
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Pugnet et al., 2015; Russo et al., 1995; Carlo Salvarani et al., 2004; Unizony et al., 2017). 
From the five, only 2 reported the same duration of 2 months/60 days prior to a diagnosis 
(Russo et al., 1995; Carlo Salvarani et al., 2004). 
 
3.6.5 Conclusion 
Diagnosing GCA based on the clinical features with which patients present with prior to GCA 
diagnosis can be challenging for healthcare professionals. This review has found that some 
“classic” features, such as headache, elevated ESR, and jaw claudication, are important 
indicators of GCA. However, even a high prevalence of an associated feature is of limited use 
if that feature is commonly seen across multiple conditions in primary care. The relationship 
between GCA and other features, such as systemic symptoms (including weight loss, fever, 
fatigue, malaise, and anorexia) needs to be further investigated. High heterogeneity 
between studies for many clinical features mean that further work is required to understand 
their prevalence and association with GCA. 
Furthermore, the articles included in this review treated individual clinical features as 
though they were independent of each other, only looking at the effect of one at a time on a 
subsequent diagnosis of GCA. Previous articles have also shown that clinical features on their 
own do not always have high predictive value of a GCA diagnosis (Smetana & Shmerling, 
2002). Identifying clinical features associated with a GCA diagnosis should include finding 
groups or clusters of clinical features that when presented together could identify a 
subsequent diagnosis, rather than treating features individually (Laskou et al., 2019). 
Observational data, such as that found in EHR, offers a large and representative sample size, 
and therefore reduces the lack of generalisability seen in small, single-centre secondary care 
studies that dominate this review. Hence the next chapter in this thesis will outline how 
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EHRs can, and will be used, to examine further the clinical features experienced by patients 




Chapter 4: The Clinical Practice Research Datalink  
4.1 Chapter Overview 
This chapter gives a general overview of EHR databases, focussing specifically on details 
related to the Clinical Practice Research Datalink (CPRD) and how it was used to conduct the 
analysis included in this thesis to determine trends in prevalence and incidence of GCA, and 
clinical features associated with GCA. It describes how medical records are kept within the 
UK and stored in the CPRD database, CPRD’s official processes of applying for data, the 
development of code lists for defining GCA and covariates, and finally the definition of the 
GCA study population used in this thesis. 
 
4.2 Electronic Health Records (EHR) 
In the UK, GCA is principally suspected, and managed over time in primary care (Helliwell et 
al., 2014), with referral to secondary care to confirm diagnosis. As a result, information on 
consultations, tests, and prescriptions are contained within the patient’s primary care 
record. Primary care consultation data is therefore a practical resource to use in the UK for 
observational studies of GCA health care utilisation and management, including diagnostic 
and prognostic studies (Herrett et al., 2015). 
 
4.2.1.1 Read codes 
Diagnoses, symptoms, and processes of care in general practices have been recorded 
historically using Read codes and corresponding Read terms (Robinson, Comp, Schulz, 
Brown, & Price, 1997), the most commonly used hierarchical system of disease identification 
in UK general practice prior to the introduction of SNOMED coding from 2018 (Herrett et al., 
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2015). Read codes were first developed in the 1980s to record clinical and administrative 
data in general practices. This first version is known as the four-byte set, as it used four-
character alpha-numeric code, with each character denoting a level in the hierarchy. Version 
2 was released to incorporate information from secondary and tertiary care, and was 
upgraded to a five-byte code to reflect this addition (Robinson et al., 1997). Version 3 was 
released in 1994 and was created through a collaboration between the National Health 
Service (NHS) Executive and the Conference Information Group of the Conference of Medical 
Royal Colleges; the Nursing, Midwifery and Health Visiting Professions; and the Professions 
Allied to Medicine (PAMS).  
Read codes are organised via chapters 0-9, and then though chapters A-U (NHS Scotland, 
2019). The numeric chapters record information on symptoms, examinations, investigations, 
and administration, whilst the alphabetical codes record information on diagnoses. Codes 
are hierarchical and version 3 allows for poly-hierarchy, rather than the 4 and 5 level 
limitations of previous versions. Top levels of the hierarchy are more general, and these 
become more specific further down the hierarchy (NHS Scotland, 2019). For example, one of 
the Read codes for GCA is G755. In this instance “G”, defined within the Read chapter of 
circulatory system, is at the top of the hierarchy. At each addition of a number or other 
letter the diagnosis becomes more specific, and complex; such as G755z00 for “Giant cell 
arteritis – not otherwise specified”, and G755100 for “Temporal arteritis” (Table 4.1). 
Table 4.1: An example of the Read code hierarchy to arrive at the Read code for giant cell 
arteritis 
Read code Read term 
G Circulatory System 
G7 Arterial, arteriole and capillary disease 
G75 Polyarteritis nodosa 
G755 Giant cell arteritis 




4.2.1.2 Availability for research 
As of 2011, population estimates published by the Office for National Statistics (ONS) and 
the National Health Service (NHS) showed that 98% of the UK population were registered 
with a general practice (GP) (NHS, 2012). Information from these practices can provide data 
on patient consultations to primary care for many conditions, their presenting symptoms, 
diagnosis, and treatment pathways for the majority of the UK population, along with 
demographic information such as age, gender, and the level of socio-economic deprivation 
associated with the patient’s local area (neighbourhood-level deprivation). As a result, there 
are electronic health databases available from several providers for use in research that 
contain pseudonymised information contributed by UK GP practices, such as registration 
information, diagnoses, prescriptions, results of tests, and referrals. Examples include The 
Health Improvement Network (THIN), the Clinical Practice Research Datalink (CPRD) (Petri et 
al., 2015; Unizony et al., 2017), QResearch (QResearch, 2020b), and ResearchOne 
(ResearchOne, 2020). All databases require approval from their research committees prior 
to the data being made available for research. Linked secondary healthcare data is also often 
available for researchers.  
Established in 2003, and with data available from 1994 to the present day, THIN is an 
anonymised primary care record database from the UK, which contains medical data on 6% 
of the population (THIN, 2020). It contains information on patient demographics, diagnoses, 
referrals, prescriptions, and test results, from general practices that use the Vision software 
for the management of their EHR (Blak, Thompson, Dattani, & Bourke, 2011).  
QResearch was developed jointly by the University of Nottingham and the Egton Medical 
Information Services (EMIS), a system used in many UK general practices to record patient 
data (Hippisley-Cox, Stables, & Pringle, 2004). It contains pseudonymised data from practices 
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that use the EMIS consultation system, and includes information on patient demographics, 
such as year of birth, sex, ethnicity, and Townsend Deprivation score (QResearch, 2020a). 
Linkage to national databases, such as the cancer registry, hospital episode statistics (HES), 
and the national death register, are also available. Currently QResearch contains information 
from approximately 1500 UK general practices (QResearch, 2020b). 
ResearchOne collects information from health and social care organisations contributing to 
The Phoenix Partnership (TPP) SystmOne database (ResearchOne, 2020). TPP SystmOne has 
over 120,000 clients across more than 1900 GP practices in the UK, and is also used in 
secondary care departments such as Accident & Emergency (A&E) (ResearchOne, 2013). 
ResearchOne is created from records held in the TPP SystmOne from primary and secondary 
healthcare organisations in England. It is a pseudonymised database where healthcare 
providers have to opt-in for their data to be available to researchers. 
THIN and ResearchOne are both smaller databases than CPRD and QResearch. ResearchOne 
only contains information from healthcare institutions in England and is therefore not 
suitable to use to investigate GCA in the UK as a whole. CPRD and QResearch are two of the 
largest databases in the UK. However, it was decided that the use of CPRD was the most 
appropriate approach for this thesis, not only because of the database size, but also because 
the host research institute for this PhD has familiarity with, and experience of using CPRD, 
and also has an institutional CPRD multi-study licence. A further benefit of using CPRD for 
this thesis is the quality checks that CPRD conducts on its database. CPRD has also been used 
for similar study designs in previous GCA research (Petri et al., 2015; Yates, Graham, Watts, 




4.3 Clinical Practice Research Datalink 
Founded in 1987, CPRD is a government-owned research database that uses NHS primary 
care coded patient records contributed from practices across the UK (Jick et al., 2003). CPRD 
contains over 30 years of anonymised patient information from primary care that can be 
used for observational research. It contains patient information from, at the time of writing, 
over 1800 primary care practices from across England, Scotland, Wales, and Northern 
Ireland, and the covered patient population is generally reported to be representative of the 
UK population, based on age, gender, and ethnicity (CPRD, 2020a; Herrett et al., 2015; Wolf 
et al., 2019).  
CPRD collects anonymised EHR from participating general practices on a monthly basis. 
Patients at registered practices are automatically opted-in to CPRD, but do have the option 
to opt-out of their data being included in the database. All patient data is psuedonymised, 
with the patient’s name, address, postcode, and day and month of birth removed.  
There are currently two databases contained within CPRD; GOLD and Aurum. The GOLD 
database contains information that has been gathered from general practices that use the 
Vision software to manage patient’s medical records. The Aurum database was first released 
in 2017 and contains data from general practices that use the EMIS software (Booth & 
Dedman, 2017). Aurum has small differences in structure compared to GOLD, but still 
contains information in separate files on patients, referrals, drug issue, and consultation 
information, including the use of unique patient IDs that enable the files to be linked. At the 
start date of this study, the institutional licence only provided access to GOLD, with access to 
Aurum requiring an upgraded licence. However, access to Aurum is now included in the full 
institutional multi-study licence, but for the purposes of this thesis only data extracted from 




4.3.1.1 Structure & Contents 
CPRD contains information on patients such as demographic data (year of birth, gender), 
lifestyle data (height, weight, smoking, and alcohol status), registration status (dates of 
joining/ leaving the general practice, and death), symptoms consulted with at each 
consultation, diagnoses applied, prescription information, immunisation information, 
referral records, and test results (Williams, van Staa, Puri, & Eaton, 2012). 
CPRD data consists of separate tables all containing information about the practice or the 
patient, with each patient being allocated a unique non-identifiable ID number so they can 
be linked across all files. Patient demographics such as year of birth, gender, and important 
dates such as practice registration, transfer out, and death are in the table “Patient”. 
Lifestyle information such as smoking status, alcohol consumption, and Body Mass index 
(BMI) are all contained within the “Additional” table. Information about consultations is 
contained within the “Clinical” table. Records of treatments, such as prescriptions of 
medications, are contained within the “Therapy” tables. Results of laboratory tests, like 
blood tests, are contained within the “Test” table. Details of patient referral to secondary 
care or specialists are contained within the “Referral” table. 
Practice level data, such as up-to-standard date (see section 4.3.1.2), region where the 
practice is situated, and last collection date are all contained in the table “Practice”. The ‘last 
collection date’ is the last date when data was collected from that practice, which can be 
used as a possible stop date for patients in studies, in conjunction with end of registration or 
end of study period. CPRD data is divided into 13 regions of the UK; 10 in England, and 1 
each for Scotland, Wales, and Northern Ireland (Herrett et al., 2015). The 10 regions in 
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England are; East Midlands, East of England, London, North East, North West, South Central, 
South East Coast, South West, West Midlands, and Yorkshire and the Humber.  
 
4.3.1.2 Quality & Validation 
There are two quality checks conducted on CPRD GOLD data, one at the patient level and the 
other at the practice level. At the practice level there is an ‘up-to-standard’ (UTS) measure 
that indicates whether the data contributed by that practice is of a high enough standard to 
be used for research. The UTS date is a quality measure based on the practice’s continuity of 
recording (gap analysis) and the number of recorded deaths in that practice (Herrett et al., 
2015). Gap analysis is used by CPRD to identify any meaningful gaps in data recording at the 
practice. A meaningful gap is a single day, or longer, where nothing is recorded at the 
practice for a specific reason, such as if the practice was shut and patients were treated 
elsewhere. Gaps in the recorded dates of death at each practice are examined by CPRD, 
taking the population of that practice into account, in conjunction with seasonal and 
geographical variation in mortality rates (Herrett et al., 2015). Similar to the continuity of 
recording, if a significant gap is found in the recorded death dates, then the earliest date 
after which the gap occurred will be identified. The UTS date is taken to be the latest of 
these two dates for each practice (Herrett et al., 2015). 
Regarding checks at the patient level, there is an acceptability flag. This is a binary variable 
that takes the value of 1 if the patient’s data is of acceptable quality to be used in research.  
The criteria for acceptable patient data are: 
1. To have a valid year of birth, gender, and age. Patients who have events before their 




2. To have consistent and valid registration dates. The first registration date needs to be 
after the date of birth, and current registration (the same as the first registration 
date unless the patient has left the practice and returned at a later date) must be 
after date of birth. 
3. To have a valid registration status. Patients without a permanent or temporary 
registration status are unacceptable. Patients must also have valid transfer out dates, 
if applicable, and reason to be considered acceptable. 
 
Diagnosis validation studies have been conducted for CPRD. A systematic review identified 
212 publications that validated diagnoses contained within CPRD (Herrett, Thomas, 
Schoonen, Smeeth, & Hall, 2010). From all 212 articles, over 183 different diagnoses were 
assessed for accuracy. Individual diagnoses are not listed in the article, but the results of a 
meta-analysis showed that overall validity of diagnosis was high, with a median positive 
predictive value (PPV) of 89%, with a range between 24% and 100% (Williams et al., 2012). 
The Aurum database, detailed in section 4.3, currently does not have the same dates 
recorded for patients as GOLD, such as the date of the last successful quality check and a 
validated death date. These dates were required to create a start and stop date for every 
patient included in this study. Therefore, it was not possible to have the same definition of 
start dates and end dates across patients in GOLD and AURUM, which would have affected 
the number of patients included in the analysis. It was decided by consensus that only GOLD 
should be used for this thesis. There is some overlap between the GOLD and Aurum 





Data contained within CPRD is taken from general practices. However, a subset of included 
practices in England, approximately 58% of all UK practices within CPRD GOLD (Herrett et al., 
2015), have consented to have their data linked to secondary care databases, such as 
Hospital Episode Statistics (HES), and the Index of Multiple Deprivation (IMD). For the 
purposes of this thesis only linkage to the IMD was required. 
The Index of Multiple Deprivation (IMD) is an official measure of socioeconomic status 
calculated across small areas of England, usually referred to as Lower-Layer Super Output 
areas (LSOAs) (Department for Comminities and Local Governments, 2019). This information 
has been released by the UK Government since 2000, and updated versions were released in 
2004, 2007, 2010, and 2015, with the most recent in 2019 (Department for Comminities and 
Local Governments, 2019). The LSOAs are designed to be of a similar population size, 
containing around 1500 people or 650 households each. LSOAs are ranked from 1 (most 
deprived) to 32,844 (least deprived) using the IMD (ONS, 2016). To create this rank value, 
the IMD is made up of seven individual Indices of Deprivation (IoD) which are weighted by: 
• Income Deprivation (22.5%) 
• Employment Deprivation (22.5%) 
• Education, Skills and Training Deprivation (13.5%) 
• Health Deprivation and Disability (13.5%) 
• Crime (9.3%) 
• Barriers to Housing and Services (9.3%) 
• Living Environment Deprivation (9.3%) 
Each of these indices is calculated from a range of Government data from the most recent 




4.3.1.4 CPRD Medcodes 
CPRD uses medcodes to record patient information such as diagnoses, symptoms, and 
processes of care, with prodcodes used to record prescriptions. Medcodes are numerical 
codes that map to the Read code hierarchy, which can be done using the CPRD browser. This 
browser is part of the licence agreement with CPRD and is an application that can be used to 
search for Read terms, Read codes, and medcodes. The search results include the 
corresponding Read code/term, the medcode, and how many times it has been used in the 
current version of CPRD. Each Read code and associated term has a unique medcode. 
Prodcodes linked to prescribed medications can also be identified through the browser. 
 
4.3.1.5 Strengths and limitations of the Clinical Practice Research Datalink 
The large population in CPRD GOLD allows more statistical precision in results for rarer 
diseases than analyses run on a smaller set of data (Douglas et al., 2013). The median length 
of follow-up available in CPRD GOLD is 4.2 years for all patients, which allows research into 
the longer-term outcomes of diseases (Herrett et al., 2015; Wolf et al., 2019). It means that 
patients’ healthcare use can often be followed from the period prior to the diagnosis, to 
longer-term follow-up. As it is routinely collected data, it does not have the same problems 
as questionnaire or survey data, such as non-response bias. Patients with records in CPRD 
GOLD are accepted to be representative of the UK population and therefore conclusions 
from CPRD GOLD research projects should be generalisable to the UK population as a whole 
in terms of age and gender (Herrett et al., 2015). CPRD carries out regular quality checks of 
its GOLD database, ensuring that the data used for research purposes is of the highest 
research quality (Herrett et al., 2015). CPRD also ensures that training in the recording of 
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patient information is given to practices contributing to GOLD to further ensure that data is 
of a high quality (Herrett et al., 2015). 
A limitation of primary care data is that routinely collected data relies on Read codes to 
identify cases of a disease, and if the correct one is not used by the GP then the disease case 
will be missed in the analysis, or included when it should not be (e.g. a false positive). 
Information sent from secondary care may be added to a patient’s record, but it has been 
shown that this is not always completed (Herrett et al., 2015). Multiple diagnoses and 
symptoms discussed in one appointment may not all be coded. A recent study found that on 
average 2.1 concerns were discussed per consultation (B. Stuart et al., 2019). A study was 
conducted to describe the differences between concerns discussed during a consultation, 
and those recorded in the patient’s medical record (Salisbury et al., 2013). They found that 
across 229 videoed consultations, an average of 2.5 problems were discussed per 
consultation. They found that 72% of consultations were about multiple conditions. Of the 
562 problems discussed across the consultations, only 37% were Read coded in the patient’s 
file (Salisbury et al., 2013). However, the problem that is coded is likely to be the one of 
most importance to the patient and/or health care professional. 
Another limitation of primary care records is missing demographic data, such as BMI, alcohol 
consumption, and smoking status. Reasons why data is missing varies, this results in 
different reasons for missingness and how they are handled prior to running analysis. For the 
purposes of this thesis only missing at random (MAR) and missing not at random (MNAR) will 
be discussed. MAR is where the missing data is missing due to other observed variables 
(Kang, 2013). MNAR is when the missing value is related to the reason it is missing, and this 
cannot be explained by the other variables in the data. Although routinely collected, there is 
evidence that some demographic information may not be collected for a specific reason 
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rather than a random instance, i.e. MNAR. BMI is one demographic that may be MNAR. 
Weight, used to calculate BMI, is more likely to be taken in women, patients who are older, 
or patients who look overweight (Bhaskaran, Forbes, Douglas, Leon, & Smeeth, 2013). Data 
that are MNAR are not suitable to be imputed by multiple imputation (MI) techniques as the 
results produced are biased (Sterne et al., 2009). 
 
4.3.1.6 Independent Scientific Advisory Committee 
A requirement before beginning a CPRD study is to obtain approval from the CPRD 
Independent Scientific Advisory Committee (ISAC), detailing a full protocol and analysis plan 
for the data. This protocol is submitted to ISAC so they can ensure the standard of studies 
using CPRD is maintained, and to ensure that the most appropriate methods are used to 
conduct the study using CPRD data (CPRD, 2020b). The ISAC application contains all the 
objectives for the project and details methods and specifics of the analysis to be carried out. 
Researchers must state in the ISAC to which databases linkage will be required. CPRD has 
ethics approval from the National Research Ethics Service Committee (NRES) for 
observational research only, as in the case for this thesis. Separate ethical approval is 
required for studies that directly involve contacting patients. 
After the ISAC is submitted it undergoes internal peer-review. Any comments or changes 
suggested by the reviewers must be addressed to receive protocol approval. Only after the 
protocol has been approved by the ISAC can the data be accessed by the CPRD licence fob 
holder from the host department. A fob holder is a member of staff at the host department 
that accesses the CPRD databases for the data required for each approved ISAC protocol. If 




4.4 GCA research in CPRD 
CPRD has been used previously to investigate GCA (Durand & Thomas, 2012; Li et al., 2017; 
Li, Neogi, & Jick, 2018; Paskins et al., 2018; Petri et al., 2015; J. C. Robson et al., 2015; 
Smeeth et al., 2006), with the majority of studies investigating the association between GCA 
and other comorbidities after a GCA diagnosis. Durand & Thomas (2012) concluded that 
patients diagnosed with GCA have an increased risk of systemic infections within the first 
few months of diagnosis. Li et al (2017) concluded that patients with GCA were more likely 
than non-vasculitis patients to have vascular diseases prior to and after a diagnosis of GCA. 
Paskins et al (2018) concluded that patients with GCA had an increased fracture risk, and 
Robson et al (2015) found that patients with GCA have a twofold increase in risk of an aortic 
aneurysm after diagnosis. 
Two of the largest studies to date were conducted by Smeeth et al (2006) and Petri et al 
(2015) and focused on the incidence and prevalence of GCA in the UK, jointly covering a 
twenty year period. Smeeth et al (2006) focused their study on the incidence and prevalence 
of GCA from 1990 to 2001. To be included as a GCA case, patients had to be 40 years or 
older, have a first diagnosis of GCA within the study period, and have two prescriptions of 
oral glucocorticoids; one within 6 months of the date of first diagnosis, and the second 
within 6 months of the first prescription, to indicate a clinical response to glucocorticoids. 
Diagnoses recorded within the first 6 months from registration were excluded from the 
analysis. This is because when a patient first registers at a practice any important or relevant 
conditions are often recorded by the doctor along with a relevant date. The date of the first 
GCA diagnosis can be subject to recall bias and may, therefore, be incorrect. Smeeth et al 
(2006) initially conducted a small validation study of GCA diagnoses in CPRD. In the UK, a 
GCA diagnosis is usually confirmed by a specialist, with the GP typically being informed by 
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clinical letter from the hospital after the patient has been referred there by their GP. These 
letters were requested from a sample of 50 patients who had a diagnosis of GCA in their 
primary care record. However, it was not stated whether these were a random sample. Of 
the 50 requested, 45 were obtained. It was found that the coding of GCA was supported in 
91% of cases. 
Smeeth et al (2006) identified 3298 patients who had a diagnosis of GCA in the study period 
and who met the inclusion criteria. The overall age-adjusted incidence rate was 2.2 per 
10,000 person-years. The study found no increase in the incidence of GCA in the UK during 
the study period. They did find that a first diagnosis of GCA was more likely to happen in the 
summer months, and after a factor for seasonality was added to the analysis, it was found 
that this association was unlikely to be due to random error (Smeeth et al., 2006). The 
largest incidence rate was 7.6 per 10,000 person-years in women between the ages of 70 
and 79 years. 
Approximately a decade after Smeeth et al, Petri et al (2015) also modelled the incidence 
and prevalence of GCA using CPRD, but for a later time period, 2000 to 2011. They also 
investigated treatment pathways for GCA patients prescribed glucocorticoids (Petri et al., 
2015). Their definition of a GCA patient was different from that used by Smeeth et al (2006). 
To be included as a GCA case, patients had to be 50 years or older at the time of diagnosis, 
have 1 or more Read codes for GCA in their record, and have 1 or more prescriptions of oral 
or systemic glucocorticoids at or within 6 months of the first diagnosis of GCA. Patients with 
a record of GCA in the first 6 months of their registration at the practice were excluded from 




Petri et al (2015) found 4671 cases of GCA after applying all of the inclusion criteria. Their 
overall incidence was 1.0 per 10,000 person-years in patients 50 years and over. They do not 
address why this value was half of that found by Smeeth et al (2006). 
 
4.5 Overview of Methods 
This section will briefly cover the development of code lists, the definition of the GCA study 
population, and information on the variables and files of CPRD GOLD that were used in the 
analysis within this thesis. The statistical software programmes R, R studio, and STATA were 




The ISAC protocol for this study, completed by LAB, was submitted in December 2018 and 
approved with no recommended changes in January 2019 (protocol number 18_315). The 
entire process, from starting draft protocol to approval took 11 months to complete. An 
amendment, indicating access to HES was no longer required, to the ISAC was submitted in 
October 2019 and approved in the same month (Appendix 4.1).  
 
4.5.2 Code lists 
In order to identify GCA cases a list of Read codes for a GCA diagnosis was compiled. Read 
code lists are developed to ensure that all cases are identified in the records as there is often 
more than one Read code that can be used to record a diagnosis. To define GCA, the CPRD 
code browser was searched for the terms “Giant cell arteritis”, “temporal arteritis”, and 
“GCA”. In the instances where previous publications (NHS, 2020; Petri et al., 2015; Springate 
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et al., 2014) had released their code lists for GCA, these were also checked and incorporated. 
A total of 5 Read codes relevant to a diagnosis of GCA were found and mapped to CPRD 
medcodes. The final list of GCA codes were approved by the supervision team (Table 4.2).  
 
Table 4.2: Read codes and terms for all GCA related conditions, with mapping to the CPRD 
Medcode. 
Read Term Read Code CPRD Medcode (GOLD) 
Giant cell arteritis G755 10432 
Giant cell arteritis NOS G755z00 68403 
Temporal Arteritis G755100 3275 
Giant cell arteritis with Polymalgia Rheumatica N200 29472 
[X] Other giant cell arteritis Nyu4100 53789 
 
Code lists for symptoms and comorbidities (clinical features) to be investigated in the study 
were identified using the CPRD code browser (Appendix 4.2, Table 1). In addition, published 
code lists from previously published studies were also searched for relevant Read codes, 
with the corresponding medcode identified through the CPRD browser. For comorbidities 
such as hypertension, anxiety/depression, diabetes, and cardiovascular/cerebrovascular 
incidents, internally developed Read codes from the host department 
(https://www.keele.ac.uk/mrr/) were included in the final lists used for analysis. A prodcode 
list of glucocorticoid prescriptions had already been internally developed and validated in 
the host department. This list was thus used in this thesis (Appendix 4.2, Table 2).  
 
4.5.3 GCA study population 
Patients who had a GCA code recorded in their file between 1990 (start date of Smeeth et al, 
2016) and end of 2017 (year of ISAC submission), who were 40 years or over and 
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contributing up to standard data at the time of first recorded diagnosis of GCA had their data 
extracted from CPRD by the fob holder. Start dates for each GCA case were defined as the 
latest of; the date the patient turned 40, the start of the study (01/01/1990), and the 
practice UTS date. End dates were defined as the earliest of; patient transfer out date, 
patient’s date of death, the end of the study (01/01/2018), the date of last collection of 
CPRD data from the practice, and date of GCA diagnosis. A sensitivity analysis was also 
conducted where feasible where the GCA case definition was widened to incorporate 
prescription information on glucocorticoids. Patients had to have one or more prescriptions 
of glucocorticoids within six months after the first GCA diagnosis. A comparison of GCA case 
definitions between this thesis and the two previously published articles most relevant to 
the work conducted in this thesis can be seen in  
Table 4.3. 
 
Table 4.3: A comparison of GCA study population definition between this thesis and two 
previously conducted studies on GCA. 
This thesis Smeeth et al (2006) Petri et al (2015) 
Main analysis: 
• 40 years or older 
 
• Contributing UTS data 
 






• All of the above 
 
• One or more prescriptions 
of glucocorticoids within 
the first 6 months after 
first GCA diagnosis 
 
 
• 40 years or older 
 
• Contributing UTS data 
 
• Diagnostic code for GCA 
 
 
• One glucocorticoid 
prescription within 6 
months of first GCA 
diagnosis 
 
• A further prescription of 
glucocorticoids within 6 
months of the first 
 




• Diagnostic Read code for 
GCA 
 
• One or more prescriptions 
for oral or systemic 
glucocorticoids at or within 





This GCA study population was the basis for all further analysis in this thesis; investigating 
the association between clinical features and a subsequent diagnosis of GCA (Chapter 6), 
ascertainment of common patterns of clinical features prior to a diagnosis of GCA (Chapter 





Chapter 5: The incidence and prevalence of GCA in UK primary care 
5.1 Chapter overview 
This chapter details the background, methods and results for an incidence and prevalence 
study of GCA in the UK using the Clinical Practice Research Datalink (CPRD).   
 
5.2 Introduction 
Incidence and prevalence data of conditions in any population is important information as 
this helps to inform relevant disease management, the allocation of healthcare funding, and 
resources for the investigation and treatment of any condition. The incidence and 
prevalence of GCA in the UK has most recently been examined by Petri et al (2015). Petri et 
al found an overall incidence of GCA of 1 per 10,000 person-years in patients 50 years and 
over from data taken from 2000-2011, in comparison to Smeeth et al (2006) who reported 
an incidence of 2 per 10,000 person-years in patients aged 40 years and over from data 
taken from 1990-2001. This difference between the two time periods of previous research 
shows the necessity for examining the entire time period, from 1990 onwards, to develop a 
clearer estimate of GCA incidence in the UK and how it is changing. The study by Petri et al 
concluded in 2012 (Petri et al., 2015)(Petri et al., 2015)(Petri et al., 2015)(Petri et al., 
2015)(Petri et al., 2015) which leaves the most recent years’ data relating to GCA unavailable 
to healthcare workers and officials and this is important given advances in investigative 
approaches and fast track pathways for suspected GCA, described in Chapter 2 section 2.3.  
Incidence is defined as how many new cases of a disease are recorded in a given period of 
time, usually on an annual basis (annual incidence). In contrast, prevalence describes how 
many cases there are overall, both new and existing, within a period (period prevalence) or 
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at a certain time (point prevalence). Previous studies into the incidence and prevalence of 
GCA have used primary care consultation data, as this is an available resource that details 
the information needed to calculate these figures based on patients presenting to 
healthcare, the subsequent findings are generalisable to the UK population, and allows 
geographical variation to be investigated. By using this data, it is possible to see how many 
patients had this condition recorded on their file and what treatment was prescribed. It is 
vital to know how prevalence and incidence changes over time so resources can be directed 
accordingly and training given where appropriate to manage these conditions suitably. This 
thesis will look at annual consultation incidence (the number of patients with the first 
recorded (coded) GCA diagnosis in primary care within a year), and the annual consultation 
prevalence (the number of patients with new or ongoing GCA, with a recorded (coded) 
diagnosis in primary care within the year). 
 
5.3 Aims and objectives 
The aim is to estimate the incidence and prevalence of GCA in UK primary care and model 
their trends over time. The primary objective is to determine trends in annual consultation 
incidence of GCA over time. The secondary objective is to determine the annual consultation 
prevalence of GCA. 
 
5.4 Methods 
5.4.1 Study design 
A cohort study was conducted to examine the annual consultation incidence and prevalence 
of GCA in the UK and their trend from 1990 to 2017, using CPRD data. The consultation 
incidence was stratified by age, gender, and geographical region of the UK to allow for closer 
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examination and comparison between these factors. Age-standardisation was applied to the 
annual consultation incidence estimates using population data published by the Office of 
National Statistics (ONS). Finally, a sensitivity analysis was conducted to test the robustness 
of the definition used to define GCA cases. 
 
5.4.1.1 GCA cases 
As described in Chapter 4, section 4.5.3, for the primary analysis GCA cases were defined 
using only relevant Read codes. In a sensitivity analysis, the requirement was added that 
patients also needed a record of a glucocorticoid prescription alongside the GCA Read code, 
i.e. GCA cases had to have a Read code for GCA, and one or more glucocorticoid 
prescriptions within 6 months of first diagnosis (Petri et al., 2015). The start date for each 
case was the latest of;  
1. The date the patient turned 40 years of age 
2. The start of the study (01/01/1990) 
3. The patient’s practice’s up to standard date 
4. The current start of registration date plus 2 years 
All four criteria were used to determine consultation incidence, whilst only the first three 
were used for consultation prevalence as the fourth was used to exclude prevalent cases 
when calculating incidence. End dates were defined as the earliest of; 
1. Patient transfer out date 
2. Patient’s date of death 
3. The end of the study (01/01/2018) 
4. The date of last collection of CPRD data from their practice 




5.4.1.2 Denominator population 
The denominator population was all patients aged 40 years or over and who had passed the 
quality checks used by CPRD detailed in chapter 4 section 4.3.1.2. A start and an end date 
were also created for each member of the denominator population using the same 
definitions as described in section 5.4.1.1, with the exception of date of GCA diagnosis which 
is not applicable to the denominator population. 
Files were merged to create one final dataset to be used for the consultation incidence 
analysis which contained demographic information for all eligible IDs (both GCA cases and 




5.4.2.1 Consultation Incidence 
To calculate the annual consultation incidence rates the numerator was the number of new 
GCA cases (i.e. patients aged 40 years and over with a first ever record of GCA) in a year 
(January-December), using the date of first GCA code recording as the index date. The 
denominator was total person-years (P-Y) at risk during that year, summed across everyone 
aged 40 years and over, with no prior record of GCA, and who contributed up-to-standard 
data during that year. 
Crude and age-standardised consultation incidence per 10,000 P-Y were calculated annually 
with 95% confidence intervals from 1990-2017. Overall crude rates (from 1990-2017) were 
then stratified by age (40-49, 50-59, 60-69, 70-79, 80-89, & 90+), gender (male and female), 
geographical region (1-13 regions), age by gender, and region by year grouped into 5-year 
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increments (1990-1994…2015-2017). Age was categorised to allow comparison of 
consultation incidence by age, and 10 year increments were chosen as this has been used in 
previous UK incidence/prevalence studies of GCA (Petri et al., 2015; Smeeth et al., 2006).  
Age standardisation using UK population estimates for 2016, the most recent year’s 
population data available taken from the ONS, was applied to the yearly incidence 
estimates. This was conducted so that the estimates from CPRD would reflect the UK 
population age-structure, thereby improving the generalisability of the consultation 
incidence estimates, and allowing fair comparison over time given that the age-gender 
structure of the population may change (B. Robson, Purdie, Cram, & Simmonds, 2007). All 
consultation incidence estimates and 95% confidence intervals were calculated using STATA 
v15 (StataCorp., 2017). All plots of consultation incidence were produced using the ggplot 
package of R v3.5.2 (R Core Team, 2017).  
Following the descriptive approach described above, the independent association of the 
covariates with consultation incidence of GCA was modelled. There are two commonly 
accepted forms of modelling count/rate data. These are Poisson regression, and negative 
binomial regression. As the names imply, Poisson regression assumes that the response 
variable, in this case incidence rates, follow the Poisson distribution, whereas the negative 
binomial assumes the incidence rates follow a negative binomial distribution. The main 
difference between the two models is that the Poisson distribution assumes that the 
conditional variance and conditional mean are the same (Frome & Checkoway, 1985). This is 
not always appropriate and is dependent on the type of response data (UCLA, 2019). This 
assumption can be checked via a Pearson Chi-squared test (UCLA, 2019). This test checks the 
goodness of fit of the models. Previous studies into the incidence of GCA (Brekke et al., 
132 
 
2017; Smeeth et al., 2006) have used Poisson models, hence for this study Poisson 
regression models will be fitted to the incidence data. 
The covariates used were age (categorised into 10-year groups), gender (male and female), 
geographical region (1-13), and year (categorised into 5-year groups). The North East of 
England was set as the reference category for region as it is coded as number 1 in CPRD and 
lack of evidence that another region should be used as reference. The age group 60-69 was 
the reference category for age as there is evidence this is the age group where the incidence 
of GCA begins to rise (Petri et al., 2015). 
 
5.4.2.2 Incident trends over time  
To estimate the change in trends over time of annual GCA consultation incidence, joinpoint 
regression was used. This methodology is often used when the temporal trend is of interest 
(Doucet, Rochette, & Hamel, 2016; John & Hanke, 2015; Tyczynski, 2005). This methodology 
was chosen over time series methods (Wah et al., 2014) as it offers more information on 
where there are changes in trend which can help to identify events or policy changes that 
affect disease incidence. 
Joinpoint regression was developed by the National Cancer Institute to model the trends in 
cancer mortality over time (National Cancer Institute, 2019d), but can be applied to measure 
the trend in most types of data (Rea et al., 2017). It fits the simplest joinpoint model that the 
data will allow (National Cancer Institute, 2019c). A joinpoint is the name given to the time 
point where there is a change in the underlying trend (National Cancer Institute, 2019d). 
There is some flexibility in regards to the number of joinpoints in the model, and the 
minimum and maximum to be assessed should be specified before fitting (National Cancer 
Institute, 2019c). However, the final number of joinpoints cannot be fixed beforehand (Rea 
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et al., 2017). The final number of joinpoints in the model are calculated from the available 
model selection criteria. For this study, three criteria were compared since there is no 
general consensus on which method provides the best model.  
The first was the Monte Carlo permutation test method, this is done through a series of 
hypothesis tests (Rea et al., 2017). The simpler model, or the one with fewer number of 
joinpoints, is the null model, and the model with one more joinpoint is the alternative 
model. If the null model (starting with no joinpoints) is rejected, then the model with the 
greater number of joinpoints is chosen as the new null model. This step is repeated until the 
null model can no longer be rejected, and this model will be the final model (Rea et al., 
2017). Permutation tests usually choose fewer joinpoints than other model selection criteria 
(National Cancer Institute, 2019b). 
The second model selection method is the Bayesian Information Criteria (BIC), which is 
discussed in further detail in Chapter 7 section 7.4.2.1. The BIC is a common method of 
model selection that relies on Bayesian methodology to choose the best method (Posada & 
Buckley, 2004). The smaller the BIC the better the model.  
The modified BIC (the third model used) was developed by Zhang and Siegmund (2007) 
specifically for change-point processes (Zhang & Siegmund, 2007). They argue that classic 
BIC does not work well in data with change-points due to the irregularities in the likelihood 
function. The Joinpoint model with the smallest BIC, or modified BIC is chosen (National 
Cancer Institute, 2019b). If all three model selection methods produced different joinpoint 
models then the most appropriate model would be reached via a consensus with the wider 
supervisory team. 
The minimum and maximum number of joinpoints are dependent on the number of points 
(years) where there is data available: this can be specified by the user. The minimum 
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number of joinpoints was selected to be 0, as there was a possibility of there being no 
change in trend in the incidence data. The recommended maximum number of joinpoints for 
the number of years included in this study is 5 (years 1990-2017 = 28 datapoints) (National 
Cancer Institute, 2019e). Joinpoint surveillance programme v4.6.0.0 was used to fit the 
Joinpoint regression, for which the three methods of model selection were compared. 
For every model the Annual Percent Change (APC) is calculated to interpret the change in 
trend over time (National Cancer Institute, 2019a). With this approach, rates are assumed to 
change each year at a constant percentage of the rate from the previous year. Each segment 
(i.e. time between two joinpoints) of the joinpoint model will have an APC value that may 
differ from other segments (National Cancer Institute, 2019a). 
 
5.4.2.3 Consultation Prevalence 
To determine annual consultation prevalence, the numerator was defined as the total 
number of people with at least one recorded GCA consultation during the year. Patients 
could only contribute one consultation of GCA per year. The denominator was the number 
of people aged 40 years and over registered at any point in the year and contributing up-to-
standard data in CPRD during that year. Consultation prevalence was calculated annually. 
Age standardisation was completed on the annual consultation prevalence using the same 
methodology as applied to the annual consultation incidence, described in section 5.4.2.1. 
 
5.4.2.4 Sensitivity analysis 
A sensitivity analysis was conducted by including glucocorticoid prescriptions in the 
definition of GCA cases, to investigate if this would have an effect on the incidence rates. In 
the main analysis, only Read codes were used to define GCA cases. Previous studies (Petri et 
135 
 
al., 2015; Smeeth et al., 2006) have incorporated prescription information into their GCA 
case definition. For this thesis, to be eligible for inclusion in the sensitivity analysis, a patient 
with GCA had to have a Read code for GCA and one or more prescriptions for glucocorticoids 
within the first 6 months after a GCA diagnosis. 
 
5.5 Results 
5.5.1 Sample characteristics 
The size of the total sample was 6,631,005 patients, which contained 9205 patients with a 
coded record of GCA and 6,621,800 without a record of GCA. 71% of the GCA patients were 
female and 52% of those without a record of GCA were female. The mean age at diagnosis 
for GCA patients was 72.6 years (SD = 10.3). For the sensitivity analysis, the total number of 
GCA patients was 8244; i.e. 89.6% of those with a GCA Read code also fulfilled the sensitivity 
analysis criteria. 
 
5.5.2 Annual Consultation Incidence 
The years with the lowest consultation incidence were 1990-1991, with 1990 having an 
incidence of 0.08 per 10,000 person-years (P-Y). Results tables for annual consultation 
incidence can be seen in Appendix 5.1, Table 1. There was an increase in the annual 
consultation incidence of GCA from 1990-1994, with a subsequent decrease in the annual 
consultation incidence from 1994 to 2001, and a further decrease from 2002 to 2017 (Figure 
5.1). The year with the highest overall consultation incidence of GCA in UK patients 40 years 
and older was 1994, with an incidence of 2.29 (95% CI: 1.96, 2.67) per 10,000 P-Y. After age-
standardisation was applied the consultation incidence rates did not greatly change (Figure 
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5.2). The results on consultation incidence from the sensitivity analysis were similar to the 












Figure 5.2: Annual incidence of GCA showing crude rates and age adjusted rates for 1990-2017. 
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Trends over time were assessed using joinpoint regression. The BIC model selection criteria 
suggested the optimal model had two joinpoints, placed at 1992 and 1999 (Figure 5.3). The 
trend from 1990-1992 was sharply increasing, but this is to be expected given these were 
the years with the lowest incidence rates. The incidence decreased from 1992-1999 by 
5.68% per year, then by 0.31% per year from 1999-2017. 
The resulting models from the permutation test and modified BIC can be seen in Appendix 
5.1, Figures 1-2, respectively. The modified BIC model produced identical results to the 
Monte Carlo permutation test. These models resulted in 1 joinpoint at 1992, and assumed 
there was a constant decreasing trend of 1.46% per year from 1992-2017.  
Due to the incidence in the years 1990-1991 being considerably lower than the rest of the 
time period, these were removed as probable outliers and the joinpoint regression model 
refitted using the same model selection criteria. The BIC (Figure 5.4) and the permutation 
test (Appendix 5.1, Figure 3) both suggested 3 joinpoints, at 1994, 2000, and 2004, as the 
optimal model. There was a sharp increasing trend from 1992-1994, with an increase in 
incidence of 10.73% per year, followed by a sharp decrease of 7.74% per year from 1994-
2000. There was then another increase of 4.58% per year from 2000-2004, and then a 
shallow decrease of 1.20% per year from 2004-2017. The modified BIC (Appendix 5.1, Figure 
4) result gave no joinpoints, and a constant decrease of 1.21% per year. 
The preferred model, reached via discussion with the wider team, was fitted to the data 
from 1992-2017 and included 3 joinpoints (Figure 5.4), and was selected by both BIC and 
permutation test model selection. It indicates there is a potentially increasing trend between 









Figure 5.4: Optimal Joinpoint model fitted on the years 1992-2017 with the BIC model selection. 
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5.5.3 Stratified incidence 
5.5.3.1 Age 
The consultation incidence rates from 1990 to 2017 were stratified by age. The highest 
incidence rate was observed in patients who were between 80 and 89 years (Table 5.1), with 
an overall consultation incidence of 4.30 per 10,000 person-years (P-Y) (95% CI: 4.10, 4.50). 
The lowest consultation incidence was for those aged between 40 and 49 years (0.15 per 
10,000 P-Y, 95% CI: 0.13, 0.17). The results from the sensitivity analysis showed a similar 
pattern (Appendix 5.1, Table 7). 
 
Table 5.1:  Incidence of GCA per 10,000 person-years stratified by age, with 95% confidence 
intervals across all years. 
Age (years) Incidence per 10,000 P-Y 95% CI 
40-49 0.15 (0.13, 0.17) 
50-59 0.64 (0.60, 0.68) 
60-69 1.90 (1.80, 2.00) 
70-79 4.10 (4.00, 4.20) 
80-89 4.30 (4.10, 4.50) 









The annual consultation incidences for women were consistently higher than those for men, 
irrespective of year (Figure 5.5).  All annual gender stratified incidence rates and 
corresponding 95% confidence intervals can be seen in Appendix 5.1, Table 3. When further 
stratified by age and combining all years from 1990-2017, females between the ages of 70 
and 79 (Figure 5.6) had the highest overall incidence rate of 5.20 per 10,000 P-Y (95% CI: 5.0, 
5.4). The highest incidence for men (3.10 (95% CI: 2.80, 3.40) per 10,000 P-Y) occurred 
between the ages of 80 and 89 years. Incidence was consistently higher for women across all 
ages (Appendix 5.1, Table 4). Results from the sensitivity analysis were similar (Appendix 5.1, 









Figure 5.6: Incidence of GCA per 10,000 person-years stratified by age and gender. 
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5.5.3.3 Consultation Incidence rates by UK region 
The region of the UK with the highest incidence rate of GCA between 2015 and 2017 (Figure 
5.8) was Yorkshire & the Humber with 2.63 per 10,000 P-Y (95% CI: 1.49, 4.63). There were 
no practices from the East Midlands contributing data to CPRD after 2014 so this region 
could not be included in the analysis between 2015 and 2017. The regions with the lowest 
incidence (both 1.13 per 10,000 P-Y) between 2015 and 2017 were the North East (95% CI: 
0.51, 2.51) and the West Midlands (95% CI: 0.85, 1.50). Incidence by region for years 1990-
2014 can be seen in Figure 5.7 & Figure 5.8. There was little consistency in regional 
differences over the time-period, with every region having varying incidence rates across 





Figure 5.7: Incidence per 10,000 person-years map of the UK by each of the 13 regions included in CPRD for the years:  





Figure 5.8: Incidence of GCA per 10,000 person-years map of the UK by each of the 13 regions included in CPRD for the years; 
(A) 2005-2009; (B) 2010-2014; (C) 2015-2017 
C B A 
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5.5.3.4 The association of covariates with consultation incidence 
The unadjusted Poisson regression (Table 5.2) showed that females had a 2.21 times higher 
consultation incidence rate than males (95% CI: 2.11, 2.31), combining all years. London and 
Northern Ireland were the only regions of the UK with the suggestion of a decreased 
consultation incidence rate of GCA compared to the North East of England, with 15.1% and 
5% decrease, respectively. However, these were not statistically significant. 
In the adjusted model (Table 5.2) females had an almost double (95.6% higher) consultation 
incidence rate compared to males (IRR: 1.96; 95% CI: 1.87, 2.05). After adjustment for other 
variables, London and Northern Ireland continued to have a (non-significant) decreased 
consultation incidence rate when compared with the North East. Yorkshire and the Humber 
had a 29.1% increase in consultation incidence rate compared to the North East across all 
years 1990-2017. Age groups 40-49, 50-59, and 90+ years all had a significantly lower 
consultation incidence rates when compared with 60-69 years. Consultation incidence rate 
for 70-79 (IRR: 2.07, 95% CI: 1.76, 2.18) and 80-89 (IRR: 2.07, 95% CI: 1.95, 2.20) age groups 





Table 5.2: Incidence rates of GCA in the UK, by covariate.  
Covariate Unadjusted 
IRR 
95% CI Adjustedꝉ 
IRR 
95% CI 




North East Ref 
 
Ref  
North West 1.138 (0.950, 1.364) 1.140 (0.951, 1.365) 
Yorkshire and The 
Humber 
1.333 (1.094, 1.624) 
1.291 (1.059, 1.574) 
East Midlands 1.360 (1.115, 1.658) 1.335 (1.094, 1.629) 
West Midlands 1.044 (0.869, 1.254) 1.019 (0.848, 1.224) 
East of England 1.293 (1.077, 1.551) 1.277 (1.064, 1.532) 
South West 1.209 (1.008, 1.449) 1.125 (0.938, 1.349) 
South Central 1.016 (0.847, 1.218) 0.972 (0.811, 1.166) 
London 0.849 (0.703, 1.024) 0.915 (0.758, 1.104) 
South East 1.163 (0.971, 1.394) 1.118 (0.933, 1.340) 
Northern Ireland 0.950 (0.773, 1.169) 0.993 (0.807, 1.221) 
Scotland 1.044 (0.871, 1.251) 1.086 (0.906, 1.303) 
Wales 1.366 (1.143, 1.633) 1.319 (1.104, 1.578) 
Age     
40-49 0.077 (0.068, 0.088) 0.080 (0.070, 0.091) 
50-59 0.331 (0.306, 0.358) 0.338 (0.312, 0.365) 
60-69 Ref  Ref  
70-79 2.128 (2.018, 2.244) 2.068 (1.761, 2.181) 
80-89 2.216 (2.087, 2.353) 2.072 (1.951, 2.200) 




1990-1994 0.894 (0.799, 1.001) 0.921 (0.823, 1.031) 
1995-1999 Ref  Ref  
2000-2004 0.888 (0.821, 0.960) 0.871 (0.805, 0.941) 
2005-2009 0.915 (0.850, 0.985) 0.898 (0.833, 0.967) 
2010-2014 0.854 (0.793, 0.920) 0.854 (0.792, 0.921) 
2015-2017 0.846 (0.775, 0.924) 0.890 (0.814, 0.974) 
ꝉ Adjusted for female, region, age, and year.  









5.5.4 Consultation Prevalence 
The highest annual consultation prevalence (Figure 5.9) was observed in 1995 with 6.86 
people consulting with GCA per 10,000 P-Y (95% CI: 6.28, 7.48). From 1995 onwards the 
annual consultation prevalence ranged between 4 and 6 per 10,000 P-Y. The trend in annual 
consultation prevalence is almost identical to the trend found for annual consultation 
incidence. A table of annual consultation prevalence estimates can be found in Appendix 5.1, 
Table 5. After age-standardisation was applied (Appendix 5.1, Table 6), the highest 














This large national study of patients with GCA has shown that the annual incidence of GCA in 
the UK has gradually decreased from 1992-2017, except for a small increase between 2000 
and 2004. Females across all ages have consistently higher incidence of GCA than men, with 
those aged between 70 and 79 having the highest overall incidence. Between 2015 and 2017 
the region of the UK with the highest incidence was Yorkshire and the Humber. After age-
standardisation was applied, the crude and adjusted incidence rates were very similar. The 
annual primary care consultation prevalence of GCA in the UK has gradually decreased from 
1996 to 2017, with small variation between years.  
 
5.1.1 Trend of GCA in the UK 
When investigating the trend in GCA incidence, it became clear that there were three time 
points where the trend in GCA consultation incidence changed between 1992 and 2017. In 
2000 the trend changed from decreasing to increasing, until 2004. There does not appear to 
be any clinical reason for this sudden change in trend as there is no obviously known 
changes to medical guidelines regarding the management or treatment of GCA in these 
years. The trend again changes in 2004, and continues to decrease for the rest of the time 
period, until 2017. 
The incidence rates from 1990-1992 are very small, compared to the incidence rate for years 
1993-1995 which are the highest of the entire time period. One reason for these results is 
the 1990 ACR criteria. Prior to the release of these criteria there was very little research 
published concerning GCA, and few clinical features that were reported to be associated 
(Gene G. Hunder et al., 1990). It could be that the low incidence estimates observed 
between 1990 and 1992 were due to a lack of recognition and understanding of GCA as a 
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condition in primary care, and the increase in incidence from 1993-1995 is an 
overcompensation, or is during a wave of GCA research following the release of the ACR 
1990 criteria. This may be a similar reason for the increase in incidence between 2000 and 
2004. 
These changes in trend were all captured by the Joinpoint model. Different methods of 
model selection were used and compared to identify which produced the best model, both 
statistically and clinically. The final model, which included 3 joinpoints that reflect the 
changes in trend as described above, was selected by two of the three model selection 
criteria that was applied in the analysis. After discussion with the supervisory team, it was 
decided that this model best described the changes in trend seen in the data, without 
overfitting. The model that was produced by the final model selection criteria (modified BIC) 
was deemed to be under-fitted, as it missed the small change in trend from 2000-2004. 
 
5.6.1 Comparison to other literature 
There have been two previous studies investigating GCA in the UK population using 
electronic health records. The study by Smeeth et al. (2006) investigated the incidence of 
GCA (defined as Temporal Arteritis) between 1990 and 2001. The overall age-adjusted 
incidence rate for the entire time-period was reported as 2.2 per 10,000 P-Y. They did report 
a small decrease in the incidence over this time-period, identical to the trend found in the 
same time period in this thesis. As with this study, females at each age group, from 40 years 
to 80+ years had consistently higher incidence rates of GCA than males. Smeeth et al (2006) 
found that the age standardised incidence rates varied by region of the UK, showing that 
GCA was more common in the south from 1990 to 2001. The results from this thesis found 
156 
 
variation in the incidence rates between regions with no discernible North/South pattern. 
Scotland did have consistently lower estimates than certain regions of England. 
 The second study was by Petri et al (2015) and was conducted on data from 2000 to 2011. 
Incidence rates were stratified by age and gender. Annual incidence rates of GCA were not 
reported in the article. The overall incidence rate of GCA reported by Petri et al (2015) was 
1.0 per 10,000 P-Y. Again females had a higher incidence rate of GCA than males, with the 
highest incidence in females aged between 70 and 79 years. 
There were a few small differences between the two articles and this thesis. All three had 
slightly different eligibility criteria for GCA cases to be included in the analysis. For instance, 
Smeeth et al (2006) required 6 months of prior registration at a practice to be eligible, 
whereas this thesis required 2 years. Regardless of differing eligibility criteria, the 
populations should be similar enough to draw some comparisons (Table 5.3). 
 
Table 5.3: Comparison of methods and patient eligibility between the two previously 
published articles on the incidence of GCA in the UK using CPRD, and this thesis. 




• Aged 40 years and over 
at first GCA diagnosis 
• Read code for GCA 
• Contributing UTS data 
• A prescription of 
glucocorticoids within 6 
months of first GCA 
diagnosis 
• A second prescription 
within 6 months of the 
first 
• Aged 50 years and 
over at first GCA 
diagnosis 
• Read code for GCA 
• Contributing UTS data 
• One or more 
prescriptions of 
glucocorticoids within 
the first 6 months of 
GCA diagnosis 
• Aged 40 years and over 
at first GCA diagnosis 
• Read code for GCA 
• Contributing UTS data 
 
• (Sensitivity) One or 
more prescriptions of 
glucocorticoids within 





1990-2001 2000-2011 1990-2017 
GCA Read 
codes used 









A comparison between annual incidence rates can only be conducted between this thesis 
and Smeeth et al (2006), as Petri et al (2015) did not report these results. Overall, the 
incidence rates in this thesis were smaller than those in Smeeth et al (2006). The main 
difference between results lies in prior registration required for all GCA cases to be included 
in the analysis. As mentioned, Smeeth et al (2006) required 6 months of prior registration at 
a practice to be eligible, in contrast to the 2 years required in this analysis. This could mean 
that more prevalent GCA patients were included in the Smeeth et al (2006) analysis than in 
this thesis, hence the smaller consultation incidence estimates produced in this thesis. 
Comparison of incidence rates by age is possible between this thesis and Smeeth et al 
(2006); however, Petri et al (2015) only included age-gender stratified incidence rates and 
presented these results in a figure. Similarly to the annual incidence rates, the incidence 
rates from 1990-2001, stratified by age, are lower in this thesis than those reported by 
Smeeth et al (2006), but show a similar pattern. The incidence of GCA in patients younger 
than 70 years is low, with an increase after the age of 70 years. Incidence rates for the age 
groups from 40 years to 70 years were similar between Smeeth et al (2006) and this thesis. 
The main divergence came for the age groups 70-79 years and 80-89 years. However, both 
studies showed that these two groups had the highest incidence rate when compared to 
younger age groups. Comparisons can be made between the incidence rates stratified by 
both age and gender. As mentioned previously, Petri et al (2015) only reported these results 
in a figure. However, estimates of the incidence rates can be derived from the figure. The 
incidence rate of GCA by age and gender between this thesis and the two previous articles 
show a similar pattern. All show that females aged between 70 and 79 years have the 
highest incidence rate for GCA in the UK. As with previous comparisons between incidence 
rates of GCA between studies, the incidence rates in this thesis are smaller to those 
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published by Smeeth et al (2006) and Petri et al (2015), possibly due to differences in GCA 
case definition. However, all show a similar pattern. That females have consistently higher 
incidence rates of GCA, and that the highest incidence rate is observed in patients aged 70-
79 years. 
The final comparison can be made between regions of the UK. Smeeth et al (2006) found 
that the age standardised incidence ratios were larger for regions in the south of the UK. 
Results from this thesis showed that in the years of the Smeeth et al study (1990-2001), 
southern and eastern regions of England had the highest GCA incidence rates. Smeeth et al 
(2006) also found that Scotland had a much lower GCA incidence rate than the rest of the 
UK, a finding which was also found in this thesis. There was no discernible pattern found 
between regions of the UK from 1990-2001. 
 
5.6.2 Strengths and limitations 
The biggest strength of this study is the scope of the analysis, with over 25 years and over six 
million patients included, and over 9000 with a diagnosis of GCA. Both previously published 
studies have completed analysis on available data, usually a period of 11 years. This study 
includes data on more than double that period, at 27 years, from 1990 to 2017 and allows 
for continuity of data as these years were all included in the same analysis. This breadth of 
information has allowed the use of Joinpoint regression methodology to investigate how the 
trend of GCA in the UK has changed. No study has previously modelled the trends in 
incidence of GCA in the UK using Joinpoint regression in a primary care electronic health 
record setting, hence this approach is novel in UK primary care research.  
The main limitation of this study were the annual incidence estimates seen for the years 
1990-1992. These appeared to be outliers, and were greatly different to the rest of the 
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years. This could be due to differing definitions of GCA cases between this study and those 
published previously, and hence all three studies including a different number of GCA cases 
(Petri et al., 2015; Smeeth et al., 2006). A previous study (Jordan et al., 2007) which used 
CPRD to estimate annual consultation prevalence of musculoskeletal (MSK) conditions in 
CPRD also showed that the consultation prevalence was lower in 1991 for all MSK conditions 
than those calculated using other primary care databases for the same year. The authors 
theorised that this low prevalence could be due to not every consultation for chronic 
conditions being coded in a patient’s record (Jordan et al., 2007; Porcheret et al., 2004). It is 
possible that the coding of GCA in the early years of CPRD had a similar problem. 
 As a result, to model the trend of GCA these years were removed for a sensitivity analysis. 
Most importantly the trend model for 1993 to 2017 did not change when these were 
removed. In the case of incidence, the data from years 1990 to 1992 were noticeably lower 
to any other year. This could be due to poorer data quality in these years, lack of quick 
communication between secondary care where GCA patients are diagnosed and primary 
care health providers, or a lack of patients with the required 2 years of prior registration. 
Alternatively, CPRD may have applied quality checks to historical data from these years, 
which may have excluded patients as their data would not be of sufficient quality to include 
in research. The reason for the discrepancy in the years 1990-1992 can only be 
hypothesised. Previous studies into the incidence and prevalence of GCA in the UK have 
used a 6 month prior registration period (Petri et al., 2015; Smeeth et al., 2006), whereas in 
this study patients had to have 2 years of prior registration before they were included in the 
analysis.  
Another limitation is connected to the use of CPRD. Although GCA diagnosis in CPRD has 
been validated (Smeeth et al., 2006), this does not mean that every case of GCA is 
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successfully coded to a patient’s record. Since a GCA diagnosis is confirmed in secondary 
care, there may also be a delay in communication between primary and secondary care, 
hence the date of diagnosis of GCA can be incomplete in a patient’s record (Herrett et al., 
2015; Smeeth et al., 2006). However, the number of GCA patients not included in the 




This chapter has established the most up to date consultation incidence and consultation 
prevalence estimates of GCA in the UK. Overall, the trend in new cases of GCA is decreasing 
slowly and the greater presence of disease continues to be seen in women and the oldest. 
Not only has this chapter established the extent to which GCA is a problem in UK primary 
care, but also defined the study sample that will be used in the following chapters. The next 
steps are to improve understanding of the association of symptoms and comorbidities that 
present prior to a diagnosis of GCA, and to assess their relationship and magnitude 




Chapter 6: Associations of presenting clinical features and a diagnosis of GCA 
6.1 Chapter overview 
This chapter details the methods and results for conducting a case-control study 
investigating the association between the clinical features with which patients present in UK 




Previous studies investigating the clinical features which patients present with prior to a 
diagnosis of GCA have mainly been single centre and conducted in secondary care settings. 
The systematic review conducted in Chapter 3 showed that these studies did not 
consistently identify clinical features related to a subsequent diagnosis of GCA. Despite the 
review results indicating that headache, jaw claudication, anorexia, and constitutional 
symptoms were highly prevalent and associated with a diagnosis of GCA, there remained 
limitations due to many clinical features also being commonly observed in other conditions, 
unexplained heterogeneity in prevalence, and strength of associations with GCA between 
studies, variation in definitions of GCA diagnosis and clinical features, the point of 
measurement of these features, and lack of evidence for other clinical features. This review 
highlighted the need for a broad, rigorous study that used a more generalisable sample of 
patients set within primary care to investigate the relationship between the existence of 






The aim of this study is to quantify the association between the presenting clinical features 




6.4.1 Study population 
Patients diagnosed with GCA (defined in Chapter 5) from 1990-2017 were used as the cases 
for a case-control study. The control population were patients registered with a practice 
contributing to CPRD who were aged 40 years and over, and who did not have any record of 
a GCA diagnosis. 
GCA cases were matched to controls by their general practice, gender, and exact year of 
birth, on a ratio of 1:5 cases to controls. Whilst increasing the number of matched controls 
improves efficiency and the precision of the effect estimate, it has been shown that this 
improvement is minor in a ratio of more than 4 (Kuo, Duan, & Grady, 2018). Incomplete sets 
were permitted, i.e. if five matches could not be found for every case, a minimum ratio of 
1:1 cases to controls was used (Hamajima et al., 1994; Hennessy, Bilker, Berlin, & Strom, 
1999). Matching is a commonly used method to adjust for confounding prior to analysis. 
Patient demographics such as age, gender, and general practice are most commonly used as 
matching factors as these are important confounders and results can be influenced if they 
differ significantly between the case and control population (Kuo et al., 2018; Wacholder, 
Sllverman, Mclaughlin, & Mandel, 1992). 
Each case-control set had an index date assigned. This was the date of GCA diagnosis for the 
case in each set. Every consultation (GP visit that had been assigned a Read code) after the 
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index date was removed from the data before analysis, since this study was only 
investigating clinical features recorded prior to or on the same day as a GCA diagnosis. This 
included any recorded BMI, smoking, or alcohol consumption status. 
 
6.4.2 Clinical features 
As part of the ISAC process detailed in Chapter 4, code lists for each of the clinical features 
found in the systematic review (Chapter 3), were created using the CPRD and Read code 
browsers, published Read code lists from previous studies, validated Read code lists created 
and used by the host department (School of Medicine), or input from the supervisory team. 
These lists included mapping of Read codes to CPRD medcodes (Appendix 4.2). Lists included 
individual codes for other conditions, such as cardiovascular/cerebrovascular diseases, along 
with all codes associated with specific clinical features such as headache, anorexia, and 
visual impairment. 
If a clinical feature had been included in the review and/or meta-analysis, (Chapter 3, 
sections 3.5.4 & 3.5.5), then it was eligible to be included in the case-control study if relevant 
Read codes could be found. A total of 14 clinical features were investigated: headache, 
weight loss/anorexia, fever, fatigue, visual impairment, elevated ESR, 
cardiovascular/cerebrovascular conditions, hypertension, anxiety/depression, PMR, 
diabetes, jaw pain, and any cancer. Patients with each clinical feature were identified if the 
Read code for the clinical feature had been used in their record. Read codes used to define 
each clinical feature can be seen in Appendix 4.1, Table 1. 
Headache, visual impairment, PMR, and elevated ESR were all clinical features that were 
reported in a large proportion of the articles included in the systematic review (Chapter 3, 
section 3.5.5). Headache and visual impairment are also viewed as “classical” symptoms of 
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GCA and particularly relevant in primary care settings, from which CPRD draws its data, due 
to them being easily recognisable (Helliwell et al., 2018). Regarding PMR and elevated ESR, 
the review conducted in Chapter 3 showed a pooled prevalence of 34% and 76%, 
respectively, and positive association between elevated ESR and a diagnosis of GCA. 
Elevated ESR was defined as a recorded ESR value of ≥50 mm/h, a cut-off value used by the 
majority of the articles in the systematic review. 
Currently there is no Read code for jaw claudication, a symptom that has been shown to be 
highly associated with a diagnosis of GCA in the systematic review conducted in Chapter 3. 
Jaw pain was the closest term to jaw claudication that was available in the Read code 
hierarchy, and after discussion with the wider supervisory team, it was decided that this 
would be the code most likely used if a patient presented with jaw claudication. 
The definition of systemic/constitutional symptoms was relatively consistent across the 
fifteen articles that reported this clinical feature in the systematic review, with only three 
articles not providing a definition. Weight loss/anorexia, fever, asthenia, malaise, and fatigue 
were the symptoms most commonly included in the term systemic/constitutional symptoms 
by the articles that did give a definition. The most common combination of these were 
weight loss/anorexia, and either asthenia/fatigue/malaise. Fever was included in the 
definition in seven of the fifteen articles. A Read code for asthenia and malaise could not be 
found, but Read codes for fatigue were compiled. In the main analysis, fever, weight 
loss/anorexia, and fatigue were kept independent of each other. As a sensitivity analysis 
they were grouped under the heading constitutional symptoms. Three articles in the review 
defined constitutional symptoms using this definition.  
Anxiety/depression, cancer, and diabetes are both common in the general population, with 
an estimated 10.2 per 100 people aged over 65 years having a recorded diagnosis of 
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anxiety/depression (Public Health England, 2017), and between 8 and 11 per 1000 person-
years diagnosed with diabetes (Sharma, Nazareth, & Petersen, 2016). These conditions were 
not commonly reported in the articles included in the systematic review (4, 2, and 4 articles, 
respectively). However, due to their high prevalence in the population of interest (patients 
aged over 50 years) and lack of previous research into their association with a subsequent 
diagnosis of GCA, both were included in the case-control study. 
Hypertension was defined by two different criteria. If a patient had a record of a 
hypertension Read code then they would be classified as having recorded hypertension. The 
second definition used prescription information. If a patient had a record of two or more 
hypertension medications prescribed on unique days during the periods of interest (as 
defined in Section 6.4.3 below) then they would be classified as having treated hypertension. 
This decision was taken because Read codes for chronic conditions, such as hypertension, 
may be added to a patient’s record when initially diagnosed, and not used again thereafter, 
and may not specifically be consulted with routinely afterwards, particularly if well 
controlled. However, these patients will be treated with hypertensive medication (and 
coded as such) as it is a chronic condition. Therefore, to ensure all patients with 
hypertension were included in the analysis, prescription information was included in the 
definition of hypertension (Hippisley-Cox, Coupland, & Brindle, 2017). 
Previous research has been conducted into the relationship between cancer and GCA 
(Miguel A. Gonzalez-Gay et al., 2007; Hill et al., 2010; Tanaz A Kermani et al., 2010; Stamatis 
et al., 2020), although the majority of published articles investigate the association with 
cancer after a diagnosis of GCA. The general consensus of these articles is that there is no 
increase in the risk of cancer for patients with GCA compared to the general population 
(Miguel A. Gonzalez-Gay et al., 2007; Hill et al., 2010; Stamatis et al., 2020). One study which 
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investigated cancer prior to a diagnosis of GCA (Tanaz A Kermani et al., 2010) found that 
there was a low prevalence of malignancy in patients prior to their diagnosis of GCA, and 
that there was no increase in the odds of GCA if there was a prior record of cancer. However, 
this study was set in the USA, and included a small sample of GCA patients which could have 
made the statistical analysis underpowered. In order to investigate if there is any increase in 
the odds of a GCA diagnosis with a prior history of malignancy in a UK population, cancer in 
any location will be included in this case-control study. 
 
6.4.2.1 Time prior to GCA diagnosis 
Research examining the clinical features that are indicative of a subsequent diagnosis of 
conditions like psychosis, schizophrenia, multiple sclerosis, rheumatoid arthritis, and 
Parkinson’s disease have been published in recent years (Disanto et al., 2018; Mikanmaa et 
al., 2019; Muller et al., 2019; Postuma, 2019; Powers et al., 2020). The examined time-
periods over which patients experience specified clinical features prior to the diagnosis of 
interest varies between conditions. For conditions with long latency periods, such as 
Parkinson’s and multiple sclerosis, these time-periods are usually 5 years prior to diagnosis 
(Disanto et al., 2018; Marrie, 2019; Postuma, 2019). For other conditions, such as Type I 
diabetes, rheumatoid arthritis, and psychosis related conditions, this time period is most 
often 2 years prior to diagnosis, but can be 1 year prior to diagnosis (Addington et al., 2015; 
Muller et al., 2019; Townson, Cannings‐John, Francis, Thayer, & Gregory, 2019). This period 
is often stratified into months; 1 month prior to diagnosis, 6 months prior, 12 or 18 months 
prior, and 24 months prior to diagnosis, with all time periods being cumulative (Addington et 
al., 2015; Muller et al., 2019). Based on these recent and previously published studies the 
167 
 
time-periods chosen for this study were ≤1 month prior, 6 months prior, 12 months prior, 
and 24 months prior to a diagnosis of GCA, with time periods being cumulative. 
Symptoms, such as headache, visual impairment, and any non-chronic conditions were 
extracted from patients’ records for the periods 24, 12, 6, and ≤1 months prior to the date of 
GCA diagnosis (Muller et al., 2019). Chronic conditions were extracted from records for the 
periods 24, 12, and 6 months prior to the date of GCA diagnosis. Due to the possibility that 
being diagnosed with any comorbidity ≤1 month prior to a GCA diagnosis could be due to 
misdiagnosis, this time-period was excluded from the comorbidity analysis. The results for 
symptoms and comorbidities are presented separately for ease of interpretability. Clinical 
features recorded on the same day as a diagnosis of GCA were included. All 14 clinical 
features were categorised into ‘yes’ or ‘no’, where yes was if a patient had 1 or more 
recorded consultations for that clinical feature, stratified by time period. 
To investigate possible delay in diagnosis of GCA in primary care, the median time from first 
record of each clinical feature, at any point prior to GCA diagnosis, to the date of GCA 
diagnosis was calculated. This delay was initially examined just in the 24 months prior to a 
GCA diagnosis, and then across the entire time period from 1990-2017 to investigate if some 
clinical features were associated with a diagnosis of GCA before the 24 month period. The 
median is reported along with the interquartile range rather than the mean due to possible 
skewness of the data. 
 
6.4.3 Covariates 
The covariates to be used in the analysis for this study were BMI, smoking status, and 
alcohol consumption as indicators of a patients’ general health status. Four articles included 
in the review in Chapter 3 recorded the prevalence of smoking in GCA patients prior to their 
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GCA diagnosis, with varying estimates. Few articles reported a patient’s BMI, and no articles 
recorded information about patients’ alcohol intake, hence there is little information about 
their relationship to GCA. In a sensitivity analysis, the Index of Multiple Deprivation (IMD 
2015) was added to the analysis for patients in England who were registered at general 
practices consenting to linkage of their deprivation status, in order to check the robustness 
of the results to adjustment for deprivation. 
BMI, smoking status, and alcohol consumption were taken as the last recorded value prior to 
the index date as these were more likely to reflect the patient’s demographics at the time of 
GCA diagnosis. If this information was completely missing, i.e. they did not have a recorded 
value at any time, then the patient was classified as unrecorded for that variable. It could 
not be assumed that if the patient was missing the information for alcohol and smoking that 
they were a non-drinker or non-smoker, so they were allocated to the missing category. 
Code lists were compiled for BMI, smoking, and alcohol status (Appendix 6.1, Table 1). For 
BMI the Read/medcodes for height and weight were used along with the general code for 
BMI. BMI values were calculated from the height and weight recorded in the patient’s 
record, if actual BMI was not recorded. Information on BMI, smoking, and alcohol 
consumption is found in the additional patient files (detailed in Chapter 4), which can be 
mapped to the clinical and referral files by the unique ID (patid) given to each patient. BMI 
was categorised into four categories; under/normal weight (<25kg/m2), overweight (25-
29.9kg/m2), obese (≥30kg/m2), and missing. These categories are based on the World Health 
Organisation’s (WHO) recommended cut-offs (Weir & Jan, 2019). Where required, categories 
were merged to ensure they contained a similar number of patients. Smoking status was 
coded into four groups: current smoker, ex-smoker, non-smoker and missing. Alcohol 
consumption was categorised into five groups; non-drinker (0 units per week), light drinker 
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(1-7 units per week), moderate drinker (8-14 units per week), heavy drinker (≥15 units per 
week), and missing. These categorisations are based on a previous study using CPRD to 
investigate alcohol consumption in patients with rheumatoid arthritis who were taking 
methotrexate (Humphreys et al., 2017).  
The IMD 2015 scores were categorised at quintile score by CPRD prior to data delivery, 
where 1 is the least deprived and 5 the most deprived compared to the rest of the 
population of England. Only patients registered at practices consenting to IMD 2015 linkage 
were included in the analysis. 
 
6.4.4 Analysis 
Patient characteristics were compared between cases and controls, and between the 
population from the main analysis, and the two sensitivity populations (described in section 
6.4.4.1). The proportion of males and females, BMI category, smoking status, alcohol 
consumption, and where available, IMD 2015 score were calculated. In order to investigate 
the relationship between a diagnosis of GCA and prior recorded clinical features in primary 
care, conditional logistic regression was used to account for the matched sets of cases to 
controls with each clinical feature included in separate regression models. 
Conditional logistic regression is implemented on matched data and conditioned on the 
matched pairs (Pearce, 2016). The response of conditional logistic regression is binary, in the 
case of this analysis an indicator variable that takes the value of 1, if the patient has GCA, 
and 0 if the patient does not have GCA. A matching variable linking each case to its controls 
must also be specified, otherwise the regression model will incorrectly assume that all 
observations are independent and will instead fit an unconditional logistic regression, which 
has been shown to give biased estimates when applied to matched data (Pearce, 2016). 
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If there are s matched sets and p independent variables, the formula used for conditional 
logistic regression is given by (3): 
logit(p) = α1 + α2z2 +⋯+ αszs + β1x1 +⋯+ βpxp   (3) 
Where zi are the binary indicators for each matched set, αi are the regression coefficients 
associated with the matched set indicator variables, xj are the covariates, and βj are the 
regression coefficients to be estimated, where i is 1:s, and j is 1:p. Conditional logistic 
regression fits models to matched data based on maximum likelihood estimation. 
Since the data was already matched on gender, year of birth, and general practice, they 
were not included as variables in the model. Unadjusted and adjusted analyses were 
conducted for each clinical feature under investigation. Models were adjusted for BMI, 
alcohol consumption, and smoking status. 
 
6.4.4.1 Sensitivity analysis 
Two sensitivity analyses were conducted on subsets of the data. Initially, as in Chapter 5, the 
definition of a GCA case was altered to include the requirement of one or more prescriptions 
of glucocorticoids within the first 6 months of a GCA diagnosis, alongside a Read code for 
GCA. A secondary sensitivity analysis was also conducted, further adjusting for deprivation 
data (as detailed in section 6.4.3) for patients with this linkage (all in England). For this 






6.5.1 Sample characteristics 
A total sample size of 55,218 contained information on 9205 GCA cases matched with 46,013 
controls. The mean age of cases was 72.6 years (SD = 10.3), and 71% were female; 32.5% 
were overweight and 20.6% were obese, 14.9% were current smokers, and 10.0% were 
moderate or heavy drinkers. The mean age of controls was also 72.6 years (SD = 10.3), 24.2% 
were overweight and 14.8% were obese, 9.9% were current smokers and 8.0% were 
moderate drinkers. Missing data on BMI, smoking status, and alcohol consumption was 
higher in controls than cases (Table 6.1). 
After restriction of GCA cases to those who had a Read code and a prescription of 
glucocorticoids (sensitivity analysis 1), the remaining sample size was 49,455 (90% of the 
total data), with 8244 GCA cases and 41,211 controls (Table 6.1). Sample characteristics 
were similar to the GCA cases defined by a Read code without need for a prescription. 
Restricting the sample to patients registered at practices in England with linkage to the IMD 
2015 (sensitivity analysis 2) left 5240 GCA cases and 26,199 controls (Table 6.1). In total, 72 
GCA cases (1.1%) in these practices did not have linkage to deprivation data, and 11.2% were 
from the most deprived area. 17.6% of cases were in the least deprived areas. Controls had a 
higher proportion of missing IMD 2015 linkage (3.9%). Similar to cases, the IMD quintile with 
the highest proportion of controls was the least deprived (17.5%), whilst the most deprived 
had the smallest proportion (9.9%).  
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Table 6.1: Patient demographics for cases and controls for main analysis and sensitivity analyses. 
 Main analysis Sensitivity analysis 
 Read code onlya Read code & prescriptionb England onlyc  
Cases (n = 9205) Controls (n = 46013) Cases (n = 8244) Controls (n = 41211) Cases (n = 5240) Controls (n = 26199)  
N % N % N % N % N % N % 
Mean age (SD) 72.6 (10.3) 72.6 (10.3) 72.9 (9.92) 72.9 (9.91) 72.6 (10.4) 72.5 (10.4) 
Median age (IQR) 74 (14) 74 (14) 74 (13) 74 (13) 74 (14) 74 (14) 
Female 6532 70.96 32659 70.98 5822 70.62 29410 71.36 3708 70.76 18540 70.77 
Male 2673 29.04 13354 29.02 2362 28.65 11801 28.64 1532 29.24 7659 29.23 
BMI 
    
        
Normal & underweight 3213 34.90 12548 27.27 2929 35.53 11328 27.49 1856 35.42 7248 27.67 
Overweight 2989 32.47 11122 24.17 2703 32.79 10029 24.34 1703 32.50 6310 24.08 
Obese 1898 20.62 6802 14.78 1664 20.18 6133 14.88 1029 19.64 3757 14.34 
Missing 1105 12.00 15541 33.78 948 11.50 13721 33.29 652 12.44 8884 33.91 
Smoking 
    
        
Current 1371 14.89 4554 9.90 1214 14.73 4071 9.88 738 14.08 2455 9.37 
Non-smoker 2895 31.45 12174 26.46 2606 31.61 11046 26.80 1820 34.73 7734 29.52 
Ex-smoker 2456 26.68 7437 16.16 2254 27.34 6804 16.51 1327 25.32 4073 15.55 
Missing 2483 26.97 21848 47.48 2170 26.32 19290 46.81 1355 25.86 11937 45.56 
Alcohol 
    
        
Never 1404 15.25 5881 12.78 1206 14.63 5206 12.63 583 11.13 2298 8.77 
Light 3204 34.81 11750 25.54 2905 35.24 10642 25.82 1950 37.21 7441 28.40 
Moderate 918 9.97 3683 8.00 835 10.13 3289 7.98 565 10.78 2248 8.58 
Heavy 642 6.97 2670 5.80 561 6.80 2365 5.74 398 7.60 1647 6.29 
Missing 3037 32.99 22029 47.88 2737 33.20 19709 47.82 1744 33.28 12565 47.96 
IMD 2015             
Least deprived - - - - - - - - 1193 17.57 5951 17.53 
2 - - - - - - - - 1138 16.76 5529 16.29 
3 - - - - - - - - 1184 17.43 5731 16.88 
4 - - - - - - - - 892 13.14 4299 12.66 
Most Deprived - - - - - - - - 761 11.21 3375 9.94 
Missing - - - - - - - - 72 1.06 1314 3.87 
a: Main analysis: GCA defined by Read code only 
b: Sensitivity analysis 1: GCA defined using Read codes and glucocorticoid prescription; c: Sensitivity analysis 2: Patients registered at practices in England consenting to linkage with IMD 2015 only. 
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6.5.2 Associations of symptoms with GCA 
In the main analysis, associations of symptoms were examined between cases and controls 
in the 24-month time-period prior to the index date of GCA diagnosis (Table 6.2 & Table 6.3). 
In the 24 months prior to index date, 43.2% of GCA cases had a record of a headache, 11.2% 
had a record of constitutional symptoms, and 32.4% had a record of elevated ESR. Only 2.0% 
of GCA cases had a record of jaw pain in the 24 months prior to index date, 0.6% had a 
record of fever, and 3.2% had a record of visual impairment in the same time-period. The 
proportions of GCA cases recording symptoms in the 24 months prior to index date was 
consistently higher than matched controls (Table 6.2). 
Patients with GCA had consistently higher adjusted odds of experiencing all symptoms 
included in this analysis in the 24 months prior to index date than controls (Table 6.3). After 
adjustment for BMI, smoking status, and alcohol consumption GCA cases had; 56.26 (95% CI: 
49.04, 64.56) times higher odds of a recorded elevated ESR than controls, and 3.07 (95% CI: 
2.82, 3.36) times higher odds of recorded constitutional symptoms in the 24 months prior to 
index date. Despite low prevalence estimates, cases still had 12.55 (95% CI: 9.93, 15.87) and 
4.06 (95% CI: 2.73, 6.04) times higher odds of visual impairment and fever, respectively, in 
the 24 months prior to index date. 
Detailed results for headache, recorded elevated ESR, and fatigue will be presented in this 
section, due to the high prevalence and strong association between these and a subsequent 
diagnosis of GCA found in the systematic review in Chapter 3.  
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  Table 6.2: Summary statistics for symptoms prior to a GCA diagnosis for cases (n = 9205) and controls (n = 46,103), stratified by time prior to diagnosis.   
24 months prior 12 months prior 6 months prior ≤1 month prior  
Cases Controls Cases Controls Cases Controls Cases Controls  
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Headache         
No 5226 (56.77) 45203 (98.24) 5448 (59.19) 45577 (99.05) 5670 (61.60) 45779 (99.49) 6478 (70.37) 45961 (99.89) 
Yes 3979 (43.23) 810 (1.76) 3757 (40.81) 436 (0.95) 3535 (38.40) 234 (0.51) 2727 (29.63) 52 (0.11) 
Fever         
No 9150 (99.40) 45959 (99.88) 9162 (99.53) 45990 (99.95) 9174 (9.66) 46005 (99.98) 9183 (99.76) - 
Yes 55 (0.60) 54 (0.12) 43 (0.47) 23 (0.05) 31 (0.34) 8 (0.02) 22 (0.24) - 
Weight loss/Anorexia         
No  8952 (97.25) 45637 (99.18) 9029 (98.09) 45825 (99.59) 9075 (98.59) 45909 (99.77) 9151 (99.41) 46000 (99.97) 
Yes 253 (2.75) 376 (0.82) 176 (1.91) 188 (0.41) 130 (1.41) 104 (0.23) 54 (0.59) 13 (0.03) 
Visual impairment         
No  8911 (96.81) 45904 (99.76) 8957 (97.31) 45954 (99.87) 8997 (97.74) 45983 (99.93) 9067 (98.50) 46008 (99.99) 
Yes 294 (3.19) 109 (0.24) 248 (2.69) 59 (0.13) 208 (2.26) 30 (0.07) 138 (1.50) 5 (0.01) 
Fatigue         
No  8429 (91.57) 44924 (97.63) 8699 (94.50) 45402 (98.67) 8881 (96.48) 45681 (99.28) 9079 (98.63) 45939 (99.84) 
Yes 776 (8.43) 1089 (2.37) 506 (5.50) 611 (1.33) 324 (3.52) 332 (0.72) 126 (1.37) 74 (0.16) 
Recorded elevated ESR 
        
No 6219 (67.56) 45537 (98.77) 6378 (69.29) 45732 (99.20) 6547 (71.12) 45845 (99.44) 7179 (77.99) 45969 (99.90) 
Yes 2986 (32.44) 476 (1.23) 2827 (30.71) 281 (0.80) 2658 (28.88) 168 (0.66) 2026 (22.01) 44 (0.10) 
Arthralgia/Myalgia 
        
No 8531 (92.68) 45358 (98.58) 8770 (95.27) 45650 (99.21) 8917 (96.87) 45821 (99.58) 9120 (99.08) 45977 (99.92) 
Yes 674 (7.32) 655 (1.42) 435 (4.73) 363 (0.79) 288 (3.13) 192 (0.42) 85 (0.92) 36 (0.08) 
Jaw pain         
No 9022 (98.01) 45979 (99.93) 9039 (98.20) 45997 (99.97) 9055 (98.37) 46001 (99.97) 9105 (98.91) - 
Yes 183 (1.99) 34 (0.07) 166 (1.80) 16 (0.03) 150 (1.63) 12 (0.03) 100 (1.09) - 
Constitutional symptoms         
No 8178 (88.84) 44538 (96.79) 8602 (93.45) 45293 (98.44) 8798 (95.58) 45620 (99.15) 9129 (99.17) 45999 (99.97) 
Yes 1027 (11.16) 1475 (3.21) 603 (6.55) 720 (1.56) 407 (4.42) 393 (0.85) 76 (0.83) 14 (0.03) 
Missing cells (-) indicate less than 5 events for that outcome, therefore CPRD does not permit reporting for those outcomes.  
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Table 6.3: Results of conditional logistic regression by symptom, showing odds ratio and 95% confidence intervals stratified by time period prior to date of GCA diagnosis. 
Missing cells (-) indicate less than 5 events for that outcome, therefore CPRD does not permit reporting for those outcomes.  
24 months prior 12 months prior 6 months prior ≤1 month prior  
Unadjusted Adjustedꝉ Unadjusted Adjustedꝉ Unadjusted Adjustedꝉ Unadjusted Adjustedꝉ  
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Headache 
      
  
No Ref Ref Ref Ref Ref Ref Ref  

















      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 









      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 




Visual  impairment 
      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 

















      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 
Yes 3.94 (3.57, 4.34) 3.12 (2.82, 3.45) 4.45 (3.93, 5.03) 3.56 (3.14, 4.05) 5.16 (4.41, 6.04) 4.19 (3.56, 4.93) 8.60 (6.44, 11.47) 7.13 (5.29, 9.60) 
Recorded elevated ESR 
      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 
Yes 62.70 
















      
  
No Ref Ref Ref Ref Ref Ref Ref Ref 




Jaw Pain         


















        
No Ref Ref Ref Ref Ref Ref Ref Ref 








In the 24 months prior to a diagnosis of GCA, 43.2% of cases had a recorded consultation for 
a headache compared to 1.76% of controls (Table 6.4). 40.8% of cases in the 12 months prior 
had a recorded consultation for headache, compared to 1.0% of controls. 29.6% of cases had 
a recorded headache in the month prior to a diagnosis of GCA, compared to 0.1% of 
controls. GCA cases had 44.31 (95% CI: 36.77, 49.37) times higher odds of reporting a 
headache in the 24 months prior to index date than controls after adjustment. This 
increased to a 402.17 (95% CI: 283.40, 570.72) times greater odds of reporting a headache in 
the 1 month prior to the index date than controls. 
 
Table 6.4: Association between time of headache consultation and subsequent diagnosis of 
GCA.  
   Conditional logistic regression 








OR (95% CI) 
Adjustedꝉ  
OR (95% CI) 
24 months 3979 (43.23) 810 (1.76) 49.80 (44.79, 55.38) 44.31 (36.77, 49.37) 
12 months 3757 (40.81) 436 (0.95) 84.01 (73.24, 96.37) 76.61 (66.64, 88.06) 
6 months 3535 (38.40) 234 (0.51) 145.70 (121.40, 174.90) 134.81 (112.08, 162.16) 
≤1 month 2727 (29.63) 52 (0.11) 424.20 (299.40, 601.10) 402.17 (283.40, 570.72) 
ꝉ Adjusted for BMI, alcohol consumption, and smoking status. 
 
6.5.2.2 Recorded elevated ESR 
In the 24 months prior to index date 32.4% and 1.2% of cases and controls had recorded 
elevated ESR, respectively (Table 6.5). In the 12 months prior to index date 30.7% of cases, 
and 0.8% of controls had a record of elevated ESR; in the 6 months prior 28.9% and 0.7%, 
and ≤1 month prior 22.0% and 0.1%, respectively. GCA cases had 56.26 (95% CI: 49.04, 
64.56) times higher odds of having a recorded elevated ESR in the 24 months prior to their 
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index date than controls after adjustment. The strength of association of recorded elevated 
ESR with GCA continued to increase at each time point closer to GCA diagnosis. 
 
Table 6.5: Association between time of recorded elevated ESR consultation and subsequent 
diagnosis of GCA 
   Conditional logistic regression 






Unadjusted OR (95% CI) Adjustedꝉ OR (95% CI) 
24 months 2986 (32.44) 476 (1.23) 62.70 (54.78, 71.77) 56.26 (49.04, 64.56) 
12 months 2827 (30.71) 281 (0.80) 96.03 (81.17, 113.60) 87.75 (74.00, 104.05) 
6 months 2658 (28.88) 168 (0.66) 128.40 (105.30, 156.40) 118.78 (97.24, 145.09) 
≤1 month 2026 (22.01) 44 (0.10) 288.60 (206.60, 403.10) 272.85 (194.96, 381.87) 
ꝉ Adjusted for BMI, alcohol consumption, and smoking status. 
 
6.5.2.3 Fatigue 
In the 24 months prior to a diagnosis of GCA 
 8.4% of cases had a record of fatigue compared to 2.4% of controls (Table 6.6). GCA cases 
had 3.12 (95% CI: 2.82, 3.45) times higher odds of reporting fatigue in the 24 months prior to 
index date than controls after adjustment. The increased odds of reporting fatigue increased 
at each subsequent time point prior to GCA diagnosis. 
 
Table 6.6: Association between time of fatigue consultation and subsequent diagnosis of 
GCA 
   Conditional logistic regression 






Unadjusted OR  
(95% CI) 
Adjustedꝉ OR (95% CI) 
24 months 776 (8.43) 1089 (2.37) 3.94 (3.57, 4.34) 3.12 (2.82, 3.45) 
12 months 506 (5.50) 611 (1.33) 4.45 (3.93, 5.03) 3.56 (3.14, 4.05) 
6 months 324 (3.52) 332 (0.72) 5.16 (4.41, 6.04) 4.19 (3.56, 4.93) 
≤1 month 126 (1.37) 74 (0.16) 8.60 (6.44, 11.47) 7.13 (5.29, 9.60) 
ꝉ Adjusted for BMI, alcohol consumption, and smoking status. 
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6.5.2.4 Time from first recorded symptom to GCA diagnosis 
Time between the first record of each symptom and the date of GCA diagnosis varied across 
symptoms (Table 6.7). Each symptom had large variation, shown by the large values of the 
IQR, implying that this data was highly skewed.  
 
Table 6.7: Median time between first record of each symptom and a diagnosis of GCA in the 
24 months prior to GCA diagnosis, and all time (1990-2017). 
Clinical feature Median number of days (IQR) 
in the 24 months prior to GCA 
diagnosis 
Median number of days 
(IQR) all time (1990-2017) 
Headache 25 (121) 255 (2385) 
Jaw pain 26 (86) 173 (1289.5) 
Visual impairment 48 (253) 657.5 (2384.8) 
Recorded elevated ESR 76 (339) 1879 (4003) 
Fever 113 (300) 1816 (3836.75) 
Weight loss/anorexia 200 (426) 1317.5 (2881.8) 
Arthralgia/myalgia 286 (412) 1969 (3251.8) 
Fatigue 300 (415) 2043 (2945.3) 
 
The symptom with the shortest time from first recorded onset to GCA diagnosis, in the 24 
months prior to index date, was headache, with a median of 25 days (IQR: 121 days). This 
implies that a headache is first reported less than a month prior to a GCA diagnosis. The 
symptom with the second shortest time was jaw pain, with a median of 26 days (IQR: 86 
days). Visual impairment had a median time from recorded onset to GCA diagnosis of 48 
days (IQR: 253 days), which approximately equates to 1 ½ months. The symptom with the 
longest time between first recorded onset and GCA diagnosis was fatigue, with a median of 
300 days (IQR: 415), which equates to just under a year from first recorded onset to eventual 
GCA diagnosis. 
The symptom with the shortest time from first recorded onset to GCA diagnosis, across the 
entire time-period (1990-2017), was jaw pain, with a median of 173 days (IQR: 1290 days). 
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This approximately equates to between 5/6 months between the first recorded onset of jaw 
pain and an eventual diagnosis of GCA. The symptom with the second shortest time was 
headache with a median of 255 days (IQR: 2385 days), or 8/9 months. Visual impairment had 
a median time from first recorded onset of 658 days (IQR: 2385 days), or 22 months. The 
symptom with the longest time was fatigue, with a media 
n of 2043 days (IQR: 2945 days), or 5/6 years. 
 
6.5.3 Associations of comorbidities with GCA 
Associations of comorbid features were examined between cases and controls in the 6, 12, 
and 24 months prior to their index date (Table 6.8,  
Table 6.9). In the 24 months prior to index date, 12.6% of GCA cases had a record of 
cardiovascular/cerebrovascular conditions; 7.8% had a record of anxiety/depression; and 
4.2% had a record of cancer. The proportions of GCA cases with recorded comorbidities in 
the 24 months prior to index date was consistently higher than matched controls (Table 6.8). 
GCA cases had consistently higher odds of all comorbidities included in this analysis recorded 
in the 24 months prior to index date than controls ( 
Table 6.9). After adjustment for BMI, smoking status, and alcohol consumption, GCA cases 
had 2.03 (95% CI: 1.88, 2.20) times higher odds of cardiovascular/cerebrovascular conditions 
than controls; 2.19 (95% CI: 1.99, 2.42) times higher odds of anxiety/depression, and 1.34 
(95% CI: 1.19, 1.52) times higher odds of cancer in the 24 months prior to index date. The 





Table 6.8: Summary statistics for comorbidities prior to a GCA diagnosis for cases (n = 9205) and controls (n = 46,103), stratified by time prior to 
diagnosis.   
 24 months prior 12 months prior 6 months prior 
 Cases Controls Cases Controls Cases Controls 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Treated 
hypertension 
      
No 3846 (41.78) 32485 (70.60) 4068 (44.19) 33964 (73.81) 4239 (46.05) 34644 (75.29) 
Yes 5359 (58.21) 13168 (28.62) 5137 (55.81) 12049 (26.19) 4966 (53.95)  11369 (24.71) 
Recorded 
hypertension 
      
No 8169 (88.75) 43320 (94.15) 8554 (92.93) 44465 (96.64) 8799 (95.59) 45146 (98.12) 
Yes 1036 (11.25) 2693 (5.85) 651 (7.07) 1548 (3.36) 406 (4.41) 867 (1.88)        
Cardiovascular/ 
Cerebrovascular 
      
No 8043 (87.38) 43452 (94.43) 8427 (91.55) 44546 (96.81) 8724 (94.77) 45196 (98.22) 
Yes 1162 (12.62) 2561 (5.57) 778 (8.45) 778 (3.19) 481 (5.23) 817 (1.78) 
Anxiety/ 
Depression 
      
No 8488 (92.21) 44559 (96.84) 8761 (95.18) 45192 (98.22) 8921 (96.91) 45570 (99.04) 
Yes 717 (7.79) 1454 (3.16) 444 (4.82) 821 (1.78) 284 (3.09) 443 (0.96) 
PMR 
      
No 8097 (87.96) 45815 (99.57) 8274 (89.89) 45887 (99.73) 8421 (91.48) 45927 (99.81) 
Yes 1108 (12.04) 198 (0.43) 931 (10.11) 126 (0.27) 784 (8.52) 86 (0.19) 
Diabetes 
      
No 8240 (89.52) 43660 (94.89) 8367 (90.90) 44136 (95.92) 8607 (93.50) 44783 (97.33) 
Yes 965 (10.48) 2353 (5.11) 838 (9.10) 1877 (4.08) 598 (6.50) 1230 (2.67) 
Cancer 
      
No 8821 (95.83) 44779 (97.32) 8972 (97.47) 45343 (98.54) 9069 (98.52) 45667 (99.25) 




Table 6.9: Results from the conditional logistic regression for comorbidities, showing odds ratios and 95% confidence intervals, stratified by 
time prior to index date. 
 24 months prior 12 months prior 6 months prior 
 Unadjusted Adjustedꝉ Unadjusted Adjustedꝉ Unadjusted Adjustedꝉ 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Recorded hypertension  
      
No Ref Ref Ref Ref Ref Ref 
Yes 2.16 (1.99, 2.33) 1.67 (1.54, 1.82) 2.32 (2.10, 2.56) 1.80 (1.62, 1.99) 2.52 (2.22, 2.85) 1.94 (1.71, 2.21)        
Treated Hypertension       
No Ref Ref Ref Ref Ref Ref 
Yes 3.80 (3.62, 3.99) 2.78 (2.64, 2.93) 3.87 (3.69, 4.07) 2.86 (2.72, 3.02) 3.86 (3.68, 5.06) 2.87 (2.73, 3.02) 
Cardiovascular/ 
Cerebrovascular 
      
No Ref Ref Ref Ref Ref Ref 
Yes 2.52 (2.34, 2.72) 2.028 (1.88, 2.20) 2.88 (2.63, 3.16) 2.32 (2.11, 2.56) 3.12 (2.77, 3.50) 2.50 (2.21, 2.83) 
Anxiety/ 
Depression 
      
No Ref Ref Ref Ref Ref Ref 
Yes 2.67 (2.43, 2.93) 2.19 (1.99, 2.42) 2.86 (2.54, 3.23) 2.38 (2.10, 2.69) 3.33 (2.86, 3.88) 2.83 (2.41, 3.32)        
PMR 
      
No Ref Ref Ref Ref Ref Ref 
Yes 33.39 (28.33, 39.36) 30.27 (25.56, 35.84) 41.92 (34.40, 51.08) 38.08 (31.11, 46.60) 52.53 (41.39, 66.67) 48.63 (38.18, 62.00) 
Diabetes 
      
No Ref Ref Ref Ref Ref Ref 
Yes 2.21 (2.04, 2.40) 1.58 (1.46, 1.72) 2.40 (2.21, 2.62) 1.72 (1.57, 1.88) 2.58 (2.33, 2.85) 1.85 (1.66, 2.05) 
Cancer 
      
No Ref Ref Ref Ref Ref Ref 
Yes 1.58 (1.41, 1.78) 1.34 (1.19, 1.52) 1.76 (1.52, 2.05) 1.50 (1.28, 1.76) 1.98 (1.62, 2.42) 1.68 (1.36, 2.06) 




There was a difference in the prevalence of hypertension between the two definitions used 
(Table 6.10). 11.3% of cases had recorded hypertension in the 24 months prior to index date, 
in contrast to 58.2% who had treated hypertension in the same time-period. There was a 
difference between controls in the 24 months prior to index date, with 5.9% having recorded 
and 28.6% having treated hypertension. 
 
Table 6.10: Association between time of first recorded hypertension and subsequent 
diagnosis of GCA 
   Conditional logistic regression 




Unadjusted OR (95% CI) Adjustedꝉ OR (95% CI) 
Recorded     
24 months 1036 (11.25) 2693 (5.85) 2.16 (1.99, 2.33) 1.67 (1.54, 1.82) 
12 months 651 (7.07) 1548 (3.36) 2.32 (2.10, 2.56) 1.80 (1.62, 1.99) 
6 months 406 (4.41) 867 (1.88) 2.52 (2.22, 2.85) 1.94 (1.71, 2.21) 
Treated     
24 months 5359 (58.21) 13168 (28.62) 3.80 (3.62, 3.99) 2.78 (2.64, 2.93) 
12 months 51375 (55.81) 12049 (26.19) 3.87 (3.69, 4.07) 2.86 (2.72, 3.02) 
6 months 4966 (53.95) 11369 (24.71) 3.86 (3.68, 5.06) 2.87 (2.73, 3.02) 
ꝉ Adjusted for BMI, alcohol consumption, and smoking status. 
 
In the conditional logistic regression, cases had higher odds of hypertension, both recorded 
and treated at every time point prior to index date. The odds ratios were larger for treated, 
than recorded hypertension. Cases had 2.78 (95% CI: 2.64, 2.93) times higher odds of 
treated hypertension after adjustment in the 24 months prior to index date (Table 6.10). This 
contrasted to the 1.67 (95% CI: 1.54, 1.82) times higher odds for cases having a recorded 
hypertension Read code in the same time-period. Odds of recorded hypertension increased 
the closer to the index date it was recorded. However, the odds of treated hypertension 





In the 24 months prior to index date, 10.5% of cases had a recorded diagnosis of diabetes, 
compared to 5.1% of controls (Table 6.11). After adjustment, cases had 1.58 (95% CI: 1.46, 
1.72) times higher odds of a recorded diagnosis of diabetes in the 24 months prior to index 
date than controls. There was consistently more cases with a recorded diagnosis of diabetes 
than controls at every time point prior to index date. Cases had consistently significant 
higher odds of diabetes prior to index date than controls. 
 
Table 6.11: Association between time of diabetes consultation and subsequent diagnosis of 
GCA 
   Conditional logistic regression 
 
Cases (%) Controls (%) Unadjusted OR (95% CI) Adjustedꝉ OR (95% CI) 
24 months 965(10.48) 2353 (5.11) 2.21 (2.04, 2.40) 1.58 (1.46, 1.72) 
12 months 838 (9.10) 1877 (4.08) 2.40 (2.21, 2.62) 1.72 (1.57, 1.88) 
6 months 598 (6.50) 1230 (2.67) 2.58 (2.33, 2.85) 1.85 (1.66, 2.05) 




In the 24 months prior to index date, 12.0% of GCA cases had a recorded diagnosis of PMR, 
compared to 0.4% of controls (Table 6.12). After adjustment, GCA cases had 30.27 (95% CI: 
25.56, 35.84) times higher odds of a PMR diagnosis in the 24 months prior to index date than 
controls. At each time point prior to index date there was consistently higher proportion of 
GCA cases with a record of PMR than controls, and significantly higher odds of a PMR 




Table 6.12: Association between time of PMR consultation and subsequent diagnosis of GCA 
   Conditional logistic regression 
 
Cases (%) Controls (%) Unadjusted OR (95% CI) Adjustedꝉ OR (95% CI) 
24 months 1108 
(12.04) 
198 (0.43) 33.39 (28.33, 39.36) 30.27 (25.56, 35.84) 
12 months 931 
(10.11) 
126 (0.27) 41.92 (34.40, 51.08) 38.08 (31.11, 46.60) 
6 months 784 (8.52) 86 (0.19) 52.53 (41.39, 66.67) 48.63 (38.18, 62.00) 
ꝉ Adjusted for BMI, alcohol consumption, and smoking status. 
 
6.5.3.4 Time from first recorded comorbidity to GCA diagnosis 
Time from first recorded comorbidity to GCA diagnosis varied between comorbidities (Table 
6.13). However, time from first recorded comorbidity onset and diagnosis of GCA varied 
between patients, evident by the large IQR values. 
 
Table 6.13: Median time between first record of each comorbidity and a diagnosis of GCA,  
Clinical feature Median number of days (IQR) 
in the 24 months prior to GCA 
diagnosis 
Median number of 
days (IQR) all time 
(1990-2017) 
PMR 215 (439) 480 (1388) 
Cancer 343 (392) 2462 (3689) 
Cardiovascular/Cerebrovascular 371 (425) 2551 (3704.5) 
Anxiety/depression 398 (411) 3875 (5075.5) 
Recorded Hypertension 404 (421) 3228 (3832) 
Diabetes 452 (360) 1742 (2676) 
 
The comorbidity with the shortest time from first record, within 24 months prior to the date 
of GCA diagnosis, was PMR, with a median of 215 days (IQR: 439 days), approximately 7 
months. Cancer had the second shortest time from first record, with a median of 343 days 
(IQR: 392), or just under a year. The comorbidity with the longest time from first record, 
within 24 months prior to GCA diagnosis, was diabetes with a median of 452 days (IQR: 360), 




The comorbidity with the shortest time from first ever record, during the entire time period 
from 1990-2017, was PMR, with a median of 480 days (IQR: 1388 days), approximately a 
year and a quarter, between first onset and a diagnosis of GCA. Diabetes had the second 
shortest period between first record and GCA diagnosis, with a median of 1742 days (IQR: 
2676), approximately four and three-quarter years. The comorbidity with the longest period 
between first onset and GCA diagnosis was anxiety/depression, with 3875 days (IQR: 5076), 
approximately ten and a half years. 
 
6.5.4 Sensitivity analyses 
The definition of a GCA case was altered for the first sensitivity analysis by including 
glucocorticoid prescription information. The definition of a GCA case in this sensitivity 
analysis has been described in section 6.4.4.1. After this condition was applied there were 
8244 GCA cases eligible to be included in the analysis, with 41,211 matched controls. Results 
from the prescription sensitivity analysis were similar to the results of the Read code only 
definition of GCA (Appendix 6.1, Tables 2 & 3). 
The second sensitivity analysis conducted on the data limited the number of cases to those 
who had an IMD 2015 value. The eligibility for cases and controls to be included in this 
analysis is given in section 6.4.4.1. In this sensitivity analysis there were 5240 GCA cases and 
26,199 matched controls. The results from this sensitivity analysis were similar to the main 






In this case-control study examining the prevalence and association of clinical features 
present in primary care prior to GCA diagnosis, patients with GCA had increased odds of 
presenting with all 14 clinical features in the 24 months prior to their diagnosis of GCA than 
matched controls. Despite this association, the prevalence of some clinical features (fever, 
fatigue, jaw pain, weight loss/anorexia, and visual impairment) was low in this study in the 
24 months prior to GCA diagnosis. Clinical features that were highly prevalent were 
headache, recorded elevated ESR, and treated hypertension. Patients who have a diagnosis 
of GCA have increased odds of a headache, recorded elevated ESR, weight loss/anorexia, 
fatigue, visual impairment, arthralgia/myalgia, jaw pain, hypertension, diabetes, 
cardiovascular/cerebrovascular diseases, anxiety/depression, cancer, and PMR in the 24 
months prior to their diagnosis of GCA. These associations reached statistical significance, 
and maintained after adjustment for BMI, alcohol, and smoking consumption.  
 
6.6.1.2 Time to diagnosis 
Four time points prior to GCA diagnosis were examined in this study; 24 months, 12 months, 
6 months, and ≤1 month prior. Symptoms had stronger associations with a GCA diagnosis 
than comorbidities, evident by the larger odds ratios observed for symptoms. The strength 
of association of all symptoms increased the closer they were recorded to the date of GCA 
diagnosis. This pattern was not the same for comorbidities, whose association with a GCA 
diagnosis remained stable at 24 and 12 months prior to diagnosis, with a small increase at 6 
months, possibly due to surveillance bias as this was the median time for the first onset of 
symptoms prior to a GCA diagnosis. 
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The time between first recorded onset and a GCA diagnosis varied across clinical features. 
The median time from recorded onset to GCA diagnosis was smaller for symptoms than 
comorbidities. In the 24 months prior to a GCA diagnosis, the symptoms with the shortest 
median time from first recorded onset to GCA diagnosis were headache and jaw pain, both 
at just under a month before the date of GCA diagnosis. Symptoms such as fever, and weight 
loss/anorexia had the longest time from first recorded onset to GCA diagnosis. This implies 
that GPs are more likely to consider GCA as a diagnosis when patients present with jaw pain 
and/or a headache, in contrast to the remaining symptoms investigated in this study. It is of 
concern that the delay between first recorded onset of visual impairment and eventual GCA 
diagnosis was almost 2 months, considering visual impairment is a medical emergency. 
The median time from first recorded onset to GCA diagnosis was longer for comorbidities. 
The comorbidity with the shortest median time from first recorded onset was PMR, at 
approximately 6/7 months. This difference in median time from first recorded onset to GCA 
diagnosis could imply a difference in the relationship between symptoms and comorbidities 
with a GCA diagnosis. Where symptoms could be indicating factors for a GCA diagnosis, 
comorbidities, due to their increased time from first onset to GCA diagnosis, could be viewed 
as risk factors. Hence, an indicator would present itself when the patient’s GCA has already 
developed, but a risk factor would increase the risk of a subsequent diagnosis of GCA, but 
not necessarily that GCA would develop.  
The source of this time from first recorded onset of clinical features to GCA diagnosis is a 
best estimate, as it is impossible to quantify this exactly in the current study. It is not 
possible in studies using EHR to quantify the time from actual first clinical feature onset to 
the time it was first recorded in their patient file. For symptoms like headache and jaw pain, 
patients may self-medicate rather than visit a GP, or with respect to jaw pain may initially 
189 
 
visit a dentist, thereby lengthening the time from symptom onset to symptom recording. 
The second source of this delay between symptom recording and diagnosis is the delay 
between a referral to a specialist to confirm diagnosis and when the diagnosis is recorded in 
the patient’s primary care record, and from the date of referral to the date of the 
appointment with a specialist. Further work should try and investigate the true source of 
delay between first recorded symptom onset and a GCA diagnosis. It should be noted that 
NICE guidelines recommend that patients suspected of having GCA should be immediately 
treated with glucocorticoids without waiting for confirmation of diagnosis (NICE CKS, 2020). 
Therefore, it is possible that despite delays in diagnosis, some patients are still treated to 
prevent future visual loss. 
 
6.6.1.3 Symptoms  
Headache, found in this analysis to be prevalent (43%) prior to a diagnosis of GCA, was 
smaller than the prevalence estimate (77%) produced in the meta-analysis of the review in 
Chapter 3. Articles included in the review were mainly conducted in secondary care, 
therefore this difference could be due to a difference in the way of recording between the 
two healthcare settings. It is also possible that the prevalence estimate in this analysis 
reflects the proportion of patients who mainly, or only, present with a headache prior to 
their GCA diagnosis, and may have missed patients who present with headache along with a 
range of other symptoms that are simply not recorded, or recorded in the free text section 
of a patient’s record that was not available for this analysis. The analysis in this chapter 
found headache to be highly associated with a diagnosis of GCA in the two years prior to 
GCA diagnosis. The result produced in the review showed less than 2 times higher odds, 
compared to the 44 times higher odds of this analysis. 
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In conjunction with headache, the review found that elevated ESR and visual impairment 
were associated with a diagnosis of GCA. The pooled prevalence of elevated ESR in the 
review was 76%, compared to the 32% in this analysis. Both the review and this study found 
a strong association between elevated ESR and a diagnosis of GCA, with the association 
stronger in this study. Regardless of possible differences, both the review and this study 
conclude that recorded elevated ESR is associated with a GCA diagnosis. Currently, NICE 
guidelines suggest that ESR should be measured in patients with suspected GCA, but may 
not always be tested in preference of other inflammatory markers i.e. c-reactive protein or 
plasma viscosity, the results from blood tests regarding specific measures like ESR are simply 
not formally coded individually into a patient’s record or entered as free text.  
The previously reported prevalence of visual loss in GCA patients prior to their diagnosis is 
20% (NICE CKS, 2020). The review found the prevalence of visual impairment, which included 
loss and other impairments such as diplopia, to be 44%. This study found the prevalence of 
visual impairment to be 3%. This disparity may be due to lack of recording of symptoms via 
Read codes in primary care. As explained in section 6.6.1.2, not all symptoms may be 
recorded via Read code during a consultation and may instead be added into the free text 
section, not available in this analysis. The current NICE guidelines instruct GPs to 
immediately give patients with visual impairment a prescription of glucocorticoids, due to 
suspected GCA and to prevent permanent vision loss (NICE CKS, 2020). This may result in 
only the prescription being coded, and not the visual symptoms. 
Fatigue, along with weight loss/anorexia and fever, was considered to come under the term 
“constitutional/systemic symptoms” highlighted in the systematic review. The articles 
included in the review did not always make it clear how many, or in what combination, these 
symptoms were presented with. In this study all three were kept independent of one 
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another to investigate their individual associations with a subsequent diagnosis of GCA, and 
subsequently incorporated to investigate their joint association with a diagnosis of GCA. 
Recording of all three were highly associated with a diagnosis of GCA. GCA cases presenting 
with fever had higher increased odds of a subsequent GCA diagnosis than those presenting 
with weight loss/anorexia, although both were significantly associated with a diagnosis of 
GCA. Including all three under the heading of constitutional symptoms maintained this 
significant association with a diagnosis of GCA. After comparison with the results of the 
systematic review, constitutional/systemic symptoms did not have a significant association 
with a positive temporal artery biopsy in the review. Overall, there is little benefit of 
combining fever, fatigue, weight loss, and anorexia under one term. Any usefulness such a 
term would bring to research and primary care recording is inhibited by the lack of 
consistency in the term’s definition regarding symptoms included, and what combination, if 
any, they are presented in. An area for future research would be to develop an official 
definition of constitutional symptoms and what symptom requirements are needed for it to 
be used in a patient’s record. 
The systematic review conducted in Chapter 3 found that jaw claudication, defined as pain in 
the jaw whilst eating, was associated with a diagnosis of GCA. There is currently no 
corresponding Read code for jaw claudication. There are codes for general and limb specific 
claudication, pain whilst chewing, amongst other related forms of claudication, but none 
were suitable to represent jaw claudication. SNOMED clinical terms (SNOMED CT) is a 
medical coding system developed in the UK which is set to replace Read codes. As of April 
2018, the NHS began to phase SNOMED codes in to replace the currently used Read codes. 
Eventually this will lead to Read codes becoming obsolete within UK general practice. There 
is a SNOMED code for jaw claudication, and an area of future work in the research of GCA in 
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primary care should be to conduct a study using SNOMED codes, thereby allowing the 
inclusion of jaw claudication as a specific clinical feature, conditional on appropriate and 
correct usage by GPs. However, it will not be available in historic data, prior to the 
introduction of SNOMED codes. The closest Read code available was jaw pain, which was 
used in this study, but does not exactly match the definition of jaw claudication. 
 
6.6.1.4 Comorbidities  
Patients who have a record of hypertension or PMR in the two years prior to their date of 
GCA diagnosis have higher odds of a diagnosis of GCA than controls. Other comorbidities 
that had a significant, but weaker, association with a diagnosis of GCA were; 
cardiovascular/cerebrovascular conditions, diabetes, cancer, and anxiety/depression. The 
articles included in the systematic review mainly reported findings on symptoms, hence 
results on the relationship between comorbidities and a diagnosis of GCA were sparse. This 
study has found that some comorbidities, like hypertension, may be risk factors for GCA. 
PMR was the only comorbidity frequently reported in review articles, this is likely due to its 
known association with GCA. The review found that PMR occurred in a third (34%) of 
patients prior to a positive temporal artery biopsy. However, the moderate positive 
association between PMR and a positive temporal artery biopsy was not statistically 
significant. Findings from this study suggest that the prevalence of PMR prior to a GCA 
diagnosis is lower (12%). However, PMR was found to be strongly associated with a 
subsequent diagnosis of GCA in this study. The difference between the results of this study 
and the review may be due to the differences in comorbidity recording between primary and 
secondary care. PMR can also be difficult to diagnose since there is no diagnostic test 
193 
 
available for this condition (G. Nesher & Breuer, 2016), hence PMR may not be diagnosed, or 
coded into a patient’s primary care record. 
Hypertension was found to be one of the most prevalent comorbidities in this study, with 
50% of cases having a record of hypertensive medication in the 24 months prior to their GCA 
diagnosis. Hypertension was also found to be strongly associated with a GCA diagnosis in this 
study. In comparison, hypertension was not frequently reported in the articles included in 
the review and had a moderate/low prevalence (31%).  
Hypertension, for the purposes of this study, was defined two ways; recorded and treated. 
Treated hypertension was found to be more prevalent in both case and control populations 
when compared to recorded. However, both were significantly associated with a subsequent 
diagnosis of GCA. This indicates that when researching hypertension using primary care EHR, 
treated hypertension should be used to ensure patients with hypertension are not missed, 
rather than relying solely on Read codes, which in this study produced low consultation 
prevalence estimates. Previous studies have found that adverse effects of long-term 
glucocorticoid use, such as that used to treat GCA, is the development of hypertension 
(Ness, Bley, Schmidt, & Lamprecht, 2013). However, this is usually after a diagnosis of GCA, 
whereas this work has identified the presence of hypertension before the GCA diagnosis. 
This could imply there is an association between pre-existing hypertension and a subsequent 
diagnosis of GCA, or that hypertension may cause GCA. However, investigation of this 
possible association is an area for future work. 
Cancer was not significantly associated with a diagnosis of GCA at all time periods prior. A 
previous case-control study investigating the association between a prior diagnosis of cancer 
and a subsequent diagnosis of GCA in the USA found that GCA patients had a lower risk of 
prevalent cancer prior to their diagnosis of GCA (Tanaz A Kermani et al., 2010). However, 
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when cancer was investigated 12 months prior to a GCA diagnosis, the OR was 1.25 after 
adjustment for age, sex, and year of GCA diagnosis, but was not statistically significant. This 
result is very similar to the odds ratio found in this study for cancer 12 months prior to 
diagnosis (OR = 1.50), which was statistically significant. The study by Kermani et al (2010) 
had a small sample size of only 207 GCA patients, and matched cases to controls on a ratio of 
1:2. Therefore it is possible that the analysis conducted in that study was underpowered. 
The results from this study, which is unlikely to be underpowered, found that there was an 
association between cancer and GCA. 
 
6.1.1.1 Comparison to the systematic review 
Overall, the prevalence estimates found in the systematic review were larger than those 
produced in this study. However, both agreed that headache, elevated ESR, and 
constitutional symptoms were the symptoms with the largest prevalence prior to a GCA 
diagnosis. The review found that PMR and hypertension were the comorbidities with the 
largest prevalence prior to GCA diagnosis. The strength of association between clinical 
features and a GCA diagnosis was stronger in this study than in the review, as has been 
described in sections 6.6.1.3 & 6.6.1.4. 
There were differences in the results found in the review and those produced in this case-
control study. There are numerous reasons why these differences occurred such as a 
difference between recording in primary care, where this study was conducted, and the 
secondary care setting of the articles included in the review. Another difference between 
this study and the articles included in the review was the time-period prior to GCA diagnosis 
that was examined. Most articles in the review recorded information on clinical features at 
the time of diagnosis/temporal artery biopsy. Few articles included the time at which clinical 
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features were recorded prior to GCA diagnosis. Difference in sample sizes, geographical 
populations, and comparator groups could also explain the difference between the odds 
ratios produced in this study compared to those found in the review, as most articles 
included in the review had small sample sizes, were conducted outside the UK, and used 
patients with a negative temporal artery biopsy as the comparator group as opposed to the 
general population used in this study. The final difference could be due to the way GCA was 
diagnosed. In the review, the majority of the articles used temporal artery biopsy to confirm 
a diagnosis, followed by the ACR 1990 criteria. The definition of GCA used in this study were 
Read codes and glucocorticoid prescription information. In UK primary care suspected GCA 
patients are referred to a specialist, usually a rheumatologist according to NICE guidelines, 
for further examination. Not all patients with GCA in the UK will undergo a temporal artery 
biopsy for confirmation of diagnosis, as ultrasound is also used to confirm a GCA diagnosis 
(NICE CKS, 2020). Therefore, the GCA population used in this review may not be the same as 
those used in the articles included in the review, and hence may produce different results. 
 
6.6.2 Strengths and limitations 
This study was conducted in a large primary care database, generalisable to the UK 
population, and included over 9000 patients diagnosed with GCA. Furthermore, due to the 
use of an EHR database, diagnosis of GCA did not rely on temporal artery biopsy alone, or on 
other less reliable methods of diagnosis (such as the ACR 1990 criteria). A strength of the 
analysis is that the results were robust to the definition of GCA and after adjustment for 
patient demographics, shown by the multiple sensitivity analyses conducted. The 
associations of clinical features and a subsequent GCA diagnosis were similar between GCA 
cases defined using only a Read code, and those defined using a Read code and a 
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prescription of glucocorticoids. GCA defined using Read code only produces a larger sample, 
but GCA defined using both Read codes and prescription information produces a more 
accurate sample since the recommended treatment for GCA are glucocorticoids which 
should be recorded in a patient’s record. After restricting to patients only registered at 
practices in England, the results did not change. A final strength was the broad scope of 
clinical features that were investigated, with 14 being included in the analysis. These 
included all but one of the key features hypothesised to be associated with GCA. The only 
key feature that could not be mapped to a Read code was abnormal temporal artery. 
There are several limitations relating to this investigation. Levels of missing data in patient 
demographics, either due to lack of recording, or historical values being lost when patients 
transfer between general practices. The missing category of both smoking status and alcohol 
consumption were the largest, composing of almost a third of cases, and almost half of 
controls. Conversely, for BMI it had the smallest amount of missing data for GCA cases, but 
almost a third of controls did not have a value recorded. Missing data is an acknowledged 
limitation of using resources such as CPRD, where there are numerous reasons for 
missingness. None of the missing variables can be reliably imputed using imputation 
techniques as they cannot be assumed to be missing at random (MAR), a key assumption of 
imputation methodology (as discussed in Chapter 4). The IMD 2015 score was missing for 
between 1% and 4% of cases and controls respectively in the subset of patients registered at 
practices in England who have linkage to IMD 2015. These are small amounts of missing 
data, and most likely would not have affected the results of the sensitivity analysis had they 
been complete. 
A limitation regarding the definition of clinical features is that severity of symptoms is not 
recorded in primary care EHR. Frequency of consultations for clinical features were also not 
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assessed. A possibility for the associations found in the remaining comorbidities is 
surveillance bias. Patients who have chronic conditions have a higher number of 
consultations to primary care (Salisbury, Johnson, Purdy, Valderas, & Montgomery, 2011). 
This increased contact time with GPs may induce surveillance bias since these patients are 
more likely to be undergoing regular check-ups and blood tests. 
 
6.6.3 Conclusions 
Patients who eventually receive a GCA diagnosis are significantly more likely to consult 
primary care with any one of 14 different clinical features in the preceding 24 months. 
However, as the recorded prevalence of many of these clinical features remains infrequent 
in the GCA population and are frequently reported in relation to many other conditions in 
primary care, identifying GCA much earlier in the disease course remains a challenge. 
General symptoms such as fever and fatigue, with the “classical” symptoms such as 
headache, and comorbidities such as hypertension are all associated with a subsequent GCA 
diagnosis. The strength of association between symptoms and a GCA diagnosis are stronger 
the closer the symptom is to the date of diagnosis. This could indicate the possibility of a 
patient consulting multiple times for the same symptom over a short period of time, thereby 
prompting the GP to investigate further, which would lead to a GCA diagnosis. However, the 
association between comorbidities and GCA remain stable over time, with a spike at 6 
months prior.  
Overall, this study suggests patients may have at least 24 months between the first 
presentation of a clinical feature and a diagnosis of GCA, with symptoms first occurring 
closer to the date of GCA diagnosis than comorbidities. Although this study indicates which 
clinical features are associated with a diagnosis of GCA individually, the use of this 
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information is limited as it remains difficult for GPs to link isolated, some commonly 
occurring, clinical features 24 months prior to GCA. Therefore, the next step is to investigate 
clusters of clinical features in the 24 months prior to a diagnosis of GCA.  
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Chapter 7: Combinations of presenting clinical features 
7.1 Chapter overview 
This chapter details the methods and results of a latent class analysis (LCA) aiming to 
investigate whether there are distinct clusters of clinical features recorded in primary care 
prior to a diagnosis of GCA in the UK. A secondary objective of this chapter was to assess 
Latent Class Analysis (LCA) applied to primary care EHR as a method to derive patterns of 
clinical features in GCA. 
 
7.2 Background 
In the previous chapter, a case-control study was conducted to investigate the relationship 
of recorded clinical features in the previous 24 months with a diagnosis of GCA. Conditional 
logistic regression was used to explore this relationship to determine the independent 
association of each clinical feature with GCA. It was concluded that although many clinical 
features are associated with a GCA diagnosis, presenting with a single feature to primary 
care may not lead to a prompt diagnosis of GCA. Therefore, it is important to investigate 
combinations of clinical features which may help GPs more promptly consider the likelihood 
of GCA in the patient before them. 
LCA has become an increasingly common methodology for health research due to its 
usefulness across diverse areas of clinical research and increasing availability of software 
(Kongsted & Nielsen, 2017). The use of LCA reaches across all health research areas, with 
studies published using LCA to quantify patterns of eating habits of families with teenage 
children (Schnettler et al., 2018), to that characterising the prodrome of rheumatoid arthritis 
(Muller et al., 2019). 
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In a study conducted by Sepriano et al (2020) to investigate the prodrome of axial 
spondyloarthritis (axSpA), a condition that is difficult to diagnose and prone to diagnostic 
delay (Sepriano et al., 2020), LCA was used to identify combinations of characteristics that 
would improve the classification criteria that currently exists regarding the diagnosis of 
axSpA. From a sample of 465 patients with axSpA, this study found that there were four 
distinct classes; no SpA, family history of axSpA but no features, inflammatory back pain and 
peripheral features prior to axSpA, and lesions present on axial imaging prior to axSpA. Due 
to LCA’s methodological superiority over distance-based clustering techniques, described in 
section 7.4.2, and its previous use to identify clusters of patients presenting with conditions 
that are difficult to diagnose, it will be used for the analysis in this study.  
 
7.3 Aim  
The main aims of this study were to identify common patterns of clinical features that are 
presented to primary care by patients in the 24 months prior to their diagnosis of GCA, and 
to assess the value of LCA for deriving patterns of clinical features presented to primary care 
prior to a GCA diagnosis. 
 
7.4 Methods 
7.4.1 Study population & clinical features 
Patients diagnosed with GCA from 1990-2017 were included in this study. Selection and 
patient eligibility has been described in Chapter 6, section 6.4.1. GCA cases from Chapter 6 
were retained, with their matched controls being removed for this analysis. The clinical 
features included in this analysis have been discussed in Chapter 6, section 6.4.3. However, 
in brief, 14 clinical features were investigated and Read code lists were created for each of 
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these and mapped to CPRD’s medcodes. The clinical features included in this chapter are; 
headache, fever, cancer, weight loss/anorexia, visual impairment, fatigue, treated 
hypertension, cardiovascular/cerebrovascular diseases, recorded elevated ESR, 
anxiety/depression, PMR, arthralgia/myalgia, diabetes, and jaw pain. 
In the analysis conducted in Chapter 6, the time prior to GCA diagnosis was categorised by 
months prior to diagnosis; 24 months, 12 months, 6 months, and ≤1 months prior. For the 
latent class analysis, the full 24 months prior to a diagnosis of GCA was used as the analysis 
conducted in Chapter 6 highlighted that symptoms may present several months prior to a 
GCA diagnosis, and therefore using a period shorter than 24 months risks missing key early 
symptoms that may be relevant from the analysis. Chapter 6 also highlighted that the 
association of comorbidities with GCA were consistent over the 24 months prior to a GCA 
diagnosis. Given that chronic comorbidities, such as hypertension and diabetes, may not be 
recorded using a disease Read code on a regular basis, but rather through prescription codes 
for related medications, using a time-period of less than 24 months may also miss the 
presence of a comorbidity. The period from 24 months prior to a GCA diagnosis was the 
time-period with the largest prevalence of clinical features, thereby increasing the power of 
the analysis. It is also possible that clinical features recorded prior to 24 months may not be 
related to a GCA diagnosis (Talarico et al., 2020), and as discussed in Chapter 6 section 




A common method of identifying patterns and combinations in data are clustering 
techniques. There are many clustering techniques that can be implemented on data, but one 
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of the simplest is k-means. Most clustering techniques are based on methodology that 
involves measuring the distance between data points (in the case of health research these 
data points would be patients), and using this distance to group the patients into clusters 
(Brusco, Shireman, & Steinley, 2017). For example, with k-means, clusters are created based 
on how far a patient’s data is from the estimated “centroid” of a cluster, also called the 
mean of the cluster. Patients who are close to the cluster centroid are assumed to be in that 
cluster (Brusco et al., 2017). K-means is an iterative process. The algorithm begins with 
random data points as centroids, and with each iteration these centroids are moved until 
either the optimal centroid has been found, or the algorithm has completed the number of 
iterations it was programmed to complete. Most clustering techniques beyond k-means are 
based on the same methodology of calculating the distance between data points and using 
these distances to allocate data to clusters. The disadvantage of these techniques is the lack 
of repeatability. Due to the process being iterative it is difficult to reach the same results 
each time the algorithm is run, and hence there may be a lack of consistency between one 
set of results and the next (Raykov, Boukouvalas, Baig, & Little, 2016). Another disadvantage, 
and the one that makes k-means unsuitable for use in this study, is that k-means assumes all 
clusters to be of the same size (Raykov et al., 2016). A further limitation of clustering 
techniques is their inability to assess the strength of cluster classification, and the lack of 
available model fit assessment criteria (Raykov et al., 2016).  
An alternative to distance-based clustering techniques is a modelling-based approach that 
uses probability methodology to allocate data into classes. Latent class analysis (LCA) is a 
mixture modelling technique that can be used to investigate common groups of presenting 
features in GCA. LCA classifies individuals into groups, called latent classes, based on 
categorical responses. In the case of this study these responses are the primary care 
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recorded clinical features (binary variable: recorded or not recorded) prior to the date of 
GCA diagnosis. LCA assumes homogeneity within clusters, i.e. patients within each cluster 
should have similar recorded features, and heterogeneity between clusters, i.e. patients in 
different clusters should have different patterns of recorded features. 
Latent class models are a form of finite mixture models, where all variables are assumed to 
be independent within each cluster, also called local independence (Beath, 2017; Linzer & 
Lewis, 2011). Assume that there are J polytomous categorical variables observed (in this case 
J = 14 clinical features), and each contains K possible outcomes (in this case K = 2, 
corresponding to the clinical feature being recorded or not recorded), for individuals i = 
1,….,N. The observed values of the J categorical variables are denoted by the binary Yijk, 
where Yijk = 1 if respondent i gives the kth response to the jth variable, and Yijk = 0 otherwise, 
for j = 1…., 14, and k = 1,..2.  
Let R denote the number of classes in the latent class model, which is chosen based on 
theoretical and practical reasons, i.e. a combination of model fit and clinical opinion, as 
discussed in section 7.4.2.1. There are two key parameters estimated by the latent class 
model. The first is the probability of having a recorded clinical feature (class-conditional 
outcome probability) within each class r = 1,…, R, denoted by πjrk. The sum of these class-
conditional probabilities, within each class, is equal to one. The second are prior probabilities 
of latent class membership and are defined as the probability that an individual will belong 
to a class prior to observing their response to the categorical variables (Yijk), and is denoted 
as pr. 
The formula of a latent class model is given by: 









The posterior probability of each individual belonging to each class in the model is the 
probability of class membership given each individual’s recorded clinical features, and is 






     (5) 
 
Where ri ϵ {1,…,R}, and 𝑝?̂? and 𝜋?̂? are the estimates of the prior probabilities and probability 
of having a clinical feature recorded conditional on class membership, respectively. Latent 
class models are estimated by maximising the log-likelihood function. 
Latent class models produce class conditional outcome probabilities for each variable 
included in the model, in the case of this study for each clinical feature. These probabilities 
are considered high if they are >70%, i.e. the probability of a patient allocated to a cluster 
having that clinical feature is over 70%. If a clinical feature has a conditional outcome 
probability of higher than 70%, it can be considered a key feature of that class (Beath, 2017; 
Linzer & Lewis, 2011). If a clinical feature has a conditional outcome probability of 50%, then 
half of the people in the cluster are estimated to have that clinical feature, and half not, and 
hence it does not help to define the cluster. 
The recommended practice for LCA is to fit a small number of classes initially, such as 1 or 2, 
and increase the number of classes by one in every iteration until the best fitting and/or 
most clinically relevant model is found (Linzer & Lewis, 2011). Therefore, initially a 2-class 
model will be fitted to the data for the 24 months prior to a diagnosis of GCA, with each 
subsequent model including one more class than the previous. The optimal number of 
classes fitted to the data depends on the model fit statistics when comparing a model to the 
model with one less class, as described in section 7.4.2.1.  
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If, by increasing the number of classes, the fit statistics become worse, then the iterative 
process should stop as the best model has already been found (Mueller et al., 2017). The 
average posterior probability of each class should also be taken into account when assessing 
model fit, as the smaller the value (usually less than 0.7) indicates that separation between 
classes is poor, and therefore may not be the most appropriate model (Mueller et al., 2017). 
That is, patients have on average less than 70% probability of being in the class they have 
been allocated to. However, the most statistically relevant model may not be the most 
clinically relevant. Therefore, a compromise needs to be reached between model fit and 
clinical applicability and this was achieved through discussion with the wider supervisory 
team after taking into account the goodness of fit statistics, average posterior probabilities, 
and class conditional outcome probabilities.  
Each latent class model was run 100 times using randomly generated starting values for 
3000 iterations so that the global maximum likelihood could be found (Linzer & Lewis, 2011). 
All analysis was conducted using the PoLCA package in R studio v3.4.2 (Linzer & Lewis, 2011; 
R Core Team, 2017). 
 
7.4.2.1 Model assessment 
With every increase in the number of classes, the risk of producing an over-fitting model 
increases (Linzer & Lewis, 2011). The purpose of model assessment criteria is to find an 
optimum model that is neither under-fitted (does not explain the associations in the data 
well) nor over-fitted (explains the data too well and is therefore not generalisable to other 
data). The most commonly reported goodness of fit methods for LCA model assessment are 
Akaike’s Information Criteria (AIC) and Bayesian Information Criteria (BIC) (Beath, 2017). 
Other model fit assessment methods include the “consistent” AIC (CAIC) and the bootstrap 
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likelihood ratio test (BLRT). The CAIC is an alternative to the AIC, and is less affected by a 
change in sample size (Anderson, Burnham, & White, 1998). The BLRT is an alternative to the 
likelihood ratio test (LRT), which cannot be used to assess LCA models due to distribution 
assumptions being violated by the LCA methodology (Tekle, Gudicha, & Vermunt, 2016). 
Bootstrapping has been suggested to empirically generate a model distribution that would 
not violate the LRT’s assumptions and would instead use the maximum likelihood estimate 
produced by the LCA model (Tekle et al., 2016). Both the CAIC and BLRT could not be 
calculated from the software used to run this analysis. However, the BIC is commonly 
accepted as the optimal model assessment criteria for LCA (Nylund, Asparouhov, & Muthén, 
2007). Hence, the AIC, BIC, and relative entropy (described below) were used to assess 
overall model fit, and the average posterior probability used to assess individual class fit.  
If we let L represent the maximum log-likelihood of the latent class model, and Φ the 
number of estimated parameters, then the AIC and BIC are defined as: 
𝐴𝐼𝐶 = −2𝐿 + 2𝛷 
𝐵𝐼𝐶 =  −2𝐿 + 𝛷 ln (𝑁) 
N is the total sample size. The BIC, AIC, relative entropy, and average posterior probability 
for each class, will be considered and used in conjunction with clinical assessment to select 
the optimum model. Smaller values of AIC and BIC indicate a better fitting model. 
 
7.4.2.2 Class assessment 
Three criteria were used to select the optimum latent class model (Table 7.1). Relative 
entropy is a fit statistic that takes a value between 0 and 1, and indicates how distinct each 
class is from the others. It is calculated via the following formula: 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦 = 1 −








?̂?(𝑟𝑖|𝑌𝑖) is the conditional posterior probability for each individual i = 1,…,N, and represents 
the probability of membership in each of the R latent classes. An indicator of good model fit 
is an entropy value approaching 1 (Celeux & Soromenho, 1996). 
 
Table 7.1: Criteria for choosing the optimum latent class model. 
 Criteria Requirement for good model 
fit 
Model fit 1. BIC 
2. AIC  
3. Relative entropy 
 
1. A smaller value 
2. A smaller value  
3. Close to 1 
 
Class separation Average posterior 
probability 
Values closer to 1 (preferably 
≥0.7) indicate good class 
separation. 
Clinical assessment Discussion with the wider supervisory team (epidemiologist, 
statistician, and a GP) to assess which model is the optimal 
based on statistical evidence, comparison between models, 
and clinical assessment. 
 
To assess class separation (definition) the average posterior probability of each class was 
calculated. The average posterior probability, as discussed in section 7.4.2, is the mean of 
the posterior probabilities for each individual allocated to that class, and is on a scale from 0 
to 1, where a value closer to 1 (usually operationalised as ≥0.7) indicates a better class fit as 
individuals have a high probability of belonging to their allocated class (Linzer & Lewis, 2011; 
Mueller et al., 2017). 
 
7.4.2.3 Demographics 
Once patients have been assigned to a class, demographics (gender, age at diagnosis, BMI, 
smoking status, and alcohol consumption) were investigated for each class to investigate if 
these vary across latent classes and provide an overview of the patients allocated to each 
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class. The mean and median age at diagnosis for each class were calculated and compared, 
in conjunction with the proportion of males and females. BMI, smoking status, and alcohol 
consumption will be categorised, as has been described in Chapter 6 section 6.4.3, and the 
proportion in each category compared across all classes. 
 
7.4.2.4 Sensitivity analysis 
A sensitivity analysis was conducted grouping fever, weight loss/anorexia, and fatigue 
together under the heading of “constitutional symptoms” to reflect that these symptoms are 
commonly combined, and can all be considered constitutional symptoms. All models will be 
assessed via model fit statistics for latent class analysis as discussed above.  
 
7.5 Results 
7.5.1 Sample characteristics 
The total number of patients with GCA included in this analysis was 9205. Demographics of 
this population have been detailed in Chapter 6, section 6.5.1. In brief, the mean age of the 
sample was 72.6 years (SD = 10.3), and 71% were female. 
 
7.5.2 Latent class analysis  
A comparison of fit between LCA models with different numbers of classes fitted to the 24-
month data can be seen in Table 7.2. Each model fit criteria suggested a different model to 
be the optimum. The AIC was smallest for the 6-class model, whereas the BIC was smallest 
for the 4-class. The relative entropy was the largest (i.e. the closest to 1) for the 3-class 
model. The AIC continued to decrease the more classes were added to the model, and hence 
was not considered to be a reliable method to choose the final model. In order to decide 
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which model was the best the average posterior probabilities for each model were 
examined, and the clinical relevance of classes with the 3, 4, and 5-class models were 
discussed with the supervisory team. The average posterior probabilities were best for the 3-
class model as all were above the accepted threshold of 0.7. Only two of the classes in the 4-
class model were above this threshold, and three in the 5-class model. After discussion with 
the supervisory team, it was decided that the 5-class model was the most clinically relevant 
as the fourth and fifth classes identified potentially important subgroups of GCA patients 
that the 3-class model did not. Comparisons of the chosen 5-class model to the 3-class 
model is given in 7.5.2.1. 
 
Table 7.2: Model comparison between the 2 through 6-class LCA models on the 24 months 
prior to a GCA diagnosis. Final model shown in bold. 
Model AIC BIC Relative 
entropy 
2-class 81498.14 81704.84 0.473 
3-class 81217.13 81530.74 0.690 
4-class 81097.51 81518.03 0.587 
5-class 81017.39 81544.82 0.676 
6-class 80990.69 81625.04 0.584 
 
In the chosen 5-class model, the first class contained 2485 (27.00%) patients. The average 
posterior probability was 0.98, indicating good class fit. There was no clinical feature in this 
class that had a conditional outcome probability of more than 70%, indicating that this class 
had no dominating presenting feature (Table 7.3). The clinical feature with the highest 
estimated conditional outcome probability was headache (39.23%), followed by treated 
hypertension (25.70%). The conditional outcome probabilities for the remaining 12 clinical 
features were all less than 10%. The median number of clinical features prior to a GCA 
diagnosis for patients in this class was 1 (IQR = 1), and 995 (40.04%) patients allocated to this 
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class only consulted with one clinical feature, and 1031 (41.49%) consulted with no clinical 
features prior to their GCA diagnosis (Table 7.4). This class was labelled as “Single or no 
feature”. 
The second class contained 1968 (21.38%) patients. The average posterior probability for 
this class was 0.76, indicating good class fit. The most common feature was recorded 
elevated ESR, followed by headache and hypertension. Patients in this class had a median of 
1 (IQR = 1) recorded clinical feature prior to their GCA diagnosis, and the majority (43.19%) 
of patients had 1 clinical feature prior to their GCA diagnosis (Table 7.4). This class was 
labelled “Elevated ESR”.  
The third class contained 500 (5.43%) patients. The average posterior probability was 0.65, 
indicating moderate class fit. The dominating feature of this class was treated hypertension, 
followed by headache (Table 7.3). The median number of clinical features prior to a GCA 
diagnosis for patients in this class was 4 (IQR = 2), with a minimum of 3 clinical features prior 
to GCA diagnosis (Table 7.4). This class was labelled as “hypertension + multiple other 
features”. 
The fourth class was the largest and contained 3285 (35.69%) of patients. The average 
posterior probability was 0.63, indicating moderate class fit. Every patient allocated to this 
class had treated hypertension prior to their GCA diagnosis (Table 7.3). The median number 
of clinical features prior to GCA diagnosis for patients in this class was 2 (IQR = 2). 949 
(28.89%) patients in this class had treated hypertension only prior to their GCA diagnosis, 
and 1348 (40.04%) patients had one other clinical feature (in addition to treated 




The fifth class contained 967 (10.51%) patients. The average posterior probability for this 
class was 0.76, indicating patients in this class were generally clearly allocated to this class 
(Table 7.3). All patients allocated to this class had a record of PMR prior to their GCA 
diagnosis. The median number of clinical features prior to GCA diagnosis for patients in this 
class was 2 (IQR = 1). 174 (17.99%) patients in this class had PMR only prior to their GCA 
diagnosis, and 369 (38.16%) patients had 1 other clinical feature (in addition to PMR) (Table 






Table 7.3: LCA model results for the 5-class final model, showing class conditional outcome probabilities. 
 Class 1 – Single or no 
feature (n = 2485 
(27.00%)) 
Class 2 – Elevated ESR 
(n = 1968 (21.38%)) 
Class 3 – 
Hypertension + 
multiple other 
features (n = 500 
(5.43%)) 
Class 4 – 
Hypertension (n = 
3285 (35.69%)) 














Headache 39.23% 55.01% 57.72% 39.35% 30.03% 
Fever 0.62% 0.42% 2.64% 0.11% 0.00% 
Cancer 3.42% 3.84% 5.55% 4.96% 3.71% 
Weight loss 2.20% 2.20% 11.40% 0.58% 2.82% 
Visual 3.28% 2.59% 6.03% 2.40% 3.24% 
Fatigue 6.24% 9.13% 26.31% 3.67% 10.04% 
Treated hypertension 25.70% 38.26% 96.91% 100.00% 50.01% 
Cardiovascular 
diseases 
4.10% 2.67% 37.93% 22.90% 3.89% 
Elevated ESR 0.04% 99.79% 41.94% 23.33% 45.65% 
Anxiety/Depression 7.18% 5.17% 17.57% 7.36% 5.22% 
PMR 1.27% 3.01% 13.42% 4.89% 100.00% 
Arthralgia/Myalgia 4.94% 5.56% 15.06% 3.92% 23.14% 
Diabetes 3.07% 5.57% 21.66% 19.79% 7.18% 
Jaw pain 1.60% 3.23% 2.73% 1.38% 2.12% 
Key: Dark red indicates dominating class features (features with the highest conditional outcome probability); orange indicates features with the highest outcome 
probability, but below cut-off of 70%. 
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Table 7.4: Number of recorded consultations prior to a GCA diagnosis for each class. 
 Class 1 – 
Single or no 
feature  
(n = 2485) 
Class 2 – Elevated 
ESR 
(n = 1968) 





(n = 500) 
Class 4 – 
Hypertension  
(n = 3285) 
Class 5 – PMR  
































298 (15.14%) 0 0 0 
1 995 (40.04%) 850 (43.19%) 0 949 (28.89%) 174 (17.99%) 
2 372 (14.97%) 612 (31.10%) 0 1348 (40.04%) 369 (38.16%) 
3 79 (3.18%) 187 (9.50%) 168 (33.60%) 808 (24.60%) 285 (29.47%) 




7.5.2.1 Comparison to 3 and 4-class models 
As described in section 7.5.2, the optimal model was different for each model selection 
criteria. The 5-class model was chosen after discussion with the wider supervisory team. 
However, the 5-class model did not have the best average posterior probabilities for each 
class and had poorer model fit based on AIC and entropy. The three classes in the 3-class 
model were the “PMR” class, with an average posterior probability of 0.85, a “Single or no 
feature” class with an average posterior probability of 0.83, and a “hypertension + multiple 
other features” class with an average posterior probability of 0.76. The classes the 3-class 
model did not define were the “hypertension” and “Elevated ESR” classes. 
The 4-class model has one of the smallest AIC values. The classes produced in the 4-class 
model (“PMR”, “hypertension + multiple other features”, and “Single or no feature”, and a 
fourth class which was similar to the “Single or no feature”) were mostly defined in the 5-
class model. The average posterior probabilities for these classes were lower in the 4-class 
model than in the 5-class model. Two of the four classes had no dominating feature, and 
only two classes had an average posterior probability of over 70%. 
 
7.5.2.2 Class demographics 
The first class, named “Single or no feature”, were on average the youngest class, with a 
mean age of 68.90 years (SD = 11.33), and a median of 70 years (IQR = 16). 38.59% were 
under/normal weight (Table 7.5). The second class, named “Elevated ESR”, had a mean age 
of 73.34 (SD = 9.55), and a median of 74 (IQR = 13) years. 40.45% were under/normal 
weight; 29.07% were non-smokers; and 36.03% were light drinkers. The third class, named 
“Hypertension + multiple other features”, were on average the oldest class, with a mean age 
of 74.65 years (SD = 9.31), and a median of 76 years (IQR = 12). 36.80% were under/normal 
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weight; 32.40% were non-smokers; and 34.00% were light drinkers. The fourth class, named 
“hypertension” had a mean age of 74.30 years (SD = 9.89), and a median age of 75 years 
(IQR = 13). 33.73% of this class were overweight; 31.87% were non-smokers; and 34.28% 
were light drinkers. The fifth class, named “PMR”, had a mean age of 73.35 years (SD = 8.50), 
and a median age of 73 years (IQR = 13). 39.71% were under/normal weight, and 35.16% 
were light drinkers (Table 7.5).
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Table 7.5: Class demographics for the 5-class LCA model. 
 
Class 1 –  
Single or no 
feature 
Class 2 – Elevated 
ESR 
Class 3 – 
Hypertension 
+ multiple 
other features  
Class 4 – 
Hypertension  
Class 5 – PMR 
 
N % N % N % N % N % 
N 2485 27.00 1968 21.38 500 5.43 3285 35.69 967 10.51 
Average posterior 
probability 
0.98 0.76 0.65 0.63 0.76 
Males 805 32.39 512 26.02 115 23.00 1030 31.35 211 21.82 
Females 1680 67.61 1456 73.98 385 77.00 2255 68.65 756 78.18 
Mean age at 
diagnosis (SD) 68.90 (11.33) 73.34 (9.55) 74.65 (9.31) 
 
74.30 (9.89) 73.35 (8.50) 
Median age at 
diagnosis (IQR) 70 (16) 74 (13) 76 (12) 
 
75 (13) 73 (11) 
BMI           
Normal/under 959 38.59 796 40.45 184 36.80 890 27.09 384 39.71 
Overweight 727 29.26 675 34.30 156 31.20 1108 33.73 323 33.40 
Obese 373 15.01 313 15.90 121 24.20 917 27.91 174 17.99 
Missing 426 17.14 184 9.35 39 7.80 370 11.26 86 8.89 
Smoking           
Non-smoker 774 31.15 572 29.07 162 32.40 1047 31.87 340 35.16 
Current 396 15.94 326 16.57 65 13.00 471 14.34 113 11.69 
Ex 517 20.80 569 28.91 149 29.80 964 29.35 257 26.58 
Missing 798 32.11 501 25.46 124 24.80 803 24.44 257 26.58 
Alcohol           
None 330 13.28 307 15.60 77 15.40 553 16.83 137 14.17 
Light 827 33.28 709 36.03 170 34.00 1126 34.28 372 38.47 
Moderate 248 9.98 202 10.26 46 9.20 317 9.65 105 10.86 
Heavy 196 7.89 147 7.47 23 4.60 220 6.70 56 5.79 
Missing 884 35.57 603 30.64 184 36.80 1069 32.54 297 30.71 
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7.5.2.3 Sensitivity analysis 
The sensitivity analysis included “constitutional symptoms” as a variable rather than the 
three individual symptoms. The model with the smallest AIC was the 6-class, and the 4-class 
model had the smallest BIC and largest entropy (Table 7.6). However, to allow comparability 
between this sensitivity analysis and the main analysis, the 5-class model is presented. 
Results from the 4-class model can be seen in Appendix 7.1, Table 3. 
 
Table 7.6: Model comparison from the sensitivity analysis combining constitutional 
symptoms on the 24 months prior to a GCA diagnosis. 
Model AIC BIC Relative 
entropy 
2-class 79621.56 79799.74 0.681 
3-class 79348.70 79619.55 0.690 
4-class 79230.22 79593.73 0.734 
5-class 79169.44 79625.60 0.676 
6-class 79142.80 79691.62 0.572 
 
The first class contained 2538 (27.57%) patients ( 
 
Table 7.7). There was no dominating feature of this class. The clinical feature with the 
highest outcome probability was headache at 39.27%. The median number of clinical 
features prior to a GCA diagnosis for patients in this class was 2 (IQR = 1), hence this class 
corresponds to the “Single or no features” class found in the main analysis. Constitutional 
symptoms had a class conditional outcome probability of 8.83%. 




Table 7.7). Every patient allocated to this class had PMR. This class corresponds to the 
“PMR” class found in the main analysis and will be labelled similarly. Patients in this class 
had an 11.98% probability of having constitutional symptoms. 
The third class contained 576 (6.26%) patients ( 
 
Table 7.7). The dominating features of this class were treated hypertension with a class 
conditional probability of 98.12%, and headache with a probability of 55.42%. This class 
corresponds to the “hypertension + multiple other features” found in the main analysis. This 
was the class with the highest probability of constitutional symptoms, at 34.65%. 
The fourth class contained 1972 (21.42%) patients. The dominating feature of this class was 
recorded elevated ESR, with a class conditional outcome probability of 99.93%. This class 
corresponds to the “Elevated ESR” class found in the main analysis. Constitutional symptoms 
had a class conditional outcome probability of 11.45%. 
The fifth class contained 3178 (34.52%) patients ( 
 
Table 7.7). Everyone in this class had a record of treated hypertension. This class 
corresponds to the “hypertension” class found in the main analysis, and was labelled 








Table 7.7: Model output from the 5-class LCA sensitivity model. Clinical feature with the largest probabilities are highlighted. 
 Class 1 – Single or no 
features  
(n = 2538 (27.57%)) 
Class 2 – PMR  
(n = 941 (10.22%)) 
 
Class 3 – 
Hypertension + 
multiple features  
(n = 576 (6.26%)) 
 
Class 4 – Elevated ESR 
(n = 1972 (21.42%)) 
 
 
Class 5 – Hypertension 












Headache 39.27% 29.51% 55.42% 55.00% 39.43% 
Cancer 3.42% 3.70% 5.53% 3.85% 4.97% 
Visual 3.31% 3.20% 6.07% 2.58% 2.18% 
Treated hypertension 26.77% 49.81% 98.12% 38.72% 100.00% 
Cardiovascular diseases 4.18% 3.68% 36.91% 2.75% 23.09% 
Elevated ESR 0.16% 45.41% 41.65% 99.93% 22.72% 
Anxiety/depression 7.20% 5.11% 16.61% 5.23% 7.27% 
PMR 15.20% 100.00% 14.58% 3.47% 4.41% 
Arthralgia/Myalgia 4.97% 23.43% 14.48% 5.59% 3.67% 
Diabetes 3.11% 7.17% 21.71% 5.65% 20.05% 




8.83% 11.98% 34.65% 11.45% 3.55% 
Mean number of Clinical 





Median number of 
Clinical features (IQR) 1 (1) 2 (1) 4 (1) 2 (2) 
 
3 (2) 
Key: Dark red indicates dominating class features (features with the highest conditional outcome probability); orange indicates features with the highest outcome 
probability, but below cut-off of 70%. 
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7.5.2.4 Comparison to the 4-class model 
The 4-class model had the largest relative entropy and the smallest BIC, and therefore was 
statistically the most appropriate. The four classes found in this model were the “PMR” class 
with an average posterior probability of 0.78, “hypertension + multiple other features” with 
an average posterior probability of 0.83, “Single or no features” with an average posterior 
probability of 0.80, and “Elevated ESR” with an average posterior probability of 0.71 




This study found that there are five distinct classes of clinical features that patients present 
with in the 24 months prior to their diagnosis of GCA (“Single or no features”, 
“hypertension”, “PMR”, “Elevated ESR”, and “hypertension + multiple other features”).  
Patients with GCA in both the “PMR”, “Single or no features”, and “Elevated ESR” classes 
were, on average, younger than the “hypertension”, and “hypertension + multiple other 
features” classes, and more likely to have lower BMI. The classes with treated hypertension 
as a dominant feature were more likely to be older, and have higher BMI. This is possibly due 
to the association between BMI and hypertension, with patients classified as being 
overweight or obese having higher risk of hypertension than someone who is of normal 
weight (Landi et al., 2018). 
These results confirm that headache, PMR, recorded elevated ESR, and hypertension are 
common features in patients diagnosed with GCA. The results of Chapter 6 have shown that 
these features are strongly associated with a GCA diagnosis. Although in this analysis 
headache was not the dominating feature of all classes, it was the most prevalent in the 
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“Single or no features” class, whilst being the second most prevalent after treated 
hypertension in the “hypertension” and “hypertension + multiple other features” classes, 
elevated ESR in the “elevated ESR” class, and PMR in the “PMR” class. Patients with PMR 
formed their own class where all patients in that class had PMR prior to their GCA diagnosis. 
Hypertension is known to be highly prevalent in this age group for both sexes (Alfie & 
Cuffaro, 2019), and similarly to headache, a patient presenting with hypertension will not 
always go on to have a diagnosis of GCA. Previous studies have established hypertension as a 
risk factor for visual loss in GCA (C Dejaco, Duftner, Buttgereit, Matteson, & Dasgupta, 2017; 
Patil et al., 2015), although these patients tended to be older, and male. Previous studies 
investigating hypertension as a risk factor for GCA have produced varying conclusions. A 
study investigating the association between cardiovascular risk factors, such as elevated 
diastolic blood pressure, smoking, and high sensitivity C-reactive protein (hs-CRP), and 
incident GCA found only smoking was a risk factor for incident GCA (Yates et al., 2020), 
although only 118 GCA cases were included in this study. Another study investigated the 
difference in features of GCA between patients over 75 years of age and found that more of 
these patients had history of cardiovascular conditions and high blood pressure than 
patients younger than 75 years of age (Daumas et al., 2019). A study conducted in Iceland 
found that hypertension was a risk factor for GCA in males, but not females, and that having 
higher BMI and having ever smoked (risk factors for cardiovascular conditions) were 
protective factors for incident GCA (Tomasson, Bjornsson, Zhang, Gudnason, & Merkel, 
2019). These findings could suggest that new onset hypertension, or a sudden increase in 
blood pressure or loss of control of existing hypertension, may be an early indicator for 
incident GCA in patients who are older. 
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Clinical features that were highly associated with a diagnosis of GCA in Chapter 6, such as 
constitutional symptoms, visual impairment, and jaw pain, did not form a distinct part of any 
cluster produced in this analysis. Each class produced had a low probability of jaw pain, 
visual impairment, fatigue, fever, weight loss/anorexia independently, and for the grouped 
variable of constitutional symptoms included as a sensitivity analysis. These features were 
associated with a GCA diagnosis in Chapter 6, but the prevalence of all these clinical features 
was low in the population. Reasons for the low prevalence may be because they are not 
commonly coded in a patient’s record, as GPs may record other more prominent symptoms, 
or record them in the free-text section. In the case of jaw pain, a patient may initially consult 
a dentist, and with visual impairment a patient may initially consult an optician. An 
alternative is that these symptoms are ignored during a consultation, or not brought up by 
the patient. A final alternative is that patients simply do not present with these or multiple 
clinical features prior to their GCA diagnosis.  
 
7.6.1 Clinical applicability 
These findings demonstrate that the number of clinical features a patient presents with prior 
to their GCA diagnosis can vary from none to multiple. Headache is still a prevalent 
presenting feature but may not always indicate a GCA diagnosis. This study has highlighted a 
possible association between hypertension and a subsequent diagnosis of GCA, despite 
previous research on this relationship producing conflicting findings. Further studies are 
needed to investigate this relationship. Patients who are diagnosed with PMR should be 
continually monitored for GCA and counselled of its association with PMR so they seek help 
early should GCA symptoms develop. Ideally, further studies would be needed to see if these 
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clusters can be replicated and to understand better how they can be incorporated into 
guidance and clinical care.  
 
7.6.2 Strengths and limitations 
The main strength of this study is that it is the first to examine combinations of (14) clinical 
features, in contrast to previous studies that have focused on clinical features in isolation.. 
The large sample size of this study, including over 9000 GCA patients, and the breadth of the 
analysis where the classes produced were robust to changes in the definition of a GCA case, 
are further strengths of this study. 
A limitation of the analysis was that not all assumptions of the LCA could be assessed. The 
main assumption of LCA is local independence, that the clinical features were independent 
within each cluster. The method of checking the local independence assumption is through 
examining bivariate residuals. A limitation of the software used to perform this analysis was 
that the bivariate residuals were unable to be extracted from the model output, and hence 
the local independence assumption could not be checked. However, the observed patterns 
for patients in each cluster reflects closely the overall cluster pattern, which gives 
sustenance to the clusters found in this study being the “true” clusters.  
A further methodological limitation was that only certain model assessment criteria could be 
produced by the software. This study used the BIC and AIC to assess model fit. However, 
there are more available in other LCA software, such as the BLRT and the CAIC, described in 
section 7.4.2.1, that were not available in the software used to conduct this analysis. The 
BLRT and CAIC have few advantages over the AIC and BIC, and both the AIC and BIC are more 
commonly reported in previous studies, and it is generally accepted that the BIC is superior 
when considering LCA model fit (Mueller et al., 2017; Nylund et al., 2007; Sepriano et al., 
224 
 
2020). It is also unlikely that other model fit criteria would have suggested a different 
number of classes. There was little difference between the classes produced in the 3 and 4-
class models and the final 5-class model. The 3-class model, although better regarding class 
fit, missed an important class of patients whose defining feature was treated hypertension. 
 
7.6.3 Conclusions 
Patients with GCA can be categorised into five distinct classes, based on the clinical features 
that are recorded in GP records within the 24 months preceding their diagnosis. There are 
distinct clinical features that dominate these clusters, including headache, treated 
hypertension, elevated ESR, and PMR. However, these are rarely in combination with 
another clinical feature. Next steps regarding the classes found in this study could be to test 
their overall generalisability by assessing whether these are replicated in other primary care 
EHR datasets, such as CPRD Aurum, or THIN. Additionally further research on clinical 
applicability would be required. Overall, LCA methodology has value for deriving patterns of 
presenting clinical features in primary care and is worth pursuing in further research around 




Chapter 8: Discussion 
8.1 Chapter summary 
The aim of this thesis was to quantify the prevalence and association of clinical features with 
a subsequent diagnosis of GCA. This chapter will discuss the findings of the studies 
conducted in this thesis, detailing strengths and limitations, areas for future research, and 
applicability to clinical practice. 
 
8.2 Overall findings of the thesis 
8.2.1 The role of individual clinical features on a diagnosis of GCA 
The cohort study investigated trends in the consultation incidence and prevalence of GCA in 
the UK between 1990 and 2017 to establish the current burden of GCA in the UK population. 
The results showed that, overall, there was a small decrease in the consultation incidence of 
GCA in the UK between 1992 and 2017, with the exception of a small increase in the early 
2000s. The highest consultation incidence rate was found in females between the ages of 70 
and 79 years, with females having consistently higher consultation incidence rates than men.  
Despite the small decrease in incidence in the UK population in recent years, there remain 
many patients who develop this medical emergency in the UK population and therefore who 
need to be identified promptly to allow subsequent management and treatment in primary 
care. In particular, it is important that patients in the group shown to have the highest 
incidence rate are identified quickly, and determining the clinical features which are 
associated or indicative of a subsequent GCA diagnosis is imperative.  
The systematic review and meta-analysis to examine the relationship between individual 
clinical features and a subsequent GCA diagnosis identified 31 clinical features studied in 
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relation to GCA. Clinical features most commonly observed in GCA patients prior to a 
diagnosis were headache, elevated ESR, and constitutional/systemic symptoms, and those 
with the strongest positive association with a diagnosis of GCA were jaw claudication, 
elevated ESR, and anorexia.  
Of the 31 clinical features identified in the systematic review and meta-analysis, it was 
possible to examine 14 of these in the case-control study (Table 8.1). The clinical features 
with the highest prevalence in this study sample was again headache, but this time also 
treated hypertension. Other clinical features that were prevalent in this sample were 
elevated ESR, and constitutional symptoms, similar to the results found in the systematic 
review. Features with the strongest association with GCA in the case-control study were 
headache, treated hypertension, visual impairment, and PMR. Comorbidities had a weaker 
association to a GCA diagnosis than symptoms. The case-control study found that the 
association between a symptom and a GCA diagnosis was stronger the closer the symptoms 
occurred to the date of GCA diagnosis. It was also able to assess the time between when the 
feature was first recorded and the date of GCA diagnosis (diagnostic delay). Within 2 years of 
GCA diagnosis, the clinical features with the shortest time from recorded onset to diagnosis 
were headache, jaw pain, and visual symptoms. Comorbidities had longer times from first 
recorded onset to GCA diagnosis, with the shortest time being between PMR onset and GCA 
diagnosis. These results imply that symptoms are generally better indicators of imminent 
GCA, in that they occur closer to formal diagnosis, and certain comorbidities may be helpful 




8.2.2 The role of patterns of clinical feature on subsequent GCA diagnosis 
The cohort study investigated classes of clinical features that patients presented to primary 
care with prior to their diagnosis of GCA. Overall, five classes were identified; “PMR”, 
“Hypertension + multiple other features”, “Hypertension”, “Single or no features”, “Elevated 
ESR”. The “Single or no features” class contained patients who had none or one recorded 
clinical features in the 2 years prior to their GCA diagnosis. The PMR class contained patients 
who had PMR prior to their diagnosis of GCA. The elevated ESR contained patients who had 
elevated ESR prior to their GCA diagnosis. Hypertension was the dominating feature of the 
remaining two classes, and patients in these classes had more than one recorded clinical 
feature prior to their GCA diagnosis.  
The results of this analysis showed that headache continues to be an important clinical 
feature, with a strong independent association with GCA, and in conjunction with other 
associated clinical features as it was prevalent in all of the classes found in the analysis. 
Hypertension, showed to be highly prevalent and strongly associated on its own with a GCA 
diagnosis, was also important at a combined level with other clinical features and was 
prominent in two of the four classes found. Previously associated features such as 
constitutional symptoms and jaw pain were not prominent features in any of the classes 
found in this analysis, hence they may have more value as indicators of GCA on their own 
rather than in conjunction with other clinical features. However, our findings do not 
necessarily negate their use in clinical practice given limitations relating to practitioner 
coding as discussed previously. This study serves as a starting point for further research that 




Table 8.1: Summary table of the findings of this thesis and recommendations for areas of future work. 
Clinical Feature   Systematic review findings Findings from electronic health records Conclusions & recommendations 
 Prevalence Association   
Headache High Strong positive 
(Odds Ratio > 1) 
• Moderately high prevalence 
• Strong association with GCA diagnosis. 
• High proportion of GCA patients in each class 
had record of presenting with headache 
• Headache has been established as an 
indicator of GCA 
• However, focus should move away from 
regarding it as the only clinical feature 
indicative of GCA 
Elevated ESR High Strong positive • Low recorded prevalence 
• Strong association with GCA diagnosis 
• ESR should continue to be recorded for 
patients with suspected GCA 
• Improvement needed for coding in 
primary care records 
Hypertension Moderate/low Not enough data • High prevalence 
• Strong association with a GCA diagnosis 
• Two of the four classes of clinical features 
were predominately patients who had been 
treated for hypertension 
• Few previously published articles have 
included hypertension as a clinical 
feature 
• Results from this thesis have shown there 
is a possible strong association between 
hypertension and a GCA diagnosis  
• Further research is required 
PMR Moderate/low Moderate positive 
(non-statistically 
significant) 
• Low prevalence 
• Strong positive association with a diagnosis of 
GCA 
• A clear class of patients who had 
predominately PMR prior to their GCA 
diagnosis 
• The extent to which PMR and GCA are 
associated requires further research to 
clarify the strength of this association 
• Findings suggest that PMR may not be as 
prevalent in patients prior to their GCA 
diagnosis, but is strongly associated 
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Clinical Feature   Systematic review findings Findings from electronic health records Conclusions & recommendations 
 Prevalence Association   
Weight loss/Anorexia Moderate/low Strong positive • Low recorded prevalence 
• Strong positive association with a GCA 
diagnosis 
• The findings from this thesis suggest 
there is an association between weight 
loss/anorexia and a diagnosis of GCA. 
• Few previous articles have investigated 
this possible association 




High Strong positive 
(non-statistically 
significant) 
• Low recorded prevalence 
• Strong positive association with GCA diagnosis 
• Health practitioners should monitor 
potential patients for these symptoms 
• A universal definition of constitutional 
symptoms is required 
Fatigue Moderate Not enough data • Low recorded prevalence 
• Strong association with GCA diagnosis 
• The low prevalence of fatigue could be 
due to lack of Read code use for this 
symptom.  
• Health practitioners should be aware that 
there could be an association between 
fatigue and a GCA diagnosis 
• Further research is required 
Fever Moderate Moderate positive 
(non-statistically 
significant) 
• Low prevalence 
• Strong association with a diagnosis of GCA 
• The coding of fever in primary care EHR 
should be improved as this could account 
for the low prevalence 
• Results imply there is an association 
between fever and a GCA diagnosis 
Jaw Claudication/Jaw 
pain 
Moderate/low Strong positive • No read code available for jaw claudication 
• Prevalence of jaw pain was low 
• Further work is required to fully 
investigate the association between jaw 
claudication and a GCA diagnosis 
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• Unable to quantify the association between 
jaw pain and a GCA diagnosis. 
• With the introduction of SNOMED in UK 
primary care in 2018 there is now a code 
in primary care for jaw claudication, 
hence future research can include this as 
a clinical feature 
Clinical Feature   Systematic review findings Findings from electronic health records Conclusions & recommendations 
 Prevalence Association   
Any visual impairment Moderate Negative (non-
statistically 
significant, OR < 1) 
• Very low recorded prevalence 
• Strongly associated with a GCA diagnosis 
• Visual impairment remains associated 
with a GCA diagnosis 
• Prevalence may not be as high as has 
been previously reported 
Abnormal temporal 
artery 
Moderate Strong positive 
(non-statistically 
significant) 
• No Read code available. • Abnormal temporal artery has been 
established as an indicator of GCA  
• A code that can be used in primary care 
to record this symptom should be 
developed. Possibly for inclusion in the 
SNOMED hierarchy 
Arthralgia/Myalgia Low Moderate positive 
(non-statistically 
significant) 
• Low prevalence 
• Strong association with a subsequent 
diagnosis of GCA 
• Further work is required to quantify this 
relationship 
Cardiovascular diseases Moderate/low Not enough data • Low prevalence 
• Moderate positive association with a 
diagnosis of GCA 
• Further work is required to quantify this 
relationship 
Diabetes Low Not enough data • Moderate prevalence 
• Strong association with a diagnosis of GCA 
• Further work is required to quantify this 
relationship 
     
     
     
231 
 
Clinical Feature   Systematic review findings Findings from electronic health records Conclusions & recommendations 















Moderate/low Not enough data No Read code available • Despite the low prevalence found in 
previous articles, further research may be 
required to quantify if these clinical 
features have any association with a 
diagnosis of GCA 
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8.2.3 Methodological findings 
8.2.3.1 Primary care electronic health records 
Primary care consultation data is a practical and useful resource for observational research 
in the UK, for studies that investigate health care utilisation and management, and for 
investigating clinical features that present prior to a diagnosis of GCA, or other similarly 
difficult to diagnose conditions. They contain patient information over a potentially long-
period of time, in some instances decades, of consultations, prescriptions, test results, and 
referrals. This allows for both long prospective and retrospective follow-up. Retrospective 
follow-up is more practical in studies, like the ones completed in this thesis, that attempt to 
investigate which clinical features are associated or indicative of a subsequent diagnosis, in 
this case GCA. Overall, clinical features that are present prior to a GCA diagnosis should be 
recorded in the patient’s primary care record. Hence, researchers can identify these clinical 
features via Read codes, record when they were coded into a patient’s record, and quantify 
if there is an association between the clinical feature and the condition of interest. It is also 
possible to quantify this association over long periods of time, thereby including a 
longitudinal aspect to the research. 
Over two decades of primary care records were available from CPRD for this study, including 
the two years prior to an eventual GCA diagnosis. This level of information would not be 
available in prospective cohort studies. Primary care records also do not rely on patient 
recall, thereby avoiding recall bias in the results. Limitations of using EHR’s for this type of 
research are mainly around the coding of clinical features. EHR’s are used for documentation 
and clinical use by clinicians delivering care and not specifically for research purposes and so 
certain limitations of their use have to be accepted. This thesis has found that not all clinical 
features of interest will have a corresponding code, and even if there is, it may not be used 
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frequently, if at all. Hence, there is a possibility of lack of recording for some important 
clinical features hypothesised to be associated with the condition of interest. Additionally 
while not coded, important information relevant to GCA may well have been recorded in the 
EHR, for example as free text, but owing to the nature of CPRD data, would not feature in 
our analysis and is a recognised limitation of this dataset and these methodologies. 
Due to the possible long periods of retrospective follow-up in EHR’s like CPRD, they have 
potential to be used in the future to identify presenting clinical features for conditions that 
are equally difficult to diagnose, such as Axial spondyloarthritis (AxSpa). 
 
8.2.3.2 Coding in primary care 
An area of difficulty in this thesis was the mapping of clinical features to Read codes. There 
were over 30 clinical features identified in the systematic review, but only 14 were available 
to be investigated via Read codes. Clinical features of interest, and that were suspected to 
be highly associated with GCA from previous studies, such as headache and visual 
impairment, were easily mapped to relevant Read codes. However, jaw claudication, a 
clinical feature thought to be associated with GCA, did not have a corresponding Read code. 
Other clinical features identified in the review, such as abnormal temporal artery, scalp 
tenderness, and limb claudication were other such features that a Read code could not be 
mapped to. In the UK, Read codes are, at the time of writing, being phased out in primary 
care, to be replaced by SNOMED codes. There is currently a SNOMED code for jaw 
claudication, meaning that future studies into GCA using primary care data could be able to 
include this clinical feature if it is used. Thirteen of the 14 clinical features were able to be 
mapped directly to a Read code, and these included the majority of the principal features 
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hypothesised to be associated with a diagnosis of GCA and that were identified in the 
review. 
Connected to this is the accuracy of Read code use in primary care health records. It is not 
guaranteed that Read codes are always correctly used by healthcare professionals. This 
could be accidental, or could be related to the point raised previously, that not all conditions 
can be mapped to the Read code hierarchy. Therefore, other less appropriate codes for 
clinical features may be used instead, not recorded at all, or recorded purely in the free text. 
Free text is not available for research purposes in CPRD. The diagnosis of GCA has been 
validated in CPRD previously (Smeeth et al., 2006), and there is a limited selection of Read 
codes for this condition, hence it is not unreasonable to assume that the accuracy of GCA 
recoding in primary care is sufficient to be used for research.  
A further aspect of coding which required careful consideration was in defining the 
prevalence of comorbidities, specifically those with a ‘recorded’ or ‘treated’ definition. This 
was undertaken because the prevalence of hypertension differed between recorded and 
treated definitions. Prevalence of hypertension was low when only Read codes were used to 
identify hypertensive patients. This prevalence improved when Read codes were used in 
conjunction with prescription information. This leads to the hypothesis that when defining 
comorbidities in EHR it may be more accurate to include prescriptions into the definition 
when feasible. The reasons for this low prevalence in comorbidities may be due to Read 
code use for chronic conditions. It may be the case that Read codes for chronic conditions 
are only used at initial diagnosis, and not subsequently added into a patient’s record after 
this unless it is for a review, commonly conducted in patients with diabetes or hypertension. 
This has been shown to be an issue for CPRD (Jordan et al., 2007). Therefore, the most 
accurate way of identifying patients with chronic conditions or comorbidities is though 
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prescription information if there is medication always and exclusively used for these 
conditions, as these patients are likely to be on long-term medication which will be reflected 
in the patient’s record. 
 
8.2.3.3 Latent class analysis in primary care EHR 
As detailed in Chapter 7 section 7.2, Latent Class Analysis (LCA) has been used in previous 
research to derive patterns of clinical features for AxSpa (Sepriano et al., 2020) to some 
success. This thesis aimed to use the same methodology applied to GCA, a condition that has 
proved difficult to promptly diagnose. The main difference between this thesis and the study 
by Sepriano et al (2020) was the use of primary care EHR. Sepriano et al (2020) used 
prospective cohorts for their study, with limited retrospective follow-up. 
The length of follow-up and the content of primary care EHR’s makes the application of LCA 
methodology in this setting useful for deriving patterns of presenting clinical features prior 
to the diagnosis of GCA, and similarly difficult to diagnose conditions. LCA methodology 
allows for comparison between latent classes based on age, gender, and any demographic 
variable that is available in primary care. Despite the problems around coding in primary 
care, as discussed in section 8.2.3.2, EHR’s are still a large resource with information on all 
consultations and thereby the clinical features that a patient presents with prior to their GCA 
diagnosis. This retrospective follow-up can be over a long period of time, thereby allowing 
greater flexibility of how far back the patient’s record is investigated. Overall, LCA 
methodology is a good tool for research investigating presenting clinical features prior to the 




8.3 Definitions in electronic health records 
8.3.1 GCA 
A diagnosis of GCA in the UK is usually recorded in a patient’s primary care record via the use 
of morbidity codes (Read codes in the timeframe of this study). Recommended clinical 
practice in primary care is to prescribe glucocorticoids to a patient with suspected GCA, and 
to refer them to a secondary care for confirmation of diagnosis (Mackie et al., 2020). 
Therefore a “true” diagnosis of GCA would include confirmation from a 
rheumatologist/specialist (which may include a positive temporal artery biopsy result of a 
GCA diagnosis) and then a Read code for GCA entered into the EHR. A diagnostic Read code 
should not ordinarily be added to the patient’s record until confirmation has been received 
following referral to secondary or specialist care, i.e. only after confirmation has been 
received from secondary or specialist care should the Read code be added (Mackie et al., 
2020). This could mean, in the case of patients found to have GCA, that the date of 
suspected diagnosis is the date of the first prescription of glucocorticoids, and the date of 
first Read code use is the confirmed diagnosis. The time between the two dates, given 
referral is meant to be urgent, should be small, and therefore have a negligible effect on the 
incidence estimates. 
The definition of GCA employed in this thesis was that patients had to have a Read code for 
GCA, with a sensitivity analysis requiring one or more prescriptions of glucocorticoids within 
6 months of diagnosis. There is a possibility that a small proportion of GCA patients included 
in this thesis, mainly those who had no or only one recorded prescription of glucocorticoids 
in the 6 months after diagnosis, did not actually have GCA. For these patients, this may mean 
that a Read code for GCA was added to the patient’s record prior to referral. As 
aforementioned, good practice is to add a diagnostic Read code to a patient’s record after 
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confirmation from secondary/specialist referral, and not before. However, the sensitivity 
analysis conducted shows that the incidence/prevalence of GCA, and the associations with 
individual clinical features did not differ significantly between GCA patients defined using a 
Read code only, and those who were required to have one or more prescriptions of 
glucocorticoids. Hence, the number of patients wrongly included as having GCA in this thesis 
should be low. 
 
8.3.2 Clinical features  
The definition of clinical features in this thesis required a coded record of the clinical feature 
in the patient’s record prior to their diagnosis of GCA. A previous study has found that only 
37% of the features discussed during a consultation are coded into the patient’s record, and 
on average 2.5 problems are discussed per consultation (Salisbury et al., 2013). This could 
indicate that not all clinical features reported in a consultation are added to the patient’s 
record. It is possible that the most indicative ones, in the case of GCA, headache, and visual 
complications, will be coded, over less recognised or non-specific features. It is also possible 
that multiple or the full list of presenting features will not be recorded or coded in the same 
consultation, and therefore from the coded EHR records it may appear as though a patient 
only had one clinical feature prior to their GCA diagnosis, when in reality they may have had 
multiple features. These may have been documented as free text. 
The Read codes used in this thesis were based around the GCA literature, input from medical 
practitioners, and finding Read codes that are used in primary care to code these conditions. 
Via this method, the code lists used throughout this thesis should be comprehensive and 
appropriate. An acknowledged limitation of all EHR research is that analysis can only use 
what is coded and cannot impute what is not recorded or coded in a consultation. However, 
238 
 
it is likely that the most important clinical features, those which are the patient’s main 
reason for consultation and potentially the ones the GP would use as indicative of possible 
GCA, would be coded in the patient’s record, and therefore would be available to use for 
analysis. 
 
8.4 Strengths & limitations of the thesis 
8.4.1 Strengths  
The main strength of this thesis is its setting within primary care. In the UK over 95% of the 
population is registered with a general practice (NHS, 2012). Primary care is where patient’s 
first present with symptoms, and is where many conditions, including GCA, are first 
identified and managed (Helliwell et al., 2014). Details of a patient’s demographics, 
symptoms, diagnosis, results from specialist referrals, and management of their condition 
will all be added to their record, which is available for practices that opt-in to CPRD. CPRD 
has been shown to be generally representative of the UK population based on age, gender, 
and ethnicity (Herrett et al., 2015), therefore the results from studies using this database are 
generalisable to the UK population. This is the biggest study of GCA in the UK, with the 
largest GCA sample taken from CPRD to be included in a study, with over 9,000 GCA cases 
used for analysis. 
This thesis used two different definitions of GCA to identify cases to be included in analyses. 
The main method was using GCA Read codes, with the second including glucocorticoid 
prescriptions in conjunction with Read codes. A diagnosis of GCA using Read codes has been 
validated in a previous study (Smeeth et al., 2006). This thesis shows that similar associations 
and results are found whether diagnosis of GCA is via glucocorticoid prescription plus Read 
code, or Read code only. Through these different methods of identifying GCA cases to be 
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included in the analysis, this thesis has shown that the results found are robust to GCA case 
definition. 
A further strength of this thesis is the novel approach to identifying and modelling clinical 
features prior to a diagnosis of GCA. A wide range of single or multi-centre studies 
investigating presenting clinical features were identified as part of the review conducted at 
the beginning of this thesis. Very few were conducted in the UK, and even fewer in primary 
care. All studies published prior to this work have considered clinical features as 
independent of each other, with their main aim being to investigate the relationship on a 
diagnosis of GCA, independent of other conditions or symptoms. However, this is not likely 
to be the usual case in older patients seen in primary care who commonly experience 
multimorbidity. Therefore, the latent class analysis methodology conducted as a part of this 
thesis is a novel approach in the research of GCA and attempted to identify classes of clinical 
features that would help GPs to identify possible GCA. To my knowledge, no previous study 
has taken a similar methodological approach. Therefore, this analysis and the results derived 
from it are novel, and the methods should be pursued for further research into GCA. 
 
8.4.2 Limitations 
One limitation was that several variables were not available to be included across several 
aspects of this thesis. Patient demographics such as age, gender, BMI, and lifestyle habits 
were available to be included in the analysis. However, variables such as family history are 
not available in CPRD. Currently there are few articles investigating the relationship of family 
history on a diagnosis of GCA, and this would be an interesting area of future research. A 
further confounding variable that was not included in this analysis, was a general variable to 
represent overall patient morbidity, such as the Charlson Comorbidity Index (CCI). The CCI is 
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a score that predicts mortality, by taking the number of comorbidities a patient has and 
creating an overall score (Hall, Ramachandran, Narayan, Jani, & Vijayakumar, 2004). 
Including this score in an analysis would have allowed the examination of whether GCA 
patients are generally frailer than non-GCA patients, or if there is an association between 
selected comorbidities, like those included in this thesis, and whether GCA is associated to 
patient fragility. However, there is evidence that individual comorbidities are a better 
measure in some instances (Austin, Wong, Uzzo, Beck, & Egleston, 2015) and  the CCI was 
also developed in secondary care, and therefore has not been validated for use in a primary 
care setting (Crooks, West, & Card, 2015). 
 
8.5 Implications for clinical practice 
GCA remains a challenging condition to diagnose due to the wide range of presenting clinical 
features, some of which are indicative of other more prevalent conditions. Though headache 
remains one of the most common and strongly associated symptoms and trigger for 
suspecting and subsequent diagnosis of GCA, this thesis has shown that there are several 
other features that should be considered, independently or in conjunction with a headache, 
such as treated hypertension, and PMR or associated PMR type symptoms at presentation. 
Headache has been established as a strong feature of GCA in people over 50 years, and is 
included in current guidelines concerning the diagnosis of GCA (Mackie et al., 2020; NICE 
CKS, 2020). It is also the symptom that GPs associate with and trigger a suspicion of potential 
GCA (Helliwell et al., 2018). The results of this thesis have supported this, with headache 
being highly prevalent and strongly associated with a diagnosis of GCA, and a predominant 
feature in each class of presenting features. The focus for guidelines should begin to 
highlight that headache, whilst associated, is not a definitive sign that a patient has GCA, and 
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that there may be other signs and symptoms, in conjunction with a headache, that may also 
indicate that the patient has GCA, such as elevated ESR. Headache, on its own, is not a 
conclusive sign that a patient has GCA, and other clinical features should also be taken into 
consideration before a patient is referred for specialist review to confirm diagnosis. 
Hypertension was found to be strongly associated with a diagnosis of GCA and was a 
dominant feature in two of the five classes. Although research into the relationship between 
hypertension and incident GCA is limited and has produced varying results, it is certainly 
worth exploring if hypertension is a risk factor or an indicator of GCA and presents a 
potential future area of research. The type of hypertension, whether it is new onset 
hypertension in the elderly that is more associated with incident GCA, or a worsening or loss 
of control of previously stable long-standing hypertension needs to be considered. This could 
also indicate that there is a spectrum of severity for GCA. A patient may have constitutional 
symptoms, secondary hypertension, and persistent raised inflammatory markers, and not be 
recognised as having GCA due to not presenting with traditional GCA-associated symptoms 
like visual disturbances or headache, and hence remain undiagnosed for a longer period of 
time. 
Comorbidities had a longer time from recorded onset to GCA diagnosis, even within the 2 
years prior to eventual GCA diagnosis. PMR was the comorbidity with the shortest time at 
6/7 months. This could suggest that where symptoms are indicators of a subsequent GCA 
diagnosis (presenting symptoms), some comorbidities may be risk factors for GCA, and this 
may not be exclusive to PMR. 
This thesis has found that although some clinical features, such as fever, weight loss, and 
visual impairment, may have low recorded prevalence, they are still associated with a GCA 
diagnosis. Low recorded prevalence could be due to coding, in that these conditions may not 
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be widely coded in a consultation. This finding implies that GPs should be aware that there 
are clinical features more than just a headache that are associated with a GCA diagnosis and 
take the time to inquire about further symptoms or features that a patient may not have 
mentioned in the consultation. 
 
8.6 Future areas for research 
There remain other potential presenting clinical features for GCA in primary care. Many 
previous studies have focused on presenting symptoms prior to a diagnosis (E. Machado et 
al., 1988; Myklebust et al., 1996; Petri et al., 2015). However, areas for future research 
should broaden to include comorbidities other than PMR, and clinical features not evaluated 
in this thesis. This thesis has shown a positive association between treated hypertension, 
cardiovascular conditions, and diabetes on a subsequent diagnosis of GCA. However, the 
results from the systematic review show that there are few published articles in which these 
have been investigated. It is possible that there are more comorbidities that are associated 
with GCA other than PMR (general cardiovascular conditions other than hypertension), and 
future research should take steps into identifying these. 
This thesis included information on GCA patient demographics, such as gender, age at 
diagnosis, BMI, smoking status, alcohol consumption, and for patients in England their IMD 
2015 score. A variable not included in this analysis was patient ethnicity as there is a lack of 
completeness in primary care records. There are few published studies that have 
investigated the association between ethnicity and GCA, with varying results (Gruener et al., 
2019; Pereira et al., 2011). It is generally thought that GCA in populations other than 
Caucasian is rare (Weyand & Goronzy, 2014). However, the study conducted by Gruener et 
al (2019) found that there was no difference in GCA incidence between white and black 
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patients. Another study (Pereira et al., 2011) investigated GCA in Asian patients, and found 
that the incidence was lower for those of Asian descent compared to Caucasians. A 
limitation of this study was the small sample size of Asian patients included in the analysis, 
which caused large variability of the estimates, and should therefore not be viewed as a firm 
conclusion. Further research into GCA should include information on ethnicity, and 
investigate the association, if one exists, between race and a diagnosis of GCA. Another 
variable not included in this thesis was family medical history, as this is not available in EHR. 
The role of genetics in GCA has been investigated (David Carmona, Gonzá Lez-Gay, & Martín, 
2014), but the role of family history has yet to be widely investigated beyond small case 
reports (Fietta, Manganelli, Zanetti, & Neri, 2002).  
The next steps for GCA research may be in predictive modelling or machine learning. GCA 
remains a difficult condition to recognise in primary care, with varying presenting symptoms 
and potentially long time-periods from symptom onset to diagnosis. It could be that a 
patient consults with a fever up to 12 months prior to their GCA diagnosis, and then 6 
months prior weight loss/anorexia, and then 1 months prior a headache. It is difficult over a 
length of time like this for a GP to connect all of these symptoms to GCA. Hence, future 
research should focus on creating an algorithm that could be implemented in general 
practices that would flag or alert the GP to the potential presence of GCA based on a 
patient’s previous consultations and the build-up of potential indicators and give a 
recommendation on whether it is suitable to refer the patient for further diagnosis. To 
create a predictive algorithm, machine learning techniques, such as decision trees, could be 
used. A decision tree is a machine learning methodology that can be used, similarly to LCA, 
to classify data into classes based on their responses to observed variables, and therefore 
can be used to predict which class a new patient would be in (Lantz, 2013). The decision tree 
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creates new decision rules (which patient goes in which class) based on the data it is given. 
The benefits of decision trees is that they are more transparent than other machine learning 
techniques as the tree produced by the analysis shows the probability it used to classify each 
point of data (i.e. a patient), and both categorical and continuous data can be used 
(Handelman et al., 2018). Their visual representation also makes them easier to understand 
by a lay audience. This methodology could be a starting point for developing an algorithm 
that could be used to flag GCA patients in primary care, so they are diagnosed more 
promptly. 
Future research could also examine the generalisability of the classes produced in this thesis, 
attempting validation of these in other data. Although CPRD is generalisable to the UK 
population, it cannot be assumed that the classes from the LCA analysis are. This is an area 
of future research, to conduct similar analysis in other databases or sets of data, not 
necessarily EHR, and see if they produce the same classes of presenting features.  
A general area which future research could expand upon is the use of LCA for identifying 
common patterns of presenting clinical features prior to a diagnosis of a specified condition, 
such as that conducted in this thesis. LCA has advantages over other clustering 
methodologies, and a wide range of comparisons can be made between classes, and even 
within classes, such as age, gender, general indicators of health, and the number of times a 
patient presented with a clinical feature. Models can be assessed via a range of model and 
class fit statistics, and software to conduct this analysis is widely available. The researcher 
has total control over what variables are included in the models and can also choose the 
most clinically and/or statistically relevant model. Classes can also be tested on more than 
one dataset to quantify their generalisability to a different population. There is also the 
potential in future research to assess if different patterns are found based on age, gender, 
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and ethnicity. A final area of research for future consideration is to expand the use of LCA by 
extending to more complex methods that better incorporate the longitudinal aspect of 
EHR's, such as Latent Class Growth Analysis (LCGA). The use of LCGA would be able to 
quantify if the patterns of presenting clinical features differed depending on how long prior 
to a GCA diagnosis they were presented with (Strauss, Jones, Kadam, & Jordan, 2014). 
 
8.7 Conclusions 
This thesis provides updated incidence and prevalence estimates for GCA in the UK 
population and presents an extensive examination of the prevalence and association of 
individual clinical features with a subsequent diagnosis of GCA, and patterns of clinical 
features linked to GCA. From this body of work, it remains clear that GCA is a difficult 
condition to recognise in primary care, with a spectrum of clinical features experienced. 
However, this work does confirm the continued importance of headache, elevated ESR, and 
PMR as indicators of a GCA diagnosis, but importantly highlights hypertension as a 
commonly experienced and strongly associated clinical feature with a subsequent diagnosis 
of GCA, and therefore warrants further investigation. This thesis has also shown the 
importance of investigating combinations of clinical features rather than just individual 
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Appendix 3.1 – Systematic review protocol 
Arthritis Research UK Primary Care Centre 
Systematic Review Protocol & Support Template 
 
This template is primarily intended to help you plan your review in a systematic way. 
A copy of this completed form will be available via the intranet to help others carrying 
out reviews in the future and to avoid duplicating work already undertaken in the 
Centre. Keeping a record of all the reviews will also assist in planning the work of the 
Centre and ensuring adequate methodological support. Not all the information will be 
relevant to every review and items should be adapted to fit the type of review that is 
being undertaken.  
The template has been updated to include all the items from the PRISMA-P checklist 
(http://www.prisma-statement.org/Extensions/Protocols.aspx). All systematic reviews 
should be registered with PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/) unless the review is methodological. 
Title of the review 
The risk associated with symptoms and comorbidities in 
patients before diagnosis of giant cell arteritis 
First reviewer Lauren Barnett 
Other reviewers (with 
role/contribution in the 
review) 
Chris Morton (second reviewer). 
 
Clinical Portfolio Group Inflammatory 













1. Background to review   
 
Giant cell arteritis (GCA) is the most common form of large vessel vasculitis, which 
affects approximately 10 in 10,000 people in the UK (Petri et al., 2015). There has been 
relatively little research investigating the clinical features (symptoms, comorbidities or 
medical abnormalities) which occur before a GCA diagnosis. There is currently a delay in 
diagnosis (an average of 9 weeks, longer if no cranial symptoms are present (Prior et al., 
2017)) between first presentation of symptoms and final GCA diagnosis. Therefore, 
understanding the most common clinical features patients present with before 
diagnosis, may aid mechanism of diagnosis and reduce delay. 
 
Clinical features include symptoms (such as headache, jaw claudication, and visual 
disturbances) (Smetana & Shmerling, 2002), comorbidities (such as cardiovascular 
disease, and polymyalgia rheumatica) (González-Gay & Pina, 2015) or medical anomalies 
(such as elevated erythrocyte sedimentation rate (ESR) which positive temporal artery 
biopsy) present before a diagnosis of GCA (Salvarani et al., 2005). 
From previous literature, and the American College of Rheumatology’s 2010 diagnosis 
criteria on GCA, headache is a common symptom of GCA (Gene G. Hunder et al., 1990). 
However studies have found that 24% of patients do not experience this symptom 
(Hassan et al., 2011). Visual complications usually tend to be a warning sign of impending 
GCA diagnosis, and complete visual loss occurs in 15-20% of patients (Salvarani et al., 
2005). Tongue or jaw claudication has been observed in GCA patients, and usually is a 
risk factor for future ischaemic complications (Smetana & Shmerling, 2002). Other 
literature has found that cerebrovascular accidents (strokes), and hypertension have also 
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been noted as symptoms pre-diagnosis (Mackie et al., 2011). Due to GCA being more 
common in patients older than 70 years old it has proven difficult to know if the 
aforementioned symptoms are linked to GCA.  
 
There are also many comorbidities linked with GCA. PMR can also be a comorbidity, with 
between 40% and 60% of GCA patients developing PMR (González-Gay & Pina, 2015). 
Patients with GCA have an increased risk of cardiovascular disease, osteoporosis, and 
severe infections such as septicaemia compared to non-GCA patients (Mohammad, 
Nilsson, Jacobsson, Merkel, & Turesson, 2015). Vision complications, such as blurred 
vision and diplopia, can also continue after diagnosis, but can usually be remedied after 
steroid treatment has commenced, however if complete vision loss has occurred then 
this is usually irreversible (Petri et al., 2015). Due to the seriousness of the complications 
associated with untreated and unrecognised GCA it is imperative that symptoms are 
diagnosed early. 
 
The overall aim of this project is to search the literature to determine the risk of 
developing certain clinical features in patients prior to their GCA diagnosis. 
 
2. Specific objectives/questions the review will address 
• To Identify the risk of patients with GCA developing certain clinical features 





3. a) Eligibility Criteria for including studies in the review  
If the PICOS format does not fit the research question of interest, please split up 
the question into separate concepts and put one under each heading 
i. Population, or participants 
and conditions of interest 
 
Patients diagnosed with GCA diagnosed in a 
medically recognised way, i.e. by health care 




iii. Comparisons or control 
groups, if any 
Controls or comparison groups must not have a 
previous diagnosis of GCA. 
iv. Outcomes of interest 
 
Since this review is looking at clinical features pre-
diagnosis, outcomes of interest encompass 
symptoms, comorbidities etc. that have been 
recorded prior to a diagnosis of GCA. 
v. Setting 
Primary and/or Secondary care. 
vi. Study designs 
All quantitative study designs. 
 
3. b) Criteria for excluding studies not covered in inclusion criteria  
Any specific populations excluded, date range, language, whether abstracts or full 
text available, etc 
• Those with a population of <18 year olds 
• There will be no restriction on language, but those which can’t be translated 




4. Search methods 
Electronic databases & 
websites 
 
Please list all databases 
that are to be searched 
and include the 
interface (eg NHS 
HDAS, EBSCO, OVID 
etc) and date ranges 
searched for each. 
 
NB All search 
strategies should be 
reviewed by Jo Jordan 
or Nadia Corp 
BEFORE searching 
begins 
MEDLINE: inception to date. (OVID) 
EMBASE: inception to date (OVID) 
CiNAHL: inception to date (EBSCO) 
Web of Science: inception to date 
 
 
Other methods used for 
identifying relevant 
research  
ie contacting experts 
and reference checking, 
citation tracking 
Reference list searching of selected papers after full text 
stage.  
Checking for papers by key researchers in the field 
Ask experts in the field 
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Journals hand searched 
If any are to be hand 
searched, please list 
which journals and date 
searched from, 
including a rationale.  
N/A 
 
5. Methods of review 
How will search results be 
managed & documented? 
ie which reference 
management software, 
how duplicates dealt with 
All search results will be exported into Mendeley, which 
has the ability to remove duplicates from lists of imported 
references. 
Selection process 
Number of reviewers, how 
agreements to be reached 
and disagreements dealt 
with, etc. 
LB will complete the main screening and selection process 
(titles and abstracts), whilst another reviewer (Chris 
Morton, PhD student) will serve as the second reviewer to 
screen abstracts only. All disagreements will be settled by 
consensus, with LB’s lead supervisors arbitrating if a 
consensus cannot be reached. Alyshah Abdul-Sultan and 





Tools or checklists used 
with references or URLs, 
was this piloted? Is it to 
be carried out at same 




How is data to be 
extracted? 
What information is to be 
collected on each 
included study? If 
databases or forms on 
Word or Excel are used, 
were these piloted and 
how is this recorded and 
by how many reviewers? 
Extracted data will be collated into an Excel file to compare 








ie which measure is 
preferred and if that is 
not available which is 
next in order of 
preference? 
The outcomes to be extracted are GCA diagnosis, and 
clinical features pre-diagnosis. Please find a data extraction 
table in the appendix of this document. 
Collected attributes are: 
Clinical features pre-diagnosis 
Defined outcome (GCA diagnosis) 
Population demographics, such as age, sex, sample size, 
etc. 
Comorbidities recorded 
Time to GCA diagnosis 






Details of what methods, 
how synthesis will be done 
and by whom. Is the 
Narrative Synthesis 
Framework to be used? 
 
Suitable articles will be compared by LB using narrative 





Details of what and how 
analysis and testing will 
be done. If no meta-
analysis is to be 
conducted, please give 
reason. 
A meta-analysis will be undertaken if sufficient data can be 
extracted. 
Will the overall strength of 
evidence be assessed? If 
so, how?  
ie GRADE? 
This review is not attempting to answer a clinical question, 
therefore the grading of evidence isn’t thought to be 
necessary. 
 
6. Presentation of results 
Outputs from review  




The main output of this systematic review is a chapter of the 
PhD thesis, and a secondary output is to publish a paper in a 
peer-reviewed journal. 
 
7. Timeline for review – when do you aim to complete each stage of the review 
Protocol  November 
Literature searching December/January 
Quality appraisal February 
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Data extraction March 
Synthesis May 
Writing up July/August 
 
Support – please state if advice/training or personnel required at each stage 
SR overview None 
Protocol development Advice needed. 
Literature searching 
Charles Hay to help with search strategy and database 
searching. 
Quality appraisal None. 
Data Extraction None. 
Synthesis None 





Appendix 3.2 – Systematic review search strategy 
Systematic review strategy 
MEDLINE (OVID): inception (1946) to 04/12/2017 (produced 4139 articles) 
1. Exp Giant cell arteritis/ 
2. Giant adj cell adj (arteritis or aoritis or aortitides).ti,ab. 
3. Cranial adj (arteritis or arteritides).ti,ab. 
4. “Horton$ disease”.ti,ab. 
5. Temporal adj (arteritis or arteritides).ti,ab. 
6. Aortic arteritis.ti,ab. 





12. (Clinical adj (features or attributes or characteristics)).ti,ab. 
13. Exp Polymyalgia rheumatica/ 
14. “Polymyalgia rheumatica”.ti,ab 
15. Visual disturbances”.ti,ab. 
16. Diplopia.ti,ab. 
17. “Double vision”.ti,ab. 
18. “Visual loss”.ti,ab. 
19. “Blindness”.ti,ab 
20. “Partial visual loss”.ti,ab. 
21. “Total visual loss”.ti,ab. 
22. “Transient visual loss”.ti,ab. 
23. “Permanent visual loss”.ti,ab. 
24. Exp cataract/ 
25. Cataract.ti,ab. 
26. “Blurred vision”.ti,ab. 
27. “Chest infection”.ti,ab. 
28. Exp Cystitis/ 
29. Cystitis.ti,ab. 
30. “Severe infections”.ti,ab. 
31. Septicaemia.ti,ab. 
32. Exp Urinary tract infections/ 
33. “Urinary tract infection”.ti,ab. 
34. “Cranial symptoms”.ti,ab. 
35. Headache.ti,ab. 
36. “Temporal headache”.ti,ab. 
37. “Abnormal temporal arter$”.ti,ab. 
38. “Scalp tenderness”.ti,ab. 
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39. “Jaw claudication”.ti,ab. 
40. “Tongue claudication”.ti,ab. 
41. “Weight loss”.ti,ab. 
42. Exp Fever/  
43. Fever.ti, ab. 
44. “Erythrocyte sedimentation rate”.ti, ab. 
45. “Isch?mic heart disease”.ti,ab. 
46. Exp stroke/ 
47. Stroke.ti,ab. 
48. “Cerebrovascular accident”.ti,ab. 
49. Exp Hypertension/ 
50. hypertension.ti,ab. 
51. “Isch?mic complications”.ti,ab. 
52. Exp Atherosclerosis/ 
53. atherosclerosis .ti, ab. 
54. Exp Aortic aneurysm/ 
55. “Aortic aneurysm”.ti,ab. 
56. Exp Diabetes mellitus/ 
57. “Diabetes mellitus”.ti,ab. 
58. Exp osteoporosis/ 
59. Osteoporosis.ti,ab. 
60. “Venous thromboembolism”.ti,ab. 
61. Exp thyroid diseases/ 
62. “Thyroid disease”.ti,ab. 
63. Falls.ti,ab. 
64. Asthenia.ti,ab. 
65. “Facial pain”.ti,ab. 
66. Exp Musculoskeletal pain/ 
67. “Musculoskeletal conditions”.ti,ab. 
68. “Back pain”.ti,ab. 
69. “Neck pain”.ti,ab. 
70. “Shoulder pain”.ti,ab. 
71. Or/9-70 
72. 8 AND 71 
73. Limit 72  to humans 
 
EMBASE via Ovid, inception (1974) to <insert current date> (scoping on 16/11/2017 
produced 3994 articles) 
1. Exp Giant cell arteritis/ 
2. Giant adj cell adj (arteritis or aoritis or aortitides).ti,ab. 
3. Cranial adj (arteritis or arteritides).ti,ab. 
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4. “Horton$ disease”.ti,ab. 
5. Temporal adj (arteritis or arteritides).ti,ab. 
6. “Aortic arteritis”.ti,ab. 





12. (Clinical adj (features or attributes or characteristics)).ti,ab. 
13. Exp Polymyalgia rheumatica/ 
14. “Polymyalgia rheumatica”.ti,ab 
15. “Visual disturbances”.ti,ab. 
16. Diplopia.ti,ab. 
17. “Double vision”.ti,ab. 
18. “Visual loss”.ti,ab. 
19. “Blindness”.ti,ab 
20. “Partial visual loss”.ti,ab. 
21. “Total visual loss”.ti,ab. 
22. “Transient visual loss”.ti,ab. 
23. “Permanent visual loss”.ti,ab. 
24. Exp cataract/ 
25. Cataract.ti,ab. 
26. “Blurred vision”.ti,ab. 
27. “Chest infection”.ti,ab. 
28. Exp Cystitis/ 
29. Cystitis.ti,ab. 
30. “Severe infections”.ti,ab. 
31. Septicaemia.ti,ab. 
32. Exp Urinary tract infections/ 
33. “Urinary tract infection”.ti,ab. 
34. “Cranial symptoms”.ti,ab. 
35. Headache.ti,ab. 
36. “Temporal headache”.ti,ab. 
37. “Abnormal temporal arter$”.ti,ab. 
38. “Scalp tenderness”.ti,ab. 
39. “Jaw claudication”.ti,ab. 
40. “Tongue claudication”.ti,ab. 
41. “Weight loss”.ti,ab. 
42. Exp Fever/  
43. Fever.ti, ab. 
44. “Erythrocyte sedimentation rate”.ti,ab. 
45. “Isch?mic heart disease”.ti,ab. 




48. “Cerebrovascular accident”.ti,ab. 
49. Exp Hypertension/ 
50. hypertension.ti,ab. 
51. “Isch?mic complications”.ti,ab. 
52. Exp Atherosclerosis/ 
53. atherosclerosis .ti, ab. 
54. Exp Aortic aneurysm/ 
55. “Aortic aneurysm”.ti,ab. 
56. Exp Diabetes mellitus/ 
57. “Diabetes mellitus”.ti,ab. 
58. Osteoporosis.ti,ab. 
59. “Venous thromboembolism”.ti,ab. 
60. Exp thyroid diseases/ 
61. “Thyroid disease”.ti,ab. 
62. Falls.ti,ab. 
63. Asthenia.ti,ab. 
64. “Facial pain”.ti,ab. 
65. Exp Musculoskeletal pain/ 
66. “Musculoskeletal conditions”.ti,ab. 
67. “Back pain”.ti,ab. 
68. “Neck pain”.ti,ab. 
69. “Shoulder pain”.ti,ab. 
70. Or/9-69 
71. 8 AND 70 
72. Limit 71  to humans 
73. Limit 72 to Embase 
 
CINAHL plus via EBSCO: inception (1986) to <insert date> (scoping on 04/12/2017 found 504, 
but only 142 after limiting to humans) 
1. MH (“Giant cell arteritis”) 
2. TI “Giant cell arteritis” OR AB “giant cell arteritis” 
3. AB “Giant cell aoritis” OR AB “giant cell aortitides” OR AB “cranial arteritis” OR AB 
“cranial arteritides” 
4. TI “Horton# disease” OR AB “Horton# disease” 
5. TI “temporal arteritis” OR AB “temporal arteritis” 
6. AB “Temporal arteritides” OR AB “aortic arteritis” OR TI “large vessel vasculitis” OR 
AB “large vessel vasculitis” 
7. Or/1-6 
8. TI Symptom# OR AB symptom# 
9. TI Manifestation# OR AB manifestation# 
10. TI Comorbid# OR AB comorbid# 
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11. TI “Clinical features” OR AB “clinical features” 
12. TI “Clinical attributes” OR Ab “clinical attributes” 
13. TI “Clinical characteristics” OR AB “clinical characteristics” 
14. MH “polymyalgia rheumatica” 
15. TI “polymyalgia rheumatica” OR AB “polymyalgia rheumatica” 
16. TI “visual disturbances” OR AB “visual disturbances” 
17. TI “diplopia” OR AB “diplopia” 
18. TI “double vision” OR AB “double vision” 
19. TI “blindness” OR AB “blindness” 
20. TI “partial visual loss” OR AB “partial visual loss 
21. TI “total visual loss” OR AB “total visual loss” 
22. TI “transient visual loss” OR AB “transient visual loss” 
23. TI “permanent visual loss” or AB “permanent visual loss” 
24. MH “Cataract” 
25. TI cataract or AB cataract 
26. TI “blurred vision” OR AB “blurred vision” 
27. TI “chest infection” or AB "chest infection" 
28. MH “Cystitis+” 
29. TI Cystitis OR AB cystitis 
30. TI “severe infections” OR AB "severe infections" 
31. TI septicaemia or AB septicaemia 
32. MH “Urinary Tract Infections+” 
33. TI “urinary tract infection” Or AB “urinary tract infection” 
34. TI “cranial symptoms” OR AB "cranial symptoms" 
35. TI headache or AB headache 
36. TI “temporal headache” OR AB “temporal headache” 
37. TI “abnormal temporal arter#” OR AB “abnormal temporal arter#” 
38. TI “scalp tenderness” OR AB “scalp tenderness” 
39. TI “jaw claudication” OR AB “jaw claudication” 
40. TI “tongue claudication” OR AB “tongue claudication” OR TI “weight loss” OR AB 
“weight loss” 
41. MH “Fever+” 
42. TI fever OR AB fever 
43. TI “Erythrocyte sedimentation rate” OR AB “Erythrocyte sedimentation rate” 
44. TI “Isch?mic heart disease” OR AB “Isch?mic heart disease” 
45. MH “Stroke+” 
46. TI “stroke” OR AB “stroke” 
47. TI “cerebrovascular accident” OR AB “cerebrovascular accident” 
48. MH “Hypertension+” 
49. TI hypertension OR AB hypertension 
50. TI “Isch?mic complications” or AB “Isch?mic complications” 
51. MH “Atherosclerosis” 
52. TI “atherosclerosis” or AB “atherosclerosis” 
53. MH “Aortic aneurysm+” 
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54. TI “aortic aneurysm” OR AB “aortic aneurysm” 
55. MH “Diabetes mellitus+” 
56. TI “diabetes mellitus” OR AB “diabetes mellitus” 
57. TI Osteoporosis OR AB Osteoporosis 
58. TI “Venous thromboembolism” OR AB “Venous thromboembolism” 
59. MH “Thyroid diseases+” 
60. TI “Thyroid disease” OR AB “Thyroid disease” 
61. TI Falls OR AB Falls 
62. TI Asthenia OR AB Asthenia 
63. TI “Facial pain” OR AB “Facial pain” 
64.  TI “musculoskeletal conditions” OR AB "musculoskeletal conditions" 
65. TI “back pain” OR AB “back pain” 
66. TI “neck pain” OR AB “neck pain” 
67. TI “shoulder pain” OR AB “shoulder pain” 
68. Or/8-67 
69. 7 AND 68 
70. Limit 69 to humans 
 
Web of Science: inception (1950) to 04/12/2017 (gave 1917 articles) 
1. TITLE “giant cell arteritis” OR TOPIC “giant cell arteritis”  
2. TITLE “giant cell aoritis” OR TOPIC  “giant cell aoritis” OR TITLE “giant cell aortitides” 
OR TOPIC “giant cell aortitides 
3. TITLE “cranial arteritis” OR TOPIC “cranial arteritides” 
4. TITLE “Horton* disease” OR TOPIC “Horton* disease” 
5. TITLE “temporal arteritis” OR TOPIC “temporal arteritis” OR TITLE “temporal 
arteritides” OR TOPIC “temporal arteritides” 
6. TITLE “aortic arteritis” OR TOPIC “aortic arteritis” 
7. TITLE “large vessel vasculitis” OR TOPIC “large vessel vasculitis” 
8. TITLE “symptom*” OR TOPIC “symptom*” 
9. TITLE “manifestation*” OR TOPIC “manifestation*” 
10. TITLE “comorbid*” OR TOPIC “comorbid*” 
11. TITLE “clinical features” or TOPIC “clinical features” 
12. TITLE “clinical attributes” OR TOPIC “clinical attributes” 
13. TITLE “clinical characteristics” OR TOPIC “clinical characteristics” 
14. TITLE “Polymyalgia rheumatica” OR TOPIC “polymyalgia rheumatica” 
15. TITLE “visual disturbances” OR TOPIC “visual disturbances” 
16. TITLE “diplopia” OR TOPIC “diplopia” 
17. TITLE “double vision” OR TOPIC “double vision” 
18. TITLE “visual loss” OR TOPIC “visual loss” 
19. TITLE “blindness” OR TOPIC “blindness” 
20. TITLE “partial visual loss” OR TOPIC “partial visual loss” 
21. TITLE “total visual loss” OR TOPIC “total visual loss” 
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22. TITLE “transient visual loss” OR TOPIC “transient visual loss” 
23. TITLE “permanent visual loss” OR TOPIC  “permanent visual loss” 
24. TITLE “cataract” OR TOPIC “cataract” 
25. TITLE “blurred vision” OR TOPIC “blurred vision” 
26. TITLE “chest infection” OR TOPIC “chest infection” 
27. TITLE “cystitis” OR TOPIC “cystitis” 
28. TITLE “severe infections” OR TOPIC “severe infections” 
29. TITLE “septic?mia” OR TOPIC  “septic?mia” 
30. TITLE “urinary tract infection*” OR TOPIC “urinary tract infection*” 
31. TITLE “cranial symptoms” OR TOPIC  “cranial symptoms” 
32. TITLE headache OR TOPIC  headache 
33. TITLE “temporal headache” OR TOPIC “temporal headache” 
34. TITLE “abnormal temporal arter*” OR TOPIC “abnormal temporal arter*” 
35. TITLE “scalp tenderness” OR TOPIC “scalp tenderness” 
36. TITLE “jaw claudication” OR TOPIC “jaw claudication” 
37. TITLE “tongue claudication” OR TOPIC “tongue claudication” 
38. TITLE “weight loss” OR TOPIC “weight loss” 
39. TITLE “fever” OR TOPIC “fever” 
40. TITLE “Erythrocyte sedimentation rate” OR TOPIC “Erythrocyte sedimentation rate” 
41. TITLE “isch?mic heart disease” OR TOPIC “isch?mic heart disease” 
42. TITLE “stroke” OR TOPIC “stroke” 
43. TITLE “cerebrovascular accident” OR TOPIC “cerebrovascular accident” 
44. TITLE “hypertension” OR TOPIC “hypertension” 
45. TITLE “isch?mic complications” OR TOPIC “isch?mic complications” 
46. TITLE “atherosclerosis” OR TOPIC “atherosclerosis” 
47. TITLE “aortic aneurysm” OR TOPIC “aortic aneurysm” 
48. TITLE “diabetes mellitus” OR TOPIC “diabetes mellitus” 
49. TITLE “osteoporosis” OR TOPIC “osteoporosis” 
50. TITLE “venous thromboembolism” OR TOPIC “venous thromboembolism” 
51. TITLE “thyroid disease” OR TOPIC “thyroid disease” 
52. TITLE “falls” OR TOPIC “falls” 
53. TITLE “asthenia” OR TOPIC “asthenia” 
54. TITLE “facial pain” OR TOPIC “facial pain” 
55. TITLE “musculoskeletal conditions” OR TOPIC “musculoskeletal conditions” 
56. TITLE “back pain” OR TOPIC “back pain” 
57. TITLE “neck pain” OR TOPIC “neck pain” 
58. TITLE “shoulder pain” OR TOPIC “shoulder pain” 
59. Or/1-7 
60. Or/8-58 
61. 59 AND 60 





Appendix 3.3 – Systematic review data extraction form 
 
Table 1: Data extraction form used for each article included in the review. 
 
Notes 
First author surname 
 




Country Country where the article was 
conducted 
Quality From the Newcastle-Ottowa scale 
Healthcare setting Primary, secondary, etc. 
GCA population How many GCA cases included in the 
article 
GCA diagnosis Type of diagnostic method used 






Patient gender (%F) 
 
Mean age (years) 
 
































Figure 2: Meta-analysis forest plot for the prevalence of constitutional/systemic symptoms stratified by point of recording, showing raw 




























































Figure 9: Meta-analysis forest plot for PMR stratified by point of recording, showing raw prevalence data, and 95% CI. 
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Figure 20: Meta-analysis forest plot for ophthalmologic symptoms, showing raw prevalence data, weight of each study, study 































































Appendix 3.5 – Subgroup prevalence meta-analysis 
 
Table 1: Subgroup meta-analysis showing frequency and prevalence for each subgroup, 
confidence intervals, and measures of heterogeneity. 
Clinical feature Duration subgroup N Prevalence 
(%) 
95% CI I2 (%) τ2 





At diagnosis/TAB 27 62 (48%, 
75)% 
96.3 0.05 
Abnormal TA At diagnosis/TAB 27 58 (46%, 
70%) 
95.6 0.06 
Fatigue At diagnosis/TAB 6 39 (31%, 
47%) 
73.0 0.01 
Any visual impairment At diagnosis/TAB 27 38 (30%, 
46%) 
92.9 0.04 
Jaw Claudication At diagnosis/TAB 26 38 (34%, 
42%) 
77.1 0.01 










At diagnosis/TAB 3 32 (5%, 67%) 92.7 0.09 
Weight loss At diagnosis/TAB 14 32 (27%, 
37%) 
67.8 0.01 
Anorexia At diagnosis/TAB 6 30 (18%, 
44%) 
89.0 0.02 










Appendix 3.6 – Meta-regression 
 
Table 1: Results of the meta-regression showing beta coefficients, 95% confidence intervals, levels of significance, and model fit (R2). 
Clinical feature I2 (%) Covariates Univariable Multivariable 
Headache 89.3 
 
Coef. 95% CI P-value R2 (%) Coef. 95% CI P-value R2 (%) 
  
Continent  
(ref = Americas) 
   
5.10 
   
27.12 
  
Europe 0.126 (-0.005, 0.256) <0.1 
 
0.041 (-0.114, 0.196) 
  
  
Other 0.066 (-0.107, 0.240) 
  
0.06 (-0.111, 0.230) 
  
  
Study quality  
(ref = Good) 
   
5.38 
    
  
Fair 0.127 (-0.001, 0.256) 
  
0.081 (-0.047, 0.208) 
  
  
Poor 0.036 (-0.209, 0.282) 
  
-0.031 (-0.266, 0.204) 
  
  
Study design  
   
0 
    
336 
 
(ref = case-control) 
  
Cohort 0.136 (-0.190, 0.461) 
      
  
Proportion female -0.003 (-0.007, 0.001) 
      
  
Year of publication  
(ref = 1970-2000) 
   
37.57 
    
  
2001-2010 0.158 (0.029, 0.287) <0.05 
 
0.119 (-0.060, 0.297) 
  
  
2011-present -0.056 (-0.181, 0.069) 
  
-0.052 (-0.187, 0.083) 
  
  
Type of diagnosis  
(ref = TAB) 
   
0 
    
  
ACR -0.025 (-0.239, 0.188) 
      
  
ACR/TAB 0.076 (-0.080, 0.232) 
      
  
Other 0.103 (-0.252, 0.458) 
      
  
Mean age -0.016 (-0.046, 0.015) 
 
0 
    
Constitutional/ 96.4 Continent  
(ref = Americas) 
   
52.2 







Europe 0.481 (0.214, 0.748) <0.001 
 
0.601 (0.254, 0.948) <0.001 
 
  
Other 0.465 (0.128, 1.802) <0.01 
 
0.691 (0.404, 0.977) <0.001 
 
  
Study quality  
(ref = Good) 
        
  
Fair -0.11 (-0.404, 0.184) 
 
0.00 
    
  
Proportion female 0.012 (0.004, 0.019) <0.01 49.60 -0.001 (-0.005, 0.004) 
  
  
Year of publication  




    
  
2001-2010 -0.059 (-0.369, 0.212) 
  
-0.317 (-0.455, -0.179) <0.001 
 
  
2011-present -0.449 (-0.846, -0.052) <0.05 
 
-0.46 (-0.688, -0.232) <0.001 
 
  
Type of diagnosis  
(ref = TAB) 
   
0.00 
    
  
ACR/TAB 0.141 (-0.170, 0.453) 




Other -0.006 (-0.545, 0.533) 
      
  
Mean age -0.027 (-0.149, 0.095) 
 
0.00 
    
Abnormal 
temporal artery 
95.8 Continent  
(ref = Americas) 
   
24.32 
   
41.71% 
  
Europe 0.326 (0.074, 0.577) <0.05 
 
0.114 (-0.241, 0.469) 
  
  
Other 0.158 (-0.118, 0.434) 
  
0.122 (-0.140, 0.383) 
  
  
Study quality  
(ref = Good) 
   
0.00 
    
  
Fair 0.051 (-0.209, 0.311) 
      
  
Poor 0.25 (-0.280, 0.780) 
      
  
Proportion female -0.005 (-0.019, 0.008) 
 
0.00 
    
  
Year of publication  




    
  
2001-2010 0.292 (0.076, 0.507) <0.01 
 
0.219 (-0.135, 0.574) 
  
  
2011-present -0.09 (-0.328, 0.247) 
  





Type of diagnosis  
(ref = TAB) 
   
0.00 
    
  
ACR -0.028 (-0.435, 0.380) 
      
  
ACR/TAB 0.078 (-0.218, 0.374) 
      
  
Mean age 0.006 (-0.028, 0.041) 
 
0.00 
    
Any visual  
impairment 
92.9 Continent  
(ref = Americas) 
   
9.76 
   
21.22 
  
Europe 0.042 (-0.129, 0.212) 
  
0.036 (-0.158, 0.230) 
  
  
Other 0.225 (0.007, 0.443) <0.05 
 
0.171 (-0.147, 0.489) 
  
  
Study quality  
(ref = Good) 
   
30.51 
    
  
Fair -0.06 (-0.214, 0.094) 
  
-0.042 (-0.230, 0146) 
  
  
Poor 0.352 (0.088, 0.616) <0.01 
 
0.309 (-0.010, 0.627) <0.1 
 
  
Study design  
(ref = case-control) 
   
0 




Cohort -0.118 (-0.518, 0.283) 
      
   
-0.039 (-0.240, 0.162) 
      
  
Proportion female 0 (-0.006, 0.006) 
 
0 
    
  
Year  
(ref = 1970-2000) 
   
0 
    
  
2001-2010 -0.083 (-0.271, 0.104) 
      
  
2011-present -0.05 (-0.251, 0.151) 
      
  
Type of diagnosis  
(ref = TAB) 
   
0 
    
  
ACR -0.172 (-0.471, 0.128) 
      
  
ACR/TAB 0.042 (-0.149, 0.234) 
      
  
Other 0.014 (-0.403, 0.430) 
      
  
Mean age -0.031 (-0.069, 0.006) <0.1 8.06 0.001 (-0.047, 0.050) 
  
Jaw claudication 77.1 Continent  
(ref = Americas) 
   
5.23 




Europe -0.05 (-0.144, 0.044) 
      
  
Other -0.11 (-0.244, 0.024) 
      
  
Study quality  
(ref = Good) 
   
7.70 
    
  
Fair -0.075 (-0.164, 0.015) 
      
  
Poor -0.057 (-0.215, 0.101) 
      
  
Study design (ref = 
case-control) 
   
0.00 
    
  
Cohort -0.004 (-0.227, 0.219) 
      
           
  
Proportion female 0.001 (-0.001, 0.004) 
 
0.59 
    
  
Year (ref = 1970-2000) 
   
0.00 
    
  
2001-2010 0.043 (-0.073, 0.158) 
      
  
2011-present 0.034 (-0.078, 0.146) 
      
  
Type of diagnosis (ref 
= TAB) 
   
37.50 




ACR 0.064 (-0.044, 0.172) 
      
  
ACR/TAB -0.024 (-0.113, 0.065) 
      
  
Other -0.295 (-0.497, -0.092) <0.01 
     
  
Mean age 0.012 (-0.005, 0.028) 
 
14.24 
    
PMR 88.7 Continent  
(ref = Americas) 
   
12.31 
   
53.97 
  
Europe 0.089 (-0.035, 0.214) 
  
0.087 (-0.041, 0.215) 
  
  
Other 0.14 (-0.030, 0.310) 
  
0.228 (0.083, 0.373) <0.01 
 
  
Study quality  
(ref = Good) 
   
0.00 
    
  
Fair -0.027 (-0.177, 0.123) 
  
-0.02 (-0.169, 0.129) 
  
  
Poor -0.048 (-0.302, 0.206) 
  
-0.169 (-0.298, -0.039) <0.05 
 
  
Proportion female 0.004 (-0.001, 0.008) 
 
1.56 0.005 (0.001, 0.009) <0.05 
 
  
Year of publication 
(ref = 1970-2000) 
   
19.37 




2001-2010 -0.007 (-0.150, 0.137) 
      
  
2011-present -0.149 (-0.288, -0.010) <0.05 
     
  
Type of diagnosis (ref 
= TAB) 
   
0.00 
    
  
ACR -0.018 (-0.198, 0.162) 
      
  
ACR/TAB 0.031 (-0.113, 0.175) 
      
  
Other 0.184 (-0.146, 0.513) 
      
  
Mean age -0.01 (-0.043, 0.023) 
 
0.00 
    
Scalp 
Tenderness 
90.6 Continent  
(ref = Americas) 
   
0.00 
    
  
Europe -0.013 (-0.229, 0.203) 
      
  
Other 0.098 (-0.201, 0.397) 
      
  
Study quality  
(ref = Good) 
   
29.28 
   
70.58 
  
Fair -0.247 (-0.428, -0.065) <0.01 
 





Poor -0.223 (-0.554, 0.107) 
  
-0.199 (-0.456, 0.058) 
  
  
Proportion female -0.003 (-0.015, 0.009) 
 
0.00 
    
  
Year (ref = 1970-2000) 
   
0.00 
    
  
2001-2010 0.043 (-0.248, 0.335) 
      
  
2011-present 0.013 (-0.257, 0.283) 
      
  
Type of diagnosis (ref 
= TAB) 
   
51.02 
    
  
ACR 0.102 (-0.081, 0.286) 
  
0.088 (-0.063, 0.240) 
  
  
ACR/TAB 0.009 (-0.156, 0.174) 
  
0.017 (-0.134, 0.169) 
  
  
Other -0.42 (-0.700, -0.140) <0.01 
 
-0.37 (-0.607, -0.134) <0.01 
 
  
Mean age -0.006 (-0.084, 0.073) 
 
0.00 




(ref = Americas) 
   
33.88 
   
95.98 
  
Europe -0.015 (-0.122, 0.093) 
  
-0.043 (-0.142, 0.056) 
  
  
Other 0.099 (-0.026, 0.223) 
  





Study quality  
(ref = Good) 
   
0.00 
    
  
Fair 0.013 (-0.129, 0.156) 
      
  
Poor 0.01 (-0.247, 0.268) 
      
  
Study design  
(ref = case-control) 
   
0.00 
    
  
Cohort 0.042 (-0.161, 0.245) 
      
  




(ref = 1970-2000) 
   
0.00 
    
  
2001-2010 0.101 (-0.130, 0.332) 
      
  
2011-present 0.042 (-0.079, 0.162) 
      
  
Type of diagnosis (ref 
= TAB) 
   
7.57 
    
  
ACR -0.092 (-0.226, 0.043) 
  





ACR/TAB 0.026 (-0.116, 0.169) 
  
0.015 (-0.098, 0.129) 
  
  
Other -0.028 (-0.190, 0.135) 
  
-0.118 (-0.286, 0.051) 
  
  
Mean age -0.025 (-0.037, -0.014) <0.001 99.98 -0.025 (-0.071, 0.021) 
  
Fever 91.8 Continent  
(ref = Americas) 
   
10.20 
   
67.41 
  
Europe 0.066 (-0.101, 0.233) 
  
0.108 (-0.030, 0.246) 
  
  
Other 0.205 (-0.015, 0.426) <0.01 
 
0.594 (0.281, 0.907) <0.01 
 
  
Study quality  
(ref = Good) 
   
1.76 
    
  
Fair 0.078 (-0.090, 0.246) 
      
  
Poor 0.23 (-0.058, 0.517) 
      
  
Study design  
(ref = case-control) 
   
0.00 
    
  
Cohort -0.047 (-0.426, 0.333) 
      
  
Proportion female -0.005 (-0.011, 0.001) <0.1 9.88 





(ref = 1970-2000) 
   
5.78 
    
  
2001-2010 -0.197 (-0.433, 0.039) 
      
  
2011-present -0.054 (-0.221, 0.113) 
      
  
Type of diagnosis (ref 
= TAB) 
        
  
ACR 0.09 (-0.121, 0.302) 
      
  
ACR/TAB 0.086 (-0.123, 0.294) 
      
  
Other -0.01 (-0.416, 0.396) 
 
0.00 
    
  
Mean age -0.036 (-0.068, -0.004) <0.05 24.92 0.018 (-0.019, 0.055) 
  
R2 = Overall model fit. 




Appendix 3.7 – Forest plots for association meta-analysis 
 
  
Figure 1: Forest plot of the association between elevated ESR and a subsequent diagnosis of GCA, showing odds ratios for each study, the 
pooled odds ratio, the weight of each study, and the 95% confidence interval. 
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Figure 2: Forest plot of the association between constitutional/systemic symptoms and a subsequent diagnosis of GCA, showing odds 





Figure 3: Forest plot of the association between abnormal temporal artery and a subsequent diagnosis of GCA, showing odds ratios for 




Figure 4: Forest plot of the association between visual impairment and a subsequent diagnosis of GCA, showing odds ratios for each 




Figure 5: Forest plot of the association between anorexia and a subsequent diagnosis of GCA, showing odds ratios for each study, the 




Figure 6: Forest plot of the association between jaw claudication and a subsequent diagnosis of GCA, showing odds ratios for each 




Figure 7: Forest plot of the association between PMR and a subsequent diagnosis of GCA, showing odds ratios for each study, the pooled 




Figure 8: Forest plot of the association between Malaise and a subsequent diagnosis of GCA, showing odds ratios for each study, the 




Figure 9: Forest plot of the association between scalp tenderness and a subsequent diagnosis of GCA, showing odds ratios for each study, 




Figure 10: Forest plot of the association between fever and a subsequent diagnosis of GCA, showing odds ratios for each study, the 




Figure 11: Forest plot of the association between myalgia and a subsequent diagnosis of GCA, showing odds ratios for each study, the 




Figure 12: Forest plot of the association between ocular symptoms and a subsequent diagnosis of GCA, showing odds ratios for each 
study, the pooled odds ratio, the weight of each study, and the 95% confidence interval. 
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Appendix 3.8 – Subgroup association meta-analysis 
 
Table 1: subgroup analysis for risk estimates 
Clinical feature Duration N Pooled Odds 
Ratio 
95% CI I2 
(%) 
τ2 
Jaw claudication At 
diagnosis/TAB 
12 4.36 (3.41, 5.57) 0.0 0.00 
Constitutional symptoms At 
diagnosis/TAB 
5 1.61 (0.75, 3.46) 74.0 0.51 
Headache At 
diagnosis/TAB 





7 1.4 (0.49, 4.06) 90.9 1.70 
Fever At 
diagnosis/TAB 






























































Appendix 4.2 – Code lists for clinical features and glucocorticoids 
 
Table 1: Read code lists for clinical features 
Medcode Read Term 
Headache 
83480 History of headache 
29394 Headache character NOS 
21663 Bilateral headache 
129 Headache 
3340 Temporal headache 
5767 C/O - a headache 
9915 Headache character 
1788 Occipital headache 
9891 Generalised headache 
11321 Unilateral headache 
130 Frontal headache 
9048 Parietal headache 
1197 [D]Headache 
95330 
[X]Vascular headache, not elsewhere 
classified 
Fever 
46292 O/E - fever NOS 
6065 Fever symptoms 
381 
 
17989 [D] Fever of unknown origin 
14744 O/E - fever - general 
66310 O/E - fever - continuous 
1020 [D] Fever NOS 
5892 O/E - fever 
35761 O/E - fever - general NOS 
106211 H/O: fever 
22444 [D]Persistent fever 
31412 O/E – fever – intermittent 
107717 O/E – fever – irregular 
Weight loss/Anorexia 
654 Weight decreasing 
4663 Abnormal weight loss 
5812 Abnormal weight loss - symptom 
102563 Unintentional weight loss 
12398 Complaining of weight loss 
29029 O/E -weight 10-20% below ideal 
126 O/E - Underweight 
24496 Body mass index less than 20 
3647 [D]Abnormal loss of weight 
12530 [D]Underweight 
53746 [D] Anorexia – NOS 
7608 Appetite loss – anorexia 
382 
 
912 [D] Anorexia 
Visual impairment 
6499 Visual symptoms 
105665 moderate visual impairment, binocular 
105493 moderate visual impairment, monocular 
104666 mild or no visual impairment, binocular 
104853 severe visual impairment, binocular 
Medcode Read Term 
55436 both eyes total visual impairment 
108199 visual impairment 
105206 severe visual impairment, monocular 
18462 Diplopia (double vision) 
1617 Diplopia 
5991 Diplopia/Double vision 
34686 refractive diplopia 
104077 Blindness, monocular 
3851 Blindness, one eye, unspecified 
47956 Blindness both eyes NOS 
98637 [X] Visual disturbances and blindness 
1990 Blindness, both eyes 
55108 Unspecified blindness both eyes 
105202 H/O Amaurosis Fugax 




6242 Fatigue – symptom 
23932 [D] Malaise and fatigue NOS 
1688 [D] Fatigue 
44215 [D] Malaise and fatigue 
5583 Lethargy - symptom 
5794 Tiredness symptom 
1404 Fatigue 
7235 Tired all the time 




Activity management for chronic fatigue 
syndrome 
29292 Tiredness symptom NOS 
3361 Neurasthenia - nervous debility 
16561 [X]Neurasthenia 









204 Hypertensive disease 
8732 BP - hypertensive disease 
799 Essential hypertension 
351 High blood pressure 
107704 Primary hypertension 
15377 Malignant essential hypertension 
1894 Benign essential hypertension 
4372 Systolic hypertension 
83473 Diastolic hypertension 
10818 Essential hypertension NOS 
3712 Hypertension NOS 
16292 Hypertensive heart disease 
50157 Malignant hypertensive heart disease 
  
Medcode Read Term 
95334 
Malignant hypertensive heart disease 
without CCF 
72668 
Malignant hypertensive heart disease with 
CCF 
103046 Malignant hypertensive heart disease NOS 




Benign hypertensive heart disease without 
CCF 
52127 Benign hypertensive heart disease with CCF 
105938 Benign hypertensive heart disease NOS 
31464 Hypertensive heart disease NOS 
61166 
Hypertensive heart disease NOS without 
CCF 
8857 Cardiomegaly - hypertensive 
62718 Hypertensive heart disease NOS with CCF 
16173 Hypertensive heart disease NOS 
4668 Hypertensive renal disease 
17434 Nephrosclerosis 
39649 Malignant hypertensive renal disease 
43935 Benign hypertensive renal disease 
32423 
Hypertensive renal disease with renal 
failure 
15106 Hypertensive renal disease NOS 
29310 Renal hypertension 
63466 Hypertensive heart and renal disease 
67232 
Malignant hypertensive heart and renal 
disease 
63000 





Hypertensive heart&renal dis wth 
(congestive) heart failure 
28684 




dis+both(congestv)heart and renal fail 
68659 Hypertensive heart and renal disease NOS 
7329 Secondary hypertension 
31755 Secondary malignant hypertension 
59383 
Secondary malignant renovascular 
hypertension 
73293 Secondary malignant hypertension NOS 
57288 Secondary benign hypertension 
25371 
Secondary benign renovascular 
hypertension 
51635 Secondary benign hypertension NOS 
34744 
Hypertension secondary to endocrine 
disorders 
16059 Secondary hypertension NOS 
31387 Secondary renovascular hypertension NOS 
31341 Hypertension secondary to drug 




Stage 1 hypertension (NICE - Nat Ins for Hth 
Clin Excl 2011) 
105316 Stage 1 hypertension 
108136 
Stage 1 hyperten (NICE 2011) without 
evidnce end organ damge 
109797 
Stage 1 hyperten (NICE 2011) with evidnce 
end organ damge 
105989 
Severe hypertension (Nat Inst for Health 
Clinical Ex 2011) 
105487 Severe hypertension 
Medcode Read Term 
105480 Hypertension resistant to drug therapy 
105274 
Stage 2 hypertension (NICE - Nat Ins for Hth 
Clin Excl 2011) 
18765 Other specified hypertensive disease 
7057 Hypertensive disease NOS 
18482 Hypertension six month review 
19070 Hypertension annual review 
102406 Hypertension 9 month review 
Cardiovascular/Cerebrovascular conditions 
7783 ECG: myocardial infarction 
26975 ECG: antero-septal infarct. 
26972 ECG:posterior/inferior infarct 
388 
 
55401 ECG: subendocardial infarct 
52705 ECG: lateral infarction 
59032 ECG: myocardial infarct NOS 
61670 
Diab mellit insulin-glucose infus acute 
myocardial infarct 
764 Acute rheumatic fever 
48189 Rheumatic fever without heart involvement 
44756 Rheumatic fever with heart involvement 
24636 Acute rheumatic pericarditis 
36886 Acute rheumatic endocarditis 
48099 Acute rheumatic myocarditis 
73540 Other acute rheumatic heart disease 
23619 Acute rheumatic pancarditis 
105615 Other acute rheumatic heart disease NOS 
68849 Acute rheumatic heart disease NOS 
5326 Rheumatic chorea 
20246 Sydenham's chorea 
69995 Rheumatic chorea with heart involvement 
63252 
Rheumatic chorea without mention of 
heart involvement 
72936 Rheumatic chorea NOS 
59942 Other specified acute rheumatic fever 
14840 Acute rheumatic fever NOS 
389 
 
9312 Chronic rheumatic heart disease 
44376 Chronic rheumatic pericarditis 
40957 Adherent rheumatic pericardium 
72628 Chronic rheumatic myopericarditis 
1267 Mitral valve diseases 
16545 Rheumatic mitral valve disease 
1885 Mitral stenosis 
32435 Rheumatic mitral stenosis 
51879 Rheumatic mitral insufficiency 
21807 Mitral incompetence - rheumatic 
22837 Mitral regurgitation - rheumatic 
44488 Mitral stenosis with insufficiency 
50983 Mitral stenosis with incompetence 
44328 Mitral stenosis with regurgitation 
28662 Nonrheumatic mitral valve stenosis 
57633 Ruptured mitral valve cusp 
30443 Mitral valve disease NOS 
18100 Rheumatic aortic valve disease 
Medcode Read Term 
9391 Rheumatic aortic stenosis 
32211 Rheumatic aortic insufficiency 
43347 Aortic incompetence - rheumatic 
7963 Aortic regurgitation - rheumatic 
390 
 
63960 Rheumatic aortic stenosis with insufficiency 
50809 Rheumatic aortic valve disease NOS 
10078 Diseases of mitral and aortic valves 
8274 Mitral and aortic stenosis 
49355 Mitral stenosis and aortic insufficiency 
61250 Mitral stenosis and aortic incompetence 
17596 Mitral stenosis and aortic regurgitation 
33262 Mitral insufficiency and aortic stenosis 
31759 Mitral incompetence and aortic stenosis 
33907 Mitral regurgitation and aortic stenosis 
31727 Mitral and aortic incompetence 
94872 Mitral and aortic insufficiency 
11878 Mitral and aortic regurgitation 
70698 
Multiple mitral and aortic valve 
involvement 
29158 Mitral and aortic valve disease NOS 
68126 
Other chronic rheumatic endocardial 
disease 
16373 Tricuspid valve disease NEC 
31505 Rheumatic tricuspid stenosis 
60266 Rheumatic tricuspid insufficiency 
21980 Tricuspid regurgitation - rheumatic 




Rheumatic tricuspid stenosis and 
insufficiency 
93113 
Rheumatic tricuspid stenosis and 
regurgitation 
62186 
Rheumatic tricuspid stenosis and 
incompetence 
56029 Tricuspid stenosis, cause unspecified 
42128 Tricuspid insufficiency, cause unspecified 
34869 Tricuspid incompetence, cause unspecified 
9286 Tricuspid regurgitation, cause unspecified 
72306 
Tricuspid stenosis and insufficiency, cause 
unspecified 
49551 
Tricuspid stenosis and regurgitation, cause 
unspecified 
72613 Rheumatic tricuspid valve disease NOS 
44167 Rheumatic pulmonary valve disease 
62207 Rheumatic pulmonary stenosis 
54088 Rheumatic pulmonary insufficiency 
105626 
Rheumatic pulmonary stenosis and 
insufficiency 
36768 Rheumatic pulmonary valve disease NOS 
15132 Rheumatic endocarditis NOS 




Other specified chronic rheumatic heart 
disease 
62404 Rheumatic myocarditis 
57980 
Other and unspecified rheumatic heart 
disease 
53878 Rheumatic heart disease unspecified 
22262 Rheumatic left ventricular failure 
59854 Other rheumatic heart disease NOS 
20001 Chronic rheumatic heart disease NOS 
240 Ischaemic heart disease 
Medcode Read Term 
24783 Arteriosclerotic heart disease 
20416 Atherosclerotic heart disease 
1792 IHD - Ischaemic heart disease 
241 Acute myocardial infarction 
13566 Attack - heart 
2491 Coronary thrombosis 
30421 
Cardiac rupture following myocardial 
infarction (MI) 
1677 MI - acute myocardial infarction 
13571 Thrombosis - coronary 
17689 Silent myocardial infarction 




Other specified anterior myocardial 
infarction 
40429 Acute anteroapical infarction 
17872 Acute anteroseptal infarction 
14897 Anterior myocardial infarction NOS 
8935 Acute inferolateral infarction 
29643 Acute inferoposterior infarction 
23892 Posterior myocardial infarction NOS 
14898 Lateral myocardial infarction NOS 
63467 True posterior myocardial infarction 
3704 Acute subendocardial infarction 
9507 Acute non-Q wave infarction 
10562 
Acute non-ST segment elevation myocardial 
infarction 
1678 Inferior myocardial infarction NOS 
30330 Acute Q-wave infarct 
17133 Mural thrombosis 
32854 Acute posterolateral myocardial infarction 
29758 
Acute transmural myocardial infarction of 
unspecif site 
12229 
Acute ST segment elevation myocardial 
infarction 
34803 Other acute myocardial infarction 
394 
 
28736 Acute atrial infarction 
62626 Acute papillary muscle infarction 
41221 Acute septal infarction 
46017 Other acute myocardial infarction NOS 
14658 Acute myocardial infarction NOS 
27951 
Other acute and subacute ischaemic heart 
disease 
23579 Postmyocardial infarction syndrome 
15661 Dressler's syndrome 
36523 Preinfarction syndrome 
4656 Crescendo angina 
39655 Impending infarction 
1431 Unstable angina 
19655 Angina at rest 
61072 Myocardial infarction aborted 
55137 MI - myocardial infarction aborted 
7347 Unstable angina 
17307 Angina at rest 
34328 Refractory angina 
Medcode Read Term 
18118 Worsening angina 
11983 Acute coronary syndrome 




Coronary thrombosis not resulting in 
myocardial infarction 
9413 
Other acute and subacute ischaemic heart 
disease 
9276 Acute coronary insufficiency 
68357 Microinfarction of heart 
39693 Subendocardial ischaemia 
21844 Transient myocardial ischaemia 
27977 
Other acute and subacute ischaemic heart 
disease NOS 
1430 Angina pectoris 
20095 Angina decubitus 
18125 Nocturnal angina 
29902 Angina decubitus NOS 
12986 Prinzmetal's angina 
11048 Variant angina pectoris 
36854 Coronary artery spasm 
25842 Angina pectoris NOS 
66388 Status anginosus 
54535 Stenocardia 
7696 Syncope anginosa 
1414 Angina on effort 
32450 Ischaemic chest pain 
396 
 
9555 Post infarct angina 
26863 New onset angina 
12804 Stable angina 
28554 Angina pectoris NOS 
28138 Other chronic ischaemic heart disease 
5413 Coronary atherosclerosis 
1655 Triple vessel disease of the heart 
1344 Coronary artery disease 
3999 Single coronary vessel disease 
5254 Double coronary vessel disease 
6331 Aneurysm of heart 
27484 Cardiac aneurysm 
2155 Ventricular cardiac aneurysm 
67087 Other cardiac wall aneurysm 
105250 Mural cardiac aneurysm 
59193 Aneurysm of coronary vessels 
91774 Acquired atrioventricular fistula of heart 
41677 Aneurysm of heart NOS 
36609 Atherosclerotic cardiovascular disease 
7320 Ischaemic cardiomyopathy 
29421 Silent myocardial ischaemia 
34633 




24540 Chronic coronary insufficiency 
23078 Chronic myocardial ischaemia 
35713 
Other specified chronic ischaemic heart 
disease NOS 
15754 Other chronic ischaemic heart disease NOS 
Medcode Read Term 
18842 Subsequent myocardial infarction 
45809 
Subsequent myocardial infarction of 
anterior wall 
38609 
Subsequent myocardial infarction of 
inferior wall 
72562 
Subsequent myocardial infarction of other 
sites 
46166 
Subsequent myocardial infarction of 
unspecified site 
36423 
Certain current complication follow acute 
myocardial infarct 
24126 
Haemopericardium/current comp folow 
acut myocard infarct 
23708 
Atrial septal defect/curr comp folow acut 
myocardal infarct 
37657 





Ruptur cardiac wall w'out 
haemopericard/cur comp fol ac MI 
59940 
Ruptur chordae tendinae/curr comp fol 
acute myocard infarct 
69474 
Rupture papillary muscle/curr comp fol 
acute myocard infarct 
29553 
Thrombosis atrium,auric append&vent/curr 
comp foll acute MI 
8568 Cardiac syndrome X 
32272 Postoperative myocardial infarction 
46112 
Postoperative transmural myocardial 
infarction anterior wall 
46276 
Postoperative transmural myocardial 
infarction inferior wall 
106812 
Postoperative transmural myocardial 
infarction unspec site 
41835 
Postoperative subendocardial myocardial 
infarction 
68748 
Postoperative myocardial infarction, 
unspecified 
105479 Coronary microvascular disease 
22383 Other specified ischaemic heart disease 
1676 Ischaemic heart disease NOS 
399 
 
7180 Pulmonary circulation diseases 
22412 Heart disease - pulmonary 
63217 Acute pulmonary heart disease 
8464 Acute cor pulmonale 
1266 Pulmonary embolism 
24444 Infarction - pulmonary 
9701 Pulmonary embolus 
18121 Post operative pulmonary embolus 
96209 Recurrent pulmonary embolism 
4717 Pulmonary infarct 
65533 Acute pulmonary heart disease NOS 
46294 Chronic pulmonary heart disease 
245 Primary pulmonary hypertension 
42901 Kyphoscoliotic heart disease 
Medcode Read Term 
54113 Other chronic pulmonary heart disease 
34065 Secondary pulmonary hypertension 
102444 Thromboembolic pulmonary hypertension 
71046 Other chronic pulmonary heart disease NOS 
15782 Chronic pulmonary heart disease NOS 
5695 Chronic cor pulmonale 
24549 Other pulmonary circulation disease 
31883 Pulmonary vessel disease 
400 
 
53377 Arteriovenous fistula of pulmonary vessels 
22781 Aneurysm of pulmonary artery 
65954 
Other specified pulmonary circulation 
disease 
37807 Pulmonary arteritis 
51540 Pulmonary vessel rupture 
41728 
Other specified pulmonary circulation 
disease NOS 
73599 Other pulmonary circulation disease NOS 
61138 
Other specified pulmonary circulation 
disease 
16084 Pulmonary circulation disease NOS 
30171 Other forms of heart disease 
41527 Acute myocarditis NOS 
33673 Conduction disorders 
19191 Conduction disorders of heart 
4549 Heart block 
3810 Complete atrioventricular block 
24377 Third degree atrioventricular block 
3603 Partial atrioventricular block 
58032 Atrioventricular block unspecified 
12149 First degree atrioventricular block 
46992 Prolonged P-R interval 
401 
 
10922 Mobitz type II atrioventricular block 
27928 
Mobitz type I (Wenckebach) 
atrioventricular block 
103752 
Mobitz type 1 second degree 
atrioventricular block 
36629 Second degree atrioventricular block 
27375 Atrioventricular block NOS 
7482 Left bundle branch hemiblock 
17840 Left bundle branch block 
62349 Left anterior fascicular block 
69809 Left posterior fascicular block 
53826 Left bundle branch hemiblock NOS 
26318 Left main stem bundle branch block 
9906 Right bundle branch block 
18117 Other bundle branch block 
3032 Bundle branch block unspecified 
98675 
Right BBB with left posterior fascicular 
block 
57069 Right BBB with left anterior fascicular block 
72653 Other bilateral bundle branch block 
10712 Trifascicular block 
17206 Bifascicular block 
39003 Other bundle branch block NOS 
402 
 
39843 Other heart block 
18437 Sinoatrial block 
Medcode Read Term 
54554 Interventricular block NOS 
35947 Right fascicular block 
46178 Other heart block NOS 
25147 Anomalous atrioventricular excitation 
50788 Accelerated atrioventricular conduction 
69216 Accessory atrioventricular conduction 
72888 Pre-excitation atrioventricular conduction 
32059 Ventricular pre-excitation 
8230 Wolff-Parkinson-White syndrome 
42803 Anomalous atrioventricular excitation NOS 
27874 Other conduction disorders 
34326 Lown-Ganong-Levine syndrome 
5714 Atrioventricular dissociation 
22691 Romano - Ward syndrome 
39956 Jervell and Lange-Nielsen syndrome 
65653 Right fascicular block 
19337 Long Q-T syndrome 
101485 Pacemaker twiddler's syndrome 
65073 Other conduction disorders NOS 
44096 Conduction disorders unspecified 
403 
 
3769 Stokes-Adams syndrome 
36227 Conduction disorders NOS 
4044 Cardiac dysrhythmias 
6503 Cardiac arrhythmias 
4940 Paroxysmal supraventricular tachycardia 
1297 Paroxysmal atrial tachycardia 
23647 Paroxysmal atrioventricular tachycardia 
51845 Paroxysmal junctional tachycardia 
29491 Paroxysmal nodal tachycardia 
35124 
Paroxysmal supraventricular tachycardia 
NOS 
3418 Paroxysmal ventricular tachycardia 
7794 Ventricular tachycardia 
25266 Paroxysmal tachycardia unspecified 
60047 Essential paroxysmal tachycardia 
70366 Bouveret-Hoffmann syndrome 
1381 Paroxysmal tachycardia NOS 
2212 Atrial fibrillation and flutter 
1664 Atrial fibrillation 
1757 Atrial flutter 
1268 Paroxysmal atrial fibrillation 
35127 Non-rheumatic atrial fibrillation 
96277 Permanent atrial fibrillation 
404 
 
96076 Persistent atrial fibrillation 




23437 Atrial fibrillation and flutter NOS 
4374 Ventricular fibrillation and flutter 
4827 Ventricular fibrillation 
25583 Cardiac arrest-ventricular fibrillation 
5484 Ventricular flutter 
41916 Ventricular fibrillation and flutter NOS 
Medcode Read Term 
2099 Cardiac arrest 
25407 Cardio-respiratory arrest 
33402 Asystole 
33899 Cardiac arrest with successful resuscitation 
51140 
Electromechanical dissociation with 
successful resuscitation 
7630 Electromechanical dissociation 
49882 Cardiac arrest, unspecified 
7457 Ectopic beats 
3909 Premature beats 




19979 Supraventricular ectopic beats 
4802 Ventricular ectopic beats 
9023 Atrial premature depolarization 
29654 Junctional premature depolarization 
31809 Ventricular premature depolarization 
27413 Ectopic beats NOS 
426 Sinus arrhythmia 
109821 Atrial standstill 
7827 Other cardiac dysrhythmias 
27463 Pulsus alternans 
9563 Pulse missed beats 
4772 Skipped beat 
4421 Heart beats irregular 
3849 Persistent sinus bradycardia 
18268 Severe sinus bradycardia 
95919 Brugada syndrome 
5576 Sick sinus syndrome 
7410 Sinoatrial node dysfunction NOS 
23494 Wandering atrial pacemaker 
8651 Nodal rhythm disorder 
7005 Sinus tachycardia 
9515 Bigeminal pulse 
406 
 
1536 Supraventricular tachycardia NOS 
31690 Re-entry ventricular arrhythmia 
31133 Other cardiac dysrhythmia NOS 
1535 Cardiac dysrhythmia NOS 
2062 Heart failure 
2906 Congestive cardiac failure 
10079 Right heart failure 
10154 Right ventricular failure 
9524 Biventricular failure 
23707 Acute congestive heart failure 
32671 Chronic congestive heart failure 
27884 Decompensated cardiac failure 
11424 Compensated cardiac failure 
94870 
Congestive heart failure due to valvular 
disease 
884 Left ventricular failure 
23481 Asthma - cardiac 
43618 Pulmonary oedema - acute 
5942 Impaired left ventricular function 
5255 Acute left ventricular failure 
Medcode Read Term 
27964 Acute heart failure 




Heart failure with preserved ejection 
fraction 
104275 Right ventricular failure 
4024 Heart failure NOS 
12590 Weak heart 
17278 Cardiac failure NOS 
36193 Other specified heart disease 
59687 Other ill-defined heart disease 
41179 Other ill-defined heart disease NOS 
1811 Other heart disease NOS 
1490 Heart disease NOS 
107462 Rheumatic heart disease 
107591 Carditis due to rheumatic fever 
52517 [X]Ischaemic heart diseases 
39546 [X]Other forms of angina pectoris 
47637 
[X]Other forms of chronic ischaemic heart 
disease 
96838 
[X]Acute transmural myocardial infarction 
of unspecif site 
109035 
[X]Subsequent myocardial infarction of 
other sites 
68401 





[X]Subsequent myocardial infarction of 
unspecified site 
1204 Heart attack 
1223 Cardiac failure 
101137 
HFNEF - heart failure with normal ejection 
fraction 
398 Congestive heart failure 
22672 Cardiovascular disease, unspecified 
10444 H/O: cardiovascular disease 
73901 [X] Cerebrovascular diseases 
1469 
Stroke and cerebrovascular accident 
unspecified 
6116 CVA – cerebrovascular accident unspecified 
2790 Peripheral neuropathy 
1664 Atrial fibrillation 
241 Acute myocardial infarction 
1677 MI – acute myocardial infarction 
48980 Cardiovascular disease annual review 
18686 Stroke/CVA annual review 
Elevated ESR 
14924 ESR raised 
46 Erythrocyte sedimentation rate 
27037 Erythrocyte sediment rate NOS 
409 
 





11890 C/O - panic attack 
Medcode Read Term 
462 Panic attack 
6408 [X] Panic attack 
13124 O/E - anxious 
93401 Anxious 
19000 O/E - panic attack 
636 Anxiety states 
1907 Phobic disorders 
11940 
Acute panic state due to acute stress 
reaction 
15220 [X]Persistant anxiety depression 
7749 [X]Mild anxiety depression 
9386 [X]Phobic anxiety disorders 
5385 [X]Other anxiety disorders 
1996 Depressed 
9796 Symptoms of depression 
10015 Depressed mood 
410 
 
1908 O/E - depressed 
12399 Depression annual review 
10610 Single major depressive episode 
4639 [X]Depressive episode 
9211 [X]Moderate depressive episode 
11717 [X]Mild depressive episode 
15099 Recurrent major depressive episode 
10825 Seasonal affective disorder 
27491 Atypical depressive disorder 
9183 Masked depression 
1055 Agitated depression 
5879 Agitated depression 
655 Anxiety with depression 
1533 Brief depressive reaction 
36246 Brief depressive reaction NOS 
16632 Prolonged depressive reaction 
324 Depressive disorder NEC 
5726 [X]Mood - affective disorders 
4639 [X]Depressive episode 
3292 [X]Recurrent depressive disorder 





[X]Other persistent mood affective 
disorders 
39767 
[X]Persistent mood affective disorder, 
unspecified 
28008 [X]Other mood affective disorders 
37090 [X]Unspecified mood affective disorder 
11913 [X]Mixed anxiety and depressive disorder 
32845 [X]Depressive conduct disorder 
PMR & Arthralgia/Myalgia 
1408 Polymyalgia rheumatica 
29472 Polymyalgia with GCA 
5864 Pain in joint – arthralgia 
202 Arthralgia of unspecified site 
1418 Arthralgia of multiple joints 
29775 Arthralgia NOS 
1338 Myalgia unspecified 
Diabetes 
13070 Initial diabetic assessment 
Medcode Read Term 
7563 Diabetic on diet only 
1684 Diabetic on oral treatment 
8842 Diabetic on insulin 
13068 Last hypo. attack 
412 
 
13281 Frequency of hypo. attacks 
31752 
Frequency of hospital treated 
hypoglycaemia 
40363 
Frequency of GP or paramedic treated 
hypoglycaemia 
13069 Has seen dietician - diabetes 
38078 Understands diet - diabetes 
25636 Diabetic diet - poor compliance 
20696 Injection sites - diabetic 
22823 Diabetic foot examination 
10977 Diabetic peripheral neuropathy screening 
18583 
Hypoglycaemic attack requiring 3rd party 
assistance 
13196 Fundoscopy - diabetic check 
90301 Insulin needles changed daily 
53238 Diabetic drug side effects 
66274 Insulin needles changed for each injection 
16490 Diabetic treatment changed 
11047 Conversion to insulin 
107331 Conversion to insulin in secondary care 
107508 





Conversion to non-insulin injectable 
medication 
13071 Diabetic - good control 
69152 
Insulin needles changed less than once a 
day 
2378 Diabetic - poor control 
9013 Unstable diabetes 
22959 Chronic hyperglycaemia 
2478 Brittle diabetes 
21420 Loss of hypoglycaemic warning 
37625 Recurrent severe hypos 
108218 Hypoglycaemic warning absent 
22023 Diabetic - poor control NOS 
43951 Diabetic - cooperative patient 
17869 Diabetic-uncooperative patient 
83485 Insulin dose changed 
29041 Date diabetic treatment start 
55123 Date diabetic treatment stopp. 
96010 Insulin treatment initiated 
12506 Diabetes: practice programme 
12675 Diabetes: shared care programme 




Unsuitable for diabetes year of care 
programme 
101190 
Declined consent for diabetes year of care 
programme 
8836 Diabetes management plan given 
100791 Insulin treatment stopped 
101728 Diabetic on subcutaneous treatment 
12307 Diabetes care by hospital only 
Medcode Read Term 
28769 Diabetic on insulin and oral treatment 
102490 Diabetic assessment of erectile dysfunction 
50175 Diabetic foot risk assessment 
102549 Insulin dose 
46577 
Diabetes: shared care in pregnancy - 
diabetol and obstet 
103847 Checking accuracy of blood glucose meter 
26604 Diabetic diet - good compliance 
26605 
Attended diabetes structured education 
programme 
51066 
Family/carer attended diabetes structured 
education prog 
35383 





Attended DESMOND structured 
programme 
94186 
Diabetes structured education programme 
completed 
94011 
Attended XPERT diabetes structured 
education programme 
93390 
Attended DAFNE diabetes structured 
education programme 
93491 
DAFNE diabetes structured education 
programme completed 
93529 
DESMOND diabetes structured education 
programme completed 
93631 
XPERT diabetes structured education 
programme completed 
93854 
Diabetes structured education programme 
declined 
711 Diabetes mellitus 
38986 
Diabetes mellitus with no mention of 
complication 
24490 
Diabetes mellitus, juvenile type, no 
mention of complication 




Diabetes mellitus, adult onset, no mention 
of complication 
14889 Maturity onset diabetes 
506 Non-insulin dependent diabetes mellitus 
50972 
Diabetes mellitus NOS with no mention of 
complication 
1682 Diabetes mellitus with ketoacidosis 
53200 
Diabetes mellitus, juvenile type, with 
ketoacidosis 
54856 
Diabetes mellitus, adult onset, with 
ketoacidosis 
38617 
Other specified diabetes mellitus with 
ketoacidosis 
42505 Diabetes mellitus NOS with ketoacidosis 
21482 Diabetes mellitus with hyperosmolar coma 
40023 
Diabetes mellitus, juvenile type, with 
hyperosmolar coma 
43139 
Diabetes mellitus, adult onset, with 
hyperosmolar coma 
Medcode Read Term 
72345 
Diabetes mellitus NOS with hyperosmolar 
coma 




Diabetes mellitus, juvenile type, with 
ketoacidotic coma 
68843 
Diabetes mellitus, adult onset, with 
ketoacidotic coma 
59288 Other specified diabetes mellitus with coma 
65062 
Diabetes mellitus NOS with ketoacidotic 
coma 
16502 Diabetes mellitus with renal manifestation 
2475 Diabetic nephropathy 
93922 
Diabetes mellitus, juvenile type, with renal 
manifestation 
35105 
Diabetes mellitus, adult onset, with renal 
manifestation 
13279 
Other specified diabetes mellitus with renal 
complications 
35107 Diabetes mellitus with nephropathy NOS 
33254 
Diabetes mellitus with ophthalmic 
manifestation 
6125 Diabetic annual review 
41389 
Diabetes mellitus, adult onset, + 
ophthalmic manifestation 
47377 





Diabetes mellitus NOS with ophthalmic 
manifestation 
16230 
Diabetes mellitus with neurological 
manifestation 
59903 Diabetic amyotrophy 
7795 Diabetes mellitus with neuropathy 
16491 Diabetes mellitus with polyneuropathy 
39317 
Diabetes mellitus, adult onset, + 
neurological manifestation 
61523 
Other specified diabetes mellitus with 
neurological comps 
22573 
Diabetes mellitus NOS with neurological 
manifestation 
35399 
Diabetes mellitus with peripheral 
circulatory disorder 
32403 Diabetes mellitus with gangrene 
32556 Diabetes with gangrene 
63357 
Diabetes mellitus, adult, + peripheral 
circulatory disorder 
33807 Diabetes mellitus, adult with gangrene 
69124 IDDM with peripheral circulatory disorder 




Other specified diabetes mellitus with 
periph circ comps 
65025 
Diabetes mellitus NOS with peripheral 
circulatory disorder 
1647 Insulin dependent diabetes mellitus 
18505 IDDM-Insulin dependent diabetes mellitus 
  
Medcode Read Term 
46963 
Insulin-dependent diabetes mellitus with 
renal complications 
49276 
Insulin-dependent diabetes mellitus with 
ophthalmic comps 
52283 
Insulin-dependent diabetes mellitus with 
neurological comps 
52104 
Insulin dependent diabetes mellitus with 
multiple complicatn 
26855 
Unstable insulin dependent diabetes 
mellitus 
44443 
Insulin dependent diabetes mellitus with 
ulcer 
60499 





Insulin dependent diabetes mellitus with 
retinopathy 
6791 
Insulin dependent diabetes mellitus - poor 
control 
31310 Insulin dependent diabetes maturity onset 
56448 
Insulin-dependent diabetes without 
complication 
24694 
Insulin dependent diabetes mellitus with 
mononeuropathy 
41716 
Insulin dependent diabetes mellitus with 
polyneuropathy 
57621 
Insulin dependent diabetes mellitus with 
nephropathy 
44440 
Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
44260 
Insulin dependent diabetes mellitus with 
diabetic cataract 
64446 
Insulin dependent diab mell with peripheral 
angiopathy 
65616 
Insulin dependent diabetes mellitus with 
arthropathy 
39809 





Other specified diabetes mellitus with 
multiple comps 
64449 
Unspecified diabetes mellitus with multiple 
complications 
4513 Non-insulin dependent diabetes mellitus 
5884 
NIDDM - Non-insulin dependent diabetes 
mellitus 
 Type 2 diabetes mellitus 
18219 Type II diabetes mellitus 
52303 
Non-insulin-dependent diabetes mellitus 
with renal comps 
50225 
Type II diabetes mellitus with renal 
complications 
18209 
Type 2 diabetes mellitus with renal 
complications 
50429 
Non-insulin-dependent diabetes mellitus 
with ophthalm comps 
59725 
Type II diabetes mellitus with ophthalmic 
complications 
Medcode Read Term 
70316 





Non-insulin-dependent diabetes mellitus 
with neuro comps 
67905 
Type II diabetes mellitus with neurological 
complications 
45919 
Type 2 diabetes mellitus with neurological 
complications 
62146 
Non-insulin-dependent diabetes mellitus 
with multiple comps 
108005 
Type 2 diabetes mellitus with multiple 
complications 
34912 
Non-insulin dependent diabetes mellitus 
with ulcer 
55075 Type II diabetes mellitus with ulcer 
65704 Type 2 diabetes mellitus with ulcer 
40401 
Non-insulin dependent diabetes mellitus 
with gangrene 
62107 Type II diabetes mellitus with gangrene 
46150 Type 2 diabetes mellitus with gangrene 
17262 
Non-insulin-dependent diabetes mellitus 
with retinopathy 
58604 Type II diabetes mellitus with retinopathy 




Non-insulin dependent diabetes mellitus - 
poor control 
24458 Type II diabetes mellitus - poor control 
45913 Type 2 diabetes mellitus - poor control 
29979 
Non-insulin-dependent diabetes mellitus 
without complication 
109103 
Type II diabetes mellitus without 
complication 
105784 
Type 2 diabetes mellitus without 
complication 
72320 
Non-insulin dependent diabetes mellitus 
with mononeuropathy 
50813 
Type II diabetes mellitus with 
mononeuropathy 
45467 
Non-insulin dependent diabetes mellitus 
with polyneuropathy 
47409 
Type II diabetes mellitus with 
polyneuropathy 
109865 
Type 2 diabetes mellitus with 
polyneuropathy 
59365 
Non-insulin dependent diabetes mellitus 
with nephropathy 
64571 Type II diabetes mellitus with nephropathy 
424 
 
24836 Type 2 diabetes mellitus with nephropathy 
43785 
Non-insulin dependent diabetes mellitus 
with hypoglyca coma 
56268 
Type II diabetes mellitus with 
hypoglycaemic coma 
61071 
Type 2 diabetes mellitus with 
hypoglycaemic coma 
69278 
Non-insulin depend diabetes mellitus with 
diabetic cataract 
48192 
Type II diabetes mellitus with diabetic 
cataract 
44779 
Type 2 diabetes mellitus with diabetic 
cataract 
Medcode Read Term 
54212 
Non-insulin-dependent d m with peripheral 
angiopath 
54899 
Type II diabetes mellitus with peripheral 
angiopathy 
60699 
Type 2 diabetes mellitus with peripheral 
angiopathy 
24693 
Non-insulin dependent diabetes mellitus 
with arthropathy 
18143 Type II diabetes mellitus with arthropathy 
425 
 
49869 Type 2 diabetes mellitus with arthropathy 
40962 
Non-insulin dependent d m with 
neuropathic arthropathy 
47816 
Type II diabetes mellitus with neuropathic 
arthropathy 
66965 
Type 2 diabetes mellitus with neuropathic 
arthropathy 
18278 Insulin treated Type 2 diabetes mellitus 
37648 
Insulin treated non-insulin dependent 
diabetes mellitus 
18264 Insulin treated Type II diabetes mellitus 
36633 
Hyperosmolar non-ketotic state in type 2 
diabetes mellitus 
52236 Malnutrition-related diabetes mellitus 
66675 
Malnutrition-related diabetes mellitus with 
coma 
33969 
Malnutrition-related diabetes mellitus with 
ketoacidosis 
100347 
Malnutritn-relat diabetes melitus wth 
periph circul complctn 
11551 Diabetes mellitus induced by steroids 
26108 




43453 Diabetes mellitus autosomal dominant 
36695 
Diabetes mellitus autosomal dominant type 
2 
59991 Insulin dependent diabetes mellitus 
1549 
Insulin-dependent diabetes mellitus with 
renal complications 
12455 
Insulin-dependent diabetes mellitus with 
ophthalmic comps 
51261 
Insulin dependent diabetes mellitus with 
multiple complicat 
102946 
Unstable insulin dependent diabetes 
mellitus 
98071 
Insulin dependent diabetes mellitus with 
ulcer 
45276 
Insulin dependent diabetes mellitus with 
gangrene 
54600 
Insulin dependent diabetes mellitus with 
retinopathy 
98704 
Insulin dependent diabetes mellitus - poor 
control 
109051 Insulin dependent diabetes maturity onset 
97849 





Type I diabetes mellitus with 
polyneuropathy 
  
Medcode Read Term 
68105 
Insulin dependent diabetes mellitus with 
polyneuropathy 
91943 
Insulin dependent diabetes mellitus with 
nephropathy 
10418 
Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
39070 
Insulin dependent diabetes mellitus with 
diabetic cataract 
97894 
Latent autoimmune diabetes mellitus in 
adult 
55239 Type 2 diabetes mellitus 
108724 Type II diabetes mellitus 
95636 
Type 2 diabetes mellitus with renal 
complications 
758 
Type II diabetes mellitus with renal 
complications 
22884 





Type II diabetes mellitus with ophthalmic 
complications 
57278 
Type 2 diabetes mellitus with neurological 
complications 
47321 
Type II diabetes mellitus with neurological 
complications 
100964 
Type 2 diabetes mellitus with multiple 
complications 
34268 
Type II diabetes mellitus with multiple 
complications 
98616 Type 2 diabetes mellitus with ulcer 
65267 Type II diabetes mellitus with ulcer 
43227 Type 2 diabetes mellitus with gangrene 
49074 Type II diabetes mellitus with gangrene 
91646 Type 2 diabetes mellitus with retinopathy 
12736 Type II diabetes mellitus with retinopathy 
104323 Type 2 diabetes mellitus - poor control 
18496 Type II diabetes mellitus - poor control 
49655 Reaven's syndrome 
25627 Metabolic syndrome X 
47315 





Type II diabetes mellitus without 
complication 
39481 
Type 2 diabetes mellitus with 
mononeuropathy 
47954 
Type II diabetes mellitus with 
mononeuropathy 
53392 
Type 2 diabetes mellitus with 
polyneuropathy 
62674 
Type II diabetes mellitus with 
polyneuropathy 
95351 Type 2 diabetes mellitus with nephropathy 
18425 Type II diabetes mellitus with nephropathy 
50527 
Type 2 diabetes mellitus with 
hypoglycaemic coma 
12640 
Type II diabetes mellitus with 
hypoglycaemic coma 
102201 
Type 2 diabetes mellitus with diabetic 
cataract 
46917 
Type II diabetes mellitus with diabetic 
cataract 
98723 
Type 2 diabetes mellitus with peripheral 
angiopathy 




Type II diabetes mellitus with peripheral 
angiopathy 
93727 Type 2 diabetes mellitus with arthropathy 
37806 Type II diabetes mellitus with arthropathy 
104639 
Type 2 diabetes mellitus with neuropathic 
arthropathy 
59253 
Type II diabetes mellitus with neuropathic 
arthropathy 
103902 Insulin treated Type 2 diabetes mellitus 
35385 Insulin treated Type II diabetes mellitus 
109197 
Hyperosmolar non-ketotic state in type 2 
diabetes mellitus 
1407 
Hyperosmolar non-ketotic state in type II 
diabetes mellitus 
64668 
Type 2 diabetes mellitus with persistent 
proteinuria 
34450 
Type II diabetes mellitus with persistent 
proteinuria 
107701 
Type 2 diabetes mellitus with persistent 
microalbuminuria 
26054 
Type II diabetes mellitus with persistent 
microalbuminuria 
60796 Type 2 diabetes mellitus with ketoacidosis 
431 
 
18390 Type II diabetes mellitus with ketoacidosis 
85991 
Type 2 diabetes mellitus with ketoacidotic 
coma 
32627 
Type II diabetes mellitus with ketoacidotic 
coma 
106528 
Type 2 diabetes mellitus with exudative 
maculopathy 
51756 
Type II diabetes mellitus with exudative 
maculopathy 
106061 Type 2 diabetes mellitus with gastroparesis 
25591 Maternally inherited diabetes mellitus 
111798 Secondary pancreatic diabetes mellitus 
63690 
Secondary pancreatic diabetes mellitus 
without complication 
95539 
Diabetes mellitus induced by non-steroid 
drugs 
51697 
DM induced by non-steroid drugs without 
complication 
96506 Insulin autoimmune syndrome 
61122 Type A insulin resistance 
67212 
Type A insulin resistance without 
complication 
68517 Lipoatrophic diabetes mellitus 
432 
 
37957 Secondary diabetes mellitus 
56885 
Secondary diabetes mellitus without 
complication 
43857 Cystic fibrosis related diabetes mellitus 
22487 Diabetes mellitus in remission 
107603 Type II diabetes mellitus in remission 
108360 Type 2 diabetes mellitus in remission 
109628 
Diabetes mellitus with other specified 
manifestation 
Medcode Read Term 
107824 
Diabetes mellitus, juvenile, + other 
specified manifestation 
110611 
Diabetes mellitus, adult, + other specified 
manifestation 
33343 
Other specified diabetes mellitus with other 
spec comps 
110997 
Diabetes mellitus NOS with other specified 
manifestation 
63371 
Diabetes mellitus with unspecified 
complication 
10098 





Diabetes mellitus, adult onset, + 
unspecified complication 
45491 
Other specified diabetes mellitus with 
unspecified comps 
68792 
Diabetes mellitus NOS with unspecified 
complication 
711 Diabetes mellitus 
3550 Diabetic monitoring 
14889 Maturity onset diabetes 
28873 Diabetic 6 month review 
83532 Diabetes type 2 review 
101801 Type II diabetic dietary review 
101177 Diabetic dietary review 
Jaw pain 
1286 [D]Jaw pain 




Table 2: Prodcode list for corticosteroids used to define GCA population in sensitivity 
analysis. 
Prodcode Product name 
44 Prednisolone 5mg gastro-resistant tablets 
95 Prednisolone 5mg tablets 
186 
Dexamethasone 500micrograms/5ml oral 
solution 
229 Cortisone 25mg tablets 
557 Prednisolone 2.5mg gastro-resistant tablets 
578 Prednisolone 1mg tablets 
955 Prednisolone 5mg soluble tablets 
1063 Prednisolone sodium phosphate 
1280 Dexamethasone 2mg tablets 
1709   
1971 
Betnesol 500microgram soluble tablets 
(Focus Pharmaceuticals Ltd) 
2044 PREDNISONE 2.5 MG TAB 
2130 Methylprednisolone 4mg tablets 
2368 Prednisolone 2.5mg tablet 
2390 PREDNISOLONE E/C 1 MG TAB 
2704 Prednisolone 25mg tablets 
2799 PREDNISOLONE 10 MG TAB 
2949 Prednisone 5mg tablets 
435 
 
3059 PREDNISOLONE 50 MG TAB 
3345 Sintisone Tablet (Pharmacia Ltd) 




3557 Prednisone 1mg tablets 
3969 DEXAMETHASONE 8 MG TAB 
3992 Deflazacort 6mg tablets 
4535 Hydrocortisone 20mg tablets 
4779 Dexamethasone 500microgram tablets 
4943 
Dexamethasone 2mg/5ml oral solution 
sugar free 
5157 Dexamethasone 2mg/5ml oral solution 
5490 
Deltacortril 5mg gastro-resistant tablets 
(Alliance Pharmaceuticals Ltd) 
5913 
Deltacortril 2.5mg gastro-resistant tablets 
(Alliance Pharmaceuticals Ltd) 
6098 
Hydrocortone 10mg tablets (Auden 
McKenzie (Pharma Division) Ltd) 
7286 
Betamethasone 500microgram soluble 
tablets sugar free 
7548 Cortisone 5mg capsules 
7584 PREDNISOLONE 4 MG TAB 
436 
 
7710 PREDNISOLONE 15 MG TAB 
7934 PREDNISONE 30 MG TAB 
8261 Medrone 16mg tablets (Pfizer Ltd) 
9375 Deflazacort 1mg tablets 
9727 Prednisolone 50mg tablets 
9994 
Decadron 500microgram tablets (Merck 
Sharp & Dohme Ltd) 
10552 Methylprednisolone 16mg tablets 
10574 Cortisone acetate 5mg tablets 
10683 Medrone 2mg tablets (Pfizer Ltd) 
10684 Methylprednisolone 2mg tablets 
10754 
Hydrocortistab 20mg Tablet (Waymade 
Healthcare Plc) 
10864 Betamethasone 500microgram tablets 
11149 
Betnelan 500microgram tablets (Focus 
Pharmaceuticals Ltd) 
12398 
Cortelan 25mg Tablet (Glaxo Laboratories 
Ltd) 
12400 Cortisyl 25mg Tablet (Aventis Pharma) 
13043 
Hydrocortone 20mg tablets (Auden 
McKenzie (Pharma Division) Ltd) 
13522 PREDNISOLONE 2 MG TAB 
13615 PREDNISONE 10 MG TAB 
437 
 
14076 Hydrocortisone 5mg/5ml Oral solution 
14172 Methylprednisolone 100mg tablets 
15471 HYDROCORTISONE 25 MG TAB 
15555 Medrone 4mg tablets (Pfizer Ltd) 
15617 
Ledercort 4mg Tablet (Wyeth 
Pharmaceuticals) 
16724 PREDNISONE 50 MG TAB 
17101 DEXAMETHASONE 750 MCG TAB 
17410 Deflazacort 30mg tablets 
18042 Medrone 100mg tablets (Pfizer Ltd) 
18637 
Cortistab 25mg Tablet (Waymade 
Healthcare Plc) 
19141 Prednisolone 5mg soluble tablets (AMCo) 
19908 Triamcinolone 2mg Tablet 
20095 
Precortisyl forte 25mg Tablet (Aventis 
Pharma) 
20577 
Calcort 6mg Tablet (Shire Pharmaceuticals 
Ltd) 
20670 PREDNISOLONE E/C 
21218 
Dexsol 2mg/5ml oral solution (Rosemont 
Pharmaceuticals Ltd) 
21417 




21465 BETAMETHASONE .1 MG TAB 
21833 
Decortisyl 5mg Tablet (Roussel Laboratories 
Ltd) 
21903 
Oradexon-organon 2mg Tablet (Organon 
Laboratories Ltd) 
22555 
Calcort 1mg tablets (Shire Pharmaceuticals 
Ltd) 
22827 BETAMETHASONE .1 MG PEL 
22894 HYDROCORTISONE 4 MG PAS 
23111 Triamcinolone 4mg Tablet 
23210 
Cortistab 5mg Tablet (Waymade Healthcare 
Plc) 
23512 
Precortisyl 5mg Tablet (Hoechst Marion 
Roussel) 
24014 
Ledercort 2mg Tablet (Wyeth 
Pharmaceuticals) 
24716 PREDNISOLONE E/C 
25272 
Precortisyl 1mg Tablet (Hoechst Marion 
Roussel) 






Deltastab 1mg Tablet (Waymade 
Healthcare Plc) 
28375 
Prednisolone 2.5mg gastro-resistant tablets 
(A A H Pharmaceuticals Ltd) 
28376 
Prednisolone 2.5mg Gastro-resistant tablet 
(Biorex Laboratories Ltd) 
28859 
Deltastab 5mg Tablet (Waymade 
Healthcare Plc) 
29112 
Calcort 30mg tablets (Shire 
Pharmaceuticals Ltd) 
29333 Prednisolone 5mg tablets (Actavis UK Ltd) 
31327 Prednisolone steaglate 6.65mg tablet 
31532 
Prednisolone 5mg gastro-resistant tablets 
(A A H Pharmaceuticals Ltd) 
32803 
Prednisolone 5mg gastro-resistant tablets 
(Actavis UK Ltd) 
32835 
Prednisolone 5mg tablets (Wockhardt UK 
Ltd) 
33691 
Prednisolone 5mg Gastro-resistant tablet 
(Biorex Laboratories Ltd) 
33988 Prednisolone 5mg Tablet (Co-Pharma Ltd) 
33990 
Prednisolone 5mg Tablet (IVAX 
Pharmaceuticals UK Ltd) 
440 
 
34109 Prednisolone 5 mg gastro-resistant tablet 
34393 
Prednisolone 5mg gastro-resistant tablets 
(Teva UK Ltd) 
34404 Prednisolone 1mg tablets (Actavis UK Ltd) 
34452 
Prednisolone 1mg tablets (A A H 
Pharmaceuticals Ltd) 
34461 
Prednisolone 2.5mg gastro-resistant tablets 
(Actavis UK Ltd) 
34631 Prednisolone 1mg Tablet (Co-Pharma Ltd) 
34660 
Prednisolone 1mg tablets (Kent 
Pharmaceuticals Ltd) 
34748 Prednisolone 1mg tablets (Teva UK Ltd) 
34781 
Prednisolone 5mg tablets (Kent 
Pharmaceuticals Ltd) 
34801 
Dexamethasone 0.5mg/5ml Oral solution 
(Rosemont Pharmaceuticals Ltd) 
34880 
Dexamethasone 2mg tablets (Aspen 
Pharma Trading Ltd) 
34914 
Prednisolone 1mg Tablet (Celltech Pharma 
Europe Ltd) 
34915 
Dexamethasone 500microgram tablets 




Prednisolone 1mg tablets (Wockhardt UK 
Ltd) 
36055 
Dexamethasone 2mg Tablet (Hillcross 
Pharmaceuticals Ltd) 
38022 Hydrocortisone 10mg/5ml oral suspension 
38054 Hydrocortisone Tablet 
38407 Prednisolone 20mg tablet 
41335 Calcort 6mg tablets (Sanofi) 
41515 Prednisolone 5mg tablets (Teva UK Ltd) 
41745 Prednisolone 25mg tablets (Zentiva) 
43544 Prednisone 5mg Tablet (Knoll Ltd) 
44380 Prednisone 1mg modified-release tablets 
44723 Prednisone 5mg modified-release tablets 
44802 
Lodotra 5mg modified-release tablets 
(Napp Pharmaceuticals Ltd) 
44803 
Lodotra 2mg modified-release tablets 
(Napp Pharmaceuticals Ltd) 
45234 Dexamethasone 100microgram capsules 
45302 
Prednisolone 5mg Tablet (Biorex 
Laboratories Ltd) 
46711 Prednisone 2mg modified-release tablets 
47142 





Betnesol 500microgram soluble tablets 
(Waymade Healthcare Plc) 
51722 Hydrocortisone 5mg/5ml oral suspension 
51753 
Prednisolone 1mg tablets (Strides Shasun 
(UK) Ltd) 
51824 
Hydrocortisone 5mg/5ml oral suspension 
sugar free 
51849 Hydrocortisone 1mg/5ml oral suspension 
51871 Hydrocortisone 2mg capsules 
51872 Hydrocortisone 2.5mg capsules 
52053 Hydrocortisone 3mg/5ml oral suspension 
52396 Dexamethasone 1mg/5ml oral solution 
53143 
Cortisone 25mg tablets (A A H 
Pharmaceuticals Ltd) 
53207 Dexamethasone tablets 
53313 Prednisolone 20mg/5ml oral suspension 
53336 
Prednisolone 25mg tablets (A A H 
Pharmaceuticals Ltd) 
53705 
Cortisone acetate 5mg Capsule (Martindale 
Pharmaceuticals Ltd) 
54118 Prednisolone 25mg/5ml oral suspension 
54432 
Lodotra 1mg modified-release tablets 
(Napp Pharmaceuticals Ltd) 
443 
 
54434 Prednisolone 2.5mg/5ml oral suspension 
54793 Dexamethasone 2mg/5ml oral suspension 
54794 
Hydrocortisone 20mg modified-release 
tablets 
55024 Prednisolone 5mg/5ml oral solution 
55401 
Dexamethasone 500microgram tablets (A A 
H Pharmaceuticals Ltd) 
55480 
Prednisolone 2.5mg gastro-resistant tablets 
(Alliance Pharmaceuticals Ltd) 
56347 Dexamethasone 5mg/5ml oral solution 
56443 Dexamethasone 10mg/5ml oral solution 
56891 
Prednisolone 1mg tablets (Waymade 
Healthcare Plc) 
57931 Hydrocortisone 20mg tablets (Teva UK Ltd) 
58000 
Prednisolone 5mg tablets (Almus 
Pharmaceuticals Ltd) 
58234 Prednisolone 10mg/5ml oral solution 
58369 
Prednisolone 5mg tablets (Boston 
Healthcare Ltd) 
58384 
Prednisolone 1mg tablets (Almus 
Pharmaceuticals Ltd) 
58987 
Prednisolone 5mg gastro-resistant tablets 




Dilacort 5mg gastro-resistant tablets 
(Auden McKenzie (Pharma Division) Ltd) 
59283 
Dilacort 2.5mg gastro-resistant tablets 
(Auden McKenzie (Pharma Division) Ltd) 
59338 Prednisolone 1mg/5ml oral solution 
59912 
Prednisolone 5mg gastro-resistant tablets 
(Waymade Healthcare Plc) 
60120 
Dexamethasone 2mg tablets (Alliance 
Healthcare (Distribution) Ltd) 
60421 
Prednisolone 5mg tablets (Strides Shasun 
(UK) Ltd) 
61132 
Prednisolone 1mg tablets (Boston 
Healthcare Ltd) 
61162 
Prednisolone 5mg tablets (Waymade 
Healthcare Plc) 
62909 
Dexamethasone 2mg tablets (A A H 
Pharmaceuticals Ltd) 
63066 Prednisolone 2.5mg tablets 
63549 
Prednisolone 1mg/ml oral solution (Logixx 
Pharma Solutions Ltd) 
64007 Pevanti 10mg tablets (AMCo) 
64008 Pevanti 2.5mg tablets (AMCo) 
64059 Hydrocortisone 2.5mg/5ml oral suspension 
445 
 
64128 Pevanti 5mg tablets (AMCo) 
64221 Prednisolone 5mg/5ml oral suspension 
64787 
Hydrocortisone 10mg tablets (Almus 
Pharmaceuticals Ltd) 
65626 Prednisolone 10mg/5ml oral suspension 
65984 
Hydrocortisone 10mg tablets (Actavis UK 
Ltd) 
66327 
Hydrocortisone 20mg tablets (Actavis UK 
Ltd) 
66550 
Prednisolone 5mg gastro-resistant tablets 
(Alliance Healthcare (Distribution) Ltd) 
66666 Hydrocortisone 10mg tablets (Teva UK Ltd) 
67107 
Prednisolone 5mg gastro-resistant tablets 
(Alliance Pharmaceuticals Ltd) 
67559 
Prednisolone 5mg/5ml oral solution unit 
dose (A A H Pharmaceuticals Ltd) 
68182 Dexamethasone 2mg tablets (Teva UK Ltd) 
68489 Dexamethasone 4mg tablets 
68497 
Prednisolone 2.5mg gastro-resistant tablets 
(Waymade Healthcare Plc) 
68593 Dexamethasone 5mg/5ml oral suspension 
69568 
Dilacort 5mg gastro-resistant tablets 
(Crescent Pharma Ltd) 
446 
 
69572 Dexamethasone 4mg/5ml oral suspension 





Appendix 5.1 – Results tables for Incidence/prevalence 
 
Table 1: Annual consultation incidence per 10,000 person-years (P-Y) for 1990-2017, with 
95% confidence intervals. The consultation incidence for 1990 cannot be reported here as 
there were less than 5 incidence cases. 
Year GCA cases Incidence per 10,000 P-Y 95% CI 
1990 - - - 
1991 36 0.76 (0.55, 1.05) 
1992 104 1.88 (1.55, 2.28) 
1993 137 2.14 (1.81, 2.53) 
1994 161 2.29 (1.96, 2.67) 
1995 172 2.24 (1.93, 2.60) 
1996 175 1.97 (1.70, 2.28) 
1997 172 1.63 (1.40, 1.89) 
1998 224 1.85 (1.63, 2.11) 
1999 227 1.56 (1.37, 1.77) 
2000 251 1.42 (1.26, 1.61) 
2001 279 1.40 (1.24, 1.57) 
2002 404 1.76 (1.60, 1.94) 
2003 398 1.59 (1.44, 1.75) 
2004 475 1.74 (1.59, 1.91) 
2005 497 1.74 (1.59, 1.90) 
2006 448 1.51 (1.38, 1.66) 
448 
 
2007 524 1.72 (1.58, 1.87) 
2008 491 1.57 (1.44, 1.72) 
2009 545 1.71 (1.57, 1.86) 
2010 492 1.53 (1.40, 1.67) 
2011 549 1.71 (1.57, 1.86) 
2012 483 1.49 (1.36, 1.63) 
2013 484 1.52 (1.39, 1.67) 
2014 431 1.44 (1.31, 1.58) 
2015 441 1.66 (1.51, 1.82) 
2016 314 1.43 (1.28, 1.59) 





Table 2: Annual consultation incidence rates of GCA in the UK from the sensitivity analysis 
using glucocorticoids to define GCA. Results from 8244 GCA cases. The consultation 
incidence for 1990 cannot be reported here as there were less than 5 incidence cases. 
Year Incidence per 10,000 P-Y 95% CI 
1990 - - 
1991 0.65 (0.46, 0.93) 
1992 1.62 (1.32, 2.00) 
1993 1.90 (1.59, 2.27) 
1994 1.95 (1.65, 2.30) 
1995 2.01 (1.71, 2.35) 
1996 1.74 (1.49, 2.04) 
1997 1.46 (1.25, 1.71) 
1998 1.58 (1.37, 1.82) 
1999 1.38 (1.20, 1.58) 
2000 1.26 (1.10, 1.44) 
2001 1.23 (1.08, 1.39) 
2002 1.48 (1.33, 1.64) 
2003 1.40 (1.26, 1.55) 
2004 1.53 (1.39, 1.69) 
2005 1.55 (1.41, 1.70) 
2006 1.35 (1.23, 1.49) 
2007 1.55 (1.42, 1.70) 
2008 1.44 (1.32, 1.58) 
450 
 
2009 1.56 (1.43, 1.70) 
2010 1.41 (1.29, 1.55) 
2011 1.57 (1.44, 1.71) 
2012 1.36 (1.24, 1.50) 
2013 1.39 (1.27, 1.53) 
2014 1.30 (1.18, 1.44) 
2015 1.51 (1.36, 1.66) 
2016 1.29 (1.15, 1.45) 






Figure 1: Joinpoint regression model for annual consultation incidence of GCA for Monte 




Figure 2: Joinpoint model for annual consultation incidence of GCA for modified BIC model 




Figure 3: Joinpoint model for annual consultation incidence of GCA showing the Monte 





Figure 4: Joinpoint model for annual consultation incidence of GCA showing the modified 




Table 3: Annual consultation incidence of GCA per 10,000 P-Y stratified by gender. 
Year Gender GCA cases Consultation Incidence  
per 10,000 P-Y 
Lower 95% CI Upper 95% CI 
1990 male 1 0.06 0.01 0.42 
 
female 2 0.10 0.03 0.42 
1991 male 13 0.58 0.34 1.00 
 
female 23 0.91 0.61 1.40 
1992 male 33 1.30 0.90 1.80 
 
female 71 2.40 1.90 3.00 
1993 male 30 1.00 0.70 1.40 
 
female 107 3.10 2.60 3.80 
1994 male 51 1.50 1.20 2.00 
 
female 110 2.90 2.40 3.50 
1995 male 66 1.80 1.40 2.30 
 
female 106 2.60 2.20 3.10 
1996 male 55 1.30 1.00 1.70 
 
female 120 2.50 2.10 3.00 
1997 male 47 0.95 0.71 1.30 
 
female 125 2.20 1.90 2.70 
1998 male 55 0.96 0.74 1.30 
 
female 169 2.60 2.30 3.10 




female 164 2.10 1.80 2.50 
2000 male 72 0.86 0.69 1.10 
 
female 179 1.90 1.70 2.20 
2001 male 68 0.72 0.57 0.91 
 
female 211 2.00 1.80 2.30 
2002 male 114 1.00 0.87 1.30 
 
female 290 2.40 2.10 2.70 
2003 male 116 0.97 0.81 1.20 
 
female 282 2.10 1.90 2.40 
2004 male 145 1.10 0.95 1.30 
 
female 330 2.30 2.10 2.60 
2005 male 134 0.99 0.83 1.20 
 
female 363 2.40 2.20 2.70 
2006 male 129 0.92 0.77 1.10 
 
female 319 2.10 1.80 2.30 
2007 male 152 1.00 0.89 1.20 
 
female 372 2.30 2.10 2.60 
2008 male 127 0.86 0.72 1.00 
 
female 364 2.20 2.00 2.50 
2009 male 168 1.10 0.95 1.30 
 
female 377 2.30 2.00 2.50 




female 350 2.10 1.90 2.30 
2011 male 168 1.10 0.95 1.30 
 
female 381 2.30 2.00 2.50 
2012 male 143 0.93 0.79 1.10 
 
female 340 2.00 1.80 2.20 
2013 male 140 0.93 0.79 1.10 
 
female 344 2.10 1.90 2.30 
2014 male 131 0.92 0.78 1.10 
 
female 300 1.90 1.70 2.10 
2015 male 133 1.10 0.89 1.20 
 
female 308 2.20 2.00 2.50 
2016 male 97 0.93 0.76 1.10 
 
female 217 1.90 1.60 2.20 
2017 male 78 0.85 0.68 1.10 
 





Table 4: Consultation incidence of GCA per 10,000 P-Y stratified by age and gender. 
Age (years) Gender GCA cases Consultation Incidence  
per 10,000 P-Y 
95% CI 
40-49 male 63 0.08 (0.06, 0.10) 
 
female 181 0.22 (0.19, 0.26) 
50-59 male 261 0.37 (0.33, 0.41) 
 
female 639 0.91 (0.84, 0.98) 
60-69 male 685 1.20 (1.10, 1.30) 
 
female 1539 2.60 (2.50, 2.70) 
70-79 male 1055 2.70 (2.60, 2.90) 
 
female 2463 5.20 (5.00, 5.40) 
80-89 male 562 3.10 (2.80, 3.40) 
 
female 1516 5.00 (4.70, 5.20) 
90+ male 45 1.10 (0.85, 1.50) 
 




Table 5: Annual consultation prevalence of GCA results from 1990-2017 showing prevalence 
per 10,000 person-years with 95% confidence intervals. 
Year Cons. 
Prevalence 
per 10,000 P-Y 
95% CI 
1990 0.025 (0.005, 0.074) 
1991 0.289 (0.202, 0.400) 
1992 0.852 (0.702, 1.025) 
1993 1.184 (1.010, 1.380) 
1994 1.491 (1.299, 1.703) 
1995 1.494 (1.306, 1.701) 
1996 1.512 (1.328, 1.715) 
1997 1.459 (1.282, 1.654) 
1998 1.739 (1.549, 1.945) 
1999 1.683 (1.501, 1.881) 
2000 1.903 (1.713, 2.108) 
2001 2.023 (1.831, 2.229) 
2002 2.539 (2.328, 2.763) 
2003 2.658 (2.447, 2.882) 
2004 2.895 (2.679, 3.123) 
2005 2.941 (2.728, 3.167) 
2006 2.596 (2.399, 2.804) 
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2007 2.749 (2.550, 2.958) 
2008 2.562 (2.374, 2.761) 
2009 2.760 (2.568, 2.963) 
2010 2.541 (2.360, 2.733) 
2011 2.558 (2.379, 2.747) 
2012 2.302 (2.135, 2.479) 
2013 2.152 (1.993, 2.321) 
2014 1.909 (1.761, 2.066) 
2015 1.792 (1.650, 1.942) 
2016 1.287 (1.169, 1.414) 








prevalence per 10,000 P-
Y 
95% CI Age-adjusted consultation prevalence 
per 10,000 P-Y 
95% CI 
1990 5 0.121 (0.039, 0.283) 0.125 (0.040, 0.322) 
1991 52 1.021 (0.763, 1.339) 1.030 (0.769, 1.366) 
1992 206 3.518 (3.054, 4.033) 3.463 (3.005, 3.980) 
1993 357 5.601 (5.035, 6.213) 5.535 (4.974, 6.148) 
1994 438 6.301 (5.725, 6.920) 6.276 (5.701, 6.900) 
1995 508 6.860 (6.276, 7.483) 6.825 (6.243, 7.452) 
1996 475 5.375 (4.903, 5.881) 5.365 (4.893, 5.875) 
1997 505 4.936 (4.515, 5.386) 4.943 (4.520, 5.397) 
1998 600 4.939 (4.552, 5.351) 4.982 (4.590, 5.399) 
1999 673 4.461 (4.130, 4.811) 4.536 (4.199, 4.894) 
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2000 814 4.681 (4.365, 5.014) 4.769 (4.446, 5.109) 
2001 931 4.661 (4.367, 4.970) 4.797 (4.494, 5.117) 
2002 1216 5.502 (5.197, 5.820) 5.705 (5.388, 6.036) 
2003 1274 5.283 (4.997, 5.581) 5.521 (5.222, 5.833) 
2004 1411 5.559 (5.273, 5.857) 5.843 (5.542, 6.157) 
2005 1444 5.537 (5.255, 5.830) 5.858 (5.559, 6.168) 
2006 1348 5.105 (4.836, 5.385) 5.388 (5.104, 5.684) 
2007 1421 5.342 (5.068, 5.627) 5.609 (5.321, 5.909) 
2008 1478 5.535 (5.256, 5.824) 5.792 (5.500, 6.095) 
2009 1604 6.003 (5.713, 6.304) 6.275 (5.972, 6.591) 
2010 1517 5.781 (5.493, 6.079) 6.053 (5.752, 6.366) 
2011 1499 5.820 (5.529, 6.122) 6.092 (5.787, 6.409) 
2012 1314 5.172 (4.896, 5.459) 5.414 (5.125, 5.715) 
2013 1273 5.328 (5.039, 5.628) 5.539 (5.238, 5.852) 
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2014 1178 5.521 (5.211, 5.846) 5.696 (5.375, 6.031) 
2015 1041 6.037 (5.676, 6.415) 6.186 (5.816, 6.574) 
2016 756 5.213 (4.848, 5.598) 5.391 (5.013, 5.790) 








Table 7: Incidence rates of GCA stratified by age for the 8244 sensitivity GCA cases. 
Age (years) Incidence per 10,000 P-Y 95% CI 
40-49 0.10 (0.09, 0.12) 
50-59 0.53 (0.49, 0.57) 
60-69 1.70 (1.70, 1.80) 
70-79 3.80 (3.60, 3.90) 
80-89 3.90 (3.70, 4.10) 





Table 8: Incidence rates of GCA stratified by age and gender including the 8244 GCA cases in 
the sensitivity analysis. 
Age 
(years) 
Gender Incidence per 10,000 P-Y 95% CI 
40-49 male 0.05 (0.03, 0.06) 
40-40 female 0.15 (0.13, 0.18) 
50-59 male 0.30 (0.26, 0.34) 
50-59 female 0.75 (0.69, 0.82) 
60-69 male 1.00 (0.95, 1.10) 
60-69 female 2.40 (2.30, 2.50) 
70-79 male 2.50 (2.40, 2.70) 
70-79 female 4.80 (4.60, 5.00) 
80-89 male 2.90 (2.60, 3.10) 
80-89 female 4.60 (4.30, 4.80) 
90+ male 0.91 (0.66, 1.30) 




Table 9: Annual incidence rates of GCA stratified by gender for the 8244 GCA cases from the 
sensitivity analysis. 
Year Gender Incidence per 10,000 P-Y 95% CI 
1990 male 0.06 (0.01, 0.42) 
1990 female 0.05 (0.01, 0.37) 
1991 male 0.49 (0.27, 0.89) 
1991 female 0.79 (0.51, 1.20) 
1992 male 1.10 (0.74, 1.60) 
1992 female 2.10 (1.60, 2.70) 
1993 male 0.86 (0.59, 1.30) 
1993 female 2.80 (2.30, 3.40) 
1994 male 1.20 (0.91, 1.70) 
1994 female 2.60 (2.10, 3.10) 
1995 male 1.50 (1.10, 2.00) 
1995 female 2.50 (2.00, 3.00) 
1996 male 1.10 (0.85, 1.50) 
1996 female 2.30 (1.90, 2.80) 
1997 male 0.83 (0.61, 1.10) 
1997 female 2.00 (1.70, 2.40) 
1998 male 0.84 (0.63, 1.10) 
1998 female 2.20 (1.90, 2.60) 
1999 male 0.81 (0.62, 1.10) 
1999 female 1.90 (1.60, 2.20) 
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2000 male 0.77 (0.60, 0.98) 
2000 female 1.70 (1.50, 2.00) 
2001 male 0.63 (0.49, 0.82) 
2001 female 1.80 (1.50, 2.00) 
2002 male 0.84 (0.68, 1.00) 
2002 female 2.10 (1.80, 2.30) 
2003 male 0.85 (0.70, 1.00) 
2003 female 1.90 (1.70, 2.10) 
2004 male 0.96 (0.80, 1.10) 
2004 female 2.10 (1.80, 2.30) 
2005 male 0.88 (0.73, 1.00) 
2005 female 2.20 (1.90, 2.40) 
2006 male 0.80 (0.67, 0.96) 
2006 female 1.90 (1.70, 2.10) 
2007 male 0.95 (0.80, 1.10) 
2007 female 2.10 (1.90, 2.30) 
2008 male 0.75 (0.63, 0.91) 
2008 female 2.10 (1.90, 2.30) 
2009 male 1.00 (0.87, 1.20) 
2009 female 2.00 (1.80, 2.30) 
2010 male 0.82 (0.69, 0.98) 
2010 female 1.90 (1.70, 2.20) 
2011 male 0.99 (0.84, 1.20) 
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2011 female 2.10 (1.90, 2.30) 
2012 male 0.84 (0.71, 1.00) 
2012 female 1.80 (1.60, 2.10) 
2013 male 0.85 (0.71, 1.00) 
2013 female 1.90 (1.70, 2.10) 
2014 male 0.83 (0.69, 1.00) 
2014 female 1.70 (1.50, 1.90) 
2015 male 0.98 (0.82, 1.20) 
2015 female 2.00 (1.80, 2.20) 
2016 male 0.85 (0.69, 1.00) 
2016 female 1.70 (1.50, 1.90) 
2017 male 0.72 (0.57, 0.92) 
2017 female 1.80 (1.60, 2.10) 
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Table 10: Incidence rate per 10,000 P-Y of GCA in the UK, stratified by region and year for the sensitivity analysis with 8244 GCA cases 
Region 1990-1994 1995-1999 2000-2004 2005-2009 2010-2014 2015-2017 
 
Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI 
North East 2.32 (1.32, 4.09) 1.34 (0.82, 2.18) 1.23 (0.82, 1.85) 1.79 (1.32, 2.43) 1.14 (0.77, 1.68) 1.13 (0.51, 2.51) 
North West 1.79 (1.38, 2.32) 1.89 (1.58, 2.26) 1.62 (1.41, 1.86) 1.41 (1.23, 1.61) 1.63 (1.44, 1.85) 1.10 (0.81, 1.48) 
Yorkshire & 
the Humber 
2.48 (1.89, 3.27) 2.30 (1.83, 2.88) 1.71 (1.38, 2.12) 1.64 (1.32, 2.04) 1.31 (0.91, 1.89) 2.63 (1.49, 4.63) 
East 
Midlands 
2.10 (1.54, 2.86) 1.83 (1.42, 2.36) 2.11 (1.75, 2.56) 1.92 (1.57, 2.34) 1.82 (1.29, 2.57) - - 
West 
Midlands 
0.96 (0.63, 1.48) 1.45 (1.15, 1.81) 1.60 (1.38, 1.87) 1.46 (1.26, 1.69) 1.51 (1.32, 1.74) 0.92 (0.67, 1.26) 
East of 
England 
2.13 (1.63, 2.79) 1.88 (1.53, 2.30) 1.83 (1.59, 2.11) 1.84 (1.61, 2.10) 1.56 (1.33, 1.83) 1.57 (1.16, 2.13) 
South West 1.58 (1.12, 2.23) 1.93 (1.56, 2.40) 1.72 (1.48, 2.00) 1.70 (1.50, 1.93) 1.62 (1.43, 1.83) 1.92 (1.52, 2.42) 
South 
Central 
1.23 (0.82, 1.86) 1.62 (1.26, 2.07) 1.40 (1.19, 1.64) 1.45 (1.27, 1.65) 1.36 (1.21, 1.54) 1.48 (1.20, 1.82) 
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London 1.53 (1.05, 2.23) 1.39 (1.07, 1.82) 1.08 (0.88, 1.32) 1.17 (0.99, 1.39) 0.98 (0.83, 1.16) 1.31 (1.02, 1.67) 
South East 
Coast 
1.11 (0.72, 1.70) 2.42 (1.97, 2.96) 1.63 (1.39, 1.91) 1.67 (1.47, 1.90) 1.63 (1.45, 1.85) 1.26 (1.03, 1.53) 
Northern 
Ireland 
1.48 (0.55, 3.93) 2.83 (1.99, 4.03) 1.08 (0.78, 1.50) 1.21 (0.94, 1.56) 1.16 (0.91, 1.48) 1.71 (1.32, 2.22) 
Scotland 1.16 (0.58, 2.31) 1.20 (0.82, 1.76) 0.79 (0.63, 1.00) 1.52 (1.34, 1.73) 1.58 (1.41, 1.78) 1.74 (1.52, 2.01) 





Appendix 6.1 – Code lists and results tables for the case-control study 
 
Table 1: Code list for alcohol consumption, smoking status, and BMI used to define the 
variables for the analysis. 





27 136..00 Alcohol consumption 
 
93415 136V.00 Alcohol units per week 
 
12980 136N.00 light drinker (1-2 u/day) 
 
749 1362.12 Drinks occasionally 
 
385 1362.11 Drinks rarely 
 
12985 136O.00 Moderate drinker 
 
12970 1361.11 Non drinker alcohol 
 
12979 136M.00 Current non drinker 
 
4447 1362.12 Non-drinker alcohol 
 
8999 136P.00 Heavy drinker (7-9 units/day 
 
12984 136Q.00 Very heavy drinker (>9 u/day) 
 
12985 136O.00 Moderate drinker 
 
27 136..00 Alcohol consumption 
 
93415 136V.00 Alcohol units per week 
 




27 136..00 Alcohol consumption 
 
93415 136V.00 Alcohol units per week 
 
749 1362.12 Drinks occasionally 
 
385 1362.11 Drinks rarely 
 
8999 136P.00 Heavy drinker (7-9 units/day 
 
12984 136Q.00 Very heavy drinker (>9 u/day) 
 
27 136..00 Alcohol consumption 
 
93415 136V.00 Alcohol units per week 
 
97126 136X.00 lcohol units consumed on heaviest 
drinking day 
 
12970 1361.11 Non drinker alcohol 
 
12979 136M.00 Current non drinker 
 
4447 1362.12 Non-drinker alcohol 
Smoking Status 
   
 
12964 137C.00 Keeps trying to stop smoking 
 
31114 137b.00 Ready to stop smoking 
 
9045 ZG23300 Advice on smoking 
 
18926 67H1.00 Lifestyle advice regarding smoking 
 
12240 137G.00 Trying to give up smoking 
 
30762 137d.00 Not interested in stopping smoking 
 
101338 137m.00 Failed attempt to stop smoking 
 
30423 137c.00 Thinking about stopping smoking 
 




12941 1372.11 Occasional smoker 
 
10558 137R.00 Current smoker 
 
93 137P.00 Cigarette smoker 
 
12943 137J.00 Cigar smoker 
 
12947 137H.00 Pipe smoker 
 
34126 13p0.00 Negotiated date for cessation of smoking 
 
776 137K.00 Stopped smoking 
 
99838 137K000 Recently stopped smoking 
 
12878 137T.00 Date ceased smoking 
 
100495 137I.00 Ex roll-up cigarette smoker 
 
19488 137O.00 Ex cigar smoker 
 
90 137S.00 Ex smoker 
 
26470 137N.00 Ex pipe smoker 
 
97210 137j.00 Ex-cigarette smoker 
 
60 137L.00 Current non-smoker 
 
11788 1371.11 Non-smoker 
BMI 8105 22K..00 Body Mass Index 
 
2 22A..00 O/E - weight 
 
3 229..00 O/E - height 
 
8105 22K..00 Body Mass Index 
 
9015 22K4.00 Body mass index index 25-29 - overweight 
 
126 22A6.00 O/E - Underweight 
 




22556 22K7.00 Body mass index 40+ - severely obese 
 




Table 2: Summary statistics for all clinical features included in the sensitivity analysis using corticosteroids to define GCA cases (n = 8244), matched to 
controls (n = 41,211), stratified by time prior to diagnosis. 
 
≤1 month prior 6 months prior 12 months prior 24 months prior 
 
Cases Controls Cases Controls Cases Controls Cases Controls 
 
N % N % N % N % N % N % N % N % 
Headache 
                
No 5695 69.08 41164 99.89 4927 59.76 41000 99.49 4721 57.27 40811 99.03 4531 54.96 40476 98.22 
Yes 2549 30.92 47 0.11 3317 40.24 211 0.51 3523 42.73 400 0.97 3713 45.04 735 1.78 
Fever 
                
No 8223 99.75 - - 8214 99.64 41203 99.98 8203 99.50 41188 99.94 8193 99.38 41162 99.88 
Yes 21 0.25 - - 30 0.36 8 0.02 41 0.50 23 0.06 51 0.62 49 0.12 
Elevated ESR 
                
No 6684 81.08 41152 99.86 5928 71.91 40925 99.31 5675 68.84 40816 99.04 5378 65.24 40771 98.93 
Yes 1560 18.92 59 0.14 2316 28.09 286 0.69 2569 31.16 395 0.96 2866 34.76 440 1.07 
Weight loss/ 




No 8191 99.36 41200 99.97 8121 98.51 41120 99.78 8080 98.01 41045 99.60 8005 97.10 40867 99.17 
Yes 53 0.64 11 0.03 123 1.49 91 0.22 164 1.99 166 0.40 239 2.90 344 0.83 
Visual impairment 
                
No 8219 99.70 41211 100.00 8198 99.44 - - 8180 99.22 41204 99.98 8168 99.08 41195 99.96 
Yes 25 0.30 0 0.00 46 0.56 - - 64 0.78 7 0.02 76 0.92 16 0.04 
Fatigue 
                
No 8223 99.75 - - 8181 99.24 41171 99.90 8149 98.85 41131 99.81 8072 97.91 41025 99.55 
Yes 21 0.25 - - 63 0.76 40 0.10 95 1.15 80 0.19 172 2.09 186 0.45 
Arthralgia/ 
Myalgia 
                
No 8228 99.81 - - 8170 99.10 41179 99.92 8129 98.61 41142 99.83 8040 97.53 41087 99.70 
Yes 16 0.19 - - 74 0.90 32 0.08 115 1.39 69 0.17 204 2.47 124 0.30 
Jaw pain 
                
No 8146 98.89 41211 100.00 82111 98.38 41211 100.00 8088 98.11 41198 99.97 8211 99.60 41182 99.30 
 ≤1 months prior 6 months prior 12 months prior 24 months prior 
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 Cases Controls Cases Controls Cases Controls Cases Controls 
 N % N % N % N % N % N % N % N % 




                
No - - - - 8079 98.00 40900 99.25 7970 96.68 40528 98.34 7682 93.18 39713 96.37 
Yes - - - - 165 2.00 311 0.75 274 3.32 683 1.66 562 6.82 1498 3.63 
Treated 
hypertension 
                
No - - - - 3719 45.11 30866 74.90 3567 43.27 30243 73.39 3367 40.84 29229 70.93 




                
No - - - - 8082 98.03 40928 99.31 7930 96.19 40647 98.63 7675 93.10 40044 97.17 
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Yes - - - - 162 1.97 283 0.69 314 3.81 564 1.37 569 6.90 1167 2.83 
Anxiety/ 
Depression 
                
No - - - - 8174 99.15 41090 99.71 8104 98.30 40976 99.43 7995 96.98 40742 98.86 
Yes - - - - 70 0.85 121 0.29 140 1.70 235 0.57 249 3.02 469 1.14 
PMR 
                
No - - - - 7510 91.10 41128 99.80 7364 89.33 41089 99.70 7189 87.20 41021 99.54 
Yes - - - - 734 8.90 83 0.20 880 10.77 122 0.30 1055 12.80 190 0.46 
Diabetes 
                
No - - - - 7927 96.15 40611 98.54 7706 93.47 39985 97.03 7499 90.96 39042 94.74 
Yes - - - - 317 3.85 600 1.46 538 6.53 1226 2.97 745 9.04 1809 4.39 
Cancer 
                
No - - - - 8211 99.60 41123 99.79 8186 99.30 41026 99.55 8141 98.75 40824 99.06 
Yes - - - - 33 
 




Table 3: Results from the conditional logistic regression fitted to the prescription sensitivity data, stratified by time prior to diagnosis of GCA, showing 
unadjusted and adjusted Odds ratios with 95% confidence intervals, for all clinical features. 
 
≤1 month prior 6 months prior 12 months prior 24 months prior 
 
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Headache 


































                























































3.56 (3.01, 4.20) 2.80 (2.35, 
3.33) 
Elevated ESR 





























68.28 (59.16,78.82) 61.16 (52.86, 
70.77) 
Visual impairment                 
















Fatigue                 
No - - - - Ref  Ref  Ref  Ref  Ref  Ref  








4.90 (3.96, 6.07) 3.88 (3.11, 
4.84) 
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 ≤1 month prior 6 months prior 12 months prior 24 months prior 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Arthralgia/ 
Myalgia 
                




















8.73 (6.94, 10.99) 6.88 (5.43, 
8.72) 
Jaw pain 
                
No - - - - - - - - Ref Ref Ref Ref Ref Ref Ref Ref 
Yes - - - - - - - - 
60.00  
(34.07, 
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No - - - - Ref  Ref  Ref  Ref  Ref  Ref  








2.78 (2.37, 3.25) 2.24 (1.90, 
2.64) 
 ≤1 month prior 6 months prior 12 months prior 24 months prior 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
                 
                 
                 
PMR 
                

























                
























1.57 (1.42,  
1.72) 
Cancer 
                


























Appendix 7.1 – Results from the LCA sensitivity analysis 
 
Table 1: LCA results from the 4-class sensitivity model including constitutional symptoms. 
Showing the number in each class, the average posterior probability (AvePP) of each class, 
and class conditional outcome probability for each clinical feature. 















AvePP 0.83 0.71 0.78 0.8 
Headache 45.40% 54.69% 29.90% 38.72% 
Cancer 5.25% 3.86% 3.85% 3.51% 
Visual 3.38% 2.77% 3.30% 3.22% 
Treated 
hypertension 
99.70% 40.46% 50.48% 34.65% 
Cardiovascular 
diseases 
30.57% 2.86% 4.19% 4.34% 
Elevated ESR 30.89% 99.98% 46.55% 0.00% 
Anxiety/ 
Depression 
10.64% 5.45% 5.25% 7.05% 





7.26% 5.75% 25.37% 4.72% 
Diabetes 23.01% 5.52% 7.38% 3.33% 
Jaw pain 1.74% 3.21% 2.15% 1.60% 
Constitutional 
symptoms 
13.85% 11.87% 13.84% 8.17% 
 
 
 
 
 
 
 
 
 
 
 
